TWI858159B - Human papillomavirus polyvalent immunogenic composition - Google Patents

Abstract

The present invention relates to a chimeric papillomavirus L1 protein and a polynucleotide encoding the same, an HPV virus-like particle, and a multivalent HPV immunogenic composition comprising at least one of the virus-like particles, and uses thereof. The chimeric papillomavirus L1 protein comprises an N-terminal fragment derived from a first type of papillomavirus L1 protein, the N-terminal fragment retains the immunogenicity of the HPV corresponding type of L1 protein; and a C-terminal fragment derived from a second type of papillomavirus L1 protein, the second type of papillomavirus L1 protein has better expression and solubility than other types of L1 proteins; wherein the chimeric papillomavirus L1 protein has the immunogenicity of the HPV corresponding type of L1 protein. The chimeric papillomavirus L protein has a relatively high expression and solubility, and can be used for large-scale production of vaccines. In one embodiment, at least one of the HPV virus-like particles is a chimeric HPV virus-like particle, and the chimeric HPV virus-like particle comprises one or more chimeric HPV L1 proteins.

Description

Human papillomavirus polyvalent immunogenic composition

The present invention relates to human papillomavirus (HPV) L1 protein and polynucleotide encoding the protein, as well as HPV-like virus particles and a multivalent immunogenic composition containing the HPV-like virus particles for preventing human papillomavirus (HPV)-related diseases or infections and uses thereof.

Papilloma virus (PV) belongs to the Papillomaviridae family and can cause papilloma in humans, cattle, dogs, rabbits, etc. Its member, human papillomavirus (HPV), is a non-enveloped DNA virus. The genome of the virus is a double-stranded closed circular DNA with a size of approximately 7.2-8 kb and 8 open reading frames. It can be divided into three regions according to its function: (1) the early region (E), approximately 4.5 kb, encoding 6 non-structural proteins E1, E2, E4-E7 related to viral replication, transcription and translation; (2) the late region (L), approximately 2.5 kb, encoding the major capsid protein L1 and the minor capsid protein L2; (3) the long regulatory region (LCR), which is located between the end of the L region and the beginning of the E region, is approximately 800-900 bp long, does not encode any protein, but has DNA replication and expression regulatory elements.

L1 and L2 proteins are synthesized in the middle and late stages of the HPV infection cycle. L1 protein is the major capsid protein and has a molecular weight of 55-60 kDa. L2 protein is the minor capsid protein. 72 L1 protein pentamers constitute the outer shell of the icosahedral HPV virus particle (diameter 45-55 nm), which encapsulates the closed-circular double-stranded DNA. L2 protein is located on the inner side of L1 protein (Structure of Small Virus-like Particles Assembled from the L1 Protein of Human Papillomavirus 16 Chen, X.S., R. L.Garcea, Mol.Cell. 5(3):557-567, 2000).

The ORF of the L1 protein is the most conserved gene in the PV genome and can be used to identify new PV types. If the complete genome is cloned and the DNA sequence of the L1 ORF differs by more than 10% from the closest known PV type, a new PV type is considered to have been isolated. Differences between 2% and 10% homology are defined as different subtypes, and differences less than 2% are defined as different variants of the same subtype (E.-M. de Villiers et al. / Virology 324 (2004) 17–27).

In the late stage of HPV infection, newly synthesized L1 protein in the cytoplasm is transported to the nucleus of terminally differentiated keratinocytes, and together with L2 protein, it packages the replicated HPV genomic DNA to form infectious viruses (Nelson, L.M, et al. 2002. Nuclear import strategies of high risk HPV16 L1 major capsid protein. J. Biol. Chem. 277: 23958-23964). This shows that nuclear import of L1 protein plays a very important role in HPV infection and production. The ability of the virus to enter the cell nucleus is determined by the nuclear localization signal (NLS) at the C-terminus of the HPV L1 protein. One of the characteristics of the nuclear localization signal is that it is rich in basic amino acids (Garcia-Bustos, J., et al. 1991. Nuclear protein localization. Biochimica et Biophysica Acta  1071: 83-101).

Fifteen high-risk (HR) HPV types can cause cervical, anal, penile, vaginal, vulvar, and oropharyngeal cancers. Of these, HPV-16 and HPV-18 are by far the most common causes of cancer, accounting for about 70% of cervical cancers, with the remainder caused by other HR-HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82). HPV-16 accounts for about 95% of HPV-positive oropharyngeal cancers (OPCs). The persistently low-risk genotypes HPV-6 and HPV-11 cause most anogenital warts and respiratory papillomas but are rarely associated with cancer (Human Papillomavirus in Cervical Cancer and Oropharyngeal Cancer: One Cause, Two Diseases Tara A. Bermanand John T. Schiller, PhD2 Cancer 2017;123:2219-29).

L1 protein is recombinantly expressed using vaccinia virus, bacilli or yeast systems. L1 protein can self-assemble to form virus-like particles (VLPs) containing approximately 72 L1 proteins, similar to the viral exosome. VLPs have no indications. VLPs can induce neutralizing antibodies in vaccinated animals and protect experimental animals from subsequent attacks by infectious viruses. Therefore, VLPs appear to be excellent candidates for papillomavirus vaccines (Structure of Small Virus-like Particles Assembled from the L1 Protein of Human Papillomavirus 16 Chen, X.S., R. L.Garcea, Mol.Cell. 5(3):557-567, 2000).

Glaxo's ^CERVARIX® is a bivalent recombinant HPV vaccine. It contains recombinant L1 proteins of HPV type 16 and HPV type 18 expressed in Trichoplusia ni insect cells by a recombinant bacilliform virus expression vector system. The L1 proteins self-assemble into virus-like particles and are used to prevent cervical cancer, grade 2 or 3 cervical intraepithelial neoplasia and adenocarcinoma in situ, and grade 1 cervical intraepithelial neoplasia (carcinogenic) caused by HPV types 16 and 18 in women aged 9-25 years (https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf).

GARDASIL ^® is a quadrivalent human papillomavirus (HPV) recombinant vaccine (types 6, 11, 16, and 18) manufactured by Merck for use in girls and women aged 9-26 years to prevent cervical cancer, genital warts (condylomata), and precancerous or developmental abnormalities caused by HPV types 6, 11, 16, and 18; and in boys and men aged 9-26 years to prevent anal cancer, genital warts (condylomata), and precancerous or developmental abnormalities caused by HPV types 6, 11, 16, and 18 (https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil).

GARDASIL ^® 9 is a nine-valent recombinant human papillomavirus vaccine produced by Merck. It contains virus-like particles of L1 protein of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. The L1 protein is produced by fermentation of brewing yeast and self-assembled into VLPs. For use in girls and women aged 9-45 years to prevent cervical, vulvar, vaginal and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, genital warts (condyloma acuminatum) caused by HPV types 6 and 11, and precancerous or proliferative abnormalities caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58; and in boys and men aged 9-45 years to prevent anal cancer caused by HPV types 16, 18, 31, 33, 45, 52 and 58, genital warts (condyloma acuminatum) caused by HPV types 6 and 11, and precancerous or proliferative abnormalities caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. Precancerous or developmental abnormalities caused by types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil-9).

The instructions for GARDASIL ^® 9 claim that HPV types 16 and 18 are the cause of approximately 70% of cervical cancer, and the remaining 20% of cases are attributed to types 31, 33, 45, 52 and 58. Therefore, GARDASIL ^® 9 can prevent 90% of cervical cancer (https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm426445.htm).

The key factor in the development of HPV vaccines is that virus-like particles can be mass-produced. Currently, the more common systems for producing virus-like particles are mainly divided into eukaryotic expression systems and prokaryotic expression systems.

Commonly used eukaryotic expression systems include poxvirus expression system, insect bacilli virus expression system, and yeast expression system. The natural conformation of HPV L1 protein expressed in eukaryotic expression system is less damaged and can spontaneously assemble to form virus-like particles, but the yield is low. The prokaryotic expression system is mainly the Escherichia coli expression system, which has high yield but mostly exists in the form of inclusion bodies, which is not conducive to purification and has a complicated production process.

Therefore, there is still a need in the art to obtain high-yield HPV virus-like particles, thereby obtaining HPV multivalent vaccines to effectively prevent HPV-related diseases or infections, including HPV-related diseases or infections caused by HPV types that are not covered by current commercial vaccines.

In one aspect, the present invention provides a chimeric papillomavirus L1 protein, comprising, from its N-terminus to the C-terminus, a. an N-terminal fragment derived from a first type of papillomavirus L1 protein, wherein the N-terminal fragment retains the immunogenicity of the HPV corresponding type L1 protein; and b. a C-terminal fragment derived from a second type of papillomavirus L1 protein, wherein the second type of papillomavirus L1 protein has better expression and solubility than other types of L1 proteins; wherein the chimeric papillomavirus L1 protein has the immunogenicity of the first type of papillomavirus L1 protein.

In another aspect, the present invention provides a papillomavirus-like particle comprising a chimeric papillomavirus L1 protein.

In another aspect, the present invention provides an isolated polynucleotide encoding a chimeric papillomavirus L1 protein.

In another aspect, the present invention provides a vector comprising a polynucleotide encoding a chimeric papillomavirus L1 protein.

In another aspect, the present invention provides a bacillivirus comprising a polynucleotide encoding a chimeric papillomavirus L1 protein.

In another aspect, the present invention provides a host cell comprising the polynucleotide, vector, or bacilli as described above.

In one aspect, the present invention provides an HPV immunogenic composition for preventing HPV-related diseases or infections, comprising the chimeric papillomavirus L1 protein, HPV virus-like particles, polynucleotides, vectors, bacilli, and cells of the above aspects;

In a specific embodiment, it comprises: HPV virus-like particles assembled from chimeric L1 proteins of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58; and HPV virus-like particles assembled from L1 proteins of HPV types 33 and 59.

In another aspect, the present invention provides a method for preventing HPV-related diseases or infections, comprising: administering a multivalent HPV immunogenic composition to a subject.

In another aspect, the present invention provides use of a multivalent HPV immunogenic composition for preparing a vaccine or a medicament for preventing HPV-related diseases or infections.

In one aspect, the present invention provides a chimeric papillomavirus L1 protein, comprising, from its N-terminus to the C-terminus: a. an N-terminal fragment derived from a first type of papillomavirus L1 protein, wherein the N-terminal fragment retains the immunogenicity of the HPV corresponding type L1 protein; and b. a C-terminal fragment derived from a second type of papillomavirus L1 protein, wherein the second type of papillomavirus L1 protein has better expression and solubility than other types of L1 proteins; wherein the chimeric papillomavirus L1 protein has the immunogenicity of the first type of papillomavirus L1 protein.

In one embodiment, the N-terminal fragment is a fragment obtained by truncating the C-terminus of the native sequence of the first type of papillomavirus L1 protein at any amino acid site in its α5 region, and a fragment having at least 98% identity therewith; the C-terminal fragment is a fragment obtained by truncating the N-terminus of the native sequence of the second type of papillomavirus L1 protein at any amino acid site in its α5 region, and a functional variant produced by further mutation, deletion and/or addition of the fragment.

In another embodiment, the N-terminal fragment is at least 98.5%, 99%, 99.5% or 100% identical to the fragment obtained by truncating the C-terminus of the native sequence of the first type of papillomavirus L1 protein at any amino acid site in its α5 region.

In one embodiment, the C-terminal fragment contains one or more nuclear localization sequences.

In one embodiment, the papillomavirus L1 protein is HPV L1 protein.

In one embodiment, the second type of papillomavirus L1 protein is selected from HPV type 1, 2, 3, 4, 6, 7, 10, 11, 13, 16, 18, 22, 26, 28, 31, 32, 33, 35, 39, 42, 44, 45, 51, 52, 53, 56, 58, 59, 60, 63, 66, 68, 73 or 82 L1 protein; Preferably, the second type of papillomavirus L1 protein is selected from HPV type 16, 28, 33, 59, or 68 L1 protein; More preferably, the second type of papillomavirus L1 protein is selected from HPV type 33 or HPV type 59 L1 protein.

In one embodiment, the second type of papillomavirus L1 protein is HPV 33 type L1 protein, the C-terminal fragment is SEQ ID No: 2; or a fragment with a length of m1 amino acids, preferably covering the fragment of amino acids 1-m1 of SEQ ID No: 2; wherein m1 is an integer of 8-26; or the C-terminal fragment is SEQ ID No: 135; or a fragment with a length of m2 amino acids, preferably covering the fragment of amino acids 1-m2 of SEQ ID No: 135; wherein m2 is an integer of 13-31.

In one embodiment, the C-terminal fragment of the HPV 33 type L1 protein has one nuclear localization sequence. In another embodiment, the C-terminal fragment of the HPV 33 type L1 protein has two nuclear localization sequences. In some embodiments, the chimeric papillomavirus L1 protein comprises one or more C-terminal fragments of the HPV 33 type L1 protein. The C-terminal fragments of the multiple HPV 33 type L1 proteins may be the same or different. In one embodiment, the amino acid sequence (KR) of amino acid sequence numbers 7-8 of SEQ ID No: 2 and the amino acid sequence (KRKK) of amino acid sequence numbers 20-23 are the nuclear localization sequences of the C-terminal fragment of the HPV 33 type L1 protein.

In another embodiment, the second type of papillomavirus L1 protein is HPV type 59 L1 protein, and the C-terminal fragment is SEQ ID No: 13; or a fragment thereof having a length of n amino acids, preferably a fragment covering amino acids 1 to n of SEQ ID No: 13; wherein n is an integer of 16-38.

In one embodiment, the C-terminal fragment of the HPV 59 L1 protein has one nuclear localization sequence. In another embodiment, the C-terminal fragment of the HPV 59 L1 protein has two nuclear localization sequences. In some embodiments, the chimeric papillomavirus L1 protein comprises one or more C-terminal fragments of the HPV 59 L1 protein. The C-terminal fragments of the multiple HPV 59 L1 proteins may be the same or different.

In one embodiment, the first type of papillomavirus L1 protein is selected from HPV type 6, type 11, type 16, type 18, type 31, type 35, type 39, type 45, type 51, type 52, type 56 or type 58 L1 protein.

In one embodiment, the N-terminal fragment of the HPV 6 L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminus of the sequence shown in SEQ ID No: 1 at any amino acid site in its α5 region; The N-terminal fragment of the HPV 11 L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminus of the sequence shown in SEQ ID No: 14 at any amino acid site in its α5 region; The N-terminal fragment of the HPV 16 L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminus of the sequence shown in SEQ ID No: 27 at any amino acid site in its α5 region; The HPV The N-terminal fragment of the HPV 18 L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminus of the sequence shown in SEQ ID No: 40 at any amino acid site in its α5 region; The N-terminal fragment of the HPV 31 L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminus of the sequence shown in SEQ ID No: 53 at any amino acid site in its α5 region; The N-terminal fragment of the HPV 35 L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminus of the sequence shown in SEQ ID No: 69 at any amino acid site in its α5 region; The N-terminal fragment of the HPV 39 L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminus of the sequence shown in SEQ ID No: 69 at any amino acid site in its α5 region; 82, the C-terminal truncation of the sequence shown in SEQ ID No: 82 at any amino acid site in its α5 region has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity; The N-terminal fragment of the HPV 45 L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 95 at any amino acid site in its α5 region; The N-terminal fragment of the HPV 51 L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 108 at any amino acid site in its α5 region; The N-terminal fragment of the HPV 52 L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 108 at any amino acid site in its α5 region; The fragment obtained by truncating the C-terminus of the sequence shown in SEQ ID No: 121 at any amino acid site in its α5 region has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity; The N-terminal fragment of the HPV 56 type L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminus of the sequence shown in SEQ ID No: 134 at any amino acid site in its α5 region; and The N-terminal fragment of the HPV 58 type L1 protein has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the fragment obtained by truncating the C-terminus of the sequence shown in SEQ ID No: 147 at any amino acid site in its α5 region.

In one embodiment, the C-terminus of the N-terminal fragment is directly linked to the N-terminus of the C-terminal fragment or via a linker.

The linker does not affect the immunogenicity of the N-terminal fragment and does not affect the expression or solubility of the protein. In one embodiment, the N-terminal fragment and the C-terminal fragment are connected by a linker consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids. In one embodiment, the linker is an artificial sequence. In another embodiment, the linker is a sequence naturally occurring in the HPV L1 protein. In another embodiment, the linker can be a partial sequence of the HPV 33 type L1 protein. In another embodiment, the linker can be a partial sequence of the HPV 59 type L1 protein.

In one embodiment, when the C-terminus of the N-terminal fragment is connected to the N-terminus of the C-terminal fragment, the following continuous amino acid sequence exists within the range of positive and negative 4 amino acid sites of the connection point: RKFL; preferably, the following continuous amino acid sequence exists within the range of positive and negative 6 amino acid sites of the connection point: LGRKFL.

In some embodiments, the chimeric HPV type 6, type 11, type 16, type 18, type 31, type 35, type 39, type 45, type 51, type 52, type 56 and type 58 chimeric HPV L1 protein has 98%, 98.5%, 99%, 99.5% or 100% identity with SEQ ID No: 3, SEQ ID No: 16, SEQ ID No: 29, SEQ ID No: 42, SEQ ID No: 55, SEQ ID No: 71, SEQ ID No: 84, SEQ ID No: 97, SEQ ID No: 110, SEQ ID No: 123, SEQ ID No: 136 and SEQ ID No: 149, respectively. and HPV type 33 L1 protein and HPV type 59 L1 protein have 98%, 98.5%, 99%, 99.5% or 100% identity with SEQ ID No: 66 and SEQ ID No: 160, respectively.

In one aspect, the present invention provides a papillomavirus-like particle comprising a chimeric papillomavirus L1 protein as described above. In one embodiment, the papillomavirus-like particle is an HPV virus-like particle, and in one embodiment, the HPV virus-like particle is an icosahedron composed of 72 pentamers of the chimeric HPV L1 protein. In one embodiment, the HPV virus-like particle has correctly formed disulfide bonds and thus has a good natural configuration. In one embodiment, the HPV virus-like particle self-assembles in an in vivo expression system.

In one aspect, the present invention provides an isolated polynucleotide encoding a chimeric papillomavirus L1 protein as described above. In one embodiment, the polynucleotide is a polynucleotide that has been codon-optimized for a different expression system. In one embodiment, the polynucleotide is a polynucleotide that has been codon-optimized for an insect bacilliform virus expression system.

In one aspect, the present invention provides a vector comprising a polynucleotide as described above. In one embodiment, the vector is a bacilli virus vector. In one embodiment, the vector may be a transfer vector for a bacilli virus expression system. In another embodiment, the vector may be an expression vector for a bacilli virus expression system. In another embodiment, the vector may be a recombinant vector for a bacilli virus expression system.

In one aspect, the present invention provides a bacillivirus comprising the polynucleotide as described above.

In one aspect, the present invention provides a host cell comprising the polynucleotide, vector, or bacillivirus as described above. In one embodiment, the host cell is an insect cell, preferably, the insect cell is selected from Sf9 cells, Sf21 cells, Hi5 cells, and S2 cells.

In one aspect, the present invention provides a multivalent immunogenic composition for preventing papillomavirus-related diseases or infections, comprising the HPV-like virus particles, polynucleotides, vectors, bacilli, and cells of the above aspects.

In one embodiment, it comprises: HPV virus-like particles assembled from chimeric L1 proteins, such as L1 proteins of HPV types 6, 11, 16, 18, 31, 35, 39, 45, 51, 52, 56 and 58; and one or more HPV virus-like particles assembled from L1 proteins of other pathogenic HPV types, such as HPV33 and 59.

In one embodiment, the L1 protein of each HPV type can be a naturally occurring L1 protein, a non-naturally occurring L1 protein, or a chimeric HPV L1 protein. In one embodiment, the HPV virus-like particle can be assembled from a single type of HPV L1 protein to form a monovalent HPV virus-like particle, or can be assembled from multiple types of HPV L1 proteins to form a multivalent HPV virus-like particle.

In one embodiment, the chimeric HPV virus-like particles can be assembled from a single type of chimeric HPV L1 protein to form monovalent HPV virus-like particles, or can be assembled from multiple types of chimeric HPV L1 proteins to form multivalent HPV virus-like particles.

In some embodiments, the chimeric HPV type 6, type 11, type 16, type 18, type 31, type 35, type 39, type 45, type 51, type 52, type 56 and type 58 chimeric HPV L1 proteins are 98%, 98.5%, 99%, 99.5% or 100% identical to SEQ ID No: 3, SEQ ID No: 16, SEQ ID No: 29, SEQ ID No: 42, SEQ ID No: 55, SEQ ID No: 71, SEQ ID No: 84, SEQ ID No: 97, SEQ ID No: 110, SEQ ID No: 123, SEQ ID No: 136 and SEQ ID No: 149, respectively; and the HPV type 33 L1 protein and the HPV type 59 L1 protein are 98%, 98.5%, 99%, 99.5% or 100% identical to SEQ ID No: 66 and SEQ ID No: 160 has 98%, 98.5%, 99%, 99.5% or 100% identity.

In one embodiment, at least one of the HPV-like virus particles is composed of a single type of chimeric HPV L1 protein, preferably, is composed of a single type of chimeric HPV L1 protein having the same amino acid sequence.

In one embodiment, the chimeric HPV virus-like particle is an icosahedron composed of 72 pentamers of the chimeric HPV L1 protein. In one embodiment, the chimeric HPV virus-like particle has correctly formed disulfide bonds and thus has a good natural configuration. In one embodiment, the chimeric HPV virus-like particle self-assembles in an in vivo expression system.

In one embodiment, the multivalent HPV immunogenic composition further comprises a physiologically acceptable carrier and optionally, an adjuvant. In one embodiment, the adjuvant comprises one or more of an aluminum salt, a lipid A derivative, and an ISCOM.

In one embodiment, the adjuvant is an aluminum phosphate adjuvant.

In one aspect, the present invention provides a method for preventing HPV-related diseases or infections, comprising: administering a polyvalent HPV immunogenic composition to a subject. The prevention can be considered as treatment, and the two can be used interchangeably. In one embodiment, the subject is a human.

In one aspect, the present invention provides use of the multivalent HPV immunogenic composition as described above for preparing a vaccine or a medicament for preventing HPV-related diseases or infections.

The papillomavirus L1 protein expressed by the eukaryotic expression system can spontaneously assemble into virus-like particles, but has the disadvantages of low expression levels and difficulty in scalable production.

The sequence of L1 protein of each type of HPV can be conveniently obtained from https://www.uniprot.org. Each type of HPV L1 can be derived from different virus strains, so its amino acid sequence has multiple versions, any of which can be used in the present invention. In the conception and design process of the present invention, the sequence of a given type of HPV L1 protein used may be different from the sequence used in the embodiments, but this difference does not affect the judgment and conclusion of the inventor.

It is generally believed by those skilled in the art that the C-terminus of the L1 protein does not contain a major neutralizing antigen epitope, and therefore attempts have been made to increase the expression level by truncating the C-terminus of the HPV L1 protein. For example, in GlaxoSmithKline's U.S. patent US6361778B1, the HPV16 L1 protein C-terminus is truncated by 1-34 amino acids, preferably 26 amino acids, and the VLP yield is claimed to be increased by many times, preferably at least 10 times, and especially about 10 to 100 times. Inspired by this, the inventors tried to truncate the C-terminus of HPV 16 L1 by 31 amino acids, and named it HPV16 L1 (1-474). However, the protein expression level was high, but the protein solubility was poor, and it was difficult to extract and purify (see comparative example).

The poor protein solubility caused by this truncation may be caused by the lack of the nuclear localization sequence at the C-terminus, and the present invention is not limited to this speculation. The inventors found in the research and production process that the HPV 16 L1 protein, HPV 28 L1 protein, HPV 33 L1 protein, HPV 59 L1 protein and HPV 68 L1 protein have better expression and solubility than other types of L1 proteins. Inspired by this, the inventors replaced the C-terminus of HPV types that are difficult to extract or have low expression with the C-terminus of L1 proteins with better expression and solubility. That is, the inventors have constructed such a chimeric protein: from its N-terminus to its C-terminus, it includes an N-terminal fragment derived from the first type of papillomavirus L1 protein (such as HPV L1 protein) and a C-terminal fragment derived from the second type of papillomavirus L1 protein (such as HPV L1 protein), the former providing the immunogenicity of the first type of papillomavirus (such as HPV), and the latter providing the characteristics of better expression and solubility. The two can be directly connected or connected through a linker.

In order to maintain the immunogenicity of the first type HPV L1 protein and ensure that it can form VLPs, the inventors determined the length of the appropriate N-terminal fragment of the HPV L1 protein. The following reports on epitope studies of common HPV subtypes:

Sunanda Baidya et al. reported that the epitopes of L1 protein 48EEYDLQFIFQLCKITLTA65, 45RHGEEYDLQFIFQLCKITLTA65, 63LPDPNKF69, 79PETQRLVWAC88, 36PVPGQYDA43, 77YNPETQRLVWAC88, 188DTGYGAMD195, 36PVPGQYDATK45, 45KQDIPKVSAYQYRVFRV61, 130RDNVSVDYKQTQLCI144 and 49YSRHVEEY DLQFIF62 can be used as tools for designing HPV16 and 18 vaccines (see Epitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18, Bioinformation 13(3):86-93 March 2014). 2017, which is incorporated herein by reference in its entirety).

Katharina Slupetzky et al. reported that the regions around aa 282–286 and 351–355 of HPV-16 contribute to neutralizing epitopes and that the latter are immunodominant sites (see Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops, Journal of General Virology (2001), 82, 2799–2804, incorporated herein by reference in its entirety).

Brooke Bishop et al. prepared the following three variants of HPV11, 16, 18, and 35 L1 proteins: 9 amino acids missing at the N-terminus, α4 (corresponding to amino acid residues 404–436 of HPV16), and 31 amino acids missing at the C-terminus, and reported that the first two could not assemble into VLPs, but did not report this phenomenon for the latter.

(Crystal Structures of Four Types of Human Papillomavirus L1 Capsid Proteins UNDERSTANDING THE SPECIFICITY OF NEUTRALIZING MONOCLONAL ANTIBODIES, The Journal of Biological Chemistry, 282, 31803-31811. The entire contents are incorporated herein by reference). The α-helix and β-fold loop regions of each type of HPV L1 protein can be easily determined using sequence analysis software commonly used in the field. The α-helix region includes the α1 region, the α2 region, the α3 region, the α4 region, and the α5 region.

The inventors aligned the sequences of 14 types of HPV L1 proteins (type 6, type 11, type 16, type 18, type 31, type 33, type 35, type 39, type 45, type 51, type 52, type 56, type 58 and type 59), and then predicted the secondary structures according to the above-cited literature (Crystal Structures of Four Types of Human Papillomavirus L1 Capsid Proteins UNDERSTANDING THE SPECIFICITY OF NEUTRALIZING MONOCLONAL ANTIBODIES, The Journal of Biological Chemistry, 282, 31803-31811). The results are shown below, in which the portion between the downward arrows corresponds to the region deleted for preparing variants in the literature.

In addition to the sequence alignment method used by the inventors, protein secondary structure prediction software that can be used for prediction includes but is not limited to: 1. JPred: http://www.compbio.dundee.ac.uk/jpred/index.html 2. ProtPredicct: http://predictprotein.org 3. PsiPred: http://bioinf.cs.ucl.ac.uk/psipred 4. SCRATCH-1D: http://download.igb.uci.edu 5. Nnpredict: http://www.cmpharm.ucsf.edu/~nomi/nnpredict 6. Predictprotein: http://www.embl-heidelberg.de/predictprotein/SOPMA http://www.ibcp.fr/predict.html 7. SSPRED: http://www.embl-heidelberg.de/sspred/ssprd_info.html.

In one embodiment of the present invention, the inventors determined the length of the N-terminal fragment derived from the first type of HPV L1 protein in the following manner: the native sequence of the L1 protein was truncated in its α5 region and its vicinity, and the sequence from its N-terminus to the newly generated C-terminus of the α5 region was retained. Such a truncated sequence can ensure that it has the immunogenicity of this type and can form VLPs.

The N-terminal fragment derived from the HPV L1 protein of the first type can be further modified to ensure that it has the immunogenicity of this type and is able to form VLP.

The inventors determined the length of the C-terminal fragment derived from the second type of HPV L1 protein in the following manner. The native sequence of the L1 protein was truncated in its α5 region and its vicinity, and the newly generated N-terminal to C-terminal sequence from its α5 region was retained. Such a truncated sequence does not have a major neutralizing antigen epitope and does not interfere with the immunogenicity of the formed chimeric protein.

The C-terminal fragment derived from the second type of HPV L1 protein can be further mutated, deleted and/or added, preferably retaining at least one nuclear localization sequence. Yang et al. predicted the nuclear localization sequences of 107 types of HPV subtypes (Yang et al. Predicting the nuclear localization signals of 107 types of HPV L1 proteins by bioinformatic analysis. Geno. Prot. Bioinfo. Vol. 4 No. 1 2006, incorporated herein by reference in its entirety), and the nuclear localization sequences of each type of HPV L1 protein can be conveniently determined by sequence analysis software commonly used in the art.

The connection between the N-terminal fragment and the C-terminal fragment occurs at the newly generated C-terminus of the former and the newly generated N-terminus of the latter. It can be directly connected or connected through a linker. If the connection point is regarded as the origin, the N-terminal side of the origin is negative, and its C-terminal side is positive.

The following shows the amino acid sequence of the 453-469 position of the HPV6 L1 protein and the corresponding sequence of multiple types of HPV L1 proteins. It can be seen that these sequences are highly similar. This sequence overlaps with the α5 region. The numbers in brackets indicate the position of the last amino acid in the listed sequence. For HPV 45, some HPV 45 strains have an additional 26 amino acids at the N-terminus of the L1 protein, while other HPV 45 strains do not have the additional 26 amino acids at the N-terminus of the L1 protein, so it is represented by (478)+26. HPV6 ELDQYPLGRKFLLQSGY(469) HPV11 ELDQFPLGRKFLLQSGY(470) HPV16 DLDQFPLGRKFLLQAGL(474) HPV18 DLDQYPLGRKFLVQAGL(475) HPV31 DLDQFPLGRKFLLQAGY(475) HPV35 DLDQFPLGRKFLLQAGL(472) HPV39 ELDQFPLGRKFLLQARV (474) HPV45 DLDQYPLGRKFLVQAGL(478)+26 HPV51 DLDQFALGRKFLLQVGV(474) HPV52 DLDQFPLGRKFLLQAGL(478) HPV56 DLDQFPLGRKFLMQLGTRS(474) HPV58  DLDQFPLGRKFLLQSGL(473) HPV33  DLDQFPLGRKFLLQAGL(473) KAKPKLKRAAPTSTRTSSAKRKKVKK, where KR at 480-481 and KRKK at 493-496 are nuclear localization sequences. HPV59 DLDQFPLGRKFLLQLGA(475) RPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK, where RKR at 484-486 and KRVKRRK at 498-504 are nuclear localization sequences.

In one embodiment of the present invention, the inventors conveniently completed the C-terminal replacement of L1 protein between different types by taking advantage of the sequence similarity of the α5 region and its surrounding regions between multiple HPV types.

In the best embodiment of the present invention, the inventors noticed that each type of HPV L1 protein has a tetrapeptide RKFL at a similar position, and more preferably a hexapeptide LGRKFL. The inventors cleverly used this highly conserved sequence to design the connection point of the chimeric protein at any amino acid position of this oligopeptide. From one aspect, the sequence from the N-terminus of the chimeric protein to RKFL or LGRKFL is the same as the sequence of the N-terminal fragment derived from the first type of HPV L1 protein, and from another aspect, the sequence from RKFL or LGRKFL to the C-terminus of the chimeric protein is the same as the sequence of the C-terminal fragment derived from the second type of L1 protein.

The chimeric protein thus produced maintains a high degree of similarity to the natural HPV L1 protein and can be expected to perform well in production and in subsequent medical or preventive processes.

Those skilled in the art will understand that, because the same type of HPV has different strains and thus different natural sequences, chimeric proteins constructed using different strains also fall within the scope of the present invention.

A person skilled in the art to which the present invention belongs will understand that, due to the high similarity of different types of HPV L1, if, during the construction of the chimeric protein, the N-terminal fragment derived from the first type of HPV L1 protein is extended to the C-terminal with more amino acid residues, or the C-terminal fragment derived from the second type of HPV L1 protein is extended to the N-terminal with more amino acid residues, it is also possible to form a chimeric protein consistent with the structure of the present invention due to the same or similar amino acids at the corresponding positions. The chimeric protein thus formed also falls within the scope of the present invention.

Those skilled in the art will appreciate that, based on the chimeric protein of the above-described embodiments, variants of the chimeric protein may be formed by mutation, deletion and/or addition of amino acid residues. These variants may have the immunogenicity of the first type of HPV L1 protein, may form VLPs, and have good yield and solubility. The chimeric protein thus formed also falls within the scope of the present invention.

Beneficial effects of the invention

Currently, the expression systems commonly used to produce virus-like particles are divided into eukaryotic expression systems and prokaryotic expression systems. The papillomavirus L protein expressed by the eukaryotic expression system can spontaneously assemble into virus-like particles, but has the disadvantages of low expression levels and difficulty in large-scale production. The natural configuration of the papillomavirus L protein expressed by the prokaryotic expression system is often destroyed, requiring subsequent in vitro treatment to obtain virus-like particles, and the yield is low, making it difficult to industrialize.

The present invention modifies the C-terminus of the L protein of a papillomavirus (e.g., human papillomavirus), for example, by replacing it with a C-terminal fragment of the L1 protein of HPV 16, HPV 28, HPV 33, HPV 59, or HPV 68, thereby increasing the expression amount and solubility of the L protein of the papillomavirus in an expression system (e.g., a host cell, such as an insect cell). This can be used for the mass production of vaccines, such as HPV vaccines.

The inventors found that the expression and solubility of HPV 16, HPV 28, HPV 33, HPV 59 and HPV 68 L1 proteins were better than those of other types of L1 proteins, and that the increased protein expression and solubility depended on the C-terminal sequence of the HPV L1 protein. Among the 107 types of HPV L1 proteins, most of them had a nuclear localization sequence at the C-terminus, and the C-terminal sequences had certain similarities.

For papillomavirus L proteins that are currently unable to be expressed, expressed at very low levels, or insoluble after expression, their C-terminal fragments are replaced with the C-terminal fragments of HPV 16 L1 proteins, HPV 28 L1 proteins, HPV 33 L1 proteins, HPV 59 L1 proteins, or HPV 68 L1 proteins, making it possible to express soluble papillomavirus L proteins that were originally expressed at very low levels or were insoluble, and subsequently purify them. This can be used for the large-scale production of more valent vaccines (such as HPV vaccines), making it possible to more comprehensively prevent infections caused by multiple papillomaviruses, especially HPV.

In order to achieve large-scale production of vaccines, there is also a need to improve the expression and solubility of HPV L1 protein in insect cells. In addition, in yeast cells, HPV L1 protein assembles into virus-like particles that lack a good conformation because disulfide bonds cannot be formed correctly.

For HPV L1 protein with low expression level and poor solubility in insect cells, the expression level and solubility are significantly improved after its C-terminal fragment is transformed into the C-terminal fragment of HPV type 33 or type 59 L1 protein, which can be used for large-scale production of HPV vaccine.

For HPV L1 proteins that have better expression and solubility in insect cells than other types of L1 proteins, such as HPV 16, HPV 28, HPV 68, etc., there is a need to further improve the expression and solubility in order to achieve large-scale production of vaccines. In the present invention, for example, after the C-terminal fragment of the HPV 16 L1 protein is transformed into the C-terminal fragment of the HPV 33 L1 protein, the expression and solubility of the transformed chimeric HPV 16 L1 protein are improved, which is conducive to the large-scale production of HPV vaccines.

In summary, the expression amount and solubility of the chimeric HPV L1 protein in insect cells are greatly improved compared to the HPV L1 protein before modification. It can be used for large-scale production of HPV vaccines. In addition, the chimeric HPV L1 protein can correctly form disulfide bonds in insect cells and assemble into HPV virus-like particles with good configuration. This can improve the immunogenicity of HPV virus-like particles and produce better immune responses.

The multivalent vaccine of the present invention can be used to prevent a variety of HPV-related diseases or infections, including HPV types that are currently unpreventable.

Definition

Unless otherwise specified, all technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs. For the convenience of understanding the present invention, the common meanings of the following terms are quoted below.

As used herein and in the appended claims, the singular forms "a/an," "another," and "the" include plural referents unless the context clearly indicates otherwise. Unless expressly stated otherwise, the terms "including/comprising/having," "such as," and the like are intended to convey inclusion rather than limitation.

The term "immunogenicity" refers to the ability of a substance, such as a protein or peptide, to stimulate an immune response, that is, the ability to stimulate the production of antibodies, especially the production of humoral or cell-mediated responses.

The term "antibody" refers to an immunoglobulin molecule that can bind to an antigen. Antibodies can be a mixture of multiple strains or a single strain. Antibodies can be complete immunoglobulins derived from natural sources or from recombinant sources or can be immunoreactive portions of complete immunoglobulins. Antibodies can exist in a variety of forms, including, for example, Fv, Fab', F(ab')2, and as single chains.

The term "antigenicity" refers to the ability of a substance, such as a protein or peptide, to generate antibodies that specifically bind to it.

The term "epitope" includes any protein determinant capable of specific binding to an antibody or T-cell receptor. Epitope determinants usually consist of chemically active surface groups of a molecule (such as amino acids or sugar side chains, or a combination thereof) and usually have specific three-dimensional structural characteristics as well as specific charge characteristics.

The terms "subtype" or "type" are used interchangeably herein to refer to the genetic variation of the viral antigens that allows one subtype to be distinguished from a different subtype by the immune system. For example, HPV 16 can be distinguished immunologically from HPV 33.

Term "HPV L1 protein" As used herein, the terms "HPV" and "human papillomavirus" refer to non-enveloped double-stranded DNA viruses of the Papillomaviridae family. Their genome is round and about 8 kilobase pairs in size. Most HPVs encode eight major proteins, six located in the "early" region (E1-E2) and two located in the "late" region (L1 (major capsid protein) and L2 (minor capsid protein)). More than 120 HPV types have been identified, and they are designated by numbers (e.g., HPV-16, HPV-18, etc.).

The term "HPV" or "HPV virus" refers to the papillomavirus of the Papillomaviridae family, which is a non-enveloped DNA virus with a double-stranded closed circular DNA genome of approximately 8 kb in size, which can usually be divided into three regions: ① The early region (E), which contains six open reading frames encoding E1, E2, E4-E7 non-structural proteins related to viral replication, transcription and translation, as well as E3 and E8 open reading frames; ② The late region (L) contains reading frames encoding the major capsid protein L1 and the minor capsid protein L2; ③ The long regulatory region (LCR) does not encode any protein, but has the origin of replication and multiple transcription factor binding sites.

The terms "HPV L1 protein" and "HPV L2 protein" refer to proteins encoded by the late region (L) of the HPV gene and synthesized in the late phase of the HPV infection cycle. L1 protein is the major capsid protein and has a molecular weight of 55‑60 kDa. L2 protein is the minor capsid protein. 72 L1 pentamers form the outer shell of the icosahedral HPV virion, enclosing the closed double-stranded DNA minichromosome. L2 protein is located on the inner side of L1 protein.

The term "virus-like particle" refers to a hollow particle containing one or more structural proteins of a virus but without viral nucleic acid.

HPV pseudoviruses utilize the non-specific nucleic acid-encapsulating properties of HPV VLPs, and are formed by encapsulating free DNA or introducing exogenous plasmids with VLPs composed of HPV L1 and L2 expressed intracellularly. It is an ideal HPV in vitro neutralization experimental model.

The "pseudovirus neutralization method" is a method for evaluating the neutralizing activity of antibodies. The immunized animal serum is incubated with a certain amount of pseudovirus and then infects cells. The number of cells will decrease as the neutralizing antibodies in the serum increase. Within a certain range, there can be a linear negative correlation. Therefore, the neutralizing activity of antibodies in the serum can be evaluated by detecting changes in the number of expressing cells.

The term "fragment thereof" or "variant thereof" refers to a portion of the nucleotide or amino acid sequence according to the present invention that is deleted, inserted and/or substituted. Preferably, the fragment or variant of the polypeptide provided by the present invention can induce humoral and/or cellular immune response in animals or humans.

The term "chimeric" means that polypeptide or nucleotide sequences derived from different parent molecules are linked together via amide bonds or 3', 5'-phosphodiester bonds, respectively. Preferably, they are not separated by additional linker sequences but are directly adjacent to each other.

The term "truncation" refers to the removal of one or more amino acids from the N- and/or C-terminus of a polypeptide or the deletion of one or more amino acids within a polypeptide.

The term "nuclear localization sequence" is an amino acid sequence that can guide a protein into the cell nucleus. In some HPV L1 proteins, there is a spacer of 10-14 amino acids between two close basic residues (i.e., nuclear localization sequences) (e.g., one is KRKR, KRKK, KRKRK, KRKKRK, KRVKRRK, etc., and the other is KR, RKR, KRK, etc.). The above basic residues belong to the nuclear localization sequence. In other HPV L1 proteins, the nuclear localization sequence is a close basic residue formed by arginine and/or lysine. The nuclear localization sequence includes but is not limited to the examples of basic residues as described above. See Jun Yang et al., Predicting the Nuclear Localization Signals of 107 Types of HPV L1 Proteins by Bioinformatic Analysis, Genomics, Proteomics & Bioinformatics Volume 4, Issue 1, 2006, Pages 34-41, the entire contents of which are incorporated herein by reference.

The term "functional variant" refers to a version of a polypeptide or protein that has been truncated, mutated, deleted and/or added but still retains the desired activity or characteristic.

"Sequence identity" between two polypeptide or nucleic acid sequences refers to the percentage of the total number of residues that are identical between the sequences and is calculated based on the size of the smaller of the molecules being compared. In calculating percent identity, the sequences being compared are aligned in a manner that produces the largest match between the sequences, and gaps in the alignment, if any, are resolved by a particular algorithm. Preferred computer program methods for determining the identity between two sequences include, but are not limited to, the GCG program package, including GAP, BLASTP, BLASTN, and FASTA (Altschul et al., 1990, J. Mol. Biol. 215: 403-410). The above programs are publicly available from the National Center for Biotechnology Information (NCBI) and other sources. The well-known Smith Waterman algorithm can also be used to determine identity.

Non-critical amino acids can be conservatively replaced without affecting the normal function of the protein. Conservative replacement means replacing an amino acid with an amino acid that is chemically or functionally similar. Conservative replacement tables that provide similar amino acids are well known in the art. For example, in some embodiments, the amino acid groups provided in Tables 1-3 are considered to be mutually conservative replacements.

Table 1 Selected groups of amino acids that are considered to be conservatively substituted with each other in certain embodiments Acidic residue D and E Basic residues K, R and H Hydrophilic uncharged residue S, T, N and Q Aliphatic uncharged residue G, A, V, L, and I Nonpolar uncharged residue C, M and P Aromatic residues F, Y and W

Table 2 Other selected groups of amino acids that are considered to be conservative substitutions of each other in certain embodiments Group 1 A, S and T Group 2 D and E Group 3 N and Q Group 4 R and K Group 5 I, L, and M Group 6 F, Y and W

Table 3 Other selected groups of amino acids that are considered to be conservative substitutions of each other in certain embodiments Group A A and G Group B D and E Group C N and Q Group D R, K and H Group E I, L, M, V Group F F, Y and W Group G S and T Group H C and M

The term "amino acid" refers to the twenty common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cystine (Cys; C); glutamine (Glu; E), glutamine (Gln; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methylamine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valeric acid (Val; V).

As used herein, a "physiologically acceptable carrier" is non-toxic to cells or mammals at the dosage and concentration used. It is usually a pH-buffered aqueous solution, and non-limiting examples include buffers; antioxidants; oligopeptides; proteins; hydrophilic polymers; amino acids; monosaccharides, disaccharides and other carbohydrates; chelating agents; sugar alcohols; salt-forming counterions, such as sodium; and/or non-ionic surfactants.

The term "adjuvant" refers to a compound or mixture that enhances an immune response. In particular, a vaccine may contain an adjuvant. The adjuvant used in the present invention may include, but is not limited to, one or more of the following: a mineral adjuvant composition, an oil-emulsion adjuvant, a saponin adjuvant preparation, a bacterial or microbial derivative.

The term "vector" means a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors as self-replicating nucleic acid structures as well as vectors that integrate into the genome of a host cell into which the vector has been introduced. Certain vectors are capable of directing the expression of a nucleic acid to which such vector is operably linked.

The term "host cell" means a cell into which an exogenous nucleic acid has been introduced, as well as the progeny of such a cell. Host cells include "transformants" (or "transformed cells"), "transfectants" (or "transfected cells"), or "infected bodies" (or "infected cells"), each of which includes the primary transformed, transfected or infected cell and the progeny derived therefrom. Such progeny may not be completely identical to the parent cell in terms of nucleic acid content, and may contain mutations.

The dosage is preferably a "prophylactically effective amount" (prevention herein may be considered treatment, and the two terms are used interchangeably), which is sufficient to show benefit to an individual.

Embodiment

Example 1 Gene construction

Example 1.1: Construction of a chimeric gene in which the HPV6 L1 C-terminus is replaced by the HPV33 L1 C-terminus

1.1.1 Construction of pFB-HPV6L1 as template

Thermo Fisher (formerly Invitrogen (Shanghai) Trading Co., Ltd.) was commissioned to synthesize the HPV6L1 gene, and the synthesized sequence had KpnⅠ and XbaI restriction sites at both ends, and its sequence is shown in SEQ ID NO: 5. The synthesized gene fragment was connected to the pcDNA3 vector (seller Thermo Fisher) through the KpnⅠ and XbaI restriction sites to obtain the plasmid pcDNA3-HPV6-L1 containing the nucleotide sequence encoding the 1-500 amino acids of HPV6L1.

The obtained pcDNA3-HPV6-L1 plasmid was double-digested with KpnⅠ and XbaI to obtain the HPV6L1 (1-500) gene fragment. The fragment was then ligated with the pFastBacTM1 vector (seller: Thermo Fisher) double-digested with KpnⅠ and XbaI to obtain a bacmid vector containing the HPV6L1 (1-500) gene fragment, named pFB-HPV6L1.

1.1.2 Construction of pFB-HPV33L1 as template

Thermo Fisher (formerly Invitrogen (Shanghai) Trading Co., Ltd.) was commissioned to synthesize the HPV33L1 gene, and the two ends of the synthetic sequence had KpnI and XbaI restriction sites, respectively. The gene fragment sequence is shown in SEQ ID NO: 6. The synthesized gene fragment was connected to the pcDNA3 vector (seller Thermo Fisher) through the KpnI and XbaI restriction sites to obtain the plasmid pcDNA3-HPV33-L1 containing the nucleotide sequence encoding the 1-499 amino acids of HPV33L1.

The obtained pcDNA3-HPV33-L1 plasmid was double-digested with KpnI and XbaI to obtain the gene fragment of HPV33L1 (1-499). The fragment was then ligated with the pFastBacTM1 vector (seller: Thermo Fisher) double-digested with KpnI and XbaI to obtain a bacmid vector containing the HPV33L1 (1-499) gene fragment, named pFB-HPV33L1.

1.1.3 Construction of pFB-HPV6L1:33C

The chimeric gene in which the C-terminus of HPV6L1 is replaced by the C-terminus of HPV33L1: the successfully constructed recombinant plasmid pFB-HPV6L1 is used as a gene template, and primers F1 and R1 are used to amplify a gene fragment with a length of 1426 bp. The primer sequence F1 is shown in SEQ ID No: 7, and the primer sequence R1 is shown in SEQ ID No: 8.

The gene fragment includes a gene fragment encoding amino acids 1-469 of HPV6L1, 10 bases overlapping with the gene fragment of amino acids 474-499 of HPV33L1, and a KpnI restriction site (GGTAC^C). The expanded sequence is shown in SEQ ID No: 9:

PCR amplification parameters: 94°C pre-denaturation for 5 min; 98°C denaturation for 10 s, 69°C annealing for 15 s, 72°C 1 kb/1 min, 30 cycles; 72°C extension for 5 min; 16°C termination.

The recombinant plasmid pFB-HPV33L1 was used as a gene template and primers F2 and R2 were used to amplify a gene fragment of 101 bp in length. The primer sequence F2 is shown in SEQ ID No: 10, and the primer sequence R2 is shown in SEQ ID No: 11.

The gene fragment contains a gene fragment of 26 (474-499) amino acids at the C-terminus of HPV33L1, a 10 bp base overlapping with the 1-469 amino acids of the C-terminal gene fragment of HPV6L1, and an XbaI (T^CTAGA) restriction site. The amplified sequence is shown in SEQ ID No: 12.

PCR amplification parameters: 94°C pre-denaturation for 5 min; 98°C denaturation for 10 s, 69°C annealing for 15 s, 72°C 1 kb/1 min, 30 cycles; 72°C extension for 5 min; 16°C termination.

PCR splicing sequence:

The splicing primers are F1 and R2, and the fragments amplified by the above primers (fragments amplified by F1 and R1, and fragments amplified by F2 and R2) are used as templates.

PCR splicing parameters: 94°C pre-denaturation for 5 min; 98°C denaturation for 10 s, 52°C annealing for 15 s, 72°C 1 kb/1 min, for 5 cycles; 98°C denaturation for 10 s, 68°C annealing for 15 s, 72°C 1 kb/1 min, for 25 cycles; 72°C extension for 5 min; 16°C end.

Finally, SEQ ID NO: 4 was obtained, encoding a nucleotide sequence consisting of amino acids 1-469 of HPV6L1 and 26 amino acids (474-499) of the C-terminus of HPV33L1, with KpnI and XbaI restriction sites at both ends (hereinafter referred to as the splicing sequence).

The pFastBacTM1 vector and the splicing sequence fragment were double-digested with KpnI+XbaI, and the splicing sequence was cloned into the pFastBacTM1 vector to obtain the recombinant plasmid pFB-HPV6L1:33C, which is a chimeric gene in which the C-terminus of HPV6L1 is replaced by the C-terminus of HPV33L1.

Example 1.2 Construction of a chimeric gene in which the HPV11L1 C-terminus is replaced by the HPV33L1 C-terminus

The experimental methods and steps are the same as those in Example 1.1, and the relevant sequences are shown in Appendix 2.

Example 1.3 Construction of a chimeric gene in which the HPV16L1 C-terminus is replaced by the HPV33L1 C-terminus

The experimental methods and steps are the same as those in Example 1.1, and the relevant sequences are shown in Appendix 3.

Example 1.4 Construction of a chimeric gene in which the HPV18 L1 C-terminus is replaced by the HPV33 L1 C-terminus

The experimental methods and steps are the same as those in Example 1.1, and the relevant sequences are shown in Appendix 4.

Example 1.5 Construction of a chimeric gene in which the HPV31L1 C-terminus is replaced by the HPV33L1 C-terminus

The experimental methods and steps are the same as those in Example 1.1, and the relevant sequences are shown in Appendix 5.

Example 1.6 Construction of HPV33L1 gene

1.6.1 Preparation of pFB-HPV33L1 gene

The HPV33L1 gene was constructed by gene synthesis and commissioned to Thermo Fisher (formerly Invitrogen (Shanghai) Trading Co., Ltd.). The two ends of the synthetic sequence have KpnⅠ and XbaI restriction sites, respectively. The gene fragment sequence is shown in SEQ ID No: 68. The synthesized gene fragment was connected to the pcDNA3 vector (seller Thermofisher) through the KpnⅠ and XbaI restriction sites to obtain the plasmid pcDNA3-HPV33-L1 containing the nucleotide sequence encoding the 1-499 amino acids of HPV33L1.

The obtained pcDNA3-HPV33-L1 plasmid was double-digested with KpnⅠ and XbaI to obtain the gene fragment of HPV33L1 (1-499). The fragment was then ligated with the pFastBacTM1 vector (seller: Thermofisher) double-digested with KpnⅠ and XbaI to obtain a bacmid vector containing the HPV33L1 (1-499) gene fragment, named pFB-HPV33L1.

Example 1.7 Construction of a chimeric gene in which the HPV35L1 C-terminus is replaced by the HPV33L1 C-terminus

The experimental methods and steps are the same as those in Example 1.1, and the relevant sequences are shown in Appendix 7.

Example 1.8 Construction of a chimeric gene in which the HPV39L1 C-terminus is replaced by the HPV59L1 C-terminus

1.8.1 Construction of pFB-HPV39L1 as template

Thermo Fisher (formerly Invitrogen (Shanghai) Trading Co., Ltd.) was commissioned to synthesize the HPV39L1 gene, and the synthesized sequence had KpnⅠ and XbaI restriction sites at both ends, and its sequence is shown in SEQ ID NO: 86. The synthesized gene fragment was connected to the pcDNA3 vector (seller Thermo Fisher) through the KpnⅠ and XbaI restriction sites to obtain the plasmid pcDNA3-HPV39-L1 containing the nucleotide sequence encoding the 1-505 amino acids of HPV39L1.

The obtained pcDNA3-HPV39-L1 plasmid was double-digested with KpnⅠ and XbaI to obtain the gene fragment of HPV39L1 (1-505). The fragment was then ligated with the pFastBacTM1 vector (seller: Thermo Fisher) double-digested with KpnⅠ and XbaI to obtain a bacmid vector containing the HPV39L1 (1-505) gene fragment, named pFB-HPV39L1.

1.8.2 Construction of pFB-HPV59L1 as template

Thermo Fisher (formerly Invitrogen (Shanghai) Trading Co., Ltd.) was commissioned to synthesize the HPV59L1 gene, and the two ends of the synthetic sequence had KpnI and XbaI restriction sites, respectively. The gene fragment sequence is shown in SEQ ID NO: 87. The synthesized gene fragment was connected to the pcDNA3 vector (seller Thermo Fisher) through the KpnI and XbaI restriction sites to obtain the plasmid pcDNA3-HPV59-L1 containing the nucleotide sequence encoding the 1-508 amino acids of HPV59L1.

The obtained pcDNA3-HPV59-L1 plasmid was double-digested with KpnI and XbaI to obtain the gene fragment of HPV59L1 (1-508). The fragment was then ligated with the pFastBacTM1 vector (seller: Thermo Fisher) double-digested with KpnI and XbaI to obtain a bacmid vector containing the HPV59L1 (1-508) gene fragment, named pFB-HPV59L1.

1.8.3 Construction of pFB-HPV39L1:59C

The chimeric gene in which the C-terminus of HPV39L1 is replaced by the C-terminus of HPV59L1: the successfully constructed recombinant plasmid pFB-HPV39L1 is used as the gene template, and the primers F1 and R1 are used to amplify the gene fragment with a length of 1428 bp. The primer sequence F1 is shown in SEQ ID No: 88, and the primer sequence R1 is shown in SEQ ID No: 89.

The gene fragment includes a gene fragment encoding amino acids 1-469 of HPV39L1, 12 bases overlapping with the gene fragment of amino acids 471-508 of HPV59L1, and a KpnI restriction site (GGTAC^C), and the expanded sequence is shown in SEQ ID No: 90:

PCR amplification parameters: 94°C pre-denaturation for 5 min; 98°C denaturation for 10 s, 69°C annealing for 15 s, 72°C 1 kb/1 min, 30 cycles; 72°C extension for 5 min; 16°C termination.

The recombinant plasmid pFB-HPV59L1 was used as a gene template and primers F2 and R2 were used to amplify a gene fragment of 139 bp in length. The primer sequence F2 is shown in SEQ ID No: 91, and the primer sequence R2 is shown in SEQ ID No: 92.

The gene fragment contains a gene fragment of 38 (471-508) amino acids at the C-terminus of HPV59L1, a 12 bp base overlapping with the 1-469 amino acids of the C-terminal gene fragment of HPV39L1, and an XbaI (T^CTAGA) restriction site. The amplified sequence is shown in SEQ ID No: 93.

PCR amplification parameters: 94°C pre-denaturation for 5 min; 98°C denaturation for 10 s, 69°C annealing for 15 s, 72°C 1 kb/1 min, 30 cycles; 72°C extension for 5 min; 16°C termination.

PCR splicing sequence:

The splicing primers are F1 and R2, and the fragments amplified by the above primers (fragments amplified by F1 and R1, and fragments amplified by F2 and R2) are used as templates.

PCR splicing parameters: 94°C pre-denaturation for 5 min; 98°C denaturation for 10 s, 52°C annealing for 15 s, 72°C 1 kb/1 min, for 5 cycles; 98°C denaturation for 10 s, 68°C annealing for 15 s, 72°C 1 kb/1 min, for 25 cycles; 72°C extension for 5 min; 16°C end.

Finally, SEQ ID NO: 85 was obtained, encoding a nucleotide sequence consisting of amino acids 1-469 of HPV39L1 and 38 amino acids (471-508) at the C-terminus of HPV59L1, with KpnI and XbaI restriction sites at both ends (hereinafter referred to as splicing sequence).

The pFastBacTM1 vector and the splicing sequence fragment were double-digested with KpnI+XbaI, and the splicing sequence was cloned into the pFastBacTM1 vector to obtain the recombinant plasmid pFB-HPV39L1:59C, which is a chimeric gene in which the C-terminus of HPV39L1 is replaced by the C-terminus of HPV59L1.

Example 1.9 Construction of a chimeric gene in which the HPV45L1 C-terminus is replaced by the HPV33L1 C-terminus

The experimental methods and steps are the same as those in Example 1.1, and the relevant sequences are shown in Appendix 9.

Example 1.10 Construction of a chimeric gene in which the HPV51 L1 C-terminus is replaced by the HPV33 L1 C-terminus

The experimental methods and steps are the same as those in Example 1.1, and the relevant sequences are shown in Appendix 10.

Example 1.11 Construction of a chimeric gene in which the HPV52 L1 C-terminus is replaced by the HPV33 L1 C-terminus

The experimental methods and steps are the same as those in Example 1.1, and the relevant sequences are shown in Appendix 11.

Example 1.12 Construction of a chimeric gene in which the HPV56 L1 C-terminus is replaced by the HPV33 L1 C-terminus

The experimental methods and steps are the same as those in Example 1.1, and the relevant sequences are shown in Appendix 12.

Example 1.13 Construction of a chimeric gene in which the HPV58 L1 C-terminus is replaced by the HPV33 L1 C-terminus

The experimental methods and steps are the same as those in Example 1.1, and the relevant sequences are shown in Appendix 13.

Example 1.14 Construction of HPV59L1 gene

Example 1.14.1 Preparation of pFB-HPV59L1 gene

The HPV59L1 gene was constructed by gene synthesis and commissioned to Thermo Fisher (formerly Invitrogen (Shanghai) Trading Co., Ltd.). The two ends of the synthetic sequence have KpnⅠ and XbaI restriction sites, respectively. The gene fragment sequence is shown in SEQ ID No: 162. The synthesized gene fragment was connected to the pcDNA3 vector (seller Thermofisher) through the KpnⅠ and XbaI restriction sites to obtain the plasmid pcDNA3-HPV59-L1 containing the nucleotide sequence encoding the 1-508 amino acids of HPV59L1.

The obtained pcDNA3-HPV59-L1 plasmid was double-digested with KpnⅠ and XbaI to obtain the gene fragment of HPV59L1 (1-508). The fragment was then ligated with the pFastBacTM1 vector (seller: Thermofisher) double-digested with KpnⅠ and XbaI to obtain a bacmid vector containing the HPV59L1 (1-508) gene fragment, named pFB-HPV59L1.

Example 2 Packaging of recombinant bacilli

Example 2.1: HPV 6L1:33C recombinant rod-shaped virus packaging

After the recombinant plasmid of pFB-HPV 6L1:33C constructed in Example 1 was correctly identified and sequenced, it was transformed into DH10Bac bacterial competent cells (Bac-to-Bac® kit, purchased from Thermo Fisher), cultured and expanded at 37°C, and plate streak culture was performed. White plaques were selected and expanded. After culturing overnight, the bacterial liquid was collected and the recombinant bacmid DNA was extracted using the alkaline lysis method.

Use cationic transfection reagent (purchased from Sino Biological) to transfect it into insect cells SF9 for recombinant bacilli virus seed packaging. The specific operation is as follows: a. Take SF9 cells in logarithmic growth phase and inoculate the dish at a density of 0.6×10 ⁶ cells/dish. Place the dish inoculated with SF9 cells at room temperature for 2 hours to adhere to the wall. b. Add 20μL Bacmid DNA of the extracted plasmid to 200μL Grace's Medium (serum-free, no additives, purchased from Gibico) and mix it by inverting 5 times. c. Add 25 μL 0.2x TF1 (transfection reagent, purchased from Sino Biological) dropwise to 200 μL Grace's Medium and mix gently. d. Mix b and c. Incubate at room temperature for 15-45 minutes. e. When the DNA is incubated with cellfectin (purchased from Sino Biological), discard the cell supernatant and add Grace Medium without serum supplement 0.8mL/dish. f. Add the DNA and transfection reagent complex incubated in step d to the dish. g. Incubate at 27℃ for 2 hours. h. Discard the cell culture medium and add 2.5 mL/dish of complete growth medium (SCD6 SF +10% FBS) (SCD6 SF purchased from Sino Biological, FBS purchased from Gibico). i. Incubate at 27℃ for 7 days and observe whether there is virus infection.

After transfection, the virus supernatant is collected after the cells produce obvious pathological changes, and the culture is generally 7-11 days. The virus supernatant is collected aseptically with a pipette, which is the HPV6L1:33C P1 virus strain. The HPV6L1:33C P1 virus strain is used to infect SF9 cells at a ratio of 1:50 (V/V). The infection density of SF9 cells is 2×10 ⁶ cells/mL. The cells are cultured and expanded at 27℃ for 3 days, and centrifuged at 1000g±200g at room temperature for 10 minutes. The collected virus supernatant is the P2 virus, which can be used for infection production.

Example 2.2: HPV 11L1:33C recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.3: HPV 16L1:33C recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.4: HPV 18L1:33C recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.5: HPV 31L1:33C recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.6: HPV 33L1 recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.7: HPV 35L1:33C recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.8: HPV 39L1:59C recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.9: HPV 45L1:33C recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.10: HPV 51L1:33C recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.11: HPV 52L1:33C recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.12: HPV 56L1:33C recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.13: HPV 58L1:33C recombinant rod-shaped virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 2.14: HPV 59L1 recombinant bacilli virus packaging

The experimental methods and steps are the same as those in Example 2.1.

Example 3 Expression of chimeric proteins or proteins

Example 3.1: HPV 6L1:33C expression production

High Five cells were infected with the bacilli containing the HPV 6L1:33C recombinant gene obtained in Example 2 at an infection ratio of 1:200 (V/V). The cell pellet was collected by centrifugation at 1000g±100g at room temperature. The cell pellet was ultrasonically lysed using PBS or MOPS buffer (pH 6.0-7.0, salt concentration 100 mM-1M), and the cell pellet was broken by low-temperature ultrasonication for 3 minutes. The cell pellet was centrifuged at a centrifugal force greater than 10000g for 10 minutes, and the supernatant was collected after centrifugation and detected by SDS-PAGE electrophoresis. Lane 1: Marker (Marker is 7 purified proteins with molecular weight ranging from 14.4 to 116 kDa, produced by Thermo Scientific); Lane 2: Cell lysate; Lane 3: Supernatant collected after centrifugation of the lysate.

The results are shown in Figure 1A. The yield of HPV 6L1:33C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is about 56 KD, which can be used for large-scale production.

Example 3.2: HPV 11L1:33C expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1B. The yield of HPV 11L1:33C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is about 56 KD, which can be used for large-scale production.

Example 3.3: HPV 16L1:33C expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1C. The yield of HPV 16L1:33C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is about 56 KD, which can be used for large-scale production.

Example 3.4: HPV 18L1:33C expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1D. The yield of HPV 18L1:33C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is approximately 56 KD, which can be used for large-scale production.

Example 3.5: HPV 31L1:33C expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1E. The yield of HPV 31L1:33C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is about 56 KD, which can be used for large-scale production.

Example 3.6: HPV 33L1 expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1F. The yield of HPV 33L1 L1 protein prepared by this method is greater than 100 mg/L, and the protein size is about 56 KD, which can be used for large-scale production.

Example 3.7: HPV 35L1:33C expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1G. The yield of HPV 35L1:33C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is approximately 56 KD, which can be used for large-scale production.

Example 3.8: HPV 39L1:59C expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1H. The yield of HPV 39L1:59C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is approximately 56 KD, which can be used for large-scale production.

Example 3.9: HPV 45L1:33C expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1I. The yield of HPV 45L1:33C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is about 56 KD, which can be used for large-scale production.

Example 3.10: HPV 51L1:33C expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1J. The yield of HPV 51L1:33C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is approximately 56 KD, which can be used for large-scale production.

Example 3.11: HPV 52L1:33C expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1K. The yield of HPV 52L1:33C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is approximately 56 KD, which can be used for large-scale production.

Example 3.12: HPV 56L1:33C expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1L. The yield of HPV 56L1:33C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is about 56 KD, which can be used for large-scale production.

Example 3.13: HPV 58L1:33C expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1M. The yield of HPV 58L1:33C L1 protein prepared by this method is greater than 100 mg/L, and the protein size is approximately 56 KD, which can be used for large-scale production.

Example 3.14: HPV 59L1 expression production

The experimental methods and steps are the same as those in Example 3.1.

The results are shown in Figure 1N. The yield of HPV 59L1 L1 protein prepared by this method is greater than 100 mg/L, and the protein size is about 56 KD, which can be used for large-scale production.

Example 4 Preparation of Purified Virus-Like Particles

Example 4.1: Preparation of purified HPV 6L1:33C virus-like particles

The HPV 6L1:33C virus-like particles were purified by a two-step chromatography method, namely, the HS-MMA method. The supernatant collected in Example 3 was purified to obtain highly pure virus-like particles.

The first step of chromatography: Medium: POROS ^® 50 HS strong cation exchange medium produced by Thermo Fisher was used. Medium volume: medium volume 150mL, linear flow rate 30mL/min. Chromatographic conditions: equilibration buffer (pH6.2, salt concentration of 50mM phosphate, 0.5M sodium chloride); washing buffer (salt concentration of 50mM phosphate, 0.75M sodium chloride, pH6.2;) The chromatography column was first equilibrated with 5 CV of buffer and then loaded with sample. After loading, the impurities were eluted with 5 CV of equilibration buffer and washing buffer respectively. Elution conditions: pH 6.2, elution salt concentration is 1.25M sodium chloride, and elution is performed using 50mM phosphate buffer containing 50mM arginine hydrochloride.

Second step of chromatography: Medium: MMA ion exchange medium produced by Shanghai Boglon Company was used. Medium volume: medium volume 150mL, linear flow rate 30mL/min. Chromatographic conditions: equilibrium buffer 50mM PB, 1.25M NaCl, pH6.2. The chromatography column was first equilibrated with 4CV equilibrium buffer, and then the sample was loaded. After the loading was completed, the impurities were washed with 5 CV equilibrium buffer, and then the target protein was eluted with elution buffer to collect the protein. Elution conditions: 100mM NaAC, 150mM NaCl, 0.01% Tween 80, pH4.5.

Example 4.2: Preparation of purified HPV 11L1:33C virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.3: Preparation of purified HPV 16L1:33C virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.4: Purification of HPV 18L1:33C virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.5: Purification of HPV 31L1:33C virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.6: Purification of HPV 33L1 virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.7: Purification of HPV 35L1:33C virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.8: Purification of HPV 39L1:59C virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.9: Preparation of purified HPV 45L1:33C virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.10: Preparation of purified HPV 51L1:33C virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.11: Preparation of purified HPV 52L1:33C virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.12: Preparation of purified HPV 56L1:33C virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.13: Preparation of purified HPV 58L1:33C virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 4.14: Preparation of purified HPV 59L1 virus-like particles

The experimental methods and steps are the same as those in Example 4.1.

Example 5 Morphological Detection of Virus-like Particles

Example 5.1: Morphological Detection of HPV 6L1:33C Virus-like Particles

Take 10μL sample for transmission electron microscope observation. Fix the sample on the carbon spray copper mesh for 2 minutes, remove the residual liquid with filter paper, and then use phospho-tungsten acid (Beijing Zhongjing Instrument Technology Co., Ltd., concentration 2%, pH 6.5) to stain twice, each time for 30 seconds, remove the residual staining liquid with filter paper, and observe under the transmission electron microscope after drying. The transmission electron microscope (brand: Hitachi, model: H-7650) is 80KV and the magnification is 80,000 times.

The results of electron microscopy observation are shown in Figure 2A. As shown in Figure 2A, the C-terminally modified HPV 6L1:33C can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.2: Morphological Detection of HPV 11L1:33C Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2B. As shown in Figure 2B, the C-terminally modified HPV 11L1:33C can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.3: Morphological Detection of HPV 16L1:33C Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2C. As shown in Figure 2C, the C-terminally modified HPV 16L1:33C can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.4: Morphological Detection of HPV 18L1:33C Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2D. As shown in Figure 2D, the C-terminally modified HPV 18L1:33C can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.5: Morphological Detection of HPV 31L1:33C Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2E. As shown in Figure 2E, the C-terminally modified HPV 31L1:33C can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.6: Morphological Detection of HPV 33L1 Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2F. As shown in Figure 2F, the C-terminally modified HPV 33L1 can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.7: Morphological Detection of HPV 35L1:33C Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2G. As shown in Figure 2G, the C-terminally modified HPV 35L1:33C can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.8: Morphological Detection of HPV 39L1:59C Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2H. As shown in Figure 2H, the C-terminally modified HPV 39L1:59C can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.9: Morphological Detection of HPV 45L1:33C Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2I. As shown in Figure 2I, the C-terminally modified HPV 45L1:33C can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.10: Morphological Detection of HPV 51L1:33C Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2J. As can be seen from Figure 2J, the C-terminally modified HPV 51L1:33C can form virus-like particles of uniform size with an average diameter of about 60nm.

Example 5.11: Morphological Detection of HPV 52L1:33C Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2K. As shown in Figure 2K, the C-terminally modified HPV 52L1:33C can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.12: Morphological Detection of HPV 56L1:33C Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2L. As shown in Figure 2L, the C-terminally modified HPV 56L1:33C can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.13: Morphological Detection of HPV 58L1:33C Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2M. As shown in Figure 2M, the C-terminally modified HPV 58L1:33C can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 5.14: Morphological Detection of HPV 59L1 Virus-like Particles

The experimental methods and steps are the same as those in Example 5.1.

The results of electron microscopy observation are shown in Figure 2N. As shown in Figure 2N, the C-terminally modified HPV 59L1 can form virus-like particles of uniform size with an average diameter of about 60 nm.

Example 6 Evaluation of the immunogenicity of virus-like particles in animals

Example 6.1: Evaluation of the immunogenicity of HPV 6L1:33C virus-like particles in animals

6.1.1 Model establishment of pseudovirus neutralization cells

Since HPV is difficult to culture in vitro and has strong host specificity, it is difficult to reproduce in organisms other than humans and there is a lack of suitable animal models. Therefore, it is necessary to establish a suitable and effective in vitro neutralization experimental model for evaluating the immune protection of vaccines.

HPV pseudovirus is an ideal HPV in vitro neutralization experimental model: HPV VLP has the property of non-specifically encapsulating nucleic acids, and VLPs composed of HPV L1 and L2 expressed intracellularly encapsulate free DNA or are introduced into exogenous plasmids to form HPV pseudoviruses.

The pseudovirus neutralization method is used to analyze the immunogenicity of animal serum samples after immunization. HPV6 virus-like particle samples can produce neutralizing antibodies against HPV6 after immunization of animals, which can neutralize HPV6 pseudoviruses. After incubating the immunized animal serum with a certain amount of pseudovirus and then infecting cells, the cells that can express GFP fluorescence will decrease as the neutralizing antibodies in the serum increase. There can be a linear negative correlation within a certain range. Therefore, the neutralizing activity of antibodies in the serum can be evaluated by detecting changes in the number of cells expressing GFP.

Pseudovirus construction method: HPV6 type pCMV3-3-HPV6L1+L2 (L1 sequence from Uniprot P69898, L2 sequence from Uniprot Q84297) plasmid (purchased from Sino Biological) and fluorescent plasmid (PSEU-GFP Spark, purchased from Sino Biological) were co-transfected into 293FT adherent cells (purchased from Thermo Fisher). For specific methods, please refer to the literature (Pastrana D V, Buck CB, Pang Y S, Thompson C D, Castle P E, FitzGerald P C, Kjaer S K, Lowy D R, Schiller J T.Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. J Virology 2004,321:205-216.). The pseudovirus supernatant was collected and packaged, and stored in a -80°C refrigerator for later use.

6.1.2 HPV 6L1:33C virus-like particles for animal immune protection

Mouse immunization procedure: HPV 6L1:33C virus-like particles were adsorbed on aluminum phosphate adjuvant. After mixing, 200µL was taken for immunization of mice. The immunization dose for each mouse was 0.15µg. Ten mice were immunized. Mice were immunized with diluted samples on the 0th, 7th and 21st days of the experiment. A blank serum control group was set up at the same time. On the 28th day of the experiment, the eyeballs of mice were removed to collect blood, and the serum was separated for pseudovirus neutralization titer detection.

Mouse EC ₅₀ test: Mouse serum was inactivated at 56°C for 30 minutes, centrifuged at 6000g, and the supernatant was taken for detection after 5 minutes. 4-8 hours before the test, 293FT cells were plated in a 96-well plate at a density of 15,000 cells/well and cultured in a carbon dioxide incubator at 37°C and 5% CO _2. The immunized mouse serum and blank control serum were serially diluted with neutralizing medium and mixed with the HPV6 pseudovirus prepared in 6.1 at a volume ratio of 1:1. After incubation in a refrigerator at 2~8°C for 1 hour, 100μL/well was added to the 293FT cells plated 4-8 hours in advance, with 2 replicates for each sample, and blank serum control wells, pseudovirus positive control wells, and negative control wells were set up at the same time. After adding the sample, the cells were cultured in a carbon dioxide incubator at 37°C and 5% _CO2 for 62-96 hours, and then the cells were scanned and photographed and counted in an enzyme-linked spot analyzer (model: S6 Universal-V Analyzer, manufacturer: CTL). The neutralization inhibition rate of each mouse serum sample was calculated, and the maximum serum dilution factor when the serum neutralization inhibition rate was 50% was calculated according to the Reed-Muench method, that is, the half effective dilution factor _EC50 .

The results of HPV6 serum pseudovirus neutralization titer test are shown in Table 4.

Table 4 Mouse serum neutralization titer test results EC ₅₀ ( GMT±SEM ) HPV type _EC50 value Type 6 4948±1831 Notes: 1. Number of animals, N=10; 2. GMT (Geometric Mean Titer): Geometric mean titer; 3. SEM (Standard Error of Mean): Standard error.

The above test results show that the HPV 6L1:33C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.2: Evaluation of the immunogenicity of HPV 11L1:33C virus-like particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was derived from Uniprot P04012, and the L2 sequence was derived from Uniprot P04013.

The results of HPV11 serum pseudovirus neutralization titer test are shown in Table 5.

surface 5 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 11 15024±8400

The above test results show that the HPV 11L1:33C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.3: Evaluation of the immunogenicity of HPV 16L1:33C virus-like particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was derived from Uniprot P03101, and the L2 sequence was derived from Uniprot P03107.

The results of HPV16 serum pseudovirus neutralization titer test are shown in Table 6.

surface 6 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 16 32449±7224

The above test results show that the HPV 16L1:33C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.4: Evaluation of the immunogenicity of HPV 18L1:33C virus-like particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was derived from Uniprot Q80B70, and the L2 sequence was derived from Uniprot P06793.

The results of HPV18 serum pseudovirus neutralization titer test are shown in Table 7.

surface 7 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 18 18480±4051

The above test results show that the HPV 18L1:33C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.5: Evaluation of the immunogenicity of HPV 31L1:33C virus-like particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was derived from Uniprot P17388, and the L2 sequence was derived from Uniprot P17389.

The results of HPV31 serum pseudovirus neutralization titer test are shown in Table 8.

surface 8 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 31 5210±1147

The above test results show that the HPV 31L1:33C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.6: Evaluation of the immunogenicity of HPV 33L1-like virus particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was derived from Uniprot P06416, and the L2 sequence was derived from Uniprot P06418.

The results of HPV33 serum pseudovirus neutralization titer test are shown in Table 9.

surface 9 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ）

The above test results show that the HPV 33L1 virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection. HPV type _EC50 value Type 33 4666±1555

Example 6.7: Evaluation of the immunogenicity of HPV 35L1:33C virus-like particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was derived from Uniprot P27232, and the L2 sequence was derived from Uniprot P27234.

The results of HPV35 serum pseudovirus neutralization titer test are shown in Table 10.

surface 10 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 35 2293±1448

The above test results show that the HPV 35L1:33C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.8: Evaluation of the immunogenicity of HPV 39L1:59C virus-like particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was derived from Uniprot P24838, and the L2 sequence was derived from Uniprot P24839.

The results of HPV39 serum pseudovirus neutralization titer test are shown in Table 11.

surface 11 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 39 25526±5857

The above test results show that the HPV 39L1:59C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.9: Evaluation of the immunogenicity of HPV 45L1:33C virus-like particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was derived from Uniprot P36741, and the L2 sequence was derived from Uniprot P36761.

The results of HPV45 serum pseudovirus neutralization titer test are shown in Table 12.

surface 12 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 45 755+935

The above test results show that the HPV 45L1:33C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.10: Evaluation of the immunogenicity of HPV 51L1:33C virus-like particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was from Uniprot P26536, and the L2 sequence was from Uniprot P26539.

The results of HPV51 serum pseudovirus neutralization titer test are shown in Table 13.

surface 13 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 51 5528±1572

The above test results show that the HPV 51L1:33C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.11: Evaluation of the immunogenicity of HPV 52L1:33C virus-like particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was from Uniprot Q05138, and the L2 sequence was from Uniprot F8S4U2.

The results of HPV52 serum pseudovirus neutralization titer test are shown in Table 14.

surface 14 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 52 19019±8604

The above test results show that the HPV 52L1:33C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.12: Evaluation of the immunogenicity of HPV 56L1:33C virus-like particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was from Uniprot P36743, and the L2 sequence was from Uniprot P36765.

The results of HPV56 serum pseudovirus neutralization titer test are shown in Table 15.

surface 15 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 56 2497±612

The above test results show that the HPV 56L1:33C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.13: Evaluation of the immunogenicity of HPV 58L1:33C virus-like particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was derived from Uniprot P26535, and the L2 sequence was derived from Uniprot B6ZB12.

The results of HPV58 serum pseudovirus neutralization titer test are shown in Table 16.

surface 16 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 58 19939±8459

The above test results show that the HPV 58L1:33C virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.14: Evaluation of the immunogenicity of HPV 59L1-like virus particles in animals

The experimental methods and steps were the same as those in Example 6.1. The L1 sequence was from Uniprot Q81971, and the L2 sequence was from Uniprot Q81970.

The results of HPV59 serum pseudovirus neutralization titer test are shown in Table 17.

surface 17 Mouse serum neutralization titer test results EC ₅₀ （ GMT±SEM ） HPV type _EC50 value Type 59 1344±335

The above test results show that the HPV 59L1 virus-like particles prepared by the present invention have good immunogenicity, can produce high-titer neutralizing antibodies in animals, and can be used to prepare vaccines for preventing HPV infection.

Example 6.15: Evaluation of the immunogenicity of 14-valent virus-like particle immune composition in animals

Mouse immunization procedure

The 14 types (HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) of virus-like particles as described above were serially diluted with aluminum phosphate blank adjuvant under sterile conditions (the HPV type with a single dose of 20 μg in the sample was used as the standard for dilution, and the sample of this type was diluted 80 times to 0.5 μg/mL, and the dilution of other types of samples varied with the changes in the proportions of each type), and 200 μL was taken for immunization of mice. The immunization dose for each mouse is shown in Table 18. SPF female Balb/c mice aged 6-8 weeks were divided into experimental group and control group with 10 mice in each group. The mice in each group were immunized with diluted samples on the 0th, 7th and 21st days of the experiment. One group of mice was immunized with the sample, and a blank serum control group was set up at the same time. On the 28th day of the experiment, the eyeballs of the mice were removed to collect blood, and the serum was separated for pseudovirus neutralization titer detection.

Table 18 Immunization dose of each type of HPV vaccine per mouse (µg) HPV type 6 11 16 18 31 33 45 52 58 35 39 51 56 59 Dosage 0.15 0.2 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Pseudovirus neutralization assay to detect the neutralization titer of mouse serum after immunization

Mouse serum was inactivated at 56 degrees for 30 minutes, centrifuged at 6000g, and the supernatant was taken for detection after 5 minutes. 4-8 hours before the detection, 293FT cells were plated in a 96-well plate at a density of 15,000 cells/well and cultured in a carbon dioxide incubator at 37°C and 5% _CO2 . The immunized mouse serum and blank control serum were diluted in series with neutralization medium and mixed with 14 pre-diluted pseudoviruses (14 HPV pseudoviruses include 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 types, and their preparation is shown in Examples 6.1-6.14, respectively) at a volume ratio of 1:1. After incubation in a refrigerator at 2~8℃ for 1 hour, 100μL/well was added to the 293FT cells plated 4-8 hours in advance. Each sample had 2 replicate wells, and blank serum control wells, pseudovirus positive control wells and negative control wells were set up at the same time. After the cells were added, they were cultured in a carbon dioxide incubator at 37℃ and 5% _CO2 for 62-96 hours, and then scanned and counted in an enzyme-linked spot analyzer (model: S6 Universal-V Analyzer, manufacturer: CTL). By calculating the neutralization inhibition rate of each mouse serum sample, the maximum serum dilution multiple when the serum neutralization inhibition rate was 50% was calculated according to the Reed-Muench method, that is, the half effective dilution multiple _EC50 . The test results are shown in Figure 3.

As shown in Figure 3, the 14-valent virus-like particle immune composition can produce good neutralizing antibodies and can be used to prepare a vaccine to prevent HPV infection.

Comparative Example 1: Expression of C-terminally truncated HPV16L1 (1-474)

The inventors tried to truncate the C-terminus of HPV16L1 by 31 amino acids and named it HPV16L1 (1-474) (SEQ ID NO: 27). However, the study found that the truncated HPV16L1 (1-474) protein had high expression levels but poor protein solubility and was difficult to extract and purify. The specific expression and extraction results are shown in Figure 4.

Although the present invention has been described in detail above by way of illustration and examples, the purpose is to facilitate understanding. A person having ordinary knowledge in the technical field to which the present invention belongs can obviously make various modifications and improvements to the technical solution of the present invention without deviating from the spirit or scope of the attached patent application.

Appendix 1: Sequence Listing - Chimeric Human Papillomavirus Type 6 L1 Protein SEQ ID No: 1 0601 HPV Amino acid sequence 1-469 of type 6 L1 protein MWRPSDSTVYVPPPNPVSKVVATDAYVTRTNIFYHASSSRLLAVGHPYFSIKRANKTVVPKVSGYQYRVFKVVLPDPNKFALPDSSLFDPTTQRLVWACTGLEV GRGQPLGVGVSGHPFLNKYDDVENSGSGGNPGQDNRVNVGMDYKQTQLCMVGCAPPLGEHWGKGKQCTNTPVQAGDCPPLELITSVIQDGDMVDTGFGAMNFADLQTNKSDVPIDICGTTCK YPDYLQMAADPYGDRLFFFLRKEQMFARHFFNRAGEVGEPVPDTLIIKGSGNRTSVGSSIYVNTPSGSLVSSEAQLFNKPYWLQKAQGHNNGICWGNQLFVTVVDTTRSTNMTLCASVTTS STYTNSDYKEYMRHVEEYDLQFIFQLCSITLSAEVMAYIHTMNPSVLEDWNFGLSPPPNGTLEDTYRYVQSQAITCQKPTPEKEKPDPYKNLSFWEVNLKEKFSSELDQYPLGRKFLLQSGY SEQ ID No: 2 0602 HPV 33 L1 protein amino acid sequence 474-499 KAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 3 0603 Chimeric HPV Amino acid sequence of type 6 L1 protein MWRPSDSTVYVPPPNPVSKVVATDAYVTRTNIFYHASSSRLLAVGHPYFSIKRANKTVVPKVSGYQYRVFKVVLPDPNKFALPDSSLFDPTTQRLVWACTGLEVGRGQPLGVGV SGHPFLNKYDDVENSGSGGNPGQDNRVNVGMDYKQTQLCMVGCAPPLGEHWGKGKQCTNTPVQAGDCPPLELITSVIQDGDMVDTGFGAMNFADLQTNKSDVPIDICGTTCKYPDYLQMAADPYGDR LFFFLRKEQMFARHFFNRAGEVGEPVPDTLIIKGSGNRTSVGSSIYVNTPSGSLVSSEAQLFNKPYWLQKAQGHNNGICWGNQLFVTVVDTTRSTNMTLCASVTTSSTYTNSDYKEYMRHVEEYDLQ FIFQLCSITLSAEVMAYIHTMNPSVLEDWNFGLSPPPNGTLEDTYRYVQSQAITCQKPTPEKEKPDPYKNLSFWEVNLKEKFSSELDQYPLGRKFLLQSGYKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 4 0604 Chimeric HPV type 6 L1 protein nucleotide sequence SEQ ID No: 5 0605 Synthetic HPV6L1 gene SEQ ID No: 6 0606 Synthetic HPV33L1 gene SEQ ID No: 7 0607 HPV6L1 F1 CTTGGTACCATGTGGAGACCATCTGACAGCACAGT SEQ ID No: 8 0608 HPV6L1 R1GCTTGGCTTTGTAGCCAGATTGGAGCAGGAACTTCC SEQ ID No: 9 0609 HPV6L1 amplification sequence 1 CTT GGTACC ¹ ATGTGGAGACCATCTGACAGCACAGTCTATGTGCCTCCTCCAAACCCTGTGAGCAAGGTG GTGGCTACAGATGCCTATGTGACCAGGACCAACATCTTCTACCATGCCTCCTCCAGCAGA CTGCTGGCTGTGGGACACCCATACTTCAGCATCAAGAGGGCTAACAAGACAGTGGTGCCA AAGGTGTCTGGCTACCAATACAGGGTGTTCAAGGTGGTGCTGCCTGACCCAAACAAGTTT GCCCTGCCTGACTCCTCCCTGTTTGACCCAACCACCCAGAGACTGGTGTGGGCTTGTACT GGATTGGAGGTGGGCAGGGGACAACCACTGGGAGTGGGAGTGTCTGGACACCCATTCCTG AACAAATATGATGATGTGGAGAACTCTGGCTCTGGAGGCAACCCTGGACAAGACAACAGG GTGAATGTGGGGATGGACTACAAGCAGACCCAACTTTGTATGGTGGGCTGTGCCCCTCCA CTGGGAGAACACTGGGGCAAGGGCAAGCAGTGTACCAACACACCTGTCCAGGCTGGAGAC TGTCCTCCATTGGAACTGATTACCTCTGTGATTCAGGATGGAGATATGGTGGACACAGGC TTTGGAGCTATGAACTTTGCTGACCTCCAAACCAACAAGTCTGATGTGCCAATTGACATC TGTGGCACCACTTGTAAATACCCTGACTACCTCCAAATGGCTGCTGACCCATATGGAGAC AGACTGTTCTTCTTCCTGAGGAAGGAACAGATGTTTGCCAGACACTTCTTCACAGGGCT GGAGAGGTGGGAGAACCTGTGCCTGACACCCTGATTATCAAGGGCTCTGGCAACAGGACC TCTGTGGGCTCCAGCATCTATGTGAACACACCATCTGGCTCCCTGTGTCCTCTGAGGCT CAACTTTTCAACAAGCCATACTGGCTCCAAAAGGCTCAAGGACACAACAATGGCATCTGT TGGGGCAACCAACTTTTTGTGACAGTGGTGGACACCACCAGGAGCACCAATATGACCCTG TGTGCCTCTGTGACCACCTCCAGCACCTACACCAACTCTGACTACAAGGAATATATGAGG CATGTGGAGGAATATGACCTCCAATTCATCTTCCAACTTTGTAGCATCACCCTGTCTGCT GAGGTGATGGCTTACATCCACACAATGAACCCATCTGTGTTGGAGGACTGGAACTTTGGA CTGAGCCCTCCTCCAAATGGCACCTTGGAGGACACCTACAGATATGTCCAGAGCCAGGCT ATCACTTGTCAGAAGCCAACACCTGAGAAGGAGAAGCCTGACCCATACAAGAACCTGTCC TTCTGGGAGGTGAACCTGAAAGAGAAGTTCTCCTCTGAACTGGACCAATACCCACTGGGC AGGAAGTTCCTGCTCCAATCTGGCTAC ² AAAGCCAAGC ³ 1: KpnⅠ restriction site; 2: gene fragment encoding amino acids 1-469 of HPV6L1; 3: 10 bases overlapping with the gene fragment of amino acids 474-499 of HPV33L1. SEQ ID No: 10 0610 HPV6L1 F2 ATCTGGCTACAAAGCCAAGCCAAAACTGAAAAGGG SEQ ID No: 11 0611 HPV6L1 R2 CTGTCTAGATTTACTTCTTCACCTTCTTCCTCTTGGC SEQ ID No: 12 0612 HPV6L1 amplified sequence 2 ATCTGGCTAC ¹ AAAGCCAAGCCAAAACTGAAAAGGGCTGCCCCAACCAGCACCAGG ACCTCCTCTGCCAAGAGGAAGAAGGTGAAGAAG ² TAA A TCTAGA ³ CAG. 1: 10 bp bases overlapping with the C-terminal gene fragment of 1-469 amino acids of HPV6L1; 2: The gene fragment of 26 (474-499) amino acids at the C-terminus of HPV33L1; 3: XbaI restriction site. SEQ ID No: 13 0613 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK

Appendix 2: Sequence Listing - Chimeric Human Papillomavirus Type 11 L1 Protein SEQ ID No: 14 1101 HPV Amino acid sequence 1-470 of type 11 L1 protein MWRPSDSTVYVPPPNPVSKVVATDAYVKRTNIFYHASSSRLLAVGHPYYSIKKVNKTVVPKVSGYQYRVFKVVLPDPNKFALPDSSLFDPTTQRLVWACTGLEV GRGQPLGVGVSGHPLLNKYDDVENSGGYGGNPGQDNRVNVGMDYKQTQLCMVGCAPPLGEHWGKGTQCSNTSVQNGDCPPLELITSVIQDGDMVDTGFGAMNFADLQTNKSDVPLDICGTVC KYPDYLQMAADPYGDRLFFYLRKEQMFARHFFNRAGTVGEPVPDDLLVKGGNNRSSVASSIYVHTPSGSLVSSEAQLFNKPYWLQKAQGHNNGICWGNHLFVTVVDTTRSTNMTLCASVSKS ATYTNSDYKEYMRHVEEFDLQFIFQLCSITLSAEVMAYIHTMNPSVLEDWNFGLSPPPNGTLEDTYRYVQSQAITCQKPTPEKEKQDPYKDMSFWEVNLKEKFSSELDQFPLGRKFLLQSGY SEQ ID No: 15 1102 HPV 33 L1 protein amino acid sequence 474-499 KAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 16 1103 Chimeric HPV Amino acid sequence of type 11 L1 protein MWRPSDSTVYVPPPNPVSKVVATDAYVKRTNIFYHASSSRLLAVGHPYYSIKKVNKTVVPKVSGYQYRVFKVVLPDPNKFALPDSSLFDPTTQRLVWACTGLEVGRGQPLGVGV SGHPLLNKYDDVENSGGYGGNPGQDNRVNVGMDYKQTQLCMVGCAPPLGEHWGKGTQCSNTSVQNGDCPPLELITSVIQDGDMVDTGFGAMNFADLQTNKSDVPLDICGTVCKYPDYLQMAADPYGD RLFFYLRKEQMFARHFFNRAGTVGEPVPDDLLVKGGNNRSSVASSIYVHTPSGSLVSSEAQLFNKPYWLQKAQGHNNGICWGNHLFVTVVDTTRSTNMTLCASVSKSATYTNSDYKEYMRHVEEFDL QFIFQLCSITLSAEVMAYIHTMNPSVLEDWNFGLSPPPNGTLEDTYRYVQSQAITCQKPTPEKEKQDPYKDMSFWEVNLKEKFSSELDQFPLGRKFLLQSGYKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 17 1104 Nucleotide sequence of chimeric HPV type 11 L1 protein SEQ ID No: 18 1105 Synthetic HPV11L1 gene SEQ ID No: 19 1106 Synthetic HPV33L1 gene SEQ ID No: 20 1107 HPV11L1 F1 CTTGGTACCATGTGGAGACCATCTGACAGCACAGT SEQ ID No: 21 1108 HPV11L1 R1GCTTGGCTTTGTAGCCAGATTGGAGCAGGAACTTCC SEQ ID No: 22 1109 HPV11L1 amplified sequence 1 CTT GGTACC ¹ ATGTGGAGACCATCTGACAGCACAGTCTATGTGCCTCCTCCAAACCCTGTGAGCAAGGTGGTGGCTACAGATGCCTATGTGAAGAGGACCAACATCTTCTACCATGCCTCCTCCAGCAGACTGCTGGCTGTGGGACACCCATACTACAGCATCAAGAAGGTGAACAAGACAGTGGT GCCAAAGGTGTCTGGCTACCAATACAGGGTGTTCAAGGTGGTGCTGCCTGACCCAAACAAGTTTGCCCTGCCTGACTCCTCCCTGTTTGACCCAACCACCCAGAGACTGGTGTGGGCTTGTACTGGATTGGAGGTGGGCAGGGGACAACCACTGGGAGTGGGAGTGTCTGGACACC CACTGCTGAACAAATATGATGATGTGGAGAACTCTGGAGGCTATGGAGGCAACCCTGGACAAGACAACAGGGTGAATGTGGGGATGGACTACAAGCAGACCCAACTTTGTATGGTGGGCTGTGCCCTCCACTGGGAGAACACTGGGGCAAGGGCACCCAGTGTAGCAACACCTCT GTCCAGAATGGAGACTGTCCTCCATTGGAACTGATTACCTCTGTGATTCAGGATGGAGATATGGTGGACACAGGCTTTGGAGCTATGAACTTTGCTGACCTCCAAACCAACAAGTCTGATGTGCCACTGGACATCTGTGGCACAGTGTGTAAATACCCTGACTACCTCCAAATGGCT GCTGACCCATATGGAGACAGACTGTTCTTCTACCTGAGGAAGGAACAGATGTTTGCCAGACACTTCTTCAACAGGGCTGGCACAGTGGGAGAACCTGTGCCTGATGACCTGCTGGTGAAGGGAGGCAACACAGGTCCTCTGTGGCATCCAGCATCTATGTGCATACACCATCTGG CTCCCTGGTGTCCTCTGAGGCTCAACTTTTCAACAAGCCATACTGGCTCCAAAAGGCTCAAGGACACAACAATGGCATCTGTTGGGGCAACCACCTGTTTGTGACAGTGGTGGACACCACCAGGAGCACCAATATGACCCTGTGTGCCTCTGTGAGCAAGTCTGCCACCTACACCA ACTCTGACTACAAGGAATATATGAGGCATGTGGAGGAGTTTGACCTCCAATTCATCTTCCAACTTTGTAGCATCACCCTGTCTGCTGAGGTGATGGCTTACATCCACACAATGAACCCATCTGTGTTGGAGGACTGGAACTTTGGACTGAGCCCTCCTCCAAATGGCACCTTGGAG GACACCTACAGATATGTCCAGAGCCAGGCTATCACTTGTCAGAAGCCAACACCTGAGAAGGAGAAGCAGGACCCATACAAGGATATGAGTTTCTGGGAGGTGAACCTGAAAGAGAAGTTCTCCTCTGAACTGGACCAGTTTCCACTGGGCAGGAAGTTCCTGCTCCAATCTGGCTAC ² AAAGCCAAGC ³ 1: KpnⅠ restriction site; 2: Gene fragment encoding amino acids 1-470 of HPV11L1; 3: 10 bases overlapping with the gene fragment encoding amino acids 474-499 of HPV33L1. SEQ ID No: 23 1110 HPV11L1 F2 ATCTGGCTACAAAGCCAAGCCAAAACTGAAAAGGG SEQ ID No: 24 1111 HPV11L1 R2 CTGTCTAGATTTACTTCTTCACCTTCTTCCTCTTGGC SEQ ID No: 25 1112 HPV11L1 amplified sequence 2 ATCTGGCTAC ¹ AAAGCCAAGCCAAAACTGAAAAGGGCTGCCCCAACCAGCACCAGG ACCTCCTCTGCCAAGAGGAAGAAGGTGAAGAAG ² TAA A TCTAGA ³ CAG. 1: 10 bp bases overlapping with the C-terminal gene fragment of 1-470 amino acids of HPV11L1; 2: The gene fragment of 26 amino acids (474-499) at the C-terminus of HPV33L1; 3: XbaI restriction site. SEQ ID No: 26 1113 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK

Appendix 3: Sequence Listing - Chimeric Human Papillomavirus Type 16 L1 Protein SEQ ID No: 27 1601 HPV Amino acid sequence 1-474 of type 16 L1 protein MSLWLPSEATVYLPPVPVSKVVSTDEYVARTNIYYHAGTSRLLAVGHPYFPIKKPNNNKILVPKVSGLQYRVFRIHLPDPNKFGFPDTSFYNPDTQRLVWACVGV EVGRGQPLGVGISGHPLLNKLDDTENASAYAANAGVDNRECISMDYKQTQLCLIGCKPPIGEHWGKGSPCTNVAVNPGDCPPLELINTVIQDGDMVDTGFGAMDFTTLQANKSEVPLDICTSI CKYPDYIKMVSEPYGDSLFFYLRREQMFVRHLFNRAGAVGENVPDDLYIKGSGSTANLASSNYFPTPSGSMVTSDAQIFNKPYWLQRAQGHNNGICWGNQLFVTVVDTTRSTNMSLCAAISTS ETTYKNTNFKEYLRHGEEYDLQFIFQLCKITLTADVMTYIHSMNSTILEDWNFGLQPPPGGTLEDTYRFVTSQAIACQKHTPPAPKEDPLKKYTFWEVNLKEKFSADLDQFPLGRKFLLQAGL SEQ ID No: 28 1602 HPV 33 L1 protein amino acid sequence 474-499 KAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 29 1603 Chimeric HPV Amino acid sequence of type 16 L1 protein MSLWLPSEATVYLPPVPVSKVVSTDEYVARTNIYYHAGTSRLLAVGHPYFPIKKPNNNKILVPKVSGLQYRVFRIHLPDPNKFGFPDTSFYNPDTQRLVWACVGVEVGRGQPLGV GISGHPLLNKLDDTENASAYAANAGVDNRECISMDYKQTQLCLIGCKPPIGEHWGKGSPCTNVAVNPGDCPPLELINTVIQDGDMVDTGFGAMDFTTLQANKSEVPLDICTSICKYPDYIKMVSEPYG DSLFFYLRREQMFVRHLFNRAGAVGENVPDDLYIKGSGSTANLASSNYFPTPSGSMVTSDAQIFNKPYWLQRAQGHNNGICWGNQLFVTVVDTTRSTNMSLCAAISTSETTYKNTNFKEYLRHGEEYD LQFIFQLCKITLTADVMTYIHSMNSTILEDWNFGLQPPPGGTLEDTYRFVTSQAIACQKHTPPAPKEDPLKKYTFWEVNLKEKFSADLDQFPLGRKFLLQAGLKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 30 1604 Nucleotide sequence of chimeric HPV type 16 L1 protein SEQ ID No: 31 1605 Synthetic HPV16L1 gene SEQ ID No: 32 1606 Synthetic HPV33L1 gene SEQ ID No: 33 1607 HPV16L1 F1 CTTGGTACCATGAGTCTGTGGCTGCCATCTGAGG SEQ ID No: 34 1608 HPV16L1 R1 GCTTGGCTTTCAGTCCTGCTTGGAGCAGGAACTTCC SEQ ID No: 35 1609 HPV16L1 extension sequence 1 CTT GGTACC ¹ ATGAGTCTGTGGCTGCCATCTGAGGCTACAGTCTACCTGCCTCCTGTGCCTGTGAGCAAGGTGGTGAGCACAGATGAATATGTGGCAAGGACCAACATCTACTACCATGCTGGCACCAGCAGACTGCTGGCTGTGGGACACCCATACTTTCCAATCAAGAAGCCAAACAACAACAAGATTCTGGTGCCAAAGGTGTCTGGACTCCAATACAGGGTGTTCAGGATTCACCTGCCTGACCCAAACAAGTTTGGCTTTCCTGACACCTCCTTCTACAACCCTGACACCCAGAGACTGGTGTGGGCTTGTGTGGGAGTGGAGGTGGGCAGGGGACAACCACTGGGAGTGGGCATCTCTGGACACCCACTGCTGAACAAACTGGATGACACAGAGAATGCCTCTGCCTATGCTGCCAATGCTGGAGTGGACAACAGGGAGTGTATCAGTATGGACTACAAGCAGACCCAACTTTGTCTGATTGGCTGTAAGCCTCCAATTGGAGAACACTGGGGCAAGGGCAGCCCATGTACCAATGTGGCTGTGAACCCTGGAGACTGTCCTCCATTGGAACTGATAAACACAGTGATTCAGGATGGAGATATGGTGGACACAGGCTTTGGAGCTATGGACTTCACCACCCTCCAAGCCAACAAGTCTGAGGTGCCACTGGACATCTGTACCAGCATCTGTAAATACCCTGACTACATCAAGATGGTGTCTGAACCATATGGAGACTCCCTGTTCTTCTACCTGAGGAGGGAACAGATGTTTGTGAGACACCTGTTCAACAGGGCTGGAGCAGTGGGAGAGAATGTGCCTGATGACCTCTACATCAAGGGCTCTGGCAGCACAGCCAACCTGGCATCCAGCAACTACTTTCCAACACCATCTGGCAGTATGGTGACCTCTGATGCCCAGATTTTCAACAAGCCATACTGGCTCCAAAGGGCTCAAGGACACAACAATGGCATCTGTTGGGGCAACCAACTTTTTGTGACAGTGG TGGACACCACCAGGAGCACCAATATGAGTCTGTGTGCTGCCATCAGCACCTCTGAGACCACCTACAAGAACACCAACTTCAAGGAATACCTGAGACATGGAGAGGAATATGACCTCCAATTCATCTTCCAACTTTGTAAGATTACCCTGACAGCAGATGTGATGACCTACATCCACAGTATGAACAGCACCATCTTGGAGGACTGGAACTT TGGACTCCAACCTCCTCCTGGAGGCACCTTGGAGGACACCTACAGGTTTGTGACCAGCCAGGCTATTGCCTGTCAGAAACACACACCTCCTGCCCCAAAGGAGGACCCACTGAAAAAATACACCTTCTGGGAGGTGAACCTGAAAGAGAAGTTCTCTGCTGACCTGGACCAGTTTCCACTGGGCAGGAAGTTCCTGCTCCAAGCAGGACTG ² AAAGCCAAGC ³ 1: KpnⅠ restriction site; 2: The gene segment encoding amino acids 1-474 of HPV16L1; 3: 10 bases overlapping with the gene segment encoding amino acids 474-499 of HPV33L1. SEQ ID No: 36 1610 HPV16L1 F2 AGCAGGACTGAAAGCCAAGCCAAAACTGAAAAGGG SEQ ID No: 37 1611 HPV16L1 R2 CTGTCTAGATTTACTTCTTCACCTTCTTCCTTCTTGG SEQ ID No: 38 1612 HPV16L1 amplified sequence 2 AGCAGGACTG ¹ AAAGCCAAGCCAAAACTGAAAAGGGCTGCCCCAACCAGCACCAGG ACCTCCTCTGCCAAGAGGAAGAAGGTGAAGAAG ² TAA A TCTAGA ³ CAG. 1: 10 bp bases overlapping with the C-terminal gene fragment of amino acids 1-474 of HPV16L1; 2: The gene fragment of 26 amino acids (474-499) at the C-terminus of HPV33L1; 3: XbaI restriction site. SEQ ID No: 39 1613 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK

Appendix 4: Sequence Listing - Chimeric Human Papillomavirus Type 18 L1 Protein SEQ ID No: 40 1801 HPV Amino acid sequence 1-470 of type 18 L1 protein MALWRPSDNTVYLPPPSVARVVNTDDYVTRTSIFYHAGSSRLLTVGNPYFRVPAGGGNKQDIPKVSAYQYRVFRVQLPDPNKFGLPDTSIYNPETQRLVWACAG VEIGRGQPLGVGLSGHPFYNKLDDTESSHAATSNVSEDVRDNVSVDYKQTQLCILGCAPAIGEHWAKGTACKSRPLSQGDCPPLELKNTVLEDGDMVDTGYGAMDFSTLQDTKCEVPLDICQ SICKYPDYLQMSADPYGDSMFFCLRREQLFARHFWNRAGTMGDTVPQSLYIKGTGMRASPGSCVYSPSPSGSIVTSDSQLFNKPYWLHKAQGHNNGVCWHNQLFVTVVDTTRSTNLTICAST QSPVPGQYDATKFKQYSRHVEEYDLQFIFQLCTITLTADVMSYIHSMNSSILEDWNFGVPPPPTTSLVDTYRFVQSVAITCQKDAAPAENKDPYDKLKFWNVDLKEKFSLDLDQYPLGRKFL SEQ ID No: 41 1802 HPV 33 L1 protein amino acid sequence 474-499 KAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 42 1803 Chimeric HPV Amino acid sequence of type 18 L1 protein MALWRPSDNTVYLPPPSVARVVNTDDYVTRTSIFYHAGSSRLLTVGNPYFRVPAGGGNKQDIPKVSAYQYRVFRVQLPDPNKFGLPDTSIYNPETQRLVWACAGVEIGRGQPLG VGLSGHPFYNKLDDTESSHAATSNVSEDVRDNVSVDYKQTQLCILGCAPAIGEHWAKGTACKSRPLSQGDCPPLELKNTVLEDGDMVDTGYGAMDFSTLQDTKCEVPLDICQSICKYPDYLQMSADP YGDSMFFCLRREQLFARHFWNRAGTMGDTVPQSLYIKGTGMRASPGSCVYSPSPSGSIVTSDSQLFNKPYWLHKAQGHNNGVCWHNQLFVTVVDTTRSTNLTICASTQSPVPGQYDATKFKQYSRHV EEYDLQFIFQLCTITLTADVMSYIHSMNSSILEDWNFGVPPPPTTSLVDTYRFVQSVAITCQKDAAPAENKDPYDKLKFWNVDLKEKFSLDLDQYPLGRKFLKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 43 1804 Nucleotide sequence of chimeric HPV type 18 L1 protein SEQ ID No: 44 1805 Synthetic HPV18L1 gene SEQ ID No: 45 1806 Synthetic HPV33L1 gene ctcgagctc SEQ ID No: 46 1807 HPV18L1 F1 CTTGGTACCATGGCCCTCTGGAGACCATCCGATA SEQ ID No: 47 1808 HPV18L1 R1 GCTTGGCTTTGAGGAACTTCCTGCCCAATGGGTAC SEQ ID No: 48 1809 HPV18L1 extension sequence 1 CTT GGTACC ¹ ATGGCCCTCTGGAGACCATCCGATAACACAGTGTACTTGCCCCCACCCAGCGTCGCCCGGGTGGTGAACACAGACGACTACGTCACCAGAACCTCAATCTTCTACCACGCCGGGTCCAGCCGGCTGCTGACCGTGGGCAACCCCTACTTCCGCGTGCCCGCCGGCGGCGGAAACAAACAAGACATCCCCAAAGTCAGCGCCTATCAGTACCGGGTGTTCCGCGTCCAACTGCCCGATCCCAACAAGTTCGGCCTGCCCGACACCTCCATCTACAACCCCGAGACCCAGAGGCTGGTCTGGGCTTGCGCCGGCGTCGAGATCGGGAGGGGCCAACCCCTGGGCGTGGGGTTGTCCGGCCACCCCTTCTACAACAAGCTGGACGATACCGAGTCCAGCCACGCAGCAACCAGCAACGTCTCCGAAGATGTGCGCGATAACGTCAGCGTGGACTACAAACAAACCCAACTGTGCATCCTGGGATGCGCACCCGCCATCGGCGAGCATTGGGCCAAGGGGACCGCCTGCAAGAGCAGGCCCCTGAGCCAAGGGGACTGTCCACCCCTGGAGTTGAAGAATACCGTGCTCGAGGACGGCGACATGGTGGACACCGGCTACGGCGCTATGGATTTCTCCACCCTCCAGGACACCAAGTGCGAAGTGCCCCTCGACATCTGCCAAAGCATCTGCAAGTACCCCGACTACCTCCAGATGAGCGCCGACCCCTACGGCGACAGCATGTTCTTCTGTCTCAGAAGGGAACAATTGTTCGCCCGCCACTTCTGGAACCGGGCCGGCACAATGGGAGATACAGTCCCCCAGAGCCTGTACATCAAGGGGACCGGAATGAGGGCCAGCCCCGGGTCCTGCGTCTACAGCCCAAGCCCCTCCGGGAGCATCGTCACAAGCGATAGCCAACTCTTCAACAAGCCCTACTGGCTCCACAAAGCCCAAGGCCACAATAACGGGGTGTGTTGGCACAACCAGCTGTTCGTGACCGTCG TGGACACAACCAGGTCCACAAACCTGACCATCTGCGCCAGCACCCAAAGCCCCGTGCCCGGCCAGTACGACGCCACAAAGTTCAAACAATACTCTCGGCACGTGGAAGAGTACGACCTCCAATTCATCTTCCAACTCTGCACCATCACCCTCACCGCCGACGTGATGAGCTACATCCACTCCATGAACTCCTCCATCCTGGAAGA CTGGAATTTCGGCGTGCCACCACCCCCTACCACCTCCCTCGTCGACACCTACAGATTCGTGCAGAGCGTGGCCATCACATGCCAGAAAGACGCCGCCCCCGCCGAGAACAAAGACCCATACGACAAACTGAAATTCTGGAACGTCGACCTGAAAGAGAAATTCAGCCTGGATCTGGACCAGTACCCATTGGGCAGGAAGTTCCTC ² AAAGCCAAGC ³ 1: KpnⅠ restriction site; 2: Gene fragment encoding 1-470 amino acids of HPV18L1; 3: 10 bases overlapping with the gene fragment of amino acids 474-499 of HPV33L1. SEQ ID No: 49 1810 HPV18L1 F2GAAGTTCCTCAAAGCCAAGCCAAAACTGAAAAGGG SEQ ID No: 50 1811 HPV18L1 R2 CTGTCTAGATTTACTTCTTCACCTTCTTCCTTCTTGG SEQ ID No: 51 1812 HPV18L1 amplified sequence 2 GAAGTTCCTC ¹ AAAGCCAAGCCAAAACTGAAAAGGGCTGCCCCAACCAGCACCAGG ACCTCCTCTGCCAAGAGGAAGAAGGTGAAGAAG ² TAA A TCTAGA ³ CAG . 1: 10 bp bases overlapping with the C-terminal gene fragment of 1-470 amino acids of HPV18L1; 2: The gene fragment of 26 (474-499) amino acids at the C-terminus of HPV33L1; 3: XbaI restriction site. SEQ ID No: 52 1813 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK

Appendix 5: Sequence Listing - Chimeric Human Papillomavirus Type 31 L1 Protein SEQ ID No: 53 3101 HPV Amino acid sequence 1-475 of type 31 L1 protein MSLWRPSEATVYLPPVPVSKVVSTDEYVTRTNIYYHAGSARLLTVGHPYYSIPKSDNPKKIVVPKVSGLQYRVFRVRLPDPNKFGFPDTSFYNPETQRLVWACVG LEVGRGQPLGVGISGHPLLNKFDDTENSNRYAGGPGTDNRECISMDYKQTQLCLLGCKPPIGEHWGKGSPCSNNAITPGDCPPLELKNSVIQDGDMVDTGFGAMDFTALQDTKSNVPLDICNS ICKYPDYLKMVAEPYGDTLFFYLRREQMFVRHFFNRSGTVGESVPTDLYIKGSGSTATLANSTYFPTPSGSMVTSDAQIFNKPYWMQRAQGHNNGICWGNQLFVTVVDTTRSTNMSVCAAIAN SDTTFKSSNFKEYLRHGEEFDLQFIFQLCKITLSADIMTYIHSMNPAILEDWNFGLTTPPSGSLEDTYRFVTSQAITCQKSAPQKPKEDPFKDYVFWEVNLKEKFSADLDQFPLGRKFLLQAGY SEQ ID No: 54 3102 HPV 33 L1 protein amino acid sequence 474-499 KAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 55 3103 Chimeric HPV Amino acid sequence of type 31 L1 protein MSLWRPSEATVYLPPVPVSKVVSTDEYVTRTNIYYHAGSARLLTVGHPYYSIPKSDNPKKIVVPKVSGLQYRVFRVRLPDPNKFGFPDTSFYNPETQRLVWACVGLEVGRGQPLG VGISGHPLLNKFDDTENSNRYAGGPGTDNRECISMDYKQTQLCLLGCKPPIGEHWGKGSPCSNNAITPGDCPPLELKNSVIQDGDMVDTGFGAMDFTALQDTKSNVPLDICNSICKYPDYLKMVAEPYG DTLFFYLRREQMFVRHFFNRSGTVGESVPTDLYIKGSGSTATLANSTYFPTPSGSMVTSDAQIFNKPYWMQRAQGHNNGICWGNQLFVTVVDTTRSTNMSVCAAIANSDTTFKSSNFKEYLRHGEEFD LQFIFQLCKITLSADIMTYIHSMNPAILEDWNFGLTTPPSGSLEDTYRFVTSQAITCQKSAPQKPKEDPFKDYVFWEVNLKEKFSADLDQFPLGRKFLLQAGYKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 56 3104 Chimeric HPV type 31 L1 protein nucleotide sequence SEQ ID No: 57 3105 Synthetic HPV31L1 gene SEQ ID No: 58 3106 Synthetic HPV33L1 gene SEQ ID No: 59 3107 HPV31L1 F1 CTTGGTACCATGAGCCTGTGGAGGCCCAGCGAG SEQ ID No: 60 3108 HPV31L1 R1GCTTGGCTTTGTAGCCGGCCTGCAGCAGGAACTTCCTG SEQ ID No: 61 3109 HPV31L1 extension sequence 1 CTT GGTACC ¹ ATGAGCCTGTGGAGGCCCAGCGAGGCCACCGTGTACCTGCCCCCCGTGCCCGTGAGCAAGGTGGTGAGCACCGACGAGTACGTGACCAGGACCAACATCTACTACCACGCCGGCAGCGCCAGGCTGCTGACCGTGGGCCACCCCTACTACAGCATCCCCAAGAGCGACAACCCCAAGAAGATCGTGGTGCCCAAGGTGAGCGGCCTGCAGTACAGGGTGTTCAGGGTGAGGCTGCCCGACCCCAACAAGTTCGGCTTCCCCGACACCAGCTTCTACAACCCCGAGACCCAGAGGCTGGTGTGGGCCTGCGTGGGCCTGGAGGTGGGCAGGGGCCAGCCCCTGGGCGTGGGCATCAGCGGCCACCCCCTGCTGAACAAGTTCGACGACACCGAGAACAGCAACAGGTACGCCGGCGGCCCCGGCACCGACAACAGGGAGTGCATCAGCATGGACTACAAGCAGACCCAGCTGTGCCTGCTGGGCTGCAAGCCCCCCATCGGCGAGCACTGGGGCAAGGGCAGCCCCTGCAGCAACAACGCCATCACCCCCGGCGACTGCCCCCCCCTGGAGCTGAAGAACAGCGTGATCCAGGACGGCGACATGGTGGACACCGGCTTCGGCGCCATGGACTTCACCGCCCTGCAGGACACCAAGAGCAACGTGCCCCTGGACATCTGCAACAGCATCTGCAAGTACCCCGACTACCTGAAGATGGTGGCCGAGCCCTACGGCGACACCCTGTTCTTCTACCTGAGGAGGGAGCAGATGTTCGTGAGGCACTTCTTCAACAGGAGCGGCACCGTGGGCGAGAGCGTGCCCACCGACCTGTACATCAAGGGCAGCGGCAGCACCGCCACCCTGGCCAACAGCACCTACTTCCCCACCCCCAGCGGCAGCATGGTGACCAGCGACGCCCAGATCTTCAACAAGCCCTACTGGATGCAGAGGGCCCAGGGCCACAACAACGGCATCTGCTGGGGCAACCAGCTGTTCGTGACCG TGGTGGACACCACCAGGAGCACCAACATGAGCGTGTGCGCCGCCATCGCCAACAGCGACACCACCTTCAAGAGCAGCAACTTCAAGGAGTACCTGAGGCACGGCGAGGAGTTCGACCTGCAGTTCATCTTCCAGCTGTGCAAGATCACCCTGAGCGCCGACATCATGACCTACATCCACAGCATGAACCCCGCCATCCTGGAGGACTGGAAC TTCGGCCTGACCCCCCCCAGCGGCAGCCTGGAGGACACCTACAGGTTCGTGACCAGCCAGGCCATCACCTGCCAGAAGTCCGCCCCCCAGAAGCCCAAGGAGGACCTTCAAGGACTACGTGTTCTGGGAGGTGAACCTGAAGGAGAAGTTCAGCGCCGACCTGGACCAGTTCCCCCTGGGCAGGAAGTTCCTGCTGCAGGCCGGCTAC ² AAAGCCAAGC ³ 1: KpnⅠ restriction site; 2: The gene segment encoding amino acids 1-475 of HPV31L1; 3: 10 bases overlapping with the gene segment encoding amino acids 474-499 of HPV33L1. SEQ ID No: 62 3110 HPV31L1 F2 GGCCGGCTACAAAGCCAAGCCAAAACTGAAAAGGG SEQ ID No: 63 3111 HPV31L1 R2 CTGTCTAGATTTACTTCTTCACCTTCTTCCTCTTGGCAGAG SEQ ID No: 64 3112 HPV31L1 amplified sequence 2 GGCCGGCTAC ¹ AAAGCCAAGCCAAAACTGAAAAGGGCTGCCCCAACCAGCACCAGG ACCTCCTCTGCCAAGAGGAAGAAGGTGAAGAAG ² TAA A TCTAGA ³ CAG. 1: 10 bp bases overlapping with the C-terminal gene fragment of 1-475 amino acids of HPV31L1; 2: The gene fragment of 26 amino acids (474-499) at the C-terminus of HPV33L1; 3: XbaI restriction site. SEQ ID No: 65 3113 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK

Appendix 6: Sequence Listing - Human Papillomavirus Type 33 L1 Protein SEQ ID No: 66 3301 HPV Amino acid sequence of type 33 L1 protein MSVWRPSEATVYLPPVPVSKVVSTDEYVSRTSIYYYAGSSRLLAVGHPYFSIKNPTNAKKLLVPKVSGLQYRVFRVRLPDPNKFGFPDTSFYNPDTQRLVWACVGLEIGRGQPLG VGISGHPLLNKFDDTETGNKYPGQPGADNRECLSMDYKQTQLCLLGCKPPTGEHWGKGVACTNAAPANDCPPLELINTIIEDGDMVDTGFGCMDFKTLQANKSDVPIDICGSTCKYPDYLKMTSEPYG DSLFFFLRREQMFVRHFFNRAGTLGEAVPDDLYIKGSGTTASIQSSAFFPTPSGSMVTSESQLFNKPYWLQRAQGHNNGICWGNQVFVTVVDTTRSTNMTLCTQVTSDSTYKNENFKEYIRHVEEYDL QFVFQLCKVTLTAEVMTYIHAMNPDILEDWQFGLTPPPSASLQDTYRFVTSQAITCQKTVPPKEDPLGKYTFWEVDLKEKFSADLDQFPLGRKFLLQAGLKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 67 3302 Nucleotide sequence of HPV type 33 L1 protein SEQ ID No: 68 3303 Synthetic HPV33L1 gene

Appendix 7: Sequence Listing - Chimeric Human Papillomavirus Type 35 L1 Protein SEQ ID No: 69 3501 HPV Amino acid sequence 1-472 of type 35 L1 protein MSLWRSNEATVYLPPVSVSKVVSTDEYVTRTNIYYHAGSSRLLAVGHPYYAIKKQDSNKIAVPKVSGLQYRVFRVKLPDPNKFGFPDTSFYDPASQRLVWACTG VEVGRGQPLGVGISGHPLLNKLDDTENSNKYVGNSGTDNRECISMDYKQTQLCLIGCRPPIGEHWGKGTPCNANQVKAGECPPLELLNTVLQDGDMVDTGFGAMDFTTLQANKSDVPLDICSS ICKYPDYLKMVSEPYGDMLFFYLRREQMFVRHLFNRAGTVGETVPADLYIKGTTGTLPSTSYFPTPSGSMVTSDAQIFNKPYWLQRAQGHNNGICWSNQLFVTVVDTTRSTNMSVCSAVSSS DSTYKNDNFKEYLRHGEEYDLQFIFQLCKITLTADVMTYIHSMNPSILEDWNFGLTPPPSGTLEDTYRYVTSQAVTCQKPSAPKPKDDPLKNYTFWEVDLKEKFSADLDQFPLGRKFLLQAGL SEQ ID No: 70 3502 HPV 33 L1 protein amino acid sequence 474-499 KAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 71 3503 Chimeric HPV Amino acid sequence of type 35 L1 protein MSLWRSNEATVYLPPVSVSKVVSTDEYVTRTNIYYHAGSSRLLAVGHPYYAIKKQDSNKIAVPKVSGLQYRVFRVKLPDPNKFGFPDTSFYDPASQRLVWACTGVEVGRGQPLG VGISGHPLLNKLDDTENSNKYVGNSGTDDNRECISMDYKQTQLCLIGCRPPIGEHWGKGTPCNANQVKAGECPPLELLNTVLQDGDMVDTGFGAMDFTTLQANKSDVPLDICSSICKYPDYLKMVSEPY GDMLFFYLRREQMFVRHLFNRAGTVGETVPADLYIKGTTGTLPSTSYFPTPSGSMVTSDAQIFNKPYWLQRAQGHNNGICWSNQLFVTVVDTTRSTNMSVCSAVSSSDSTYKNDNFKEYLRHGEEYDL QFIFQLCKITLTADVMTYIHSMNPSILEDWNFGLTPPPSGTLEDTYRYVTSQAVTCQKPSAPKPKDDPLKNYTFWEVDLKEKFSADLDQFPLGRKFLLQAGLKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 72 3504 Chimeric HPV type 35 L1 protein nucleotide sequence SEQ ID No: 73 3505 Synthetic HPV35L1 gene SEQ ID No: 74 3506 Synthetic HPV33L1 gene SEQ ID No: 75 3507 HPV35L1 F1 CTTGGTACCATGAGTCTGTGGAGGAGCAATGAGG SEQ ID No: 76 3508 HPV35L1 R1 GCTTGGCTTTCAGTCCTGCTTGGAGCAGGAACTTCC SEQ ID No: 77 3509 HPV35L1 extension sequence 1 CTT GGTACC ¹ ATGAGTCTGTGGAGGAGCAATGAGGCTACAGTCTACCTGCCTCCTGTGTCTGTGAGCAAGGTGGTGAGCACAGATGAATATGTGACCAGGACCAACATCTACTACCATGCTGGCTCCAGCAGACTGCTGGCTGTGGGACACCCATACTATGCCATCAAGAAGCAGGACAGCAACAAGATTGCTGTGCCAAAGGTGTCTGGACTCCAATACAGGGTGTTCAGGGTGAAACTGCCTGACCCAAACAAGTTTGGCTTTCCTGACACCTCCTTCTATGACCCTGCCAGCCAGAGACTGGTGTGGGCTTGTACTGGAGTGGAGGTGGGCAGGGGACAACCACTGGGAGTGGGCATCTCTGGACACCCACTGCTGAACAAACTGGATGACACAGAGAACAGCAACAAATATGTGGGCAACTCTGGCACAGACAACAGGGAGTGTATCAGTATGGACTACAAGCAGACCCAACTTTGTCTGATTGGCTGTAGACCTCCAATTGGAGAACACTGGGGCAAGGGCACACCATGTAATGCCAACCAGGTGAAGGCTGGAGAGTGTCCTCCATTGGAACTGCTGAACACAGTGCTCCAAGATGGAGATATGGTGGACACAGGCTTTGGAGCTATGGACTTCACCACCCTCCAAGCCAACAAGTCTGATGTGCCACTGGACATCTGTTCCAGCATCTGTAAATACCCTGACTACCTGAAAATGGTGTCTGAACCATATGGAGATATGCTGTTCTTCTACCTGAGGAGGGAACAGATGTTTGTGAGACACCTGTTCAACAGGGCTGGCACAGTGGGAGAGACAGTGCCTGCTGACCTCTACATCAAGGGCACCACAGGCACCCTGCCAAGCACCTCCTACTTTCCAACACCATCTGGCAGTATGGTGACCTCTGATGCCCAGATTTTCAACAAGCCATACTGGCTCCAAAGGGCTCAAGGACACAACAATGGCATCTGTTGGAGCAACCAACTTTTTGTGACAGTGGTGGACA CCACCAGGAGCACCAATATGAGTGTGTTCTGCTGTGTCCTCCTCTGACAGCACCTACAAGAATGACAACTTCAAGGAATACCTGAGACATGGAGAGGAATATGACCTCCAATTCATCTTCCAACTTTGTAAGATTACCCTGACAGCAGATGTGATGACCTACATCCACAGTATGAACCCAAGCATCTTGGAGGACTGGAACTTTGG ACTGACACCTCCTCCATCTGGCACCTTGGAGGACACCTACAGATATGTGACCAGCCAGGCTGTGACTTGTCAGAAGCCATCTGCCCCAAAGCCAAAGGATGACCCACTGAAAAACTACACCTTCTGGGAGGTGGACCTGAAAGAGAAGTTCTCTGCTGACCTGGACCAGTTTCCACTGGGCAGGAAGTTCCTGCTCCAAGCAGGACTG ² AAAGCCAAGC ³ 1: KpnⅠ restriction site; 2: The gene segment encoding amino acids 1-472 of HPV35L1; 3: 10 bases overlapping with the gene segment encoding amino acids 474-499 of HPV33L1. SEQ ID No: 78 3510 HPV35L1 F2 AGCAGGACTGAAAGCCAAGCCAAAACTGAAAGGG SEQ ID No: 79 3511 HPV35L1 R2 CTGTCTAGATTTACTTCTTCACCTTCTTCCTTCTTGG SEQ ID No: 80 3512 HPV35L1 amplified sequence 2 AGCAGGACTG ¹ AAAGCCAAGCCAAAACTGAAAAGGGCTGCCCCAACCAGCACCAGG ACCTCCTCTGCCAAGAGGAAGAAGGTGAAGAAG ² TAA A TCTAGA ³ CAG. 1: 10 bp bases overlapping with the C-terminal gene fragment of amino acids 1-472 of HPV35L1; 2: The gene fragment of 26 amino acids (474-499) at the C-terminus of HPV33L1; 3: XbaI restriction site. SEQ ID No: 81 3513 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK

Appendix 8: Sequence Listing - Chimeric Human Papillomavirus Type 39 L1 Protein SEQ ID No: 82 3901 HPV Amino acid sequence 1-469 of type 39 L1 protein MAMWRSSDSMVYLPPPSVAKVVNTDDYVTRTGIYYYAGSSRLLTVGHPYFKVGMNGGRKQDIPKVSAYQYRVFRVTLPDPNKFSIPDASLYNPETQRLVWACV GVEVGRGQPLGVGISGHPLYNRQDDTENSPFSSTNKDSRDNVSVDYKQTQLCIIGCVPAIGEHWGKGKACKPNNVSTGDCPPLELVNTPIEDGDMIDTGYGAMDFGALQETKSEVPLDICQ SICKYPDYLQMSADVYGDSMFFCLRREQLFARHFWNRGGMVGDAIPAQLYIKGTDIRANPGSSVYCPSPSGSMVTSDSQLFNKPYWLHKAQGHNNGICWHNQLFLTVVDTTRSTNFTLSTSI ESSIPSTYDPSKFKEYTRHVEEYDLQFIFQLCTVTLTTDVMSYIHTMNSSILDNWNFAVAPPPSASLVDTYRYLQSAAITCQKDAPAPEKKDPYDGLKFWNVDLREKFSLELDQFPLGRKFL SEQ ID No: 83 3902 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK SEQ ID No: 84 3903 Chimeric HPV Amino acid sequence of type 39 L1 protein MAMWRSSDSMVYLPPPSVAKVVNTDDYVTRTGIYYYAGSSRLLTVGHPYFKVGMNGGRKQDIPKVSAYQYRVFRVTLPDPNKFSIPDASLYNPETQRLVWACVGVEVGRGQPLGVGI SGHPLYNRQDDTENSPFSSTNKDSRDNVSVDYKQTQLCIIGCVPAIGEHWGKGKACKPNNVSTGDCPPLELVNTPIEDGDMIDTGYGAMDFGALQETKSEVPLDICQSICKYPDYLQMSADVYGDSMFF CLRREQLFARHFWNRGGMVGDAIPAQLYIKGTDIRANPGSSVYCPSPSGSMVTSDSQLFNKPYWLHKAQGHNNGICWHNQLFLTVVDTTRSTNFTLSTSIESSIPSTYDPSKFKEYTRHVEEYDLQFIFQ LCTVTLTTDVMSYIHTMNSSILDNWNFAVAPPPSASLVDTYRYLQSAAITCQKDAPAPEKKDPYDGLKFWNVDLREKFSLELDQFPLGRKFLLQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK SEQ ID No: 85 3904 Chimeric HPV type 39 L1 protein nucleotide sequence SEQ ID No: 86 3905 Synthetic HPV39L1 gene SEQ ID No: 87 3906 Synthetic HPV59L1 gene ctcgagctc SEQ ID No: 88 3907 HPV39L1 F1 CTTGGTACCATGGCTATGTGGAGGTCCTCTGACAGTAT SEQ ID No: 89 3908 HPV39L1 R1TCCAAGTTGGAGCAGGAACTTCCTGCCCAGTGGAAACT SEQ ID No: 90 3909 HPV39L1 extension sequence 1 CTT GGTACC ¹ ATGGCTATGTGGAGGTCCTCTGACAGTATGGTCTACCTGCCTCCTCCATCTGTGGCTAAGGTGGTGAACACAGATGACTATGTGACCAGGACAGGCATCTACTACTATGCTGGCTCCAGCAGACTGCTGACAGTGGGACACCCATACTTCAAGGTGGGGATGAATGGAGGCAGGAAGCAGGACATCCCAAAGGTGTCTGCCTACCAATACAGGGTGTTCAGGGTGACCCTGCCTGACCCAAACAAGTTCAGCATCCCTGATGCCTCCCTCTACAACCCTGAGACCCAGAGACTGGTGTGGGCTTGTGTGGGAGTGGAGGTGGGCAGGGGACAACCACTGGGAGTGGGCATCTCTGGACACCCACTCTACAACAGACAGGATGACACAGAGAACAGCCCATTCTCCAGCACCACCAACAAGGACAGCAGGGACAATGTGTCTGTGGACTACAAGCAGACCCAACTTTGTATCATTGGCTGTGTGCCTGCCATTGGAGAACACTGGGGCAAGGGCAAGGCTTGTAAGCCAAACAATGTGAGCACAGGAGACTGTCCTCCATTGGAACTGGTGAACACACCAATTGAGGATGGAGATATGATTGACACAGGCTATGGAGCTATGGACTTTGGAGCCCTCCAAGAGACCAAGTCTGAGGTGCCACTGGACATCTGTCAGAGCATCTGTAAATACCCTGACTACCTCCAAATGAGTGCTGATGTCTATGGAGACAGTATGTTCTTCTGTCTGAGGAGGGAACAACTTTTTGCCAGACACTTCTGGAACAGGGGAGGGATGGTGGGAGATGCCATCCCTGCCCAACTCTACATCAAGGGCACAGACATCAGGGCTAACCCTGGCTCCTCTGTCTACTGTCCAAGCCCATCTGGCAGTATGGTGACCTCTGACAGCCAACTTTTCAACAAGCCATACTGGCTGCACAAGGCTCAAGGACACAACAATGGCATCTGTTGGCACAACCAACTTTTCCTGACAGTGGTGG ACACCACCAGGAGCACCAACTTCACCCTGAGCACCAGCATTGAGTCCAGCATCCCAAGCACCTATGACCCAAGCAAGTTCAAGGAATACACCAGGCATGTGGAGGAATATGACCTCCAATTCATCTTCCAACTTTGTACTGTGACCCTGACCACAGATGTGATGAGTTACATCCACACAATGAACTCCAGCATCCTGGACAAC TGGAACTTTGCTGTGGCTCCTCCTCCATCTGCCTCCCTGGTGGACACCTACAGATACCTCCAATCTGCTGCCATCACTTGTCAGAAGGATGCCCCTGCCCCTGAGAAGAAGGACCCATATGATGGACTGAAGTTCTGGAATGTGGACCTGAGGGAGAAGTTCTCCTTGGAACTGGACCAGTTTCCACTGGGCAGGAAGTTCCTG ² CTCCAACTTGGA ³ 1: KpnⅠ restriction site; 2: The gene segment encoding amino acids 1-469 of HPV39L1; 3: 12 bases overlapping with the gene segment encoding amino acids 471-508 of HPV59L1. SEQ ID No: 91 3910 HPV39L1 F2 AGGAAGTTTCCTGCTCCAACTTGGAGCCAGACCAAAGC SEQ ID No: 92 3911 HPV39L1 R2 CTGTCTAGATTTACTTCCTGCTGGACTTCCTCCTCTCAC SEQ ID No: 93 3912 HPV39L1 amplified sequence 2 AGGAAGTTCCTG ¹ CTCCAACTTGGAGCCAGACCAAAGCCAACCATTGGACCAAGGAAGGGCTGCCCCTGCCCCAACCAGCACACCAAGCCCAAAGAGGGTGAAGAGGAGGAAGTCCAGCAGGAAG ² TAA A TCTAGA ³ CAG. 1: 12 bp bases overlapping with the C-terminal gene fragment of 1-469 amino acids of HPV39L1; 2: The gene fragment of 38 amino acids (471-508) at the C-terminus of HPV59L1; 3: XbaI restriction site. SEQ ID No: 94 3913 HPV 33 L1 protein amino acid sequence 474-499 KAKPKLKRAAPTSTRTSSAKRKKVKK

Appendix 9: Sequence Listing - Chimeric Human Papillomavirus Type 45 L1 Protein SEQ ID No: 95 4501 HPV Amino acid sequence 1-478 of type 45 L1 protein MALWRPSDSTVYLPPPSVARVVNTDDYVSRTSIFYHAGSSRLLTVGNPYFRVVPSGAGNKQAVPKVSAYQYRVFRVALPDPNKFGLPDSTIYNPETQRLVWACVGM EIGRGQPLGIGLSGHPFYNKLDDTESAHAATAVITQDVRDNVSVDYKQTQLCILGCVPAIGEHWAKGTLCKPAQLQPGDCPPLELKNTIIEDGDMVDTGYGAMDFSTLQDTKCEVPLDICQSIC KYPDYLQMSADPYGDSMFFCLRREQLFARHFWNRAGVMGDTVPTDLYIKGTSANMRETPGSCVYSPSPSGSITTSDSQLFNKPYWLHKAQGHNNGICWHNQLFVTVVDTTRSTNLTLCASTQNP VPNTYDPTKFKHYSRHVEEYDLQFIFQLCTITLTAEVMSYIHSMNSSILENWNFGVPPPPTTSLVDTYRFVQSVAVTCQKDTTPPEKQDPYDKLKFWTVDLKEKFSSDLDQYPLGRKFLVQAGL SEQ ID No: 96 4502 HPV 33 L1 protein amino acid sequence 474-499 KAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 97 4503 Chimeric HPV Amino acid sequence of type 45 L1 protein MALWRPSDSTVYLPPPSVARVVNTDDYVSRTSIFYHAGSSRLLTVGNPYFRVVPSGAGNKQAVPKVSAYQYRVFRVALPDPNKFGLPDSTIYNPETQRLVWACVGMEIGRGQPLGI GLSGHPFYNKLDDTESAHAATAVITQDVRDNVSVDYKQTQLCILGCVPAIGEHWAKGTLCKPAQLQPGDCPPLELKNTIIEDGDMVDTGYGAMDFSTLQDTKCEVPLDICQSICKYPDYLQMSADPYGD SMFFCLRREQLFARHFWNRAGVMGDTVPTDLYIKGTSANMRETPGSCVYSPSPSGSITTSDSQLFNKPYWLHKAQGHNNGICWHNQLFVTVVDTTRSTNLTLCASTQNPVPNTYDPTKFKHYSRHVEEY DLQFIFQLCTITLTAEVMSYIHSMNSSILENWNFGVPPPPTTSLVDTYRFVQSVAVTCQKDTTPPEKQDPYDKLKFWTVDLKEKFSSDLDQYPLGRKFLVQAGLKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 98 4504 Chimeric HPV type 45 L1 protein nucleotide sequence SEQ ID No: 99 4505 Synthetic HPV45L1 gene ctcgagctc SEQ ID No: 100 4506 Synthetic HPV33L1 gene SEQ ID No: 101 4507 HPV45L1 F1 CTTGGTACCATGGCTCTGTGGAGACCATCTGAC SEQ ID No: 102 4508 HPV45L1 R1 GCTTGGCTTTCAGTCCAGCCTGGACCAGGAAC SEQ ID No: 103 4509 HPV45L1 extension sequence 1 CTT GGTACC ¹ ATGGCTCTGTGGAGACCATCTGACAGCACAGTCTACCTGCCTCCTCCATCTGTGGCAAGGGTGGTGAACACAGATGACTATGTGAGCAGGACCAGCATCTTCTACCATGCTGGCTCCAGCAGACTGCTGACAGTGGGCAACCCATACTTCAGGGTGGTGCCAAGTGGAGCAGGCAACAAGCAGGCTGTGCCAAAGGTGTCTGCCTACCAATACAGGGTGTTCAGGGTGGCTCTGCCTGACCCAAACAAGTTTGGACTGCCTGACAGCACCATCTACAACCCTGAGACCCAGAGACTGGTGTGGGCTTGTGTGGGGATGGAGATTGGCAGGGGACAACCACTGGGCATTGGACTGTCTGGACACCCATTCTACAACAAACTGGATGACACAGAGTCTGCCCATGCTGCCACAGCAGTGATTACCCAGGATGTGAGGGACAATGTGTCTGTGGACTACAAGCAGACCCAACTTTGTATCCTGGGCTGTGTGCCTGCCATTGGAGAACACTGGGCTAAGGGCACCCTGTGTAAGCCTGCCCAACTCCAACCTGGAGACTGTCCTCCATTGGAACTGAAAAACACCATCATTGAGGATGGAGATATGGTGGACACAGGCTATGGAGCTATGGACTTCAGCACCCTCCAAGACACCAAGTGTGAGGTGCCACTGGACATCTGTCAGAGCATCTGTAAATACCCTGACTACCTCCAAATGAGTGCTGACCCATATGGAGACAGTATGTTCTTCTGTCTGAGGAGGGAACAACTTTTTGCCAGACACTTCTGGAACAGGGCTGGAGTGATGGGAGACACAGTGCCAACAGACCTCTACATCAAGGGCACCTCTGCCAATATGAGGGAGACACCTGGCTCCTGTGTCTACAGCCCAAGCCCATCTGGCAGCATCACCACCTCTGACAGCCAACTTTTCAACAAGCCATACTGGCTGCACAAGGCTCAAGGACACAACAATGGCATCTGTTGGCACAACCAACTTTTTG TGACAGTGGTGGACACCACCAGGAGCACCAACCTGACCCTGTGTGCCAGCACCCAGAACCCTGTGCCAAACACCTATGACCCAACCAAGTTCAAGCACTACAGCAGGCATGTGGAGGAATATGACCTCCAATTCATCTTCCAACTTTGTACCATCACCCTGACAGCAGAGGTGATGAGTTACATCCACAGTATGAACTCCAGCATCTTGGAGAACTG GAACTTTGGAGTGCCTCCTCCTCCAACCACCTCCCTGGTGGACACCTACAGGTTTGTCCAGTCTGTGGCTGTGACTTGTCAGAAGGACACCACACCTCCTGAGAAGCAGGACCCATATGACAAACTGAAGTTCTGGACAGTGGACCTGAAAGAGAAGTTCTCCTCTGACCTGGACCAATACCCACTGGGCAGGAAGTTCCTGGTCCAGGCTGGACTG ² AAAGCCAAGC ³ 1: KpnⅠ restriction site; 2: The gene segment encoding the amino acids 1-478 of HPV45L1; 3: 10 bases overlapping with the gene segment encoding the amino acids 474-499 of HPV33L1. SEQ ID No: 104 4510 HPV45L1 F2 GGCTGGACTGAAAGCCAAGCCAAAACTGAAAGGG SEQ ID No: 105 4511 HPV45L1 R2 CTGTCTAGATTTACTTCTTCACCTTCTTCCTCTTGGC SEQ ID No: 106 4512 HPV45L1 amplified sequence 2 GGCTGGACTG ¹ AAAGCCAAGCCAAAACTGAAAAGGGCTGCCCCAACCAGCACCAGG ACCTCCTCTGCCAAGAGGAAGAAGGTGAAGAAG ² TAA A TCTAGA ³ CAG. 1: 10 bp bases overlapping with the C-terminal gene fragment of 1-478 amino acids of HPV45L1; 2: The gene fragment of 26 amino acids (474-499) at the C-terminus of HPV33L1; 3: XbaI restriction site. SEQ ID No: 107 4513 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK

Appendix 10: Sequence Listing - Chimeric Human Papillomavirus Type 51 L1 Protein SEQ ID No: 108 5101 HPV Amino acid sequence 1-474 of type 51 L1 protein MALWRTNDSKVYLPPAPVSRIVNTEEYITRTGIYYYAGSSRLITLGHPYFPIPKTSTRAAIPKVSAFQYRVFRVQLPDPNKFGLPDPNLYNPDTDRLVWGCVGVE VGRGQPLGVGLSGHPLFNKYDDTENSRIANGNAQQDVRDNTSVDNKQTQLCIIGCAPPIGEHWGIGTTCKNTPVPPGDCPPLELVSSVIQDGDMIDTGFGAMDFAALQATKSDVPLDISQSVC KYPDYLKMSADTYGNSMFFHLRREQIFARHYYNKLVGVGEDIPNDYYIKGSGNGRDPIESYIYSATPSGSMITSDSQIFNKPYWLHRAQGHNNGICWNNQLFITCVDTTTRSTNLTISTATAAV SPTFTPSNFKQYIRHGEEYELQFIFQLCKITLTTEVMAYLHTMDPTILEQWNFGLTLPPSASLEDAYRFVRNAATSCQKDTPPQAKPDPLAKYKFWDVDLKERFSLDLDQFALGRKFLLQVGV SEQ ID No: 109 5102 HPV 33 L1 protein amino acid sequence 474-499 KAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 110 5103 Amino acid sequence of chimeric HPV type 51 L1 protein MALWRTNDSKVYLPPAPVSRIVNTEEYITRTGIYYYAGSSRLITLGHPYFPIPKTSTRAAIPKVSAFQYRVFRVQLPDPNKFGLPDPNLYNPDTDRLVWGCVGVEVGRGQPLGVGLSGHPLFNKYDDTENSRIANGNAQQDVRDNTSVDNKQTQLCIIGCAPPIGEHWGIGTTCKNTPVPPGDCPPLELVSSVIQDGDMIDTGFGAMDFAALQATKSDVPLDISQSVCKYPDYLKMSADTYGN SMFFHLRREQIFARHYYNKLVGVGEDIPNDYYIKGSGNGRDPIESYIYSATPSGSMITSDSQIFNKPYWLHRAQGHNNGICWNNQLFITCVDTTRSTNLTISTATAAVSPTFTPSNFKQYIRHGEEYE LQFIFQLCKITLTTEVMAYLHTMDPTILEQWNFGLTLPPSASLEDAYRFVRNAATSCQKDTPPQAKPDPLAKYKFWDVDLKERFSLDLDQFALGRKFLLQVGVKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 111 5104 Nucleotide sequence of chimeric HPV type 51 L1 protein SEQ ID No: 112 5105 Synthetic HPV51L1 gene SEQ ID No: 113 5106 Synthetic HPV33L1 gene SEQ ID No: 114 5107 HPV51L1 F1 CTTGGTACCATGGCTTCTGTGGAGGACCAATGACA SEQ ID No: 115 5108 HPV51L1 R1 GCTTGGCTTTGACTCCCACTTGGAGCAGGAAC SEQ ID No: 116 5109 HPV51L1 extension sequence 1 CTT GGTACC ¹ ATGGCTCTGTGGAGGACCAATGACAGCAAGGTCTACCTGCCTCCTGCCCCTGTGAGCAGGATTGTGAACACAGAGGAATACATCACCAGGACAGGCATCTACTACTATGCTGGCTCCAGCAGACTGATTACCCTGGGACACCCATACTTTCCAATCCCAAAGACCAGCACCAGGGCTGCCATCCCAAAGGTGTCTGCCTTCCAATACAGGGTGTTCAGGGTCCAACTTCCTGACCCAAACAAGTTTGGACTGCCTGACCCAAACCTCTACAACCCTGACACAGACAGACTGGTGTGGGGCTGTGTGGGAGTGGAGGTGGGCAGGGGACAACCACTGGGAGTGGGACTGTCTGGACACCCACTGTTCAACAAATATGATGACACAGAGAACAGCAGGATTGCCAATGGCAATGCCCAACAGGATGTGAGGGACAACACCTCTGTGGACAACAAGCAGACCCAACTTTGTATCATTGGCTGTGCCCCTCCAATTGGAGAACACTGGGGCATTGGCACCACTTGTAAGAACACACCTGTGCCTCCTGGAGACTGTCCTCCATTGGAACTGGTGTCCTCTGTGATTCAGGATGGAGATATGATTGACACAGGCTTTGGAGCTATGGACTTTGCTGCCCTCCAAGCCACCAAGTCTGATGTGCCACTGGACATCAGCCAGTCTGTGTGTAAATACCCTGACTACCTGAAAATGAGTGCTGACACCTATGGCAACAGTATGTTCTTCCACCTGAGGAGGGAACAGATTTTTGCCAGACACTACTACAACAAACTGGTGGGAGTGGGAGAGGACATCCCAAATGACTACTACATCAAGGGCTCTGGCAATGGCAGGGACCCAATTGAGTCCTACATCTACTCTGCCACACCATCTGGCAGTATGATTACCTCTGACAGCCAGATTTTCAACAAGCCATACTGGCTGCACAGGGCTCAAGGACACAACAATGGCATCTGTTGGAACAACCAACTTTTCATCACTTGTG TGGACACCACCAGGAGCACCAACCTGACCATCAGCACAGCCACAGCAGCAGTGAGCCCAACCTTCACACCAAGCAACTTCAAGCAATACATCAGACATGGAGAGGAATATGAACTCCAATTCATCTTCCAACTTTGTAAGATTACCCTGACCACAGAGGTGATGGCTTACCTGCACACAATGGACCCAACCATCTTGGAACAGTGGAACTT TGGACTGACCCTGCCTCCATCTGCCTCCTTGGAGGATGCCTACAGGTTTGTGAGGAATGCTGCCACCTCCTGTCAGAAGGACACACCTCCACAGGCTAAGCCTGACCCACTGGCTAAATACAAGTTCTGGGATGTGGACCTGAAAGAGAGGTTCTCCCTGGACCTGGACCAGTTTGCCCTGGGCAGGAAGTTCCTGCTCCAAGTGGGAGTC ² AAAGCCAAGC ³ 1: KpnⅠ restriction site; 2: The gene segment encoding amino acids 1-474 of HPV51L1; 3: 10 bases overlapping with the gene segment encoding amino acids 474-499 of HPV33L1 SEQ ID No: 117 5110 HPV51L1 F2 AGTGGGAGTCAAAGCCAAGCCAAAACTGAAAAGGG SEQ ID No: 118 5111 HPV51L1 R2 CTGTCTAGATTTACTTCTTCACCTTCTTCCTTCTTGG SEQ ID No: 119 5112 HPV51L1 amplified sequence 2 AGTGGGAGTC ¹ AAAGCCAAGCCAAAACTGAAAAGGGCTGCCCCAACCAGCACCAGG ACCTCCTCTGCCAAGAGGAAGAAGGTGAAGAAG ² TAA A TCTAGA ³ CAG. 1: 10 bp bases overlapping with the C-terminal gene fragment of 1-474 amino acids of HPV51L1; 2: The gene fragment of 26 amino acids (474-499) at the C-terminus of HPV33L1; 3: XbaI restriction site. SEQ ID No: 120 5113 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK

Appendix 11: Sequence Listing - Chimeric Human Papillomavirus Type 52 L1 Protein SEQ ID No: 121 5201 HPV Amino acid sequence 1-478 of type 52 L1 protein MSVWRPSEATVYLPPVPVSKVVSTDEYVSRTSIYYYAGSSRLLTVGHPYFSIKNTSSGNGKKVLVPKVSGLQYRVFRIKLPDPNKFGFPDTSFYNPETQRLVWACT GLEIGRGQPLGVGISGHPLLNKFDDTETSNKYAGKPGIDNRECLSMDYKQTQLCILGCKPPIGEHWGKGTPCNNNSGNPGDCPPLQLINSVIQDGDMVDTGFGCMDFNTLQASKSDVPIDICSS VCKYPDYLQMASEPYGDSLFFFLRREQMFVRHFFNRAGTLGDPVPGDLYIQGSNSGNTATVQSSAFFPTPSGSMVTSESQLFNKPYWLQRAQGHNNGICWGNQLFVTVVDTTRSTNMTLCAEVK KESTYKNENFKEYLRHGEEFDLQFIFQLCKITLTADVMTYIHKMDATILEDWQFGLTPPPSASLEDTYRFVTSTAITCQKNTPPKGKEDPLKDYMFWEVDLKEKFSADLDQFPLGRKFLLQAGL SEQ ID No: 122 5202 HPV 33 L1 protein amino acid sequence 474-499 KAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 123 5203 Chimeric HPV Amino acid sequence of type 52 L1 protein MSVWRPSEATVYLPPVPVSKVVSTDEYVSRTSIYYYAGSSRLLTVGHPYFSIKNTSSGNGKKVLVPKVSGLQYRVFRIKLPDPNKFGFPDTSFYNPETQRLVWACTGLEIGRGQPL GVGISGHPLLNKFDDTSNKYAGKPGIDNRECLSMDYKQTQLCILGCKPPIGEHWGKGTPCNNNSGNPGDCPPLQLINSVIQDGDMVDTGFGCMDFNTLQASKSDVPIDICSSVCKYPDYLQMASEPY GDSLFFFLRREQMFVRHFFNRAGTLGDPVPGDLYIQGSNSGNTATVQSSAFFPTPSGSMVTSESQLFNKPYWLQRAQGHNNGICWGNQLFVTVVDTTRSTNMTLCAEVKKESTYKNENFKEYLRHGEEF DLQFIFQLCKITLTADVMTYIHKMDATILEDWQFGLTPPPSASLEDTYRFVTSTAITCQKNTPPKGKEDPLKDYMFWEVDLKEKFSADLDQFPLGRKFLLQAGLKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 124 5204 Chimeric HPV type 52 L1 protein nucleotide sequence SEQ ID No: 125 5205 Synthetic HPV52L1 gene SEQ ID No: 126 5206 Synthetic HPV33L1 gene SEQ ID No: 127 5207 HPV52L1 F1 CTTGGTACCATGAGCGTGTGGAGGCCCAGCGAGG SEQ ID No: 128 5208 HPV52L1 R1GCTTGGCTTTCAGGCCGGCCTGCAGCAGGAACTTC SEQ ID No: 129 5209 HPV52L1 amplified sequence 1 CTT GGTACC ¹ ATGAGCGTTGGAGGCCCAGCGAGCCACCGTGTACCTGCCCCCCGTGCCCGTGAGCAAGGTGGTGAGCACCGACGAGTACGTGAGCAGGACCAGCATCTACTACTACGCCGGCAGCAGCAGGCTGCTGACCGTGGGCCACCCCTACTTCAGCATCAAGAACACCAGCAGCGGCAACGG CAAGAAGGTGCTGGTGCCCAAGGTGAGCGGCCTGCAGTACAGGGTGTTCAGGATCAAGCTGCCCGACCCCAACAAGTTCGGCTTCCCCGACACCAGCTTCTACAACCCCGAGACCCAGAGGCTGGTGTGGGCCTGCACCGGCCTGGAGATCGGCAGGGGCCAGCCCCTGGGCGTGGGCA TCAGCGGCCACCCCCTGCTGAACAAGTTCGACGACACCGAGACCAGCAACAAGTACGCCGGCAAGCCCGGCATCGACAACAGGGAGTGCCTGAGCATGGACTACAAGCAGACCCAGCTGTGCATCCTGGGCTGCAAGCCCCCCATCGGCGAGCACTGGGGCAAGGGCACCCCCTGCAAC AACAACAGCGGCAACCCCGGCGACTGCCCCCCCCTGCAGCTGATCAACAGCGTGATCCAGGACGGCGACATGGTGGACACCGGCTTCGGCTGCATGGACTTCAACACCCTGCAGGCCAGCAAGAGCGACGTGCCCATCGACATCTGCAGCAGCGTGTGCAAGTACCCCGACTACCTGCAG ATGGCCAGCGAGCCCTACGGCGACAGCCTGTTCTTCTTCCTGAGGAGGGAGCAGATGTTCGTGAGGCACTTCTTCAACAGGGCCGGCACCCTGGGCGACCCCGTGCCCGGCGACCTGTACATCCAGGGCAGCAACAGCGGCAACACCGCCACCGTGCAGAGCAGCGCCTTCTTCCCCAC CCCCAGCGGCAGCATGGTGACCAGCGAGAGCCAGCTGTTCAACAAGCCCTACTGGCTGCAGAGGGCCCAGGGCCACAACAACGGCATCTGCTGGGGCAACCAGCTGTTCGTGACCGTGGTGGACACCACCAGGAGCACCAACATGACCCTGTGCGCCGAGGTGAAGAAGGAGAGCACCT ACAAGAACGAGAACTTCAAGGAGTACCTGAGGCACGGCGAGGAGTTCGACCTGCAGTTCATCTTCCAGCTGTGCAAGATCACCCTGACCGCCGACGTGATGACCTACATCCACAAGATGGACGCCACCATCCTGGAGGACTGGCAGTTCGGCCTGACCCCCCCCAGCGCCAGCCTG GAGGACACCTACAGGTTCGTGACCAGCACCGCCATCACCTGCCAGAAGAACACCCCCCCAAGGGCAAGGAGGACCCCCTGAAGGACTACATGTTCTGGGAGGTGGACCTGAAGGAGAAGTTCAGCGCCGACCTGGACCAGTTCCCCCTGGGCAGGAAGTTCCTGCTGCAGGCCGGCCTG ² AAAGCCAAGC ³ 1: KpnⅠ restriction site; 2: Gene fragment encoding amino acids 1-478 of HPV52L1; 3: 10 bases overlapping with the gene fragment encoding amino acids 474-499 of HPV33L1. SEQ ID No: 130 5210 HPV52L1 F2 GGCCGGCCTGAAAGCCAAGCCAAAACTGAAAAGGG SEQ ID No: 131 5211 HPV52L1 R2 CTGTCTAGATTTACTTCTTCACCTTCTTCCTTCTTGG SEQ ID No: 132 5212 HPV52L1 amplified sequence 2 GGCCGGCCTG ¹ AAAGCCAAGCCAAAACTGAAAAGGGCTGCCCCAACCAGCACCAGG ACCTCCTCTGCCAAGAGGAAGAAGGTGAAGAAG ² TAA A TCTAGA ³ CAG. 1: 10 bp of bases overlapping with the C-terminal gene fragment of 1-478 amino acids of HPV52L1; 2: The gene fragment of 26 amino acids (474-499) at the C-terminus of HPV33L1; 3: XbaI restriction site SEQ ID No: 133 5213 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK

Appendix 12: Sequence Listing - Chimeric Human Papillomavirus Type 56 L1 Protein SEQ ID No: 134 5601 HPV Amino acid sequence 1-467 of type 56 L1 protein MATWRPSENKVYLPPTPVSKVVATDSYVKRTSIFYHAGSSRLLAVGHPYYSVTKDNTKTNIPKVSAYQYRVFRVRLPDPNKFGLPDTNIYNPDQERLVWACVG LEVGRGQPLGAGLSGHPLFNRLDDTESSNLANNNVIEDSRDNISVDGKQTQLCIVGCTPAMGEHWTKGAVCKSTQVTTGDCPPLALINTPIEDGDMIDTGFGAMDFKVLQESKAEVPLDIV QSTCKYPDYLKMSADAYGDSMWFYLRREQLFARHYFNRAGKVGETIPAELYLKGSNGREPPPSSVYVATPSGSMITSEAQLFNKPYWLQRAQGHNNGICWGNQLFVTVVDTTRSTNMTIST ATEQLSKYDARKINQYLRHVEEYELQFVFQLCKITLSAEVMAYLHNMNANLLEDWNIGLSPPVATSLEDKYRYVRSTAITCQREQPPTEKQDPLAKYKFWDVNLQDSFSTDLDQFPLGRKFL SEQ ID No: 135 5602 HPV 33 L1 protein amino acid sequence 469-499 LQAGLKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 136 5603 Amino acid sequence of chimeric HPV type 56 L1 protein MATWRPSENKVYLPPTPVSKVVATDSYVKRTSIFYHAGSSRLLAVGHPYYSVTKDNTKTNIPKVSAYQYRVFRVRLPDPNKFGLPDTNIYNPDQERLVWACVGLEVGRGQPLGAGLSGHPLFNRLDDTESSNLANNNVIEDSRDNISVDGKQTQLCIVGCTPAMGEHWTKGAVCKSTQVTTGDCPPLALINTPIEDGDMIDTGFGAMDFKVLQESKAEVPLDIVQSTCKYPDYLKMSADAYG DSMWFYLRREQLFARHYFNRAGKVGETIPAELYLKGSNGREPPPSSVYVATPSGSMITSEAQLFNKPYWLQRAQGHNNGICWGNQLFVTVVDTTRSTNMTISTATEQLSKYDARKINQYLRHVEEYEL QFVFQLCKITLSAEVMAYLHNMNANLLEDWNIGLSPPVATSLEDKYRYVRSTAITCQREQPPTEKQDPLAKYKFWDVNLQDSFSTDLDQFPLGRKFLLQAGLKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 137 5604 Chimeric HPV type 56 L1 protein nucleotide sequence SEQ ID No: 138 5605 Synthetic HPV56L1 gene SEQ ID No: 139 5606 Synthetic HPV33L1 gene SEQ ID No: 140 5607 HPV56L1 F1 CTTGGTACCATGGCTACCTGGAGACCATCTGAG SEQ ID No: 141 5608 HPV56L1 R1 CTGCTTTGGAGCAGGAACTTCCTGCCCAGTGG SEQ ID No: 142 5609 HPV56L1 amplified sequence 1 CTT GGTACC ¹ ATGGCTACCTGGAGACCATCTGAGAACAAGGTCTACCTGCCTCCAACACCTGTGAGCAAGGTGGTGGCTACAGACTCCTATGTGAAGAGGACCAGCATCTTCTACCATGCTGGCTCCAGCAGACTGCTGGCTGTGGGACACCCATACTACTCTGTGACCAAGGACAACACCAAGA CCAACATCCCAAAGGTGTCTGCCTACCAATACAGGGTGTTCAGGGTGAGACTGCCTGACCCAAACAAGTTTGGACTGCCTGACACCAACATCTACAACCCTGACCAGGAGAGACTGGTGTGGGCTTGTGTGGGATTGGAGGTGGGCAGGGGACAACCACTGGGAGCAGGACTGTC TGGACACCCACTGTTCAACAGACTGGATGACACAGAGTCCAGCAACCTGGCTAACAACAATGTGATTGAGGACAGCAGGGACAACATCTCTGTGGATGGCAAGCAGACCCAACTTTGTATTGTGGGCTGTACTCCTGCTATGGGAGAACACTGGACCAAGGGAGCAGTGTGTAAG AGCACCCAGGTGACCACAGGAGACTGTCCTCCACTGGCTCTGATAAACACACCAATTGAGGATGGAGATATGATTGACACAGGCTTTGGAGCTATGGACTTCAAGGTGCTCCAAGAGAGCAAGGCTGAGGTGCCACTGGACATTGTCCAGAGCACTTGTAAATACCCTGACTACC TGAAAATGAGTGCTGATGCCTATGGAGACAGTATGTGGTTCTACCTGAGGAGGGAACAACTTTTTGCCAGACACTACTTCAACAGGGCTGGCAAGGTGGGAGAGACCATCCCTGCTGAACTCTACCTGAAAGGCAGCAATGGCAGGGAACCTCCTCCATCCTCTGTCTATGTGGC TACACCATCTGGCAGTATGATTACCTCTGAGGCTCAACTTTTCAACAAGCCATACTGGCTCCAAAGGGCTCAAGGACACAACAATGGCATCTGTTGGGGCAACCAACTTTTTGTGACAGTGGTGGACACCACCAGGAGCACCAATATGACCATCAGCACAGCCACAGAACAACTT AGCAAATATGATGCCAGGAAGATAAACCAATACCCTGAGGCATGTGGAGGAATATGAACTCCAATTTGTGTTCCAACTTTGTAAGATTACCCTGTCTGCTGAGGTGATGGCTTACCTGCACAATATGAATGCCAACCTGTTGGAGGACTGGAACATTGGACTGAGCCCTCCTGTGG CTACCTCCTTGGAGGACAAATACAGATATGTGAGGAGCACAGCCATCACTTGTCAGAGGGAACAACCTCCAACAGAGAAGCAGGACCCACTGGCTAAATACAAGTTCTGGGATGTGAACCTCCAAGACTCCTTCAGCACAGACCTGGACCAGTTTCCACTGGGCAGGAAGTTCCTG ² CTCCAAGCAG ³ 1: KpnⅠ restriction site; 2: Gene fragment encoding amino acids 1-467 of HPV56L1; 3: 10 bases overlapping with the gene fragment encoding amino acids 469-499 of HPV33L1. SEQ ID No: 143 5610 HPV56L1 F2 GAAGTTCCTGCTCCAAGCAGGACTGAAAGCCAAGCC SEQ ID No: 144 5611 HPV56L1 R2 CTGTCTAGATTTACTTCTTCACCTTCTTCCCTCTTGG SEQ ID No: 145 5612 HPV56L1 amplified sequence 2 GAAGTTCCTG ¹ CTCCAAGCAGGACTGAAAGCCAAGCCAAAACTGAAAAGGGCTGCCCCAACCAGCACCAGGACCTCCTCTGCCAAGAGGAAGAAGGTGAAGAAG ² TAA A TCTAGA ³ CAG. 1: 10 bp bases overlapping with the C-terminal gene fragment of 1-467 amino acids of HPV56L1; 2: The gene fragment of 31 amino acids (469-499) at the C-terminus of HPV33L1; 3: XbaI restriction site. SEQ ID No: 146 5613 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK

Appendix 13: Sequence Listing - Chimeric Human Papillomavirus Type 58 L1 Protein SEQ ID No: 147 5801 HPV Amino acid sequence 1-473 of type 58 L1 protein MSVWRPSEATVYLPPVPVSKVVSTDEYVSRTSIYYYAGSSRLLAVGNPYFSIKSPNNNKKVLVPKVSGLQYRVFRVRLPDPNKFGFPDTSFYNPDTQRLVWACV GLEIGRGQPLGVGVSGHPYLNKFDDTETSNRYPAQPGSDNRECLSMDYKQTQLCLIGCKPPTGEHWGKGVACNNNAAATDCPPLELFNSIIEDGDMVDTGFGCMDFGTLQANKSDVPIDICNS TCKYPDYLKMASEPYGDSLFFFLRREQMFVRHFFNRAGKLGEAVPDDLYIKGSGNTAVIQSSAFFPTPSGSIVTSESQLFNKPYWLQRAQGHNNGICWGNQLFVTVVDTTRSTNMTLCTEVTK EGTYKNDNFKEYVRHVEEYDLQFVFQLCKITLTAEIMTYIHTMDSNILEDWQFGLTPPPSASLQDTYRFVTSQAITCQKTAPPKEKEDPLNKYTFWEVNLKEKFSADLDQFPLGRKFLLQSGL SEQ ID No: 148 5802 HPV 33 L1 protein amino acid sequence 474-499 KAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 149 5803 Chimeric HPV Amino acid sequence of type 58 L1 protein MSVWRPSEATVYLPPVPVSKVVSTDEYVSRTSIYYYAGSSRLLAVGNPYFSIKSPNNNKKVLVPKVSGLQYRVFRVRLPDPNKFGFPDTSFYNPDTQRLVWACVGLEIGRGQPLG VGVSGHPYLNKFDDTETSNRYPAQPGSDNRECLSMDYKQTQLCLIGCKPPTGEHWGKGVACNNNAAATDCPPLELLFNSIIEDGDMVDTGFGCMDFGTLQANKSDVPIDICNSTCKYPDYLKMASEPYG DSLFFFLRREQMFVRHFFNRAGKLGEAVPDDLYIKGSGNTAVIQSSAFFPTPSGSIVTSESQLFNKPYWLQRAQGHNNGICWGNQLFVTVVDTTRSTNMTLCTEVTKEGTYKNDNFKEYVRHVEEYDL QFVFQLCKITLTAEIMTYIHTMDSNILEDWQFGLTPPPSASLQDTYRFVTSQAITCQKTAPPKEKEDPLNKYTFWEVNLKEKFSADLDQFPLGRKFLLQSGLKAKPKLKRAAPTSTRTSSAKRKKVKK SEQ ID No: 150 5804 Chimeric HPV type 58 L1 protein nucleotide sequence SEQ ID No: 151 5805 Synthetic HPV58L1 gene ctcgagctc SEQ ID No: 152 5806 Synthetic HPV33L1 gene SEQ ID No: 153 5807 HPV58L1 F1 CTTGGTACCATGAGCGTGTGGAGGCCCAGCGAGG SEQ ID No: 154 5808 HPV58L1 R1GCTTGGCTTTCAGGCCGCTCTGCAGCAGGAACTTCC SEQ ID No: 155 5809 HPV58L1 extension sequence 1 CTT GGTACC ¹ ATGAGCGTGTGGAGGCCCAGCGAGGCCACCGTGTACCTGCCCCCCGTGCCCGTGAGCAAGGTGGTGAGCACCGACGAGTACGTGAGCAGGACCAGCATCTACTACTACGCCGGCAGCAGCAGGCTGCTGGCCGTGGGCAACCCCTACTTCAGCATCAAGAGCCCCAACAACAACAAGAAGGTGCTGGTGCCCAAGGTGAGCGGCCTGCAGTACAGGGTGTTCAGGGTGAGGCTGCCCGACCCCAACAAGTTCGGCTTCCCCGACACCAGCTTCTACAACCCCGACACCCAGAGGCTGGTGTGGGCCTGCGTGGGCCTGGAGATCGGCAGGGGCCAGCCCCTGGGCGTGGGCGTGAGCGGCCACCCCTACCTGAACAAGTTCGACGACACCGAGACCAGCAACAGGTACCCCGCCCAGCCCGGCAGCGACAACAGGGAGTGCCTGAGCATGGACTACAAGCAGACCCAGCTGTGCCTGATCGGCTGCAAGCCCCCCACCGGCGAGCACTGGGGCAAGGGCGTGGCCTGCAACAACAACGCCGCCGCCACCGACTGCCCCCCCCTGGAGCTGTTCAACAGCATCATCGAGGACGGCGACATGGTGGACACCGGCTTCGGCTGCATGGACTTCGGCACCCTGCAGGCCAACAAGAGCGACGTGCCCATCGACATCTGCAACAGCACCTGCAAGTACCCCGACTACCTGAAGATGGCCAGCGAGCCCTACGGCGACAGCCTGTTCTTCTTCCTGAGGAGGGAGCAGATGTTCGTGAGGCACTTCTTCAACAGGGCCGGCAAGCTGGGCGAGGCCGTGCCCGACGACCTGTACATCAAGGGCAGCGGCAACACCGCCGTGATCCAGAGCAGCGCCTTCTTCCCCACCCCCAGCGGCAGCATCGTGACCAGCGAGAGCCAGCTGTTCAACAAGCCCTACTGGCTGCAGAGGGCCCAGGGCCACAACAACGGCATCTGCTGGGGCAACCAGCTGTTCGTGACCGTGG TGGACACCACCAGGAGCACCAACATGACCCTGTGCACCGAGGTGACCAAGGAGGGCACCTACAAGAACGACAACTTCAAGGAGTACGTGAGGCACGTGGAGGAGTACGACCTGCAGTTCGTGTTCCAGCTGTGCAAGATCACCCTGACCGCCGAGATCATGACCTACATCCACACCATGGACAGCAACATCCTGGAGGACTGGCAGTTC GGCCTGACCCCCCCCAGCGCCAGCCTGCAGGACACCTACAGGTTCGTGACCAGCCAGGCCATCACCTGCCAGAAGACCGCCCCCCCCAAGGAGAAGGAGGACCCCCTGAACAAGTACACCTTCTGGGAGGTGAACCTGAAGGAGAAGTTCAGCGCCGACCTGGACCAGTTCCCCCTGGGCAGGAAGTTCCTGCTGCAGAGCGGCCTG ² AAAGCCAAGC ³ 1: KpnⅠ restriction site; 2: The gene segment encoding amino acids 1-473 of HPV58L1; 3: 10 bases overlapping with the gene segment encoding amino acids 474-499 of HPV33L1. SEQ ID No: 156 5810 HPV58L1 F2GAGCGGCCTGAAAGCCAAGCCAAAACTGAAAAGGG SEQ ID No: 157 5811 HPV58L1 R2 CTGTCTAGATTTACTTCTTCACCTTCTTCCCTCTTGG SEQ ID No: 158 5812 HPV58L1 amplified sequence 2 GAGCGGCCTG ¹ AAAGCCAAGCCAAAACTGAAAAGGGCTGCCCCAACCAGCACCAGG ACCTCCTCTGCCAAGAGGAAGAAGGTGAAGAAG ² TAA A TCTAGA ³ CAG. 1: 10 bp of bases overlapping with the C-terminal gene fragment of amino acids 1-473 of HPV58L1; 2: The gene fragment of 26 amino acids (474-499) at the C-terminus of HPV33L1; 3: XbaI restriction site SEQ ID No: 159 5813 HPV 59 L1 protein amino acid sequence 471-508 LQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK

Appendix 14: Sequence Listing - Human Papillomavirus Type 59 L1 Protein SEQ ID No: 160 5901 HPV Amino acid sequence of type 59 L1 protein MALWRSSDNKVYLPPPSVAKVVSTDEYVTRTSIFYHAGSSRLLTVGHPYFKVPKGGNGRQDVPKVSAYQYRVFRVKLPDPNKFGLPDNTVYDPNSQRLVWACVGVEIGRGQPLGVGL SGHPLYNKLDDTENSHVASAVDTKDTRDNVSVDYKQTQLCIIGCVPAIGEHWTKGTACKPTTVVQGDCPPLELINTPIEDGDMVDTGYGAMDFKLLQDNKSEVPLDICQSICKYPDYLQMSADAYGDSMF FCLRREQVFARHFWNRSGTMGDQLPESLYIKGTDIRANPGSYLYSPSPSGSVVTSDSQLFNKPYWLHKAQGLNNGICWHNQLFLTVVDTTRSTNLSVCASTTSSIPNVYTPTSFKEYARHVEEFDLQFIF QLCKITLTTEVMSYIHNMNTTILEDWNFGVTPPPTASLVDTYRFVQSAAVTCQKDTAPPVKQDPYDKLKFWPVDLKERFSADLDQFPLGRKFLLQLGARPKPTIGPRKRAAPAPTSTPSPKRVKRRKSSRK SEQ ID No: 161 5902 Nucleotide sequence of HPV type 59 L1 protein SEQ ID No: 162 5903 Synthetic HPV59L1 gene

without

Figure 1A Expression of L1 protein of HPV 6 L1:33C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Figure 1B Expression of L1 protein of HPV 11 L1:33C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Fig. 1C Expression of L1 protein of HPV 16 L1:33C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Fig. 1D Expression of L1 protein of HPV 18 L1:33C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Fig. 1E Expression of L1 protein of HPV 31 L1:33C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Fig. 1F Expression of L1 protein of HPV 33 L1. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Fig. 1G Expression of L1 protein of HPV 35 L1:33C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Fig. 1H Expression of L1 protein of HPV 39 L1:59C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Figure 1I Expression of L1 protein of HPV 45 L1:33C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Fig. 1J Expression of L1 protein of HPV 51 L1:33C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Figure 1K Expression of L1 protein of HPV 52 L1:33C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Fig. 1L Expression of L1 protein of HPV 56 L1:33C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Fig. 1M Expression of L1 protein of HPV 58 L1:33C. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Figure 1N Expression of L1 protein of HPV 59 L1. M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

Figure 2A Transmission electron microscopy observation of HPV 6 L1:33C virus-like particles.

Figure 2B: HPV 11 L1:33C virus-like particles observed under transmission electron microscopy.

Figure 2C Transmission electron microscopy observation of HPV 16 L1:33C virus-like particles.

Figure 2D: HPV 18 L1:33C virus-like particles observed under transmission electron microscopy.

Figure 2E HPV 31 L1:33C virus-like particles observed under transmission electron microscopy.

Figure 2F HPV 33 L1 virus-like particles observed under transmission electron microscopy.

Figure 2G HPV 35 L1:33C virus-like particles observed under transmission electron microscopy.

Figure 2H HPV 39 L1:59C virus-like particles observed under transmission electron microscopy.

Figure 2I HPV 45 L1:33C virus-like particles observed under transmission electron microscopy.

Figure 2J HPV 51 L1:33C virus-like particles observed under transmission electron microscopy.

Figure 2K. HPV 52 L1:33C virus-like particles observed under a transmission electron microscope.

Figure 2L HPV 56 L1:33C virus-like particles observed under transmission electron microscopy.

Figure 2M Transmission electron microscopy observation of HPV 58 L1:33C virus-like particles.

Figure 2N HPV 59 L1 virus-like particles observed under a transmission electron microscope.

Fig. 3 Pseudovirus neutralization titer of mice immunized with type 14 virus-like particle composition. Number of animals, N=10. GMT (Geometric Mean Titer): Geometric mean titer.

Fig. 4 Expression of C-terminally truncated HPV16L1 (1-474). M: Marker; L: Cell lysate; E-S: Supernatant collected after centrifugation of the lysate.

without

          Sequence Listing
 <![CDATA[ <110> China-based company Shenzhou Cell Engineering Co., Ltd.]]>
 <![CDATA[ <120> Human papillomavirus multivalent immunogenic composition]]>
 <![CDATA[ <140> TW109135395]]>
           <![CDATA[ <141> 2020-10-13]]>
           <![CDATA[ <160> 162]]>
 <![CDATA[ <170> BiSSAP 1.3.6]]>
           <![CDATA[ <210> 1]]>
 <![CDATA[ <211> 469]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0601 HPV type 6 L1 protein amino acid sequence 1-469]]>
 <![CDATA[ <400> 1]]> Met Trp Arg Pro Ser Asp Ser Thr Val Tyr Val Pro Pro Pro Asn Pro 1 5 10 15 Val Ser Lys Val Val Ala Thr Asp Ala Tyr Val Thr Arg Thr Asn Ile 20 25 30 Phe Tyr His Ala Ser Ser Ser Arg Leu Leu Ala Val Gly His Pro Tyr 35 40 45 Phe Ser Ile Lys Arg Ala Asn Lys Thr Val Val Pro Lys Val Ser Gly 50 55 60 Tyr Gln Tyr Arg Val Phe Lys Val Val Leu Pro Asp Pro Asn Lys Phe 65 70 75 80 Ala Leu Pro Asp Ser Ser Leu Phe Asp Pro Thr Thr Gln Arg Leu Val 85 90 95 Trp Ala Cys Thr Gly Leu Glu Val Gly Arg Gly Gln Pro Leu Gly Val 100 105 110 Gly Val Ser Gly His Pro Phe Leu Asn Lys Tyr Asp Asp Val Glu Asn 115 120 125 Ser Gly Ser Gly Gly Asn Pro Gly Gln Asp Asn Arg Val Asn Val Gly 130 135 140 Met Asp Tyr Lys Gln Thr Gln Leu Cys Met Val Gly Cys Ala Pro Pro 145 150 155 160 Leu Gly Glu His Trp Gly Lys Gly Lys Gln Cys Thr Asn Thr Pro Val 165 170 175 Gln Ala Gly Asp Cys Pro Pro Leu Glu Leu Ile Thr Ser Val Ile Gln 180 185 190 Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala Met Asn Phe Ala Asp 195 200 205 Leu Gln Thr Asn Lys Ser Asp Val Pro Ile Asp Ile Cys Gly Thr Thr 210 215 220 Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ala Ala Asp Pro Tyr Gly Asp 225 230 235 240 Arg Leu Phe Phe Phe Leu Arg Lys Glu Gln Met Phe Ala Arg His Phe 245 250 255 Phe Asn Arg Ala Gly Glu Val Gly Glu Pro Val Pro Asp Thr Leu Ile 260 265 270 Ile Lys Gly Ser Gly Asn Arg Thr Ser Val Gly Ser Ser Ile Tyr Val 275 280 285 Asn Thr Pro Ser Gly Ser Leu Val Ser Ser Glu Ala Gln Leu Phe Asn 290 295 300 Lys Pro Tyr Trp Leu Gln Lys Ala Gln Gly His Asn Asn Gly Ile Cys 305 310 315 320 Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp Thr Thr Arg Ser Thr 325 330 335 Asn Met Thr Leu Cys Ala Ser Val Thr Thr Ser Ser Thr Tyr Thr Asn 340 345 350 Ser Asp Tyr Lys Glu Tyr Met Arg His Val Glu Glu Tyr Asp Leu Gln 355 360 365 Phe Ile Phe Gln Leu Cys Ser Ile Thr Leu Ser Ala Glu Val Met Ala 370 375 380 Tyr Ile His Thr Met Asn Pro Ser Val Leu Glu Asp Trp Asn Phe Gly 385 390 395 400 Leu Ser Pro Pro Pro Asn Gly Thr Leu Glu Asp Thr Tyr Arg Tyr Val 405 410 415 Gln Ser Gln Ala Ile Thr Cys Gln Lys Pro Thr Pro Glu Lys Glu Lys 420 425 430 Pro Asp Pro Tyr Lys Asn Leu Ser Phe Trp Glu Val Asn Leu Lys Glu 435 440 445 Lys Phe Ser Ser Glu Leu Asp Gln Tyr Pro Leu Gly Arg Lys Phe Leu 450 455 460 Leu Gln Ser Gly Tyr 465
           <![CDATA[ <210> 2]]>
 <![CDATA[ <211> 26]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0602 HPV 33 L1 protein amino acid sequence 474-499]]>
 <![CDATA[ <400> 2]]> Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr 1 5 10 15 Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25
           <![CDATA[ <210> 3]]>
 <![CDATA[ <211> 495]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0603 Amino acid sequence of chimeric HPV type 6 L1 protein]]>
 <![CDATA[ <400> 3]]> Met Trp Arg Pro Ser Asp Ser Thr Val Tyr Val Pro Pro Pro Asn Pro 1 5 10 15 Val Ser Lys Val Val Ala Thr Asp Ala Tyr Val Thr Arg Thr Asn Ile 20 25 30 Phe Tyr His Ala Ser Ser Ser Arg Leu Leu Ala Val Gly His Pro Tyr 35 40 45 Phe Ser Ile Lys Arg Ala Asn Lys Thr Val Val Pro Lys Val Ser Gly 50 55 60 Tyr Gln Tyr Arg Val Phe Lys Val Val Leu Pro Asp Pro Asn Lys Phe 65 70 75 80 Ala Leu Pro Asp Ser Ser Leu Phe Asp Pro Thr Thr Gln Arg Leu Val 85 90 95 Trp Ala Cys Thr Gly Leu Glu Val Gly Arg Gly Gln Pro Leu Gly Val 100 105 110 Gly Val Ser Gly His Pro Phe Leu Asn Lys Tyr Asp Asp Val Glu Asn 115 120 125 Ser Gly Ser Gly Gly Asn Pro Gly Gln Asp Asn Arg Val Asn Val Gly 130 135 140 Met Asp Tyr Lys Gln Thr Gln Leu Cys Met Val Gly Cys Ala Pro Pro 145 150 155 160 Leu Gly Glu His Trp Gly Lys Gly Lys Gln Cys Thr Asn Thr Pro Val 165 170 175 Gln Ala Gly Asp Cys Pro Pro Leu Glu Leu Ile Thr Ser Val Ile Gln 180 185 190 Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala Met Asn Phe Ala Asp 195 200 205 Leu Gln Thr Asn Lys Ser Asp Val Pro Ile Asp Ile Cys Gly Thr Thr 210 215 220 Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ala Ala Asp Pro Tyr Gly Asp 225 230 235 240 Arg Leu Phe Phe Phe Leu Arg Lys Glu Gln Met Phe Ala Arg His Phe 245 250 255 Phe Asn Arg Ala Gly Glu Val Gly Glu Pro Val Pro Asp Thr Leu Ile 260 265 270 Ile Lys Gly Ser Gly Asn Arg Thr Ser Val Gly Ser Ser Ile Tyr Val 275 280 285 Asn Thr Pro Ser Gly Ser Leu Val Ser Ser Glu Ala Gln Leu Phe Asn 290 295 300 Lys Pro Tyr Trp Leu Gln Lys Ala Gln Gly His Asn Asn Gly Ile Cys 305 310 315 320 Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp Thr Thr Arg Ser Thr 325 330 335 Asn Met Thr Leu Cys Ala Ser Val Thr Thr Ser Ser Thr Tyr Thr Asn 340 345 350 Ser Asp Tyr Lys Glu Tyr Met Arg His Val Glu Glu Tyr Asp Leu Gln 355 360 365 Phe Ile Phe Gln Leu Cys Ser Ile Thr Leu Ser Ala Glu Val Met Ala 370 375 380 Tyr Ile His Thr Met Asn Pro Ser Val Leu Glu Asp Trp Asn Phe Gly 385 390 395 400 Leu Ser Pro Pro Pro Asn Gly Thr Leu Glu Asp Thr Tyr Arg Tyr Val 405 410 415 Gln Ser Gln Ala Ile Thr Cys Gln Lys Pro Thr Pro Glu Lys Glu Lys 420 425 430 Pro Asp Pro Tyr Lys Asn Leu Ser Phe Trp Glu Val Asn Leu Lys Glu 435 440 445 Lys Phe Ser Ser Glu Leu Asp Gln Tyr Pro Leu Gly Arg Lys Phe Leu 450 455 460 Leu Gln Ser Gly Tyr Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro 465 470 475 480 Thr Ser Thr Arg Thr Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 485 490 495
           <![CDATA[ <210> 4]]>
 <![CDATA[ <211> 1488]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0604 Nucleotide sequence of chimeric HPV type 6 L1 protein]]>
 <![CDATA[ <400> 4]]> atgtggagac catctgacag cacagtctat gtgcctcctc caaaccctgt gagcaaggtg 60 gtggctacag atgcctatgt gaccaggacc aacatcttct accatgcctc ctccagcaga 120 ctgctggctg tgggacaccc atacttcagc atcaagaggg ctaacaagac agtggtgcca 180 aaggtgtctg gctaccaata cagggtgttc aaggtggtgc tgcctgaccc aaacaagttt 240 gccctgcctg actcctccct gtttgaccca accacccaga gactggtgtg ggcttgtact 300 ggattggagg tgggcagggg acaaccactg ggagtggggag tgtctggacaccattcctg 360 aacaaatatg atgatgtgga gaactctggc tctggaggca accctggaca agacaacagg 420 gtgaatgtgg ggatggacta caagcagacc caactttgta tggtgggctg tgcccctcca 480 ctgggagaac actggggcaa gggcaagcag tgtaccaaca cacctgtcca ggctggagac 540 tgtcctccat tggaactgat tacctctgtg attcaggatg gagatatggt ggacacaggc 600 tttggagcta tgaactttgc tgacctccaa accaacaagt ctgatgtgcc aattgacatc 660 tgtggcacca cttgtaaata ccctgactac ctccaaatgg ctgctgaccc atatggagac 720 agactgttct tcttcctgag gaaggaacag atgtttgcca gacacttctt caacagggct 780 ggagaggtgg gagaacctgt gcctgacacc ctgattatca agggctctgg caacaggacc 840 tctgtgggct ccagcatcta tgtgaacaca ccatctggct ccctggtgtc ctctgaggct 900 caacttttca acaagccata ctggctccaa aaggctcaag gacacaacaa tggcatctgt 960 tggggcaacc aactttttgt gacagtggtg gacaccacca ggagcaccaa tatgaccctg 1020 tgtgcctctg tgaccacctc cagcacctac accaactctg actacaagga atatatgagg 1080 catgtggagg aatatgacct ccaattcatc ttccaacttt gtagcatcac cctgtctgct 1140 gaggtgatgg cttacatcca cacaatgaac ccatctgtgt tggaggactg gaactttgga 1200 ctgagccctc ctccaaatgg caccttggag gacacctaca gatatgtcca gagccaggct 1260 atcacttgtc agaagccaac acctgagaag gagaagcctg acccatacaa gaacctgtcc 1320 ttctgggagg tgaacctgaa agagaagttc tcctctgaac tggaccaata cccactgggc 1380 aggaagttcc tgctccaatc tggctacaaa gccaagccaa aactgaaaag ggctgcccca 1440 accagcacca ggacctcctc tgccaagagg aagaaggtga agaagtaa 1488
           <![CDATA[ <210> 5]]>
 <![CDATA[ <211> 1522]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0605 Synthetic HPV6L1 gene]]>
 <![CDATA[ <400> 5]]> ctgggtacca tgtggagacc atctgacagc acagtctatg tgcctcctcc aaaccctgtg 60 agcaaggtgg tggctacaga tgcctatgtg accaggacca acatcttcta ccatgcctcc 120 tccagcagac tgctggctgt gggacaccca tacttcagca tcaagagggc taacaagaca 180 gtggtgccaa aggtgtctgg ctaccaatac agggtgttca aggtggtgct gcctgaccca 240 aacaagtttg ccctgcctga ctcctccctg tttgacccaa ccacccagag actggtgtgg 300 gcttgtactg gattggaggt gggcagggga caaccactgg gagtggggagt gtctggacac 360 ccattcctga acaaatatga tgatgtggag aactctggct ctggaggcaa ccctggacaa 420 gacaacaggg tgaatgtggg gatggactac aagcagaccc aactttgtat ggtgggctgt 480 gcccctccac tgggagaaca ctggggcaag ggcaagcagt gtaccaacac acctgtccag 540 gctggagact gtcctccatt ggaactgatt acctctgtga ttcaggatgg agatatggtg 600 gacacaggct ttggagctat gaactttgct gacctccaaa ccaacaagtc tgatgtgcca 660 attgacatct gtggcaccac ttgtaaatac cctgactacc tccaaatggc tgctgaccca 720 tatggagaca gactgttctt cttcctgagg aaggaacaga tgtttgccag acacttcttc 780 aacagggctg gagaggtggg agaacctgtg cctgacaccc tgattatcaa gggctctggc 840 aacaggacct ctgtgggctc cagcatctat gtgaacacac catctggctc cctggtgtcc 900 tctgaggctc aacttttcaa caagccatac tggctccaaa aggctcaagg acacaacaat 960 ggcatctgtt ggggcaacca actttttgtg acagtggtgg acaccaccag gagcaccaat 1020 atgaccctgt gtgcctctgt gaccacctcc agcacctaca ccaactctga ctacaaggaa 1080 tatatgaggc atgtggagga atatgacctc caattcatct tccaactttg tagcatcacc 1140 ctgtctgctg aggtgatggc ttacatccac acaatgaacc catctgtgtt ggaggactgg 1200 aactttggac tgagccctcc tccaaatggc accttggagg acacctacag atatgtccag 1260 agccaggcta tcacttgtca gaagccaaca cctgagaagg agaagcctga cccatacaag 1320 aacctgtcct tctgggaggt gaacctgaaa gagaagttct cctctgaact ggaccaatac 1380 ccactgggca ggaagttcct gctccaatct ggctacaggg gcaggtccag catcaggaca 1440 ggagtgaaga gacctgctgt gagcaaggca tctgctgccc caaagaggaa gagggctaag 1500 accaagaggt aaactcgagc tc 1522
           <![CDATA[ <210> 6]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <22]]>3> 0606 Synthetic HPV33L1 gene]]&gt;
 <br/>
 <br/> &lt;![CDATA[ &lt;400&gt;6]]&gt;
           <br/> <![CDATA[ctgggtacca tgagtgtgtg gagaccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtgagcagga ccagcatcta ctactatgct 120 ggctccagca gactgctggc tgtgggacac ccatacttca gcatcaagaa cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgtgt gggattggag attggcaggg gacaaccact gggagtgggc 360 atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct 420 ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt 480 tgtctgctgg gctgtaagcc tccaacagga gaacactggg gcaagggagt ggcttgtacc 540 aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat 600 ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag 660 tctgatgtgc caattgacat ctgtggcagc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga ggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 aagggctctg gcaccacagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggagcacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctggggag gtggacctga aagagaagtt ctctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519
           <![CDATA[ <210> 7]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0607 HPV6L1 F1]]>
           <![CDATA[ <400> 7]]> cttggtacca tgtggagacc atctgacagc acagt 35
           <![CDATA[ <210> 8]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0608 HPV6L1 R1]]>
           <![CDATA[ <400> 8]]> gcttggcttt gtagccagat tggagcagga acttcc 36 <![CDATA[ <210> 9]]>
 <![CDATA[ <211> 1426]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0609 HPV6L1 expansion sequence 1]]>
 <![CDATA[ <400> 9]]> cttggtacca tgtggagacc atctgacagc acagtctatg tgcctcctcc aaaccctgtg 60 agcaaggtgg tggctacaga tgcctatgtg accaggacca acatcttcta ccatgcctcc 120 tccagcagac tgctggctgt gggacaccca t acttcagca tcaagagggc taacaagaca 180 gtggtgccaa aggtgtctgg ctaccaatac agggtgttca aggtggtgct gcctgaccca 240 aacaagtttg ccctgcctga ctcctccctg tttgacccaa ccacccagag actggtgtgg 300 gcttgtactg gattgg aggt gggcagggga caaccactgg gagtgggagt gtctggacac 360 ccattcctga acaaatatga tgatgtggag aactctggct ctggaggcaa ccctggacaa 420 gacaacaggg tgaatgtggg gatggactac aagcagaccc aactttgtat ggtgggctgt 480 gcccctccac tgggagaaca ct ggggcaag ggcaagcagt gtaccaacac acctgtccag 540 gctggagact gtcctccatt ggaactgatt acctctgtga ttcaggatgg agatatggtg 600 gacacaggct ttggagctat gaactttgct gacctccaaa ccaacaagtc tgatgtgcca 660 attgacatct gt ggcaccac ttgtaaatac cctgactacc tccaaatggc tgctgaccca 720 tatggagaca gactgttctt cttcctgagg aaggaacaga tgtttgccag acacttcttc 780 aacagggctg gagaggtggg agaacctgtg cctgacaccc tgattatcaa gggctctggc 840 a acaggacct ctgtgggctc cagcatctat gtgaacacac catctggctc cctggtgtcc 900 tctgaggctc aacttttcaa caagccatac tggctccaaa aggctcaagg acacaacaat 960 ggcatctgtt ggggcaacca actttttgtg acagtggtgg acaccaccag gagcaccaat 1020 atgaccctgt gtgcctctgt gaccacctcc agcacctaca ccaactctga ctacaaggaa 1080 tatatgaggc atgtggagga atatgacctc caattcatct tccaactttg tagcatcacc 1140 ctgtctgctg aggtgatggc ttacatccac acaatgaacc catctgtgtt ggaggactgg 12 00 aactttggac tgagccctcc tccaaatggc accttggagg acacctacag atatgtccag 1260 agccaggcta tcacttgtca gaagccaaca cctgagaagg agaagcctga cccatacaag 1320 aacctgtcct tctgggaggt gaacctgaaa gagaagttct cctctga act ggaccaatac 1380 ccactgggca ggaagttcct gctccaatct ggctacaaag ccaagc 1426 <![CDATA[ <210> 10]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0610 HPV6L1 F2]]> <![CDATA[ <400> 10]]> atctggctac aaagccaagc caaaactgaa aaggg 35 <![CDATA[ <210> 11]]>
 <![CDATA[ <211> 37]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0611 HPV6L1 R2]]> <![CDATA[ <400> 11]]> ctgtctagat ttacttcttc accttcttcc tcttggc 37 <![CDATA[ <210> 12]]>
 <![CDATA[ <211> 101]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0612 HPV6L1 expansion sequence 2]]>
 <![CDATA[ <400> 12]]> atctggctac aaagccaagc caaaactgaa aagggctgcc ccaaccagca ccaggacctc 60 ctctgccaag aggaagaagg tgaagaagta aatctagaca g 101 <![CDATA[ <210> 13]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 0613 HPV 59 L1 protein amino acid sequence 471-508]]>
 <![CDATA[ <400> 13]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35 <![CDATA[ <210> 14]]>
 <![CDATA[ <211> 470]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1101 HPV type 11 L1 protein amino acid sequence 1-470]]>
 <![CDATA[ <400> 14]]> Met Trp Arg Pro Ser Asp Ser Thr Val Tyr Val Pro Pro Pro Asn Pro 1 5 10 15 Val Ser Lys Val Val Ala Thr Asp Ala Tyr Val Lys Arg Thr Asn Ile 20 25 30 Phe Tyr His Ala Ser Ser Ser Arg Leu Leu Ala Val Gly His Pro Tyr 35 40 45 Tyr Ser Ile Lys Lys Val Asn Lys Thr Val Val Pro Lys Val Ser Gly 50 55 60 Tyr Gln Tyr Arg Val Phe Lys Val Val Leu Pro Asp Pro Asn Lys Phe 65 70 75 80 Ala Leu Pro Asp Ser Ser Leu Phe Asp Pro Thr Thr Gln Arg Leu Val 85 90 95 Trp Ala Cys Thr Gly Leu Glu Val Gly Arg Gly Gln Pro Leu Gly Val 100 105 110 Gly Val Ser Gly His Pro Leu Leu Asn Lys Tyr Asp Asp Val Glu Asn 115 120 125 Ser Gly Gly Tyr Gly Gly Gly Asn Pro Gly Gln Asp Asn Arg Val Asn Val 130 135 140 Gly Met Asp Tyr Lys Gln Thr Gln Leu Cys Met Val Gly Cys Ala Pro 145 150 155 160 Pro Leu Gly Glu His Trp Gly Lys Gly Thr Gln Cys Ser Asn Thr Ser 165 170 175 Val Gln Asn Gly Asp Cys Pro Pro Leu Glu Leu Ile Thr Ser Val Ile 180 185 190 Gln Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala Met Asn Phe Ala 195 200 205 Asp Leu Gln Thr Asn Lys Ser Asp Val Pro Leu Asp Ile Cys Gly Thr 210 215 220 Val Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ala Ala Asp Pro Tyr Gly 225 230 235 240 Asp Arg Leu Phe Phe Tyr Leu Arg Lys Glu Gln Met Phe Ala Arg His 245 250 255 Phe Phe Asn Arg Ala Gly Thr Val Gly Glu Pro Val Pro Asp Asp Leu 260 265 270 Leu Val Lys Gly Gly Asn Asn Arg Ser Ser Val Ala Ser Ser Ile Tyr 275 280 285 Val His Thr Pro Ser Gly Ser Leu Val Ser Ser Ser Glu Ala Gln Leu Phe 290 295 300 Asn Lys Pro Tyr Trp Leu Gln Lys Ala Gln Gly His Asn Asn Gly Ile 305 310 315 320 Cys Trp Gly Asn His Leu Phe Val Thr Val Val Asp Thr Thr Arg Ser 325 330 335 Thr Asn Met Thr Leu Cys Ala Ser Val Ser Lys Ser Ala Thr Tyr Thr 340 345 350 Asn Ser Asp Tyr Lys Glu Tyr Met Arg His Val Glu Glu Phe Asp Leu 355 360 365 Gln Phe Ile Phe Gln Leu Cys Ser Ile Thr Leu Ser Ala Glu Val Met 370 375 380 Ala Tyr Ile His Thr Met Asn Pro Ser Val Leu Glu Asp Trp Asn Phe 385 390 395 400 Gly Leu Ser Pro Pro Pro Asn Gly Thr Leu Glu Asp Thr Tyr Arg Tyr 405 410 415 Val Gln Ser Gln Ala Ile Thr Cys Gln Lys Pro Thr Pro Glu Lys Glu 420 425 430 Lys Gln Asp Pro Tyr Lys Asp Met Ser Phe Trp Glu Val Asn Leu Lys 435 440 445 Glu Lys Phe Ser Ser Glu Leu Asp Gln Phe Pro Leu Gly Arg Lys Phe 450 455 460 Leu Leu Gln Ser Gly Tyr 465 470 <![CDATA[ <210> 15]]>
 <![CDATA[ <211> 26]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1102 HPV 33 L1 protein amino acid sequence 474-499]]>
 <![CDATA[ <400> 15]]> Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr 1 5 10 15 Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25 <![CDATA[ <210> 16]]>
 <![CDATA[ <211> 496]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1103 Amino acid sequence of chimeric HPV type 11 L1 protein]]>
 <![CDATA[ <400> 16]]> Met Trp Arg Pro Ser Asp Ser Thr Val Tyr Val Pro Pro Pro Asn Pro 1 5 10 15 Val Ser Lys Val Val Ala Thr Asp Ala Tyr Val Lys Arg Thr Asn Ile 20 25 30 Phe Tyr His Ala Ser Ser Ser Arg Leu Leu Ala Val Gly His Pro Tyr 35 40 45 Tyr Ser Ile Lys Lys Val Asn Lys Thr Val Val Pro Lys Val Ser Gly 50 55 60 Tyr Gln Tyr Arg Val Phe Lys Val Val Leu Pro Asp Pro Asn Lys Phe 65 70 75 80 Ala Leu Pro Asp Ser Ser Leu Phe Asp Pro Thr Thr Gln Arg Leu Val 85 90 95 Trp Ala Cys Thr Gly Leu Glu Val Gly Arg Gly Gln Pro Leu Gly Val 100 105 110 Gly Val Ser Gly His Pro Leu Leu Asn Lys Tyr Asp Asp Val Glu Asn 115 120 125 Ser Gly Gly Tyr Gly Gly Gly Asn Pro Gly Gln Asp Asn Arg Val Asn Val 130 135 140 Gly Met Asp Tyr Lys Gln Thr Gln Leu Cys Met Val Gly Cys Ala Pro 145 150 155 160 Pro Leu Gly Glu His Trp Gly Lys Gly Thr Gln Cys Ser Asn Thr Ser 165 170 175 Val Gln Asn Gly Asp Cys Pro Pro Leu Glu Leu Ile Thr Ser Val Ile 180 185 190 Gln Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala Met Asn Phe Ala 195 200 205 Asp Leu Gln Thr Asn Lys Ser Asp Val Pro Leu Asp Ile Cys Gly Thr 210 215 220 Val Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ala Ala Asp Pro Tyr Gly 225 230 235 240 Asp Arg Leu Phe Phe Tyr Leu Arg Lys Glu Gln Met Phe Ala Arg His 245 250 255 Phe Phe Asn Arg Ala Gly Thr Val Gly Glu Pro Val Pro Asp Asp Leu 260 265 270 Leu Val Lys Gly Gly Asn Asn Arg Ser Ser Val Ala Ser Ser Ile Tyr 275 280 285 Val His Thr Pro Ser Gly Ser Leu Val Ser Ser Ser Glu Ala Gln Leu Phe 290 295 300 Asn Lys Pro Tyr Trp Leu Gln Lys Ala Gln Gly His Asn Asn Gly Ile 305 310 315 320 Cys Trp Gly Asn His Leu Phe Val Thr Val Val Asp Thr Thr Arg Ser 325 330 335 Thr Asn Met Thr Leu Cys Ala Ser Val Ser Lys Ser Ala Thr Tyr Thr 340 345 350 Asn Ser Asp Tyr Lys Glu Tyr Met Arg His Val Glu Glu Phe Asp Leu 355 360 365 Gln Phe Ile Phe Gln Leu Cys Ser Ile Thr Leu Ser Ala Glu Val Met 370 375 380 Ala Tyr Ile His Thr Met Asn Pro Ser Val Leu Glu Asp Trp Asn Phe 385 390 395 400 Gly Leu Ser Pro Pro Pro Asn Gly Thr Leu Glu Asp Thr Tyr Arg Tyr 405 410 415 Val Gln Ser Gln Ala Ile Thr Cys Gln Lys Pro Thr Pro Glu Lys Glu 420 425 430 Lys Gln Asp Pro Tyr Lys Asp Met Ser Phe Trp Glu Val Asn Leu Lys 435 440 445 Glu Lys Phe Ser Ser Glu Leu Asp Gln Phe Pro Leu Gly Arg Lys Phe 450 455 460 Leu Leu Gln Ser Gly Tyr Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala 465 470 475 480 Pro Thr Ser Thr Arg Thr Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 485 490 495 <![CDATA[ <210> 17]]>
 <![CDATA[ <211> 1492]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1104 Nucleotide sequence of chimeric HPV type 11 L1 protein]]>
 <![CDATA[ <400> 17]]>
          atgtggagac catctgacag cacagtctat gtgcctcctc caaaccctgt gagcaaggtg      60
          gtggctacag atgcctatgt gaagaggacc aacatcttct accatgcctc ctccagcaga     120
          ctgctggctg tgggacaccc atactacagc atcaagaagg tgaacaagac agtggtgcca     180
          aaggtgtctg gctaccaata cagggtgttc aaggtggtgc tgcctgaccc aaacaagttt     240
          gccctgcctg actcctccct gtttgaccca accacccaga gactggtgtg ggcttgtact     300
          ggattggagg tgggcagggg acaaccactg ggagtgggag tgtctggaca cccactgctg     360
          aacaaatatg atgatgtgga gaactctgga ggctatggag gcaaccctgg acaagacaac     420
          agggtgaatg tggggatgga ctacaagcag acccaacttt gtatggtggg ctgtgcccct     480
          ccactgggag aacactgggg caagggcacc cagtgtagca acacctctgt ccagaatgga     540
          gactgtcctc cattggaact gattacctct gtgattcagg atggagatat ggtggacaca     600
          ggctttggag ctatgaactt tgctgacctc caaaccaaca agtctgatgt gccactggac     660
          atctgtggca cagtgtgtaa ataccctgac tacctccaaa tggctgctga cccatatgga 720 gacagactgt tcttctacct gaggaaggaa cagatgtttg ccagacactt cttcaacagg 780 gctggcacag tgggagaacc tgtgcctgat gacctgctgg tgaagggagg caacaacagg 840 tcc tctgtgg catccagcat ctatgtgcat acaccatctg gctccctggt gtcctctgag 900 gctcaacttt tcaacaagcc atactggctc caaaaggctc aaggacacaa caatggcatc 960 tgttggggca accacctgtt tgtgacagtg gtggacacca ccaggagcac caatatgacc 102 0 ctgtgtgcct ctgtgagcaa gtctgccacc taccaact ctgactacaa ggaatatatg 1080 aggcatgtgg aggagtttga cctccaattc atcttccaac tttgtagcat caccctgtct 1140 gctgaggtga tggcttacat ccacacaatg aacccatctg tgttggag ga ctggaacttt 1200 ggactgagcc ctcctccaaa tggcaccttg gaggacacct acagatatgt ccagagccag 1260 gctatcactt gtcagaagcc aacacctgag aaggagaagc aggacccata caaggatatg 1320 agtttctggg aggtgaacct gaaagagaag ttctcct ctg aactggacca gtttccactg 1380 ggcaggaagt tcctgctcca atctggctac aaagccaagc caaaactgaa aagggctgcc 1440 ccaaccagca ccaggacctc ctctgccaag aggaagaagg tgaagaagta aa 1492 <![CDATA[ <210> 18]]>
 <![CDATA[ <211> 1525]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1105 Synthetic HPV11L1 gene]]>
 <![CDATA[ <400> 18]]> ctgggtacca tgtggagacc atctgacagc acagtctatg tgcctcctcc aaaccctgtg 60 agcaaggtgg tggctacaga tgcctatgtg aagaggacca acatcttcta ccatgcctcc 120 tccagcagac tgctggctgt gggacaccca t actacagca tcaagaaggt gaacaagaca 180 gtggtgccaa aggtgtctgg ctaccaatac agggtgttca aggtggtgct gcctgaccca 240 aacaagtttg ccctgcctga ctcctccctg tttgacccaa ccacccagag actggtgtgg 300 gcttgtactg gattgga ggt gggcagggga caaccactgg gagtgggagt gtctggacac 360 ccactgctga acaaatatga tgatgtggag aactctggag gctatggagg caaccctgga 420 caagacaaca gggtgaatgt ggggatggac tacaagcaga cccaactttg tatggtgggc 480 tgtgcccctc cactgggaga acactgg ggc aagggcaccc agtgtagcaa cacctctgtc 540 cagaatggag actgtcctcc attggaactg attacctctg tgattcagga tggagatatg 600 gtggacacag gctttggagc tatgaacttt gctgacctcc aaaccaacaa gtctgatgtg 660 ccactggaca tctgtggcac agtgtgtaaa taccctgact acctccaaat ggctgctgac 720 ccatatggag acagactgtt cttctacctg aggaaggaac agatgtttgc cagacacttc 780 ttcaacaggg ctggcacagt gggagaacct gtgcctgatg acctgctggt gaagg gaggc 840 aacaacaggt cctctgtggc atccagcatc tatgtgcata caccatctgg ctccctggtg 900 tcctctgagg ctcaactttt caacaagcca tactggctcc aaaaggctca aggacacaac 960 aatggcatct gttggggcaa ccacctgttt gtgacagtgg tggac accac caggagcacc 1020 aatatgaccc tgtgtgcctc tgtgagcaag tctgccacct acaccaactc tgactacaag 1080 gaatatatga ggcatgtgga ggagtttgac ctccaattca tcttccaact ttgtagcatc 1140 accctgtctg ctgaggtgat ggctta catc cacacaatga acccatctgt gttggaggac 1200 tggaactttg gactgagccc tcctccaaat ggcaccttgg aggacaccta cagatatgtc 1260 cagagccagg ctatcacttg tcagaagcca acacctgaga aggagaagca ggacccatac 1320 aaggatatga gtttct ggga ggtgaacctg aaagagaagt tctcctctga actggaccag 1380 tttccactgg gcaggaagtt cctgctccaa tctggctaca ggggcaggac ctctgccagg 1440 acaggcatca agagacctgc tgtgagcaag ccaagcacag ccccaaagag gaagaggacc 1500 aagac caaga agtaaactcg agctc 1525 <![CDATA[ <210> 19]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1106 Synthetic HPV33L1 gene]]>
 <![CDATA[ <400> 19]]> ctgggtacca tgagtgtgtg gagaccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtgagcagga ccagcatcta ctactatgct 120 ggctccagca gactgctggc tgtgggacac ccatact tca gcatcaagaa cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgtg t gggattggag attggcaggg gacaaccact gggagtgggc     360
          atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct     420
          ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt     480
          tgtctgctgg gctgtaagcc tccaacagga gaacactggg gcaagggagt ggcttgtacc     540
          aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat     600
          ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag     660
          tctgatgtgc caattgacat ctgtggcagc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga gggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 a agggctctg gcaccacagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggagcacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctgggag gtggacctga aaga gaagtt ctctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519 <![CDATA[ <210> 20]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1107 HPV11L1 F1]]> <![CDATA[ <400> 20]]> cttggtacca tgtggagacc atctgacagc acagt 35 <![CDATA[ <21]]>0> 21]]&gt;
 <br/> &lt;![CDATA[ &lt;211&gt;36]]&gt; <br/> &lt;![CDATA[ &lt;212&gt;DNA]]&gt; <br/> &lt;![CDATA[ &lt;213&gt; Artificial sequence]]&gt;
 <br/>
 <br/>
 <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
 <br/> &lt;![CDATA[ &lt;223&gt; 1108 HPV11L1 R1]]&gt; <br/>
 <br/> &lt;![CDATA[ &lt;400&gt;21]]&gt; <br/> <![CDATA[gcttggcttt gtagccagat tggagcagga acttcc 36 <![CDATA[ <210> 22]]>
 <![CDATA[ <211> 1429]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1109 HPV11L1 expansion sequence 1]]>
 <![CDATA[ <400> 22]]> cttggtacca tgtggagacc atctgacagc acagtctatg tgcctcctcc aaaccctgtg 60 agcaaggtgg tggctacaga tgcctatgtg aagaggacca acatcttcta ccatgcctcc 120 tccagcagac tgctggctgt gggacaccca t actacagca tcaagaaggt gaacaagaca 180 gtggtgccaa aggtgtctgg ctaccaatac agggtgttca aggtggtgct gcctgaccca 240 aacaagtttg ccctgcctga ctcctccctg tttgacccaa ccacccagag actggtgtgg 300 gcttgtactg gattgga ggt gggcagggga caaccactgg gagtgggagt gtctggacac 360 ccactgctga acaaatatga tgatgtggag aactctggag gctatggagg caaccctgga 420 caagacaaca gggtgaatgt ggggatggac tacaagcaga cccaactttg tatggtgggc 480 tgtgcccctc cactgggaga acactgg ggc aagggcaccc agtgtagcaa cacctctgtc 540 cagaatggag actgtcctcc attggaactg attacctctg tgattcagga tggagatatg 600 gtggacacag gctttggagc tatgaacttt gctgacctcc aaaccaacaa gtctgatgtg 660 ccactggaca tctgtggcac agtgtgtaaa taccctgact acctccaaat ggctgctgac 720 ccatatggag acagactgtt cttctacctg aggaaggaac agatgtttgc cagacacttc 780 ttcaacaggg ctggcacagt gggagaacct gtgcctgatg acctgctggt gaagg gaggc 840 aacaacaggt cctctgtggc atccagcatc tatgtgcata caccatctgg ctccctggtg 900 tcctctgagg ctcaactttt caacaagcca tactggctcc aaaaggctca aggacacaac 960 aatggcatct gttggggcaa ccacctgttt gtgacagtgg tggac accac caggagcacc 1020 aatatgaccc tgtgtgcctc tgtgagcaag tctgccacct acaccaactc tgactacaag 1080 gaatatatga ggcatgtgga ggagtttgac ctccaattca tcttccaact ttgtagcatc 1140 accctgtctg ctgaggtgat ggctta catc cacacaatga acccatctgt gttggaggac 1200 tggaactttg gactgagccc tcctccaaat ggcaccttgg aggacaccta cagatatgtc 1260 cagagccagg ctatcacttg tcagaagcca acacctgaga aggagaagca ggacccatac 1320 aaggatatga gtttct ggga ggtgaacctg aaagagaagt tctcctctga actggaccag 1380 tttccactgg gcaggaagtt cctgctccaa tctggctaca aagccaagc 1429 <![CDATA[ <210> 23]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1110 HPV11L1 F2]]> <![CDATA[ <400> 23]]> atctggctac aaagccaagc caaaactgaa aaggg 35 <![CDATA[ <210> 24]]>
 <![CDATA[ <211]]>> 37]]&gt;
 <br/> &lt;![CDATA[ &lt;212&gt;DNA]]&gt; <br/> &lt;![CDATA[ &lt;213&gt; Artificial sequence]]&gt;
 <br/>
 <br/>
 <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
 <br/> &lt;![CDATA[ &lt;223&gt; 1111 HPV11L1 R2]]&gt; <br/>
 <br/> &lt;![CDATA[ &lt;400&gt;24]]&gt; <br/> <![CDATA[ctgtctagat ttacttcttc accttcttcc tcttggc 37 <![CDATA[ <210> 25]]>
 <![CDATA[ <211> 101]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1112 HPV11L1 expansion sequence 2]]>
 <![CDATA[ <400> 25]]> atctggctac aaagccaagc caaaactgaa aagggctgcc ccaaccagca ccaggacctc 60 ctctgccaag aggaagaagg tgaagaagta aatctagaca g 101 <![CDATA[ <210> 26]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1113 HPV 59 L1 protein amino acid sequence 471-508]]>
 <![CDATA[ <400> 26]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35 <![CDATA[ <210> 27]]>
 <![CDATA[ <211> 474]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1601 HPV type 16 L1 protein amino acid sequence 1-474]]>
 <![CDATA[ <400> 27]]> Met Ser Leu Trp Leu Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val 1 5 10 15 Pro Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Ala Arg Thr Asn 20 25 30 Ile Tyr Tyr His Ala Gly Thr Ser Arg Leu Leu Ala Val Gly His Pro 35 40 45 Tyr Phe Pro Ile Lys Lys Pro Asn Asn Asn Lys Ile Leu Val Pro Lys 50 55 60 Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Ile His Leu Pro Asp Pro 65 70 75 80 Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asn Pro Asp Thr Gln 85 90 95 Arg Leu Val Trp Ala Cys Val Gly Val Glu Val Gly Arg Gly Gln Pro 100 105 110 Leu Gly Val Gly Ile Ser Gly His Pro Leu Leu Asn Lys Leu Asp Asp 115 120 125 Thr Glu Asn Ala Ser Ala Tyr Ala Ala Asn Ala Asn Val Ala Val Asn Pro Gly Asp Cys Pro Pro Leu Glu Leu Ile Asn 180 185 190 Thr Val Ile Gln Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala Met 195 200 205 Asp Phe Thr Thr Leu Gln Ala Asn Lys Ser Glu Val Pro Leu Asp Ile 210 215 220 Cys Thr Ser Ile Cys Lys Tyr Pro Asp Tyr Ile Lys Met Val Ser Glu 225 230 235 240 Pro Tyr Gly Asp Ser Leu Phe Phe Tyr Leu Arg Arg Glu Gln Met Phe 245 250 255 Val Arg His Leu Phe Asn Arg Ala Gly Ala Val Gly Glu Asn Val Pro 260 265 270 Asp Asp Leu Tyr Ile Lys Gly Ser Gly Ser Thr Ala Asn Leu Ala Ser 275 280 285 Ser Asn Tyr Phe Pro Thr Pro Ser Gly Ser Met Val Thr Ser Asp Ala 290 295 300 Gln Ile Phe Asn Lys Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn 305 310 315 320 Asn Gly Ile Cys Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp Thr 325 330 335 Thr Arg Ser Thr Asn Met Ser Leu Cys Ala Ala Ile Ser Thr Ser Glu 340 345 350 Thr Thr Tyr Lys Asn Thr Asn Phe Lys Glu Tyr Leu Arg His Gly Glu 355 360 365 Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu Thr 370 375 380 Ala Asp Val Met Thr Tyr Ile His Ser Met Asn Ser Thr Ile Leu Glu 385 390 395 400 Asp Trp Asn Phe Gly Leu Gln Pro Pro Pro Pro Gly Gly Thr Leu Glu Asp 405 410 415 Thr Tyr Arg Phe Val Thr Ser Gln Ala Ile Ala Cys Gln Lys His Thr 420 425 430 Pro Pro Ala Pro Lys Glu Asp Pro Leu Lys Lys Tyr Thr Phe Trp Glu 435 440 445 Val Asn Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro Leu 450 455 460 Gly Arg Lys Phe Leu Leu Gln Ala Gly Leu 465 470 <![CDATA[ <210> 28]]>
 <![CDATA[ <211> 26]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1602 HPV type 33 L1 protein amino acid sequence 474-499]]>
 <![CDATA[ <400> 28]]> Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr 1 5 10 15 Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25 <![CDATA[ <210> 29]]>
 <![CDATA[ <211> 500]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1603 Amino acid sequence of chimeric HPV type 16 L1 protein]]>
 <![CDATA[ <400> 29]]> Met Ser Leu Trp Leu Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val 1 5 10 15 Pro Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Ala Arg Thr Asn 20 25 30 Ile Tyr Tyr His Ala Gly Thr Ser Arg Leu Leu Ala Val Gly His Pro 35 40 45 Tyr Phe Pro Ile Lys Lys Pro Asn Asn Asn Lys Ile Leu Val Pro Lys 50 55 60 Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Ile His Leu Pro Asp Pro 65 70 75 80 Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asn Pro Asp Thr Gln 85 90 95 Arg Leu Val Trp Ala Cys Val Gly Val Glu Val Gly Arg Gly Gln Pro 100 105 110 Leu Gly Val Gly Ile Ser Gly His Pro Leu Leu Asn Lys Leu Asp Asp 115 120 125 Thr Glu Asn Ala Ser Ala Tyr Ala Ala Asn Ala Asn Val Ala Val Asn Pro Gly Asp Cys Pro Pro Leu Glu Leu Ile Asn 180 185 190 Thr Val Ile Gln Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala Met 195 200 205 Asp Phe Thr Thr Leu Gln Ala Asn Lys Ser Glu Val Pro Leu Asp Ile 210 215 220 Cys Thr Ser Ile Cys Lys Tyr Pro Asp Tyr Ile Lys Met Val Ser Glu 225 230 235 240 Pro Tyr Gly Asp Ser Leu Phe Phe Tyr Leu Arg Arg Glu Gln Met Phe 245 250 255 Val Arg His Leu Phe Asn Arg Ala Gly Ala Val Gly Glu Asn Val Pro 260 265 270 Asp Asp Leu Tyr Ile Lys Gly Ser Gly Ser Thr Ala Asn Leu Ala Ser 275 280 285 Ser Asn Tyr Phe Pro Thr Pro Ser Gly Ser Met Val Thr Ser Asp Ala 290 295 300 Gln Ile Phe Asn Lys Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn 305 310 315 320 Asn Gly Ile Cys Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp Thr 325 330 335 Thr Arg Ser Thr Asn Met Ser Leu Cys Ala Ala Ile Ser Thr Ser Glu 340 345 350 Thr Thr Tyr Lys Asn Thr Asn Phe Lys Glu Tyr Leu Arg His Gly Glu 355 360 365 Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu Thr 370 375 380 Ala Asp Val Met Thr Tyr Ile His Ser Met Asn Ser Thr Ile Leu Glu 385 390 395 400 Asp Trp Asn Phe Gly Leu Gln Pro Pro Pro Pro Gly Gly Thr Leu Glu Asp 405 410 415 Thr Tyr Arg Phe Val Thr Ser Gln Ala Ile Ala Cys Gln Lys His Thr 420 425 430 Pro Pro Ala Pro Lys Glu Asp Pro Leu Lys Lys Tyr Thr Phe Trp Glu 435 440 445 Val Asn Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro Leu 450 455 460 Gly Arg Lys Phe Leu Leu Gln Ala Gly Leu Lys Ala Lys Pro Lys Leu 465 470 475 480 Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr Ser Ser Ala Lys Arg Lys 485 490 495 Lys Val Lys Lys 500 <![CDATA[ <210> 30]]>
 <![CDATA[ <211>]]> 1504
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1604 Nucleotide sequence of chimeric HPV type 16 L1 protein]]>
 <![CDATA[ <400> 30]]> atgagtctgt ggctgccatc tgaggctaca gtctacctgc ctcctgtgcc tgtgagcaag 60 gtggtgagca cagatgaata tgtggcaagg accaacatct actaccatgc tggcaccagc 120 agactgctgg ctgtgggaca cccatacttt ccaatca aga agccaaacaa caacaagatt 180 ctggtgccaa aggtgtctgg actccaatac agggtgttca ggattcacct gcctgaccca 240 aacaagtttg gctttcctga cacctccttc tacaaccctg acacccag actggtgtgg 300 gcttgtgtgg gagtggaggt gggca gggga caaccactgg gagtgggcat ctctggacac 360 ccactgctga acaaactgga tgacacagag aatgcctctg cctatgctgc caatgctgga 420 gtggacaaca gggagtgtat cagtatggac tacaagcaga cccaactttg tctgattggc 480 tgtaagcctc caattggaga acactggggc aag ggcagcc catgtaccaa tgtggctgtg 540 aaccctggag actgtcctcc attggaactg ataaacacag tgattcagga tggagatatg 600 gtggacacag gctttggagc tatggacttc accaccctcc aagccaacaa gtctgaggtg 660 ccactggaca tctgtaccag catctgtaaa taccctgact acatcaagat ggtgtctgaa 720 ccatatggag actccctgtt cttctacctg aggagggaac agatgtttgt gagacacctg 780 ttcaacaggg ctggagcagt gggagagaat gtgcctgatg acctctacat caagggctct 840 ggcagcacag ccaac ctggc atccagcaac tactttccaa caccatctgg cagtatggtg 900 acctctgatg cccagatttt caacaagcca tactggctcc aaagggctca aggacacaac 960 aatggcatct gttggggcaa ccaacttttt gtgacagtgg tggacaccac caggagcacc 1020 aatatgagtc tgtgtgctgc catcagcacc tctgagacca cctacaagaa caccaacttc 1080 aaggaatacc tgagacatgg agaggaatat gacctccaat tcatcttcca actttgtaag 1140 attaccctga cagcagatgt gatgacctac atccacagta tgaacagcac catcttggag 1200 gact ggaact ttggactcca acctcctcct ggaggcacct tggaggacac ctacaggttt 1260 gtgaccagcc aggctattgc ctgtcagaaa cacacacctc ctgccccaaa ggaggaccca 1320 ctgaaaaaat acaccttctg ggaggtgaac ctgaaagaga agttctctgc t gacctggac 1380 cagtttccac tgggcaggaa gttcctgctc caagcaggac tgaaagccaa gccaaaactg 1440 aaaagggctg ccccaaccag caccaggacc tcctctgcca agaggaagaa ggtgaagaag 1500 taaa 1504 <![CDATA[ <210> 31]]>
 <![CDATA[ <211> 1537]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1605 Synthetic HPV16L1 gene]]>
 <![CDATA[ <400> 31]]> ctgggtacca tgagtctgtg gctgccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtggcaagga ccaacatcta ctaccatgct 120 ggcaccagca gactgctggc tgtgggacac ccatact ttc caatcaagaa gccaaacaac 180 aacaagattc tggtgccaaa ggtgtctgga ctccaataca gggtgttcag gattcacctg 240 cctgacccaa acaagtttgg ctttcctgac acctccttct acaaccctga cacccagaga 300 ctggtgtggg cttgtg tggg agtggaggtg ggcaggggac aaccactggg agtgggcatc 360 tctggacacc cactgctgaa caaactggat gacacagaga atgcctctgc ctatgctgcc 420 aatgctggag tggacaacag ggagtgtatc agtatggact acaagcagac ccaactttgt 480 ctgattggct g taagcctcc aattggagaa cactggggca agggcagccc atgtaccaat 540 gtggctgtga accctggaga ctgtcctcca ttggaactga taaacacagt gattcaggat 600 ggagatatgg tggacacagg ctttggagct atggacttca ccaccctcca agccaacaag 660 tctgaggt gc cactggacat ctgtaccagc atctgtaaat accctgacta catcaagatg 720 gtgtctgaac catatggaga ctccctgttc ttctacctga gggagggaaca gatgtttgtg 780 agacacctgt tcaacagggc tggagcagtg ggagagaatg tgcctgatga cctctacatc 840 aaggg ctctg gcagcacagc caacctggca tccagcaact actttccaac accatctggc 900 agtatggtga cctctgatgc ccagattttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caactttttg tgacagtggt ggacaccacc 1020 aggagcacca atatgagtct gtgtgctgcc atcagcacct ctgagaccac ctacaagaac 1080 accaacttca aggaatacct gagacatgga gaggaatatg acctccaatt catcttccaa 1140 ctttgtaaga ttaccctgac agcagatgtg atgacctaca tccacagtat gaacagcacc 1200 atcttgg agg actggaactt tggactccaa cctcctcctg gaggcacctt ggaggacacc 1260 tacaggtttg tgaccagcca ggctattgcc tgtcagaaac acacacctcc tgccccaaag 1320 gaggacccac tgaaaaaata caccttctgg gaggtgaacc tgaaagagaa gttctct gct 1380 gacctggacc agtttccact gggcaggaag ttcctgctcc aagcaggact gaaagccaag 1440 ccaaagttca ccctgggcaa gaggaaggct acaccaacca cctccagcac cagcaccaca 1500 gccaagagga agaagaggaa actgtaaact cgagctc 1537 <![CDATA[ <210> 32]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1606 Synthetic HPV33L1 gene]]>
 <![CDATA[ <400> 32]]> ctgggtacca tgagtgtgtg gagaccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtgagcagga ccagcatcta ctactatgct 120 ggctccagca gactgctggc tgtgggacac ccatact tca gcatcaagaa cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgtg t gggattggag attggcaggg gacaaccact gggagtgggc     360
          atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct     420
          ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt     480
          tgtctgctgg gctgtaagcc tccaacagga gaacactggg gcaagggagt ggcttgtacc     540
          aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat     600
          ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag     660
          tctgatgtgc caattgacat ctgtggcagc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga gggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 a agggctctg gcaccacagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggagcacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctgggag gtggacctga aaga gaagtt ctctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519 <![CDATA[ <210> 33]]>
 <![CDATA[ <211> 34]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1607 HPV16L1 F1]]> <![CDATA[ <400> 33]]> cttggtacca tgagtctgtg gctgccatct gagg 34 <![CDATA[ <210> 34]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1608 HPV16L1 R1]]> <![CDATA[ <400> 34]]> gcttggcttt cagtcctgct tggagcagga acttcc 36 <![CDATA[ <210> 35]]>
 <![CDATA[ <211> 1441]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1609 HPV16L1 expansion sequence 1]]>
 <![CDATA[ <400> 35]]> cttggtacca tgagtctgtg gctgccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtggcaagga ccaacatcta ctaccatgct 120 ggcaccagca gactgctggc tgtgggacac ccatact ttc caatcaagaa gccaaacaac 180 aacaagattc tggtgccaaa ggtgtctgga ctccaataca gggtgttcag gattcacctg 240 cctgacccaa acaagtttgg ctttcctgac acctccttct acaaccctga cacccagaga 300 ctggtgtggg cttgtg tggg agtggaggtg ggcaggggac aaccactggg agtgggcatc 360 tctggacacc cactgctgaa caaactggat gacacagaga atgcctctgc ctatgctgcc 420 aatgctggag tggacaacag ggagtgtatc agtatggact acaagcagac ccaactttgt 480 ctgattggct g taagcctcc aattggagaa cactggggca agggcagccc atgtaccaat 540 gtggctgtga accctggaga ctgtcctcca ttggaactga taaacacagt gattcaggat 600 ggagatatgg tggacacagg ctttggagct atggacttca ccaccctcca agccaacaag 660 tctgaggt gc cactggacat ctgtaccagc atctgtaaat accctgacta catcaagatg 720 gtgtctgaac catatggaga ctccctgttc ttctacctga gggagggaaca gatgtttgtg 780 agacacctgt tcaacagggc tggagcagtg ggagagaatg tgcctgatga cctctacatc 840 aaggg ctctg gcagcacagc caacctggca tccagcaact actttccaac accatctggc 900 agtatggtga cctctgatgc ccagattttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caactttttg tgacagtggt ggacaccacc 1020 aggagcacca atatgagtct gtgtgctgcc atcagcacct ctgagaccac ctacaagaac 1080 accaacttca aggaatacct gagacatgga gaggaatatg acctccaatt catcttccaa 1140 ctttgtaaga ttaccctgac agcagatgtg atgacctaca tccacagtat gaacagcacc 1200 atcttgg agg actggaactt tggactccaa cctcctcctg gaggcacctt ggaggacacc 1260 tacaggtttg tgaccagcca ggctattgcc tgtcagaaac acacacctcc tgccccaaag 1320 gaggacccac tgaaaaaata caccttctgg gaggtgaacc tgaaagagaa gttctct gct 1380 gacctggacc agtttccact gggcaggaag ttcctgctcc aagcaggact gaaagccaag 1440 c 1441 <![CDATA[ <210> 36]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1610 HPV16L1 F2]]> <![CDATA[ <400> 36]]> agcaggactg aaagccaagc caaaactgaa aaggg 35 <![CDATA[ <210> 37]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1611 HPV16L1 R2]]> <![CDATA[ <400> 37]]> ctgtctagat ttacttcttc accttcttcc tcttgg 36 <![CDATA[ <210> 38]]>
 <![CDATA[ <211> 101]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1612 HPV16L1 expansion sequence 2]]>
 <![CDATA[ <400> 38]]> agcaggactg aaagccaagc caaaactgaa aagggctgcc ccaaccagca ccaggacctc 60 ctctgccaag aggaagaagg tgaagaagta aatctagaca g 101 <![CDATA[ <210> 39]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1613 HPV 59 L1 protein amino acid sequence 471-508]]>
 <![CDATA[ <400> 39]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35 <![CDATA[ <210> 40]]>
 <![CDATA[ <211> 470]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1801 HPV type 18 L1 protein amino acid sequence 1-470]]>
 <![CDATA[ <400> 40]]> Met Ala Leu Trp Arg Pro Ser Asp Asn Thr Val Tyr Leu Pro Pro Pro 1 5 10 15 Ser Val Ala Arg Val Val Asn Thr Asp Asp Tyr Val Thr Arg Thr Ser 20 25 30 Ile Phe Tyr His Ala Gly Ser Ser Arg Leu Leu Thr Val Gly Asn Pro 35 40 45 Tyr Phe Arg Val Pro Ala Gly Gly Gly Asn Lys Gln Asp Ile Pro Lys 50 55 60 Val Ser Ala Tyr Gln Tyr Arg Val Phe Arg Val Gln Leu Pro Asp Pro 65 70 75 80 Asn Lys Phe Gly Leu Pro Asp Thr Ser Ile Tyr Asn Pro Glu Thr Gln 85 90 95 Arg Leu Val Trp Ala Cys Ala Gly Val Glu Ile Gly Arg Gly Gln Pro 100 105 110 Leu Gly Val Gly Leu Ser Gly His Pro Phe Tyr Asn Lys Leu Asp Asp 115 120 125 Thr Glu Ser Ser His Ala Ala Thr Ser Asn Val Ser Glu Asp Val Arg 130 135 140 Asp Asn Val Ser Val Asp Tyr Lys Gln Thr Gln Leu Cys Ile Leu Gly 145 150 155 160 Cys Ala Pro Ala Ile Gly Glu His Trp Ala Lys Gly Thr Ala Cys Lys 165 170 175 Ser Arg Pro Leu Ser Gln Gly Asp Cys Pro Pro Leu Glu Leu Lys Asn 180 185 190 Thr Val Leu Glu Asp Gly Asp Met Val Asp Thr Gly Tyr Gly Ala Met 195 200 205 Asp Phe Ser Thr Leu Gln Asp Thr Lys Cys Glu Val Pro Leu Asp Ile 210 215 220 Cys Gln Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser Ala Asp 225 230 235 240 Pro Tyr Gly Asp Ser Met Phe Phe Cys Leu Arg Arg Glu Gln Leu Phe 245 250 255 Ala Arg His Phe Trp Asn Arg Ala Gly Thr Met Gly Asp Thr Val Pro 260 265 270 Gln Ser Leu Tyr Ile Lys Gly Thr Gly Met Arg Ala Ser Pro Gly Ser 275 280 285 Cys Val Tyr Ser Pro Ser Pro Pro Ser Gly Ser Ile Val Thr Ser Asp Ser 290 295 300 Gln Leu Phe Asn Lys Pro Tyr Trp Leu His Lys Ala Gln Gly His Asn 305 310 315 320 Asn Gly Val Cys Trp His Asn Gln Leu Phe Val Thr Val Val Asp Thr 325 330 335 Thr Arg Ser Thr Asn Leu Thr Ile Cys Ala Ser Thr Gln Ser Pro Val 340 345 350 Pro Gly Gln Tyr Asp Ala Thr Lys Phe Lys Gln Tyr Ser Arg His Val 355 360 365 Glu Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Thr Ile Thr Leu 370 375 380 Thr Ala Asp Val Met Ser Tyr Ile His Ser Met Asn Ser Ser Ile Leu 385 390 395 400 Glu Asp Trp Asn Phe Gly Val Pro Pro Pro Pro Thr Thr Ser Leu Val 405 410 415 Asp Thr Tyr Arg Phe Val Gln Ser Val Ala Ile Thr Cys Gln Lys Asp 420 425 430 Ala Ala Pro Ala Glu Asn Lys Asp Pro Tyr Asp Lys Leu Lys Phe Trp 435 440 445 Asn Val Asp Leu Lys Glu Lys Phe Ser Leu Asp Leu Asp Gln Tyr Pro 450 455 460 Leu Gly Arg Lys Phe Leu 465 470 <![CDATA[ <210> 41]]>
 <![CDATA[ <211> 26]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1802 HPV 33 L1 protein amino acid sequence 474-499]]>
 <![CDATA[ <400> 41]]> Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr 1 5 10 15 Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25 <![CDATA[ <210> 42]]>
 <![CDATA[ <211> 496]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> ]]>Artificial sequence
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1803 Amino acid sequence of chimeric HPV type 18 L1 protein]]>
 <![CDATA[ <400> 42]]> Met Ala Leu Trp Arg Pro Ser Asp Asn Thr Val Tyr Leu Pro Pro Pro 1 5 10 15 Ser Val Ala Arg Val Val Asn Thr Asp Asp Tyr Val Thr Arg Thr Ser 20 25 30 Ile Phe Tyr His Ala Gly Ser Ser Arg Leu Leu Thr Val Gly Asn Pro 35 40 45 Tyr Phe Arg Val Pro Ala Gly Gly Gly Asn Lys Gln Asp Ile Pro Lys 50 55 60 Val Ser Ala Tyr Gln Tyr Arg Val Phe Arg Val Gln Leu Pro Asp Pro 65 70 75 80 Asn Lys Phe Gly Leu Pro Asp Thr Ser Ile Tyr Asn Pro Glu Thr Gln 85 90 95 Arg Leu Val Trp Ala Cys Ala Gly Val Glu Ile Gly Arg Gly Gln Pro 100 105 110 Leu Gly Val Gly Leu Ser Gly His Pro Phe Tyr Asn Lys Leu Asp Asp 115 120 125 Thr Glu Ser Ser His Ala Ala Thr Ser Asn Val Ser Glu Asp Val Arg 130 135 140 Asp Asn Val Ser Val Asp Tyr Lys Gln Thr Gln Leu Cys Ile Leu Gly 145 150 155 160 Cys Ala Pro Ala Ile Gly Glu His Trp Ala Lys Gly Thr Ala Cys Lys 165 170 175 Ser Arg Pro Leu Ser Gln Gly Asp Cys Pro Pro Leu Glu Leu Lys Asn 180 185 190 Thr Val Leu Glu Asp Gly Asp Met Val Asp Thr Gly Tyr Gly Ala Met 195 200 205 Asp Phe Ser Thr Leu Gln Asp Thr Lys Cys Glu Val Pro Leu Asp Ile 210 215 220 Cys Gln Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser Ala Asp 225 230 235 240 Pro Tyr Gly Asp Ser Met Phe Phe Cys Leu Arg Arg Glu Gln Leu Phe 245 250 255 Ala Arg His Phe Trp Asn Arg Ala Gly Thr Met Gly Asp Thr Val Pro 260 265 270 Gln Ser Leu Tyr Ile Lys Gly Thr Gly Met Arg Ala Ser Pro Gly Ser 275 280 285 Cys Val Tyr Ser Pro Ser Pro Pro Ser Gly Ser Ile Val Thr Ser Asp Ser 290 295 300 Gln Leu Phe Asn Lys Pro Tyr Trp Leu His Lys Ala Gln Gly His Asn 305 310 315 320 Asn Gly Val Cys Trp His Asn Gln Leu Phe Val Thr Val Val Asp Thr 325 330 335 Thr Arg Ser Thr Asn Leu Thr Ile Cys Ala Ser Thr Gln Ser Pro Val 340 345 350 Pro Gly Gln Tyr Asp Ala Thr Lys Phe Lys Gln Tyr Ser Arg His Val 355 360 365 Glu Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Thr Ile Thr Leu 370 375 380 Thr Ala Asp Val Met Ser Tyr Ile His Ser Met Asn Ser Ser Ile Leu 385 390 395 400 Glu Asp Trp Asn Phe Gly Val Pro Pro Pro Pro Thr Thr Ser Leu Val 405 410 415 Asp Thr Tyr Arg Phe Val Gln Ser Val Ala Ile Thr Cys Gln Lys Asp 420 425 430 Ala Ala Pro Ala Glu Asn Lys Asp Pro Tyr Asp Lys Leu Lys Phe Trp 435 440 445 Asn Val Asp Leu Lys Glu Lys Phe Ser Leu Asp Leu Asp Gln Tyr Pro 450 455 460 Leu Gly Arg Lys Phe Leu Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala 465 470 475 480 Pro Thr Ser Thr Arg Thr Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 485 490 495 <![CDATA[ <210> 43]]>
 <![CDATA[ <211> 1492]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1804 Nucleotide sequence of chimeric HPV type 18 L1 protein]]>
 <![CDATA[ <400> 43]]> atggccctct ggagaccatc cgataacaca gtgtacttgc ccccacccag cgtcgcccgg 60 gtggtgaaca cagacgacta cgtcaccaga acctcaatct tctaccacgc cgggtccagc 120 cggctgctga ccgtgggcaa cccctacttc cgcgt gcccg ccggcggcgg aaacaaacaa 180 gacatcccca aagtcagcgc ctatcagtac cgggtgttcc gcgtccaact gcccgatccc 240 aacaagttcg gcctgcccga cacctccatc tacaacccg agacccag gctggtctgg 300 gcttgcgccg gc gtcgagat cgggaggggc caacccctgg gcgtggggtt gtccggccac 360 cccttctaca acaagctgga cgataccgag tccagccacg cagcaaccag caacgtctcc 420 gaagatgtgc gcgataacgt cagcgtggac tacaaacaaa cccaactgtg catcctggga 480 tgcgc acccg ccatcggcga gcattgggcc aaggggaccg cctgcaagag caggcccctg 540 agccaagggg actgtccacc cctggagttg aagaataccg tgctcgagga cggcgacatg 600 gtggacaccg gctacggcgc tatggatttc tccaccctcc aggacaccaa gtgcgaagtg 660 cccctcgaca tctgccaaag catctgcaag taccccgact acctccagat gagcgccgac 720 ccctacggcg acagcatgtt cttctgtctc agaagggaac aattgttcgc ccgccacttc 780 tggaaccggg ccggcacaat gggagataca gtcccccaga gcctgtacat caaggg gacc 840 ggaatgaggg ccagccccgg gtcctgcgtc tacagcccaa gcccctccgg gagcatcgtc 900 acaagcgata gccaactctt caacaagccc tactggctcc acaaagccca aggccacaat 960 aacggggtgt gttggcacaa ccagctgttc gtgaccgtcg tggac acaac caggtccaca 1020 aacctgacca tctgcgccag cacccaaagc cccgtgcccg gccagtacga cgccacaaag 1080 ttcaaacaat actctcggca cgtggaagag tacgacctcc aattcatctt ccaactctgc 1140 accatcaccc tcaccgccga cgtgatgagc ta catccact ccatgaactc ctccatcctg 1200 gaagactgga atttcggcgt gccaccaccc cctaccacct ccctcgtcga cacctacaga 1260 ttcgtgcaga gcgtggccat cacatgccag aaagacgccg cccccgccga gaacaaagac 1320 ccatacgaca aactgaaatt ctgga acgtc gacctgaaag agaaattcag cctggatctg 1380 gaccagtacc cattgggcag gaagttcctc aaagccaagc caaaactgaa aagggctgcc 1440 ccaaccagca ccaggacctc ctctgccaag aggaagaagg tgaagaagta aa 1492 <![CDATA[ <210> 44]]>
 <![CDATA[ <211> 1543]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1805 Synthetic HPV18L1 gene]]>
 <![CDATA[ [400] gtgcccgc cggcggcgga 180 aacaaacaag acatccccaa agtcagcgcc tatcagtacc gggtgttccg cgtccaactg 240 cccgatccca acaagttcgg cctgcccgac acctccatct acaacccgga gacccagagg 300 ctggtctggg cttgcgccgg cg tcgagatc gggaggggcc aacccctggg cgtggggttg 360 tccggccacc ccttctacaa caagctggac gataccgagt ccagccacgc agcaaccagc 420 aacgtctccg aagatgtgcg cgataacgtc agcgtggact acaaacaaac ccaactgtgc 480 atcctggggat gc gcacccgc catcggcgag cattgggcca aggggaccgc ctgcaagagc 540 aggcccctga gccaagggga ctgtccaccc ctggagttga agaataccgt gctcgaggac 600 ggcgacatgg tggacaccgg ctacggcgct atggatttct ccaccctcca ggacaccaag 660 tgc gaagtgcccctcgacat ctgccaaagc atctgcaagt accccgacta cctccagatg 720 agcgccgacc cctacggcga cagcatgttc ttctgtctca gaagggaaca attgttcgcc 780 cgccacttct ggaaccgggc cggcacaatg ggagatacag tcccccagag cctgtacatc 840 a aggggaccg gaatgagggc cagccccggg tcctgcgtct acagcccaag cccctccggg 900 agcatcgtca caagcgatag ccaactcttc aacaagccct actggctcca caaagcccaa 960 ggccacaata acggggtgtg ttggcacaac cagctgttcg tgaccgtcgt ggaca caacc 1020 aggtccacaa acctgaccat ctgcgccagc acccaaagcc ccgtgcccgg ccagtacgac 1080 gccacaaagt tcaaacaata ctctcggcac gtggaagagt acgacctcca attcatcttc 1140 caactctgca ccatcaccct caccgccgac gtgatgagct acatccactc catga actcc 1200 tccatcctgg aagactggaa tttcggcgtg ccaccacccc ctaccacctc cctcgtcgac 1260 acctacagat tcgtgcagag cgtggccatc acatgccaga aagacgccgc ccccgccgag 1320 aacaaagacc catacgacaa actgaaattc tggaacg tcg acctgaaaga gaaattcagc 1380 ctggatctgg accagtaccc attgggcagg aagttcctcg tgcaagccgg cctcaggaga 1440 aaaccaacaa tcgggcccag gaagaggagc gcccccagcg caaccaccag cagcaagccc 1500 gcaaaaaggg tcagagtgag gg cacgcaaa taaactcgag ctc 1543 <![CDATA[ <210> 45]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1806 Synthetic HPV33L1 gene]]>
 <![CDATA[ <400> 45]]> ctgggtacca tgagtgtgtg gagaccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtgagcagga ccagcatcta ctactatgct 120 ggctccagca gactgctggc tgtgggacac ccatact tca gcatcaagaa cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgtg t gggattggag attggcaggg gacaaccact gggagtgggc     360
          atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct     420
          ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt     480
          tgtctgctgg gctgtaagcc tccaacagga gaacactggg gcaagggagt ggcttgtacc     540
          aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat     600
          ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag     660
          tctgatgtgc caattgacat ctgtggcagc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga gggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 a agggctctg gcaccacagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggagcacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctgggag gtggacctga aaga gaagtt ctctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519 <![CDATA[ <210> 46]]>
 <![CDATA[ <211> 34]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1807 HPV18L1 F1]]> <![CDATA[ <400> 46]]> cttggtacca tggccctctg gagaccatcc gata 34 <![CDATA[ <210> 47]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1808 HPV18L1 R1]]> <![CDATA[ <400> 47]]> gcttggcttt gaggaacttc ctgcccaatg ggtac 35 <![CDATA[ <210> 48]]>
 <![CDATA[ <211> 1429]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1809 HPV18L1 expansion sequence 1]]>
 <![CDATA[ <400> 48]]> cttggtacca tggccctctg gagaccatcc gataacacag tgtacttgcc cccacccagc 60 gtcgcccggg tggtgaacac agacgactac gtcaccagaa cctcaatctt ctaccacgcc 120 gggtccagcc ggctgctgac cgtgggcaac ccctacttcc gc gtgcccgc cggcggcgga 180 aacaaacaag acatccccaa agtcagcgcc tatcagtacc gggtgttccg cgtccaactg 240 cccgatccca acaagttcgg cctgcccgac acctccatct acaacccgga gacccagagg 300 ctggtctggg cttgcgccgg cg tcgagatc gggaggggcc aacccctggg cgtggggttg 360 tccggccacc ccttctacaa caagctggac gataccgagt ccagccacgc agcaaccagc 420 aacgtctccg aagatgtgcg cgataacgtc agcgtggact acaaacaaac ccaactgtgc 480 atcctggggat gc gcacccgc catcggcgag cattgggcca aggggaccgc ctgcaagagc 540 aggcccctga gccaagggga ctgtccaccc ctggagttga agaataccgt gctcgaggac 600 ggcgacatgg tggacaccgg ctacggcgct atggatttct ccaccctcca ggacaccaag 660 tgc gaagtgcccctcgacat ctgccaaagc atctgcaagt accccgacta cctccagatg 720 agcgccgacc cctacggcga cagcatgttc ttctgtctca gaagggaaca attgttcgcc 780 cgccacttct ggaaccgggc cggcacaatg ggagatacag tcccccagag cctgtacatc 840 a aggggaccg gaatgagggc cagccccggg tcctgcgtct acagcccaag cccctccggg 900 agcatcgtca caagcgatag ccaactcttc aacaagccct actggctcca caaagcccaa 960 ggccacaata acggggtgtg ttggcacaac cagctgttcg tgaccgtcgt ggaca caacc 1020 aggtccacaa acctgaccat ctgcgccagc acccaaagcc ccgtgcccgg ccagtacgac 1080 gccacaaagt tcaaacaata ctctcggcac gtggaagagt acgacctcca attcatcttc 1140 caactctgca ccatcaccct caccgccgac gtgatgagct acatccactc catga actcc 1200 tccatcctgg aagactggaa tttcggcgtg ccaccacccc ctaccacctc cctcgtcgac 1260 acctacagat tcgtgcagag cgtggccatc acatgccaga aagacgccgc ccccgccgag 1320 aacaaagacc catacgacaa actgaaattc tggaacg tcg acctgaaaga gaaattcagc 1380 ctggatctgg accagtaccc attgggcagg aagttcctca aagccaagc 1429 <![CDATA[ <210> 49]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1810 HPV18L1 F2]]> <![CDATA[ <400> 49]]> gaagttcctc aaagccaagc caaaactgaa aaggg 35 <![CDATA[ <210> 50]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1811 HPV18L1 R2]]> <![CDATA[ <400> 50]]> ctgtctagat ttacttcttc accttcttcc tcttgg 36 <![CDATA[ <210> 51]]>
 <![CDATA[ <211> 101]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1812 HPV18L1 expansion sequence 2]]>
 <![CDATA[ <400> 51]]> gaagttcctc aaagccaagc caaaactgaa aagggctgcc ccaaccagca ccaggacctc 60 ctctgccaag aggaagaagg tgaagaagta aatctagaca g 101 <![CDATA[ <210> 52]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 1813 HPV 59 L1 protein amino acid sequence 471-508]]>
 <![CDATA[ <400> 52]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35 <![CDATA[ <210> 53]]>
 <![CDATA[ <211> 475]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3101 HPV 31 L1 protein amino acid sequence 1-475]]>
 <![CDATA[ <400> 53]]> Met Ser Leu Trp Arg Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val 1 5 10 15 Pro Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Thr Arg Thr Asn 20 25 30 Ile Tyr Tyr His Ala Gly Ser Ala Arg Leu Leu Thr Val Gly His Pro 35 40 45 Tyr Tyr Ser Ile Pro Lys Ser Asp Asn Pro Lys Lys Ile Val Val Pro 50 55 60 Lys Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Val Arg Leu Pro Asp 65 70 75 80 Pro Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asn Pro Glu Thr 85 90 95 Gln Arg Leu Val Trp Ala Cys Val Gly Leu Glu Val Gly Arg Gly Gln 100 105 110 Pro Leu Gly Val Gly Ile Ser Gly His Pro Leu Leu Asn Lys Phe Asp 115 120 125 Asp Thr Glu Asn Ser Asn Arg Tyr Ala Gly Gly Pro Gly Thr Asp Asn 130 135 140 Arg Glu Cys Ile Ser Met Asp Tyr Lys Gln Thr Gln Leu Cys Leu Leu 145 150 155 160 Gly Cys Lys Pro Pro Ile Gly Glu His Trp Gly Lys Gly Ser Pro Cys 165 170 175 Ser Asn Asn Ala Ile Thr Pro Gly Asp Cys Pro Pro Leu Glu Leu Lys 180 185 190 Asn Ser Val Ile Gln Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala 195 200 205 Met Asp Phe Thr Ala Leu Gln Asp Thr Lys Ser Asn Val Pro Leu Asp 210 215 220 Ile Cys Asn Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Lys Met Val Ala 225 230 235 240 Glu Pro Tyr Gly Asp Thr Leu Phe Phe Tyr Leu Arg Arg Glu Gln Met 245 250 255 Phe Val Arg His Phe Phe Asn Arg Ser Gly Thr Val Gly Glu Ser Val 260 265 270 Pro Thr Asp Leu Tyr Ile Lys Gly Ser Gly Ser Thr Ala Thr Leu Ala 275 280 285 Asn Ser Thr Tyr Phe Pro Thr Pro Ser Gly Ser Met Val Thr Ser Asp 290 295 300 Ala Gln Ile Phe Asn Lys Pro Tyr Trp Met Gln Arg Ala Gln Gly His 305 310 315 320 Asn Asn Gly Ile Cys Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp 325 330 335 Thr Thr Arg Ser Thr Asn Met Ser Val Cys Ala Ala Ile Ala Asn Ser 340 345 350 Asp Thr Thr Phe Lys Ser Ser Asn Phe Lys Glu Tyr Leu Arg His Gly 355 360 365 Glu Glu Phe Asp Leu Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu 370 375 380 Ser Ala Asp Ile Met Thr Tyr Ile His Ser Met Asn Pro Ala Ile Leu 385 390 395 400 Glu Asp Trp Asn Phe Gly Leu Thr Thr Pro Pro Ser Gly Ser Leu Glu 405 410 415 Asp Thr Tyr Arg Phe Val Thr Ser Gln Ala Ile Thr Cys Gln Lys Ser 420 425 430 Ala Pro Gln Lys Pro Lys Glu Asp Pro Phe Lys Asp Tyr Val Phe Trp 435 440 445 Glu Val Asn Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro 450 455 460 Leu Gly Arg Lys Phe Leu Leu Gln Ala Gly Tyr 465 470 475 <![CDATA[ <210> 54]]>
 <![CDATA[ <211> 26]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3102 HPV 33 L1 protein amino acid sequence 474-499]]>
 <![CDATA[ <400> 54]]> Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr 1 5 10 15 Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25 <![CDATA[ <210> 55]]>
 <![CDATA[ <211> 501]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3103 Amino acid sequence of chimeric HPV type 31 L1 protein]]>
 <![CDATA[ <400> 55]]> Met Ser Leu Trp Arg Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val 1 5 10 15 Pro Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Thr Arg Thr Asn 20 25 30 Ile Tyr Tyr His Ala Gly Ser Ala Arg Leu Leu Thr Val Gly His Pro 35 40 45 Tyr Tyr Ser Ile Pro Lys Ser Asp Asn Pro Lys Lys Ile Val Val Pro 50 55 60 Lys Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Val Arg Leu Pro Asp 65 70 75 80 Pro Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asn Pro Glu Thr 85 90 95 Gln Arg Leu Val Trp Ala Cys Val Gly Leu Glu Val Gly Arg Gly Gln 100 105 110 Pro Leu Gly Val Gly Ile Ser Gly His Pro Leu Leu Asn Lys Phe Asp 115 120 125 Asp Thr Glu Asn Ser Asn Arg Tyr Ala Gly Gly Pro Gly Thr Asp Asn 130 135 140 Arg Glu Cys Ile Ser Met Asp Tyr Lys Gln Thr Gln Leu Cys Leu Leu 145 150 155 160 Gly Cys Lys Pro Pro Ile Gly Glu His Trp Gly Lys Gly Ser Pro Cys 165 170 175 Ser Asn Asn Ala Ile Thr Pro Gly Asp Cys Pro Pro Leu Glu Leu Lys 180 185 190 Asn Ser Val Ile Gln Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala 195 200 205 Met Asp Phe Thr Ala Leu Gln Asp Thr Lys Ser Asn Val Pro Leu Asp 210 215 220 Ile Cys Asn Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Lys Met Val Ala 225 230 235 240 Glu Pro Tyr Gly Asp Thr Leu Phe Phe Tyr Leu Arg Arg Glu Gln Met 245 250 255 Phe Val Arg His Phe Phe Asn Arg Ser Gly Thr Val Gly Glu Ser Val 260 265 270 Pro Thr Asp Leu Tyr Ile Lys Gly Ser Gly Ser Thr Ala Thr Leu Ala 275 280 285 Asn Ser Thr Tyr Phe Pro Thr Pro Ser Gly Ser Met Val Thr Ser Asp 290 295 300 Ala Gln Ile Phe Asn Lys Pro Tyr Trp Met Gln Arg Ala Gln Gly His 305 310 315 320 Asn Asn Gly Ile Cys Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp 325 330 335 Thr Thr Arg Ser Thr Asn Met Ser Val Cys Ala Ala Ile Ala Asn Ser 340 345 350 Asp Thr Thr Phe Lys Ser Ser Asn Phe Lys Glu Tyr Leu Arg His Gly 355 360 365 Glu Glu Phe Asp Leu Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu 370 375 380 Ser Ala Asp Ile Met Thr Tyr Ile His Ser Met Asn Pro Ala Ile Leu 385 390 395 400 Glu Asp Trp Asn Phe Gly Leu Thr Thr Pro Pro Ser Gly Ser Leu Glu 405 410 415 Asp Thr Tyr Arg Phe Val Thr Ser Gln Ala Ile Thr Cys Gln Lys Ser 420 425 430 Ala Pro Gln Lys Pro Lys Glu Asp Pro Phe Lys Asp Tyr Val Phe Trp 435 440 445 Glu Val Asn Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro 450 455 460 Leu Gly Arg Lys Phe Leu Leu Gln Ala Gly Tyr Lys Ala Lys Pro Lys 465 470 475 480 Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr Ser Ser Ala Lys Arg 485 490 495 Lys Lys Val Lys Lys 500 <![CDATA[ <210> 56]]>
 <![CDATA[ <211> 1507]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3104 Nucleotide sequence of chimeric HPV type 31 L1 protein]]>
 <![CDATA[ <400> 56]]> atgagcctgt ggaggcccag cgaggccacc gtgtacctgc cccccgtgcc cgtgagcaag 60 gtggtgagca ccgacgagta cgtgaccagg accaacatct actaccacgc cggcagcgcc 120 aggctgctga ccgtgggcca cccctactac agcatcc cca agagcgacaa ccccaagaag 180 atcgtggtgc ccaaggtgag cggcctgcag tacagggtgt tcagggtgag gctgcccgac 240 cccaacaagt tcggcttccc cgacaccagc ttctacaacc ccgagaccca gaggctggtg 300 tgggcctgcg tg ggcctgga ggtgggcagg ggccagcccc tgggcgtggg catcagcggc 360 caccccctgc tgaacaagtt cgacgacacc gagaacagca acaggtacgc cggcggcccc 420 ggcaccgaca acagggagtg catcagcatg gactacaagc agacccagct gtgcctgctg 480 ggctgcaagc cccccatcgg c gagcactgg ggcaagggca gcccctgcag caacaacgcc 540 atcaccccg gcgactgccc ccccctggag ctgaagaaca gcgtgatcca ggacggcgac 600 atggtggaca ccggcttcgg cgccatggac ttcaccgccc tgcaggacac caagagcaac 660 gtgcccctgg acatctgcaa cagcatctgc aagtaccccg actacctgaa gatggtggcc 720 gagccctacg gcgacaccct gttcttctac ctgaggaggg agcagatgtt cgtgaggcac 780 ttcttcaaca ggagcggcac cgtgggcgag agcgtgccca ccgacctgta catca agggc 840 agcggcagca ccgccaccct ggccaacagc acctacttcc ccacccccag cggcagcatg 900 gtgaccagcg acgcccagat cttcaacaag ccctactgga tgcagagggc ccagggccac 960 aacaacggca tctgctgggg caaccagctg ttcgtgaccg tggtggacac caccaggagc 1020 accaacatga gcgtgtgcgc cgccatcgcc aacagcgaca ccaccttcaa gagcagcaac 1080 ttcaaggagt acctgaggca cggcgaggag ttcgacctgc agttcatctt ccagctgtgc 1140 aagatcaccc tgag cgccga catcatgacc tacatccaca gcatgaaccc cgccatcctg 1200 gaggactgga acttcggcct gaccaccccc cccagcggca gcctggagga cacctacagg 1260 ttcgtgacca gccaggccat cacctgccag aagtccgccc cccagaagcc caaggaggac 1320 cccttcaagg actacgt gtt ctgggaggtg aacctgaagg agaagttcag cgccgacctg 1380 gaccagttcc ccctgggcag gaagttcctg ctgcaggccg gctacaaagc caagccaaaa 1440 ctgaaaaggg ctgccccaac cagcaccagg acctcctctg ccaagaggaa gaaggtgaag 15 00 aagtaaa 1507 <![CDATA[ <210> 57]]>
 <![CDATA[ <211> 1534]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3105 Synthetic HPV31L1 gene]]>
 <![CDATA[ <400> 57]]> ctgggtacca tgagcctgtg gaggcccagc gaggccaccg tgtacctgcc ccccgtgccc 60 gtgagcaagg tggtgagcac cgacgagtac gtgaccagga ccaacatcta ctaccacgcc 120 ggcagcgcca ggctgctgac cgtgggcc ac ccctactaca gcatccccaa gagcgacaac 180 cccaagaaga tcgtggtgcc caaggtgagc ggcctgcagt acagggtgtt cagggtgagg 240 ctgcccgacc ccaacaagtt cggcttcccc gacaccagct tctacaaccc cgagacccag 300 aggctggtgt gggcctg cgt gggcctggag gtgggcaggg gccagcccct gggcgtgggc 360 atcagcggcc accccctgct gaacaagttc gacgacaccg agaacagcaa caggtacgcc 420 ggcggccccg gcaccgacaa cagggagtgc atcagcatgg actacaagca gacccagctg 480 tgcctgctgg gct gcaagcc ccccatcggc gagcactggg gcaagggcag cccctgcagc 540 aacaacgcca tcacccccgg cgactgcccc cccctggagc tgaagaacag cgtgatccag 600 gacggcgaca tggtggacac cggcttcggc gccatggact tcaccgccct gcaggacacc 660 aagagcaacg tgcccctgga catctgcaac agcatctgca agtaccccga ctacctgaag 720 atggtggccg agccctacgg cgacaccctg ttcttctacc tgaggaggga gcagatgttc 780 gtgaggcact tcttcaacag gagcggcacc gtgggcgaga gcgtgcccac cgacct gtac 840 atcaagggca gcggcagcac cgccaccctg gccaacagca cctacttccc cacccccagc 900 ggcagcatgg tgaccagcga cgcccagatc ttcaacaagc cctactggat gcagagggcc 960 cagggccaca acaacggcat ctgctggggc aaccagctgt tcgtga ccgt ggtggacacc 1020 accaggagca ccaacatgag cgtgtgcgcc gccatcgcca acagcgacac caccttcaag 1080 agcagcaact tcaaggagta cctgaggcac ggcgaggagt tcgacctgca gttcatcttc 1140 cagctgtgca agatcaccct gagcgccg ac atcatgacct acatccacag catgaaccc 1200 gccatcctgg aggactggaa cttcggcctg accaccccccc ccagcggcag cctggaggac 1260 acctacaggt tcgtgaccag ccaggccatc acctgccaga agtccgcccc ccagaagccc 1320 aaggaggacc ccttcaagga ctacgtgttc tgggaggtga acctgaagga gaagttcagc 1380 gccgacctgg accagttccc cctgggcagg aagttcctgc tgcaggccgg ctacagggcc 1440 aggcccaagt tcaaggccgg caagaggagc gcccccagcg ccagcaccac cacccccgcc 1500 aagaggaaga agacca agaa gtaaactcga gctc 1534 <![CDATA[ <210> 58]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3106 Synthetic HPV33L1 gene]]>
 <![CDATA[ <400> 58]]> ctgggtacca tgagtgtgtg gagaccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtgagcagga ccagcatcta ctactatgct 120 ggctccagca gactgctggc tgtgggacac ccatact tca gcatcaagaa cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgtg t gggattggag attggcaggg gacaaccact gggagtgggc     360
          atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct     420
          ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt     480
          tgtctgctgg gctgtaagcc tccaacagga gaacactggg gcaagggagt ggcttgtacc     540
          aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat     600
          ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag     660
          tctgatgtgc caattgacat ctgtggcagc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga gggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 a agggctctg gcaccacagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggagcacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctgggag gtggacctga aaga gaagtt ctctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519 <![CDATA[ <210> 59]]>
 <![CDATA[ <211> 33]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3107 HPV31L1 F1]]> <![CDATA[ <400> 59]]> cttggtacca tgagcctgtg gaggcccagc gag 33 <![CDATA[ <210> 60]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3108 HPV31L1 R1]]> <![CDATA[ <400> 60]]> gcttggcttt gtagccggcc tgcagcagga acttcctg 38 <![CDATA[ <210> 61]]>
 <![CDATA[ <211> 1444]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3109 HPV31L1 expansion sequence 1]]>
 <![CDATA[ <400> 61]]> cttggtacca tgagcctgtg gaggcccagc gaggccaccg tgtacctgcc ccccgtgccc 60 gtgagcaagg tggtgagcac cgacgagtac gtgaccagga ccaacatcta ctaccacgcc 120 ggcagcgcca ggctgctgac cgtgggcc ac ccctactaca gcatccccaa gagcgacaac 180 cccaagaaga tcgtggtgcc caaggtgcagc ggcctgcagt acagggtgtt cagggtgagg 240 ctgcccgacc ccaacaagtt cggcttcccc gacaccagct tctacaaccc cgagacccag 300 aggctggtgt gggcctg cgt gggcctggag gtgggcaggg gccagcccct gggcgtgggc 360 atcagcggcc accccctgct gaacaagttc gacgacaccg agaacagcaa caggtacgcc 420 ggcggccccg gcaccgacaa cagggagtgc atcagcatgg actacaagca gacccagctg 480 tgcctgctgg gct gcaagcc ccccatcggc gagcactggg gcaagggcag cccctgcagc 540 aacaacgcca tcacccccgg cgactgcccc cccctggagc tgaagaacag cgtgatccag 600 gacggcgaca tggtggacac cggcttcggc gccatggact tcaccgccct gcaggacacc 660 aagagcaacg tgcccctgga catctgcaac agcatctgca agtaccccga ctacctgaag 720 atggtggccg agccctacgg cgacaccctg ttcttctacc tgaggaggga gcagatgttc 780 gtgaggcact tcttcaacag gagcggcacc gtgggcgaga gcgtgcccac cgacct gtac 840 atcaagggca gcggcagcac cgccaccctg gccaacagca cctacttccc cacccccagc 900 ggcagcatgg tgaccagcga cgcccagatc ttcaacaagc cctactggat gcagagggcc 960 cagggccaca acaacggcat ctgctggggc aaccagctgt tcgtga ccgt ggtggacacc 1020 accaggagca ccaacatgag cgtgtgcgcc gccatcgcca acagcgacac caccttcaag 1080 agcagcaact tcaaggagta cctgaggcac ggcgaggagt tcgacctgca gttcatcttc 1140 cagctgtgca agatcaccct gagcgccg ac atcatgacct acatccacag catgaaccc 1200 gccatcctgg aggactggaa cttcggcctg accaccccccc ccagcggcag cctggaggac 1260 acctacaggt tcgtgaccag ccaggccatc acctgccaga agtccgcccc ccagaagccc 1320 aaggaggacc ccttcaagga ctacgtgttc tgggaggtga acctgaagga gaagttcagc 1380 gccgacctgg accagttccc cctgggcagg aagttcctgc tgcaggccgg ctacaaagcc 1440 aagc 1444 <![CDATA[ <210> 62]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3110 HPV31L1 F2]]> <![CDATA[ <400> 62]]> ggccggctac aaagccaagc caaaactgaa aaggg 35 <![CDATA[ <210> 63]]>
 <![CDATA[ <211> 41]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3111 HPV31L1 R2]]> <![CDATA[ <400> 63]]> ctgtctagat ttacttcttc accttcttcc tcttggcaga g 41 <![CDATA[ <210> 64]]>
 <![CDATA[ <211> 101]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3112 HPV31L1 expansion sequence 2]]>
 <![CDATA[ <400> 64]]> ggccggctac aaagccaagc caaaactgaa aagggctgcc ccaaccagca ccaggacctc 60 ctctgccaag aggaagaagg tgaagaagta aatctagaca g 101 <![CDATA[ <210> 65]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3113 HPV 59 L1 protein amino acid sequence 471-508]]>
 <![CDATA[ <400> 65]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35 <![CDATA[ <210> 66]]>
 <![CDATA[ <211> 499]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3301 Amino acid sequence of HPV type 33 L1 protein]]>
 <![CDATA[ <400> 66]]> Met Ser Val Trp Arg Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val 1 5 10 15 Pro Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Ser Arg Thr Ser 20 25 30 Ile Tyr Tyr Tyr Ala Gly Ser Ser Arg Leu Leu Ala Val Gly His Pro 35 40 45 Tyr Phe Ser Ile Lys Asn Pro Thr Asn Ala Lys Lys Leu Leu Val Pro 50 55 60 Lys Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Val Arg Leu Pro Asp 65 70 75 80 Pro Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asn Pro Asp Thr 85 90 95 Gln Arg Leu Val Trp Ala Cys Val Gly Leu Glu Ile Gly Arg Gly Gln 100 105 110 Pro Leu Gly Val Gly Ile Ser Gly His Pro Leu Leu Asn Lys Phe Asp 115 120 125 Asp Thr Glu Thr Gly Asn Lys Tyr Pro Gly Gln Pro Gly Ala Asp Asn 130 135 140 Arg Glu Cys Leu Ser Met Asp Tyr Lys Gln Thr Gln Leu Cys Leu Leu 145 150 155 160 Gly Cys Lys Pro Pro Thr Gly Glu His Trp Gly Lys Gly Val Ala Cys 165 170 175 Thr Asn Ala Ala Pro Ala Asn Asp Cys Pro Pro Leu Glu Leu Ile Asn 180 185 190 Thr Ile Ile Glu Asp Gly Asp Met Val Asp Thr Gly Phe Gly Cys Met 195 200 205 Asp Phe Lys Thr Leu Gln Ala Asn Lys Ser Asp Val Pro Ile Asp Ile 210 215 220 Cys Gly Ser Thr Cys Lys Tyr Pro Asp Tyr Leu Lys Met Thr Ser Glu 225 230 235 240 Pro Tyr Gly Asp Ser Leu Phe Phe Phe Leu Arg Arg Glu Gln Met Phe 245 250 255 Val Arg His Phe Phe Asn Arg Ala Gly Thr Leu Gly Glu Ala Val Pro 260 265 270 Asp Asp Leu Tyr Ile Lys Gly Ser Gly Thr Thr Ala Ser Ile Gln Ser 275 280 285 Ser Ala Phe Phe Pro Thr Pro Ser Gly Ser Met Val Thr Ser Glu Ser 290 295 300 Gln Leu Phe Asn Lys Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn 305 310 315 320 Asn Gly Ile Cys Trp Gly Asn Gln Val Phe Val Thr Val Val Asp Thr 325 330 335 Thr Arg Ser Thr Asn Met Thr Leu Cys Thr Gln Val Thr Ser Asp Ser 340 345 350 Thr Tyr Lys Asn Glu Asn Phe Lys Glu Tyr Ile Arg His Val Glu Glu 355 360 365 Tyr Asp Leu Gln Phe Val Phe Gln Leu Cys Lys Val Thr Leu Thr Ala 370 375 380 Glu Val Met Thr Tyr Ile His Ala Met Asn Pro Asp Ile Leu Glu Asp 385 390 395 400 Trp Gln Phe Gly Leu Thr Pro Pro Pro Ser Ala Ser Leu Gln Asp Thr 405 410 415 Tyr Arg Phe Val Thr Ser Gln Ala Ile Thr Cys Gln Lys Thr Val Pro 420 425 430 Pro Lys Glu Lys Glu Asp Pro Leu Gly Lys Tyr Thr Phe Trp Glu Val 435 440 445 Asp Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro Leu Gly 450 455 460 Arg Lys Phe Leu Leu Gln Ala Gly Leu Lys Ala Lys Pro Lys Leu Lys 465 470 475 480 Arg Ala Ala Pro Thr Ser Thr Arg Thr Ser Ser Ala Lys Arg Lys Lys 485 490 495 Val Lys Lys <![CDATA[ <210> 67]]>
 <![CDATA[ <211> 1501]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3302 Nucleotide sequence of HPV type 33 L1 protein]]>
 <![CDATA[ <400> 67]]> atgagtgtgt ggagaccatc tgaggctaca gtctacctgc ctcctgtgcc tgtgagcaag 60 gtggtgagca cagatgaata tgtgagcagg accagcatct actactatgc tggctccagc 120 agactgctgg ctgtgggaca cccatacttc agcatcaaga acccaaccaa tgccaagaaa 180 ctgctggtgc caaaggtgtc tggactccaa tacagggtgt tcagggtgag actgcctgac 240 ccaaacaagt ttggctttcc tgacacctcc ttctacaacc ctgacaccca gagactggtg 300 tgggcttgtg tg ggattgga gattggcagg ggacaaccac tgggagtggg catctctgga     360
          cacccactgc tgaacaagtt tgatgacaca gagacaggca acaaataccc tggacaacct     420
          ggagcagaca acagggagtg tctgagtatg gactacaagc agacccaact ttgtctgctg     480
          ggctgtaagc ctccaacagg agaacactgg ggcaagggag tggcttgtac caatgctgcc     540
          cctgccaatg actgtcctcc attggaactg ataaacacca tcattgagga tggagatatg     600
          gtggacacag gctttggctg tatggacttc aagaccctcc aagccaacaa gtctgatgtg     660
          ccaattgaca tctgtggcag cacttgtaaa taccctgact acctgaaaat gacctctgaa     720
          ccatatggag actccctgtt cttcttcctg aggagggaac agatgtttgt gagacacttc     780
          ttcaacaggg ctggcaccct gggagaggct gtgcctgatg acctctacat caagggctct     840
          ggcaccacag ccagcatcca gtcctctgcc ttctttccaa caccatctgg cagtatggtg     900
          acctctgaga gccaactttt caacaagcca tactggctcc aaagggctca aggacacaac     960
          aatggcatct gttggggcaa ccaggtgttt gtgacagtgg tggacaccac caggagcacc 1020 aatatgaccc tgtgtaccca ggtgacctct gacagcacct acaagaatga gaacttcaag 1080 gaatacatca ggcatgtgga ggaatatgac ctccaatttg tgttccaact ttgtaaggtg 1140 accctgacag cagaggtgat gacctacatc catgctatga accctgacat cttggaggac 1200 tggcagtttg gactgacacc tcctccatct gcctccctcc aagacaccta caggtttgtg 1260 accagccagg ctatcacttg tcagaagaca gtgcctccaa aggagaagga ggacccactg 1320 ggcaaataca ccttctggga ggtggacct g aaagagaagt tctctgctga cctggaccag 1380 tttccactgg gcaggaagtt cctgctccaa gcaggactga aagccaagcc aaaactgaaa 1440 agggctgccc caaccagcac caggacctcc tctgccaaga ggaagaaggt gaagaagtaa 1500 a 1501 <![CDATA[ <210> 68]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3303 Synthetic HPV33L1 gene]]>
 <![CDATA[ <400> 68]]> ctgggtacca tgagtgtgtg gagaccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtgagcagga ccagcatcta ctactatgct 120 ggctccagca gactgctggc tgtgggacac ccatact tca gcatcaagaa cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgtg t gggattggag attggcaggg gacaaccact gggagtgggc     360
          atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct     420
          ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt     480
          tgtctgctgg gctgtaagcc tccaacagga gaacactggg gcaagggagt ggcttgtacc     540
          aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat     600
          ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag     660
          tctgatgtgc caattgacat ctgtggcagc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga gggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 a agggctctg gcaccacagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggagcacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctgggag gtggacctga aaga gaagtt ctctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519 <![CDATA[ <210> 69]]>
 <![CDATA[ <211> 472]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3501 HPV 35 L1 protein amino acid sequence 1-472]]>
 <![CDATA[ <400> 69]]> Met Ser Leu Trp Arg Ser Asn Glu Ala Thr Val Tyr Leu Pro Pro Val 1 5 10 15 Ser Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Thr Arg Thr Asn 20 25 30 Ile Tyr Tyr His Ala Gly Ser Ser Arg Leu Leu Ala Val Gly His Pro 35 40 45 Tyr Tyr Ala Ile Lys Lys Gln Asp Ser Asn Lys Ile Ala Val Pro Lys 50 55 60 Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Val Lys Leu Pro Asp Pro 65 70 75 80 Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asp Pro Ala Ser Gln 85 90 95 Arg Leu Val Trp Ala Cys Thr Gly Val Glu Val Gly Arg Gly Gln Pro 100 105 110 Leu Gly Val Gly Ile Ser Gly His Pro Leu Leu Asn Lys Leu Asp Asp 115 120 125 Thr Glu Asn Ser Asn Lys Tyr Val Gly Asn Ser Gly Thr Asp Asn Arg 130 135 140 Glu Cys Ile Ser Met Asp Tyr Lys Gln Thr Gln Leu Cys Leu Ile Gly 145 150 155 160 Cys Arg Pro Pro Ile Gly Glu His Trp Gly Lys Gly Thr Pro Cys Asn 165 170 175 Ala Asn Gln Val Lys Ala Gly Glu Cys Pro Pro Leu Glu Leu Leu Asn 180 185 190 Thr Val Leu Gln Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala Met 195 200 205 Asp Phe Thr Thr Leu Gln Ala Asn Lys Ser Asp Val Pro Leu Asp Ile 210 215 220 Cys Ser Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Lys Met Val Ser Glu 225 230 235 240 Pro Tyr Gly Asp Met Leu Phe Phe Tyr Leu Arg Arg Glu Gln Met Phe 245 250 255 Val Arg His Leu Phe Asn Arg Ala Gly Thr Val Gly Glu Thr Val Pro 260 265 270 Ala Asp Leu Tyr Ile Lys Gly Thr Thr Gly Thr Leu Pro Ser Thr Ser 275 280 285 Tyr Phe Pro Thr Pro Ser Gly Ser Met Val Thr Ser Asp Ala Gln Ile 290 295 300 Phe Asn Lys Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn Asn Gly 305 310 315 320 Ile Cys Trp Ser Asn Gln Leu Phe Val Thr Val Val Asp Thr Thr Thr Arg 325 330 335 Ser Thr Asn Met Ser Val Cys Ser Ala Val Ser Ser Ser Asp Ser Thr 340 345 350 Tyr Lys Asn Asp Asn Phe Lys Glu Tyr Leu Arg His Gly Glu Glu Tyr 355 360 365 Asp Leu Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu Thr Ala Asp 370 375 380 Val Met Thr Tyr Ile His Ser Met Asn Pro Ser Ile Leu Glu Asp Trp 385 390 395 400 Asn Phe Gly Leu Thr Pro Pro Pro Ser Gly Thr Leu Glu Asp Thr Tyr 405 410 415 Arg Tyr Val Thr Ser Gln Ala Val Thr Cys Gln Lys Pro Ser Ala Pro 420 425 430 Lys Pro Lys Asp Asp Pro Leu Lys Asn Tyr Thr Phe Trp Glu Val Asp 435 440 445 Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro Leu Gly Arg 450 455 460 Lys Phe Leu Leu Gln Ala Gly Leu 465 470 <![CDATA[ <210> 70]]>
 <![CDATA[ <211> 26]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> ]]>Homo sapiens
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3502 HPV 33 L1 protein amino acid sequence 474-499]]>
 <![CDATA[ <400> 70]]> Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr 1 5 10 15 Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25 <![CDATA[ <210> 71]]>
 <![CDATA[ <211> 498]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3503 Amino acid sequence of chimeric HPV type 35 L1 protein]]>
 <![CDATA[ <400]]>> 71]]&gt;
 <br/> <![CDATA[Met Ser Leu Trp Arg Ser Asn Glu Ala Thr Val Tyr Leu Pro Pro Val 1 5 10 15 Ser Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Thr Arg Thr Asn 20 25 30 Ile Tyr Tyr His Ala Gly Ser Ser Arg Leu Leu Ala Val Gly His Pro 35 40 45 Tyr Tyr Ala Ile Lys Lys Gln Asp Ser Asn Lys Ile Ala Val Pro Lys 50 55 60 Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Val Lys Leu Pro Asp Pro 65 70 75 80 Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asp Pro Ala Ser Gln 85 90 95 Arg Leu Val Trp Ala Cys Thr Gly Val Glu Val Gly Arg Gly Gln Pro 100 105 110 Leu Gly Val Gly Ile Ser Gly His Pro Leu Leu Asn Lys Leu Asp Asp 115 120 125 Thr Glu Asn Ser Asn Lys Tyr Val Gly Asn Ser Gly Thr Asp Asn Arg 130 135 140 Glu Cys Ile Ser Met Asp Tyr Lys Gln Thr Gln Leu Cys Leu Ile Gly 145 150 155 160 Cys Arg Pro Pro Ile Gly Glu His Trp Gly Lys Gly Thr Pro Cys Asn 165 170 175 Ala Asn Gln Val Lys Ala Gly Glu Cys Pro Pro Leu Glu Leu Leu Asn 180 185 190 Thr Val Leu Gln Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala Met 195 200 205 Asp Phe Thr Thr Leu Gln Ala Asn Lys Ser Asp Val Pro Leu Asp Ile 210 215 220 Cys Ser Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Lys Met Val Ser Glu 225 230 235 240 Pro Tyr Gly Asp Met Leu Phe Phe Tyr Leu Arg Arg Glu Gln Met Phe 245 250 255 Val Arg His Leu Phe Asn Arg Ala Gly Thr Val Gly Glu Thr Val Pro 260 265 270 Ala Asp Leu Tyr Ile Lys Gly Thr Thr Gly Thr Leu Pro Ser Thr Ser 275 280 285 Tyr Phe Pro Thr Pro Ser Gly Ser Met Val Thr Ser Asp Ala Gln Ile 290 295 300 Phe Asn Lys Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn Asn Gly 305 310 315 320 Ile Cys Trp Ser Asn Gln Leu Phe Val Thr Val Val Asp Thr Thr Thr Arg 325 330 335 Ser Thr Asn Met Ser Val Cys Ser Ala Val Ser Ser Ser Asp Ser Thr 340 345 350 Tyr Lys Asn Asp Asn Phe Lys Glu Tyr Leu Arg His Gly Glu Glu Tyr 355 360 365 Asp Leu Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu Thr Ala Asp 370 375 380 Val Met Thr Tyr Ile His Ser Met Asn Pro Ser Ile Leu Glu Asp Trp 385 390 395 400 Asn Phe Gly Leu Thr Pro Pro Pro Ser Gly Thr Leu Glu Asp Thr Tyr 405 410 415 Arg Tyr Val Thr Ser Gln Ala Val Thr Cys Gln Lys Pro Ser Ala Pro 420 425 430 Lys Pro Lys Asp Asp Pro Leu Lys Asn Tyr Thr Phe Trp Glu Val Asp 435 440 445 Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro Leu Gly Arg 450 455 460 Lys Phe Leu Leu Gln Ala Gly Leu Lys Ala Lys Pro Lys Leu Lys Arg 465 470 475 480 Ala Ala Pro Thr Ser Thr Arg Thr Ser Ser Ala Lys Arg Lys Lys Val 485 490 495 Lys Lys <![CDATA[ <210> 72]]>
 <![CDATA[ <211> 1498]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3504 Nucleotide sequence of chimeric HPV type 35 L1 protein]]>
 <![CDATA[ <400> 72]]> atgagtctgt ggaggagcaa tgaggctaca gtctacctgc ctcctgtgtc tgtgagcaag 60 gtggtgagca cagatgaata tgtgaccagg accaacatct actaccatgc tggctccagc 120 agactgctgg ctgtgggaca cccatactat gccatcaaga agcaggacag caacaagatt 180 gctgtgccaa aggtgtctgg actccaatac agggtgttca gggtgaaact gcctgaccca 240 aacaagtttg gctttcctga cacctccttc tatgaccctg ccagccagag actggtgtgg 300 gcttgtactg gagtggaggt gggcagggga ca accactgg gagtgggcat ctctggacac     360
          ccactgctga acaaactgga tgacacagag aacagcaaca aatatgtggg caactctggc     420
          acagacaaca gggagtgtat cagtatggac tacaagcaga cccaactttg tctgattggc     480
          tgtagacctc caattggaga acactggggc aagggcacac catgtaatgc caaccaggtg     540
          aaggctggag agtgtcctcc attggaactg ctgaacacag tgctccaaga tggagatatg     600
          gtggacacag gctttggagc tatggacttc accaccctcc aagccaacaa gtctgatgtg     660
          ccactggaca tctgttccag catctgtaaa taccctgact acctgaaaat ggtgtctgaa 720 ccatatggag atatgctgtt cttctacctg aggagggaac agatgtttgt gagacacctg 780 ttcaacaggg ctggcacagt gggagagaca gtgcctgctg acctctacat caagggcacc 840 acaggcaccc tgccaagc ac ctcctacttt ccaacaccat ctggcagtat ggtgacctct 900 gatgcccaga ttttcaacaa gccatactgg ctccaaaggg ctcaaggaca caacaatggc 960 atctgttgga gcaaccaact ttttgtgaca gtggtggaca ccaccaggag caccaatatg 1020 agtgt gtgtt ctgctgtgtc ctcctctgac agcacctaca agaatgacaa cttcaaggaa 1080 tacctgagac atggagagga atatgacctc caattcatct tccaactttg taagattacc 1140 ctgacagcag atgtgatgac ctacatccac agtatgaacc caagcatctt ggaggactgg 1200 aact ttggac tgacacctcc tccatctggc accttggagg acacctacag atatgtgacc 1260 agccaggctg tgacttgtca gaagccatct gccccaaagc caaaggatga cccactgaaa 1320 aactacacct tctgggaggt ggacctgaaa gagaagttct ctgctgacct ggaccagttt 1380 ccactgggca ggaagttcct gctccaagca ggactgaaag ccaagccaaa actgaaaagg 1440 gctgccccaa ccagcaccag gacctcctct gccaagagga agaaggtgaa gaagtaaa 1498 <![CDATA[ <210> 73]]>
 <![CDATA[ <211> 1528]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3505 Synthetic HPV35L1 gene]]>
 <![CDATA[ <400> 73]]> ctgggtacca tgagtctgtg gaggagcaat gaggctacag tctacctgcc tcctgtgtct 60 gtgagcaagg tggtgagcac agatgaatat gtgaccagga ccaacatcta ctaccatgct 120 ggctccagca gactgctggc tgtgggacac ccatactat g ccatcaagaa gcaggacagc 180 aacaagattg ctgtgccaaa ggtgtctgga ctccaataca gggtgttcag ggtgaaactg 240 cctgacccaa acaagtttgg ctttcctgac acctccttct atgaccctgc cagccagaga 300 ctggtgtggg cttgtactgg a gtggaggtg ggcaggggac aaccactggg agtgggcatc 360 tctggacacc cactgctgaa caaactggat gacacagaga acagcaacaa atatgtgggc 420 aactctggca cagacaacag ggagtgtatc agtatggact acaagcagac ccaactttgt 480 ctgattggct gtagacctcc aattggagaa cact ggggca agggcacacc atgtaatgcc 540 aaccaggtga aggctggaga gtgtcctcca ttggaactgc tgaacacagt gctccaagat 600 ggagatatgg tggacacagg ctttggagct atggacttca ccaccctcca agccaacaag 660 tctgatgtgc cactggacat ctgt tccagc atctgtaaat accctgacta cctgaaaatg 720 gtgtctgaac catatggaga tatgctgttc ttctacctga gggagggaaca gatgtttgtg 780 agacacctgt tcaacagggc tggcacagtg ggagagacag tgcctgctga cctctacatc 840 aagggcacca caggcaccct gccaagcacc tcctactttc caacaccatc tggcagtatg 900 gtgacctctg atgcccagat tttcaacaag ccatactggc tccaaagggc tcaaggacac 960 aacaatggca tctgttggag caaccaactt tttgtgacag tggtggacac caccaggagc 1 020 accaatatga gtgtgtgttc tgctgtgtcc tcctctgaca gcacctacaa gaatgacaac 1080 ttcaaggaat acctgagaca tggagaggaa tatgacctcc aattcatctt ccaactttgt 1140 aagattaccc tgacagcaga tgtgatgacc tacatccaca gtatga accc aagcatcttg 1200 gaggactgga actttggact gacacctcct ccatctggca ccttggagga cacctacaga 1260 tatgtgacca gccaggctgt gacttgtcag aagccatctg ccccaaagcc aaaggatgac 1320 ccactgaaaa actacacctt ctgggaggtg gacctgaa agaagttctc tgctgacctg 1380 gaccagtttc cactgggcag gaagttcctg ctccaagcag gactgaaagc cagaccaaac 1440 ttcagactgg gcaagagggc tgcccctgcc agcaccagca agaagtccag caccaagagg 1500 aggaaggtga agagctaaac tcgagctc 1528 <![CDATA[ <210> 74]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3506 Synthetic HPV33L1 gene]]>
 <![CDATA[ <400> 74]]> ctgggtacca tgagtgtgtg gagaccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtgagcagga ccagcatcta ctactatgct 120 ggctccagca gactgctggc tgtgggacac ccatact tca gcatcaagaa cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgtg t gggattggag attggcaggg gacaaccact gggagtgggc     360
          atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct     420
          ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt     480
          tgtctgctgg gctgtaagcc tccaacagga gaacactggg gcaagggagt ggcttgtacc     540
          aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat     600
          ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag     660
          tctgatgtgc caattgacat ctgtggcagc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga gggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 a agggctctg gcaccacagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggagcacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctgggag gtggacctga aaga gaagtt ctctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519 <![CDATA[ <210> 75]]>
 <![CDATA[ <211> 34]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3507 HPV35L1 F1]]> <![CDATA[ <400> 75]]> cttggtacca tgagtctgtg gaggagcaat gagg 34 <![CDATA[ <210> 76]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3508 HPV35L1 R1]]> <![CDATA[ <400> 76]]> gcttggcttt cagtcctgct tggagcagga acttcc 36 <![CDATA[ <210> 77]]>
 <![CDATA[ <211> 1435]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3509 HPV35L1 expansion sequence 1]]>
 <![CDATA[ <400> 77]]> cttggtacca tgagtctgtg gaggagcaat gaggctacag tctacctgcc tcctgtgtct 60 gtgagcaagg tggtgagcac agatgaatat gtgaccagga ccaacatcta ctaccatgct 120 ggctccagca gactgctggc tgtgggacac ccatactat g ccatcaagaa gcaggacagc 180 aacaagattg ctgtgccaaa ggtgtctgga ctccaataca gggtgttcag ggtgaaactg 240 cctgacccaa acaagtttgg ctttcctgac acctccttct atgaccctgc cagccagaga 300 ctggtgtggg cttgtactgg a gtggaggtg ggcaggggac aaccactggg agtgggcatc 360 tctggacacc cactgctgaa caaactggat gacacagaga acagcaacaa atatgtgggc 420 aactctggca cagacaacag ggagtgtatc agtatggact acaagcagac ccaactttgt 480 ctgattggct gtagacctcc aattggagaa cact ggggca agggcacacc atgtaatgcc 540 aaccaggtga aggctggaga gtgtcctcca ttggaactgc tgaacacagt gctccaagat 600 ggagatatgg tggacacagg ctttggagct atggacttca ccaccctcca agccaacaag 660 tctgatgtgc cactggacat ctgt tccagc atctgtaaat accctgacta cctgaaaatg 720 gtgtctgaac catatggaga tatgctgttc ttctacctga gggagggaaca gatgtttgtg 780 agacacctgt tcaacagggc tggcacagtg ggagagacag tgcctgctga cctctacatc 840 aagggcacca caggcaccct gccaagcacc tcctactttc caacaccatc tggcagtatg 900 gtgacctctg atgcccagat tttcaacaag ccatactggc tccaaagggc tcaaggacac 960 aacaatggca tctgttggag caaccaactt tttgtgacag tggtggacac caccaggagc 1 020 accaatatga gtgtgtgttc tgctgtgtcc tcctctgaca gcacctacaa gaatgacaac 1080 ttcaaggaat acctgagaca tggagaggaa tatgacctcc aattcatctt ccaactttgt 1140 aagattaccc tgacagcaga tgtgatgacc tacatccaca gtatga accc aagcatcttg 1200 gaggactgga actttggact gacacctcct ccatctggca ccttggagga cacctacaga 1260 tatgtgacca gccaggctgt gacttgtcag aagccatctg ccccaaagcc aaaggatgac 1320 ccactgaaaa actacacctt ctgggaggtg gacctgaa agaagttctc tgctgacctg 1380 gaccagtttc cactgggcag gaagttcctg ctccaagcag gactgaaagc caagc 1435 <![CDATA[ <210> 78]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <22]]>3> 3510 HPV35L1 F2]]&gt; <br/>
 <br/> &lt;![CDATA[ <400>78]]&gt; <br/> <![CDATA[agcaggactg aaagccaagc caaaactgaa aaggg 35 <![CDATA[ <210> 79]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3511 HPV35L1 R2]]> <![CDATA[ <400> 79]]> ctgtctagat ttacttcttc accttcttcc tcttgg 36 <![CDATA[ <210> 80]]>
 <![CDATA[ <211> 101]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3512 HPV35L1 extended sequence 2]]>
 <![CDATA[ <400> 80]]> agcaggactg aaagccaagc caaaactgaa aagggctgcc ccaaccagca ccaggacctc 60 ctctgccaag aggaagaagg tgaagaagta aatctagaca g 101 <![CDATA[ <210> 81]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3513 HPV 59 L1 protein amino acid sequence 471-508]]>
 <![CDATA[ <400> 81]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35 <![CDATA[ <210> 82]]>
 <![CDATA[ <211> 469]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3901 HPV 39 type L1 protein 1-469 amino acid sequence]]>
 <![CDATA[ <400> 82]]> Met Ala Met Trp Arg Ser Ser Asp Ser Met Val Tyr Leu Pro Pro Pro 1 5 10 15 Ser Val Ala Lys Val Val Asn Thr Asp Asp Tyr Val Thr Arg Thr Gly 20 25 30 Ile Tyr Tyr Tyr Ala Gly Ser Ser Arg Leu Leu Thr Val Gly His Pro 35 40 45 Tyr Phe Lys Val Gly Met Asn Gly Gly Arg Lys Gln Asp Ile Pro Lys 50 55 60 Val Ser Ala Tyr Gln Tyr Arg Val Phe Arg Val Thr Leu Pro Asp Pro 65 70 75 80 Asn Lys Phe Ser Ile Pro Asp Ala Ser Leu Tyr Asn Pro Glu Thr Gln 85 90 95 Arg Leu Val Trp Ala Cys Val Gly Val Glu Val Gly Arg Gly Gln Pro 100 105 110 Leu Gly Val Gly Ile Ser Gly His Pro Leu Tyr Asn Arg Gln Asp Asp 115 120 125 Thr Glu Asn Ser Pro Phe Ser Ser Thr Thr Asn Lys Asp Ser Arg Asp 130 135 140 Asn Val Ser Val Asp Tyr Lys Gln Thr Gln Leu Cys Ile Ile Gly Cys 145 150 155 160 Val Pro Ala Ile Gly Glu His Trp Gly Lys Gly Lys Ala Cys Lys Pro 165 170 175 Asn Asn Val Ser Thr Gly Asp Cys Pro Pro Leu Glu Leu Val Asn Thr 180 185 190 Pro Ile Glu Asp Gly Asp Met Ile Asp Thr Gly Tyr Gly Ala Met Asp 195 200 205 Phe Gly Ala Leu Gln Glu Thr Lys Ser Glu Val Pro Leu Asp Ile Cys 210 215 220 Gln Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser Ala Asp Val 225 230 235 240 Tyr Gly Asp Ser Met Phe Phe Cys Leu Arg Arg Glu Gln Leu Phe Ala 245 250 255 Arg His Phe Trp Asn Arg Gly Gly Met Val Gly Asp Ala Ile Pro Ala 260 265 270 Gln Leu Tyr Ile Lys Gly Thr Asp Ile Arg Ala Asn Pro Gly Ser Ser 275 280 285 Val Tyr Cys Pro Ser Pro Ser Gly Ser Met Val Thr Ser Asp Ser Gln 290 295 300 Leu Phe Asn Lys Pro Tyr Trp Leu His Lys Ala Gln Gly His Asn Asn 305 310 315 320 Gly Ile Cys Trp His Asn Gln Leu Phe Leu Thr Val Val Asp Thr Thr 325 330 335 Arg Ser Thr Asn Phe Thr Leu Ser Thr Ser Ser Ile Glu Ser Ser Ile Pro 340 345 350 Ser Thr Tyr Asp Pro Ser Lys Phe Lys Glu Tyr Thr Arg His Val Glu 355 360 365 Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Thr Val Thr Leu Thr 370 375 380 Thr Asp Val Met Ser Tyr Ile His Thr Met Asn Ser Ser Ile Leu Asp 385 390 395 400 Asn Trp Asn Phe Ala Val Ala Pro Pro Pro Ser Ala Ser Leu Val Asp 405 410 415 Thr Tyr Arg Tyr Leu Gln Ser Ala Ala Ile Thr Cys Gln Lys Asp Ala 420 425 430 Pro Ala Pro Glu Lys Lys Asp Pro Tyr Asp Gly Leu Lys Phe Trp Asn 435 440 445 Val Asp Leu Arg Glu Lys Phe Ser Leu Glu Leu Asp Gln Phe Pro Leu 450 455 460 Gly Arg Lys Phe Leu 465 <![CDATA[ <210> 83]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3902 HPV 59 type L1 protein amino acid sequence 471-508]]>
 <![CDATA[ <400> 83]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35 <![CDATA[ <210> 84]]>
 <![CDATA[ <211> 507]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3903 Amino acid sequence of chimeric HPV type 39 L1 protein]]>
 <![CDATA[ <400> 84]]> Met Ala Met Trp Arg Ser Ser Asp Ser Met Val Tyr Leu Pro Pro Pro 1 5 10 15 Ser Val Ala Lys Val Val Asn Thr Asp Asp Tyr Val Thr Arg Thr Gly 20 25 30 Ile Tyr Tyr Tyr Ala Gly Ser Ser Arg Leu Leu Thr Val Gly His Pro 35 40 45 Tyr Phe Lys Val Gly Met Asn Gly Gly Arg Lys Gln Asp Ile Pro Lys 50 55 60 Val Ser Ala Tyr Gln Tyr Arg Val Phe Arg Val Thr Leu Pro Asp Pro 65 70 75 80 Asn Lys Phe Ser Ile Pro Asp Ala Ser Leu Tyr Asn Pro Glu Thr Gln 85 90 95 Arg Leu Val Trp Ala Cys Val Gly Val Glu Val Gly Arg Gly Gln Pro 100 105 110 Leu Gly Val Gly Ile Ser Gly His Pro Leu Tyr Asn Arg Gln Asp Asp 115 120 125 Thr Glu Asn Ser Pro Phe Ser Ser Thr Thr Asn Lys Asp Ser Arg Asp 130 135 140 Asn Val Ser Val Asp Tyr Lys Gln Thr Gln Leu Cys Ile Ile Gly Cys 145 150 155 160 Val Pro Ala Ile Gly Glu His Trp Gly Lys Gly Lys Ala Cys Lys Pro 165 170 175 Asn Asn Val Ser Thr Gly Asp Cys Pro Pro Leu Glu Leu Val Asn Thr 180 185 190 Pro Ile Glu Asp Gly Asp Met Ile Asp Thr Gly Tyr Gly Ala Met Asp 195 200 205 Phe Gly Ala Leu Gln Glu Thr Lys Ser Glu Val Pro Leu Asp Ile Cys 210 215 220 Gln Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser Ala Asp Val 225 230 235 240 Tyr Gly Asp Ser Met Phe Phe Cys Leu Arg Arg Glu Gln Leu Phe Ala 245 250 255 Arg His Phe Trp Asn Arg Gly Gly Met Val Gly Asp Ala Ile Pro Ala 260 265 270 Gln Leu Tyr Ile Lys Gly Thr Asp Ile Arg Ala Asn Pro Gly Ser Ser 275 280 285 Val Tyr Cys Pro Ser Pro Ser Gly Ser Met Val Thr Ser Asp Ser Gln 290 295 300 Leu Phe Asn Lys Pro Tyr Trp Leu His Lys Ala Gln Gly His Asn Asn 305 310 315 320 Gly Ile Cys Trp His Asn Gln Leu Phe Leu Thr Val Val Asp Thr Thr 325 330 335 Arg Ser Thr Asn Phe Thr Leu Ser Thr Ser Ser Ile Glu Ser Ser Ile Pro 340 345 350 Ser Thr Tyr Asp Pro Ser Lys Phe Lys Glu Tyr Thr Arg His Val Glu 355 360 365 Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Thr Val Thr Leu Thr 370 375 380 Thr Asp Val Met Ser Tyr Ile His Thr Met Asn Ser Ser Ile Leu Asp 385 390 395 400 Asn Trp Asn Phe Ala Val Ala Pro Pro Pro Ser Ala Ser Leu Val Asp 405 410 415 Thr Tyr Arg Tyr Leu Gln Ser Ala Ala Ile Thr Cys Gln Lys Asp Ala 420 425 430 Pro Ala Pro Glu Lys Lys Asp Pro Tyr Asp Gly Leu Lys Phe Trp Asn 435 440 445 Val Asp Leu Arg Glu Lys Phe Ser Leu Glu Leu Asp Gln Phe Pro Leu 450 455 460 Gly Arg Lys Phe Leu Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile 465 470 475 480 Gly Pro Arg Lys Arg Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro 485 490 495 Lys Arg Val Lys Arg Arg Lys Ser Ser Arg Lys 500 505 <![CDATA[ <210> 85]]>
 <![CDATA[ <211> 1525]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3904 Nucleotide sequence of chimeric HPV type 39 L1 protein]]>
 <![CDATA[ <400> 85]]> atggctatgt ggaggtcctc tgacagtatg gtctacctgc ctcctccatc tgtggctaag 60 gtggtgaaca cagatgacta tgtgaccagg acaggcatct actactatgc tggctccagc 120 agactgctga cagtgggaca cccatacttc aaggtgggg a tgaatggagg caggaagcag 180 gacatcccaa aggtgtctgc ctaccaatac agggtgttca gggtgaccct gcctgaccca 240 aacaagttca gcatccctga tgcctccctc tacaaccctg agacccag actggtgtgg 300 gcttgtgtgg gagtggaggt gggcagggg a caaccactgg gagtgggcat ctctggacac 360 ccactctaca acagacagga tgacacagag aacagcccat tctccagcac caccaacaag 420 gacagcaggg acaatgtgtc tgtggactac aagcagaccc aactttgtat cattggctgt 480 gtgcctgcca ttggagaaca ctggggcaag gg caaggctt gtaagccaaa caatgtgagc 540 acaggagact gtcctccatt ggaactggtg aacacaccaa ttgaggatgg agatatgatt 600 gacacaggct atggagctat ggactttgga gccctccaag agaccaagtc tgaggtgcca 660 ctggacatct gtcagagcat ctgtaaat ac cctgactacc tccaaatgag tgctgatgtc 720 tatggagaca gtatgttctt ctgtctgagg agggaacaac tttttgccag acacttctgg 780 aacaggggag ggatggtggg agatgccatc cctgcccaac tctacatcaa gggcacagac 840 atcagggc ta accctggctc ctctgtctac tgtccaagcc catctggcag tatggtgacc 900 tctgacagcc aacttttcaa caagccatac tggctgcaca aggctcaagg acacaacaat 960 ggcatctgtt ggcacaacca acttttcctg acagtggtgg acaccaccag gagcaccaac 1020 ttcaccctga gcaccagcat tgagtccagc atcccaagca cctatgaccc aagcaagttc 1080 aaggaataca ccaggcatgt ggaggaatat gacctccaat tcatcttcca actttgtact 1140 gtgaccctga ccacagatgt gatgagttac atccacacaa tgaactccag catcctggac 1200 aactggaact ttgctgtggc tcctcctcca tctgcctccc tggtggacac ctacagatac 1260 ctccaatctg ctgccatcac ttgtcagaag gatgcccctg cccctgagaa gaaggaccca 1320 tatgatggac tgaagttctg gaatgtggac ctga gggaga agttctcctt ggaactggac 1380 cagtttccac tgggcaggaa gttcctgctc caacttggag ccagaccaaa gccaaccatt 1440 ggaccaagga agagggctgc ccctgcccca accagcacac caagcccaaa gagggtgaag 1500 aggaggaagt ccagcaggaa gtaaa 1525 <![CDATA[ <210> 86]]>
 <![CDATA[ <211> 1537]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3905 Synthetic HPV39L1 gene]]>
 <![CDATA[ <400> 86]]>
          ctgggtacca tggctatgtg gaggtcctct gacagtatgg tctacctgcc tcctccatct      60
          gtggctaagg tggtgaacac agatgactat gtgaccagga caggcatcta ctactatgct     120
          ggctccagca gactgctgac agtgggacac ccatacttca aggtggggat gaatggaggc     180
          aggaagcagg acatcccaaa ggtgtctgcc taccaataca gggtgttcag ggtgaccctg     240
          cctgacccaa acaagttcag catccctgat gcctccctct acaaccctga gacccagaga     300
          ctggtgtggg cttgtgtggg agtggaggtg ggcaggggac aaccactggg agtgggcatc     360
          tctggacacc cactctacaa cagacaggat gacacagaga acagcccatt ctccagcacc     420
          accaacaagg acagcaggga caatgtgtct gtggactaca agcagaccca actttgtatc     480
          attggctgtg tgcctgccat tggagaacac tggggcaagg gcaaggcttg taagccaaac     540
          aatgtgagca caggagactg tcctccattg gaactggtga acacaccaat tgaggatgga     600
          gatatgattg acacaggcta tggagctatg gactttggag ccctccaaga gaccaagtct     660
          gaggtgccac tggacatctg tcagagcatc tgtaaatacc ctgactacct ccaaatgagt 720 gctgatgtct atggagacag tatgttcttc tgtctgagga gggaacaact ttttgccaga 780 cacttctgga acaggggagg gatggtggga gatgccatcc ctgcccaact ctacatcaag 840 ggcacagaca tcagggctaa ccctggctcc tctgtctact gtccaagccc atctggcagt 900 atggtgacct ctgacagcca acttttcaac aagccatact ggctgcacaa ggctcaagga 960 cacaacaatg gcatctgttg gcacaaccaa cttttcctga cagtggtgga caccaccagg 1020 agcaccaact tcaccctgag caccagcatt gagtccagca tcccaagcac ctatgaccca 1080 agcaagttca aggaatacac caggcatgtg gaggaatatg acctccaatt catcttccaa 1140 ctttgtactg tgaccctgac cacagatgtg atgagttaca tccacacaat gaactccagc 1200 atcctggaca actggaactt tgctgtggct cctcctccat ctgcctccct ggtggacacc 1260 tacagatacc tccaatctgc tgccatcact tgtcagaagg atgcccctgc ccctgagaag 1320 aaggacccat atgatggact gaagttctgg aatgtggacc tgag ggagaa gttctccttg 1380 gaactggacc agtttccact gggcaggaag ttcctgctcc aagccagggt gaggaggaga 1440 ccaaccattg gaccaaggaa gagacctgct gccagcacct cctcctcctc tgccaccaaa 1500 cacaagagga agagggtgag caagtaaact cgagctc 1 537 <![CDATA[ <210> 87]]>
 <![CDATA[ <211> 1546]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3906 Synthetic HPV59L1 gene]]>
 <![CDATA[ <400> 87]]> ctgggtacca tggctctgtg gaggtcctct gacaacaagg tctacctgcc tcctccatct 60 gtggctaagg tggtgagcac agatgaatat gtgaccagga ccagcatctt ctaccatgct 120 ggctccagca gactgctgac agtgggacac ccatacttca aggtgccaaa gggaggcaat 180 ggcagacagg atgtgccaaa ggtgtctgcc taccaataca gggtgttcag ggtgaaactg 240 cctgacccaa acaagtttgg actgcctgac aacacagtct atgacccaaa cagccagaga 300 ctggtgtggg cttgtgtggg a gtggagatt ggcaggggac aaccactggg agtgggactg 360 tctggacacc cactctacaa caaactggat gacacagaga actctcatgt ggcatctgct 420 gtggacacca aggacaccag ggacaatgtg tctgtggact acaagcagac ccaactttgt 480 atcattggct gtgtgcctgc cattggagaa cactggacca agggcacagc ctgtaagcca 540 accacagtgg tccagggaga ctgtcctcca ttggaactga taaacacacc aattgaggat 600 ggagatatgg tggacacagg ctatggagct atggacttca aactgctcca agacaacaag 660 tctgaggtgc cactggacat ctgtc agagc atctgtaaat accctgacta cctccaaatg 720 agtgctgatg cctatggaga cagtatgttc ttctgtctga ggagggaaca ggtgtttgcc 780 agacacttct ggaacaggtc tggcacaatg ggagaccaac ttcctgagtc cctctacatc 840 aagggca cag acatcagggc taaccctggc tcctacctct acagcccaag cccatctggc 900 tctgtggtga cctctgacag ccaacttttc aacaagccat actggctgca caaggctcaa 960 ggactgaaca atggcatctg ttggcacaac caacttttcc tgacagtggt ggacaccacc 1020 aggagcacca acctgtctgt gtgtgccagc accacctcca gcatcccaaa tgtctacaca 1080 ccaacctcct tcaaggaata tgccaggcat gtggaggagt ttgacctcca attcatcttc 1140 caactttgta agattaccct gaccacagag gtgatgagtt acatccacaa tatgaacac c 1200 accatcttgg aggactggaa ctttggagtg acacctcctc caacagcctc cctggtggac 1260 acctacaggt ttgtccagtc tgctgctgtg acttgtcaga aggacacagc ccctcctgtg 1320 aagcaggacc catatgacaa actgaagttc tggcctgt gg acctgaaaga gaggttctct 1380 gctgacctgg accagtttcc actgggcagg aagttcctgc tccaacttgg agccagacca 1440 aagccaacca ttggaccaag gaagagggct gcccctgccc caaccagcac accaagccca 1500 aagagggtga agaggaggaa gtccagcagg aagtaaactc ctc 1546 <![CDATA[ <210> 88]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3907 HPV39L1 F1]]> <![CDATA[ <400> 88]]> cttggtacca tggctatgtg gaggtcctct gacagtat 38 <![CDATA[ <210> 89]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3908 HPV39L1 R1]]> <![CDATA[ <400> 89]]> tccaagttgg agcaggaact tcctgcccag tggaaact 38 <![CDATA[ <210> 90]]>
 <![CDATA[ <211> 1428]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3909 HPV39L1 expansion sequence 1]]>
 <![CDATA[ <400> 90]]>
          cttggtacca tggctatgtg gaggtcctct gacagtatgg tctacctgcc tcctccatct      60
          gtggctaagg tggtgaacac agatgactat gtgaccagga caggcatcta ctactatgct     120
          ggctccagca gactgctgac agtgggacac ccatacttca aggtggggat gaatggaggc     180
          aggaagcagg acatcccaaa ggtgtctgcc taccaataca gggtgttcag ggtgaccctg     240
          cctgacccaa acaagttcag catccctgat gcctccctct acaaccctga gacccagaga     300
          ctggtgtggg cttgtgtggg agtggaggtg ggcaggggac aaccactggg agtgggcatc     360
          tctggacacc cactctacaa cagacaggat gacacagaga acagcccatt ctccagcacc     420
          accaacaagg acagcaggga caatgtgtct gtggactaca agcagaccca actttgtatc     480
          attggctgtg tgcctgccat tggagaacac tggggcaagg gcaaggcttg taagccaaac     540
          aatgtgagca caggagactg tcctccattg gaactggtga acacaccaat tgaggatgga     600
          gatatgattg acacaggcta tggagctatg gactttggag ccctccaaga gaccaagtct     660
          gaggtgccac tggacatctg tcagagcatc tgtaaatacc ctgactacct ccaaatgagt 720 gctgatgtct atggagacag tatgttcttc tgtctgagga gggaacaact ttttgccaga 780 cacttctgga acaggggagg gatggtggga gatgccatcc ctgcccaact ctacatcaag 840 ggcacagaca tcagggctaa ccctggctcc tctgtctact gtccaagccc atctggcagt 900 atggtgacct ctgacagcca acttttcaac aagccatact ggctgcacaa ggctcaagga 960 cacaacaatg gcatctgttg gcacaaccaa cttttcctga cagtggtgga caccaccagg 1020 agcaccaact tcaccctgag caccagcatt gagtccagca tcccaagcac ctatgaccca 1080 agcaagttca aggaatacac caggcatgtg gaggaatatg acctccaatt catcttccaa 1140 ctttgtactg tgaccctgac cacagatgtg atgagttaca tccacacaat gaactccagc 1200 atcctggaca actggaactt tgctgtggct cctcctccat ctgcctccct ggtggacacc 1260 tacagatacc tccaatctgc tgccatcact tgtcagaagg atgcccctgc ccctgagaag 1320 aaggacccat atgatggact gaagttctgg aatgtggacc tgag ggagaa gttctccttg 1380 gaactggacc agtttccact gggcaggaag ttcctgctcc aacttgga 1428 <![CDATA[ <210> 91]]>
 <![CDATA[ <211> 37]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3910 HPV39L1 F2]]> <![CDATA[ <400> 91]]> aggaagttcc tgctccaact tggagccaga ccaaagc 37 <![CDATA[ <210> 92]]>
 <![CDATA[ <211> 40]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3911 HPV39L1 R2]]> <![CDATA[ <400> 92]]> ctgtctagat ttacttcctg ctggacttcc tcctcttcac 40 <![CDATA[ <210> 93]]>
 <![CDATA[ <211> 139]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3912 HPV39L1 expansion sequence 2]]>
 <![CDATA[ <400> 93]]> aggaagttcc tgctccaact tggagccaga ccaaagccaa ccattggacc aaggaagagg 60 gctgcccctg ccccaaccag cacaccaagc ccaaagaggg tgaagaggag gaagtccagc 120 aggaagtaaa tctagacag 139 <![CDATA[ <210> 94]]>
 <![CDATA[ <211> 26]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 3913 HPV 33 L1 protein amino acid sequence 474-499]]>
 <![CDATA[ <400> 94]]> Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr 1 5 10 15 Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25 <![CDATA[ <210> 95]]>
 <![CDATA[ <211> 478]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 450]]>1 Amino acid sequence 1-478 of HPV type 45 L1 protein
 <![CDATA[ <400> 95]]> Met Ala Leu Trp Arg Pro Ser Asp Ser Thr Val Tyr Leu Pro Pro Pro 1 5 10 15 Ser Val Ala Arg Val Val Asn Thr Asp Asp Tyr Val Ser Arg Thr Ser 20 25 30 Ile Phe Tyr His Ala Gly Ser Ser Arg Leu Leu Thr Val Gly Asn Pro 35 40 45 Tyr Phe Arg Val Val Pro Ser Gly Ala Gly Asn Lys Gln Ala Val Pro 50 55 60 Lys Val Ser Ala Tyr Gln Tyr Arg Val Phe Arg Val Ala Leu Pro Asp 65 70 75 80 Pro Asn Lys Phe Gly Leu Pro Asp Ser Thr Ile Tyr Asn Pro Glu Thr 85 90 95 Gln Arg Leu Val Trp Ala Cys Val Gly Met Glu Ile Gly Arg Gly Gln 100 105 110 Pro Leu Gly Ile Gly Leu Ser Gly His Pro Phe Tyr Asn Lys Leu Asp 115 120 125 Asp Thr Glu Ser Ala His Ala Ala Thr Ala Val Ile Thr Gln Asp Val 130 135 140 Arg Asp Asn Val Ser Val Asp Tyr Lys Gln Thr Gln Leu Cys Ile Leu 145 150 155 160 Gly Cys Val Pro Ala Ile Gly Glu His Trp Ala Lys Gly Thr Leu Cys 165 170 175 Lys Pro Ala nnJL Gln Pro Gly Asp Cys Pro Pro Leu Glu Leu Lys 180 185 190 Asn Thr Ile Ile Glu Asp Gly Asp Met Val Asp Thr Gly Tyr Gly Ala 195 200 205 Met Asp Phe Ser Thr Leu Gln Asp Thr Lys Cys Glu Val Pro Leu Asp 210 215 220 Ile Cys Gln Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser Ala 225 230 235 240 Asp Pro Tyr Gly Asp Ser Met Phe Phe Cys Leu Arg Arg Glu Gln Leu 245 250 255 Phe Ala Arg His Phe Trp Asn Arg Ala Gly Val Met Gly Asp Thr Val 260 265 270 Pro Thr Asp Leu Tyr Ile Lys Gly Thr Ser Ala Asn Met Arg Glu Thr 275 280 285 Pro Gly Ser Cys Val Tyr Ser Pro Ser Pro Ser Gly Ser Ile Thr Thr 290 295 300 Ser Asp Ser Gln Leu Phe Asn Lys Pro Tyr Trp Leu His Lys Ala Gln 305 310 315 320 Gly His Asn Asn Gly Ile Cys Trp His Asn Gln Leu Phe Val Thr Val 325 330 335 Val Asp Thr Thr Arg Ser Thr Asn Leu Thr Leu Cys Ala Ser Thr Gln 340 345 350 Asn Pro Val Pro Asn Thr Tyr Asp Pro Thr Lys Phe Lys His Tyr Ser 355 360 365 Arg His Val Glu Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Thr 370 375 380 Ile Thr Leu Thr Ala Glu Val Met Ser Tyr Ile His Ser Met Asn Ser 385 390 395 400 Ser Ile Leu Glu Asn Trp Asn Phe Gly Val Pro Pro Pro Pro Thr Thr 405 410 415 Ser Leu Val Asp Thr Tyr Arg Phe Val Gln Ser Val Ala Val Thr Cys 420 425 430 Gln Lys Asp Thr Thr Pro Pro Glu Lys Gln Asp Pro Tyr Asp Lys Leu 435 440 445 Lys Phe Trp Thr Val Asp Leu Lys Glu Lys Phe Ser Ser Asp Leu Asp 450 455 460 Gln Tyr Pro Leu Gly Arg Lys Phe Leu Val Gln Ala Gly Leu 465 470 475 <![CDATA[ <210> 96]]>
 <![CDATA[ <211> 26]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 4502 HPV type 33 L1 protein amino acid sequence 474-499]]>
 <![CDATA[ <400> 96]]> Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr 1 5 10 15 Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25 <![CDATA[ <210> 97]]>
 <![CDATA[ <211> 504]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 4503 Amino acid sequence of chimeric HPV type 45 L1 protein]]>
 <![CDATA[ <400> 97]]> Met Ala Leu Trp Arg Pro Ser Asp Ser Thr Val Tyr Leu Pro Pro Pro 1 5 10 15 Ser Val Ala Arg Val Val Asn Thr Asp Asp Tyr Val Ser Arg Thr Ser 20 25 30 Ile Phe Tyr His Ala Gly Ser Ser Arg Leu Leu Thr Val Gly Asn Pro 35 40 45 Tyr Phe Arg Val Val Pro Ser Gly Ala Gly Asn Lys Gln Ala Val Pro 50 55 60 Lys Val Ser Ala Tyr Gln Tyr Arg Val Phe Arg Val Ala Leu Pro Asp 65 70 75 80 Pro Asn Lys Phe Gly Leu Pro Asp Ser Thr Ile Tyr Asn Pro Glu Thr 85 90 95 Gln Arg Leu Val Trp Ala Cys Val Gly Met Glu Ile Gly Arg Gly Gln 100 105 110 Pro Leu Gly Ile Gly Leu Ser Gly His Pro Phe Tyr Asn Lys Leu Asp 115 120 125 Asp Thr Glu Ser Ala His Ala Ala Thr Ala Val Ile Thr Gln Asp Val 130 135 140 Arg Asp Asn Val Ser Val Asp Tyr Lys Gln Thr Gln Leu Cys Ile Leu 145 150 155 160 Gly Cys Val Pro Ala Ile Gly Glu His Trp Ala Lys Gly Thr Leu Cys 165 170 175 Lys Pro Ala nnJL Gln Pro Gly Asp Cys Pro Pro Leu Glu Leu Lys 180 185 190 Asn Thr Ile Ile Glu Asp Gly Asp Met Val Asp Thr Gly Tyr Gly Ala 195 200 205 Met Asp Phe Ser Thr Leu Gln Asp Thr Lys Cys Glu Val Pro Leu Asp 210 215 220 Ile Cys Gln Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser Ala 225 230 235 240 Asp Pro Tyr Gly Asp Ser Met Phe Phe Cys Leu Arg Arg Glu Gln Leu 245 250 255 Phe Ala Arg His Phe Trp Asn Arg Ala Gly Val Met Gly Asp Thr Val 260 265 270 Pro Thr Asp Leu Tyr Ile Lys Gly Thr Ser Ala Asn Met Arg Glu Thr 275 280 285 Pro Gly Ser Cys Val Tyr Ser Pro Ser Pro Ser Gly Ser Ile Thr Thr 290 295 300 Ser Asp Ser Gln Leu Phe Asn Lys Pro Tyr Trp Leu His Lys Ala Gln 305 310 315 320 Gly His Asn Asn Gly Ile Cys Trp His Asn Gln Leu Phe Val Thr Val 325 330 335 Val Asp Thr Thr Arg Ser Thr Asn Leu Thr Leu Cys Ala Ser Thr Gln 340 345 350 Asn Pro Val Pro Asn Thr Tyr Asp Pro Thr Lys Phe Lys His Tyr Ser 355 360 365 Arg His Val Glu Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Thr 370 375 380 Ile Thr Leu Thr Ala Glu Val Met Ser Tyr Ile His Ser Met Asn Ser 385 390 395 400 Ser Ile Leu Glu Asn Trp Asn Phe Gly Val Pro Pro Pro Pro Thr Thr 405 410 415 Ser Leu Val Asp Thr Tyr Arg Phe Val Gln Ser Val Ala Val Thr Cys 420 425 430 Gln Lys Asp Thr Thr Pro Pro Glu Lys Gln Asp Pro Tyr Asp Lys Leu 435 440 445 Lys Phe Trp Thr Val Asp Leu Lys Glu Lys Phe Ser Ser Asp Leu Asp 450 455 460 Gln Tyr Pro Leu Gly Arg Lys Phe Leu Val Gln Ala Gly Leu Lys Ala 465 470 475 480 Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr Ser Ser 485 490 495 Ala Lys Arg Lys Lys Val Lys Lys 500 <![CDATA[ <210> 98]]>
 <![CDATA[ <211> 1516]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 4504]]> Nucleotide sequence of chimeric HPV type 45 L1 protein
 <![CDATA[ <400> 98]]> atggctctgt ggagaccatc tgacagcaca gtctacctgc ctcctccatc tgtggcaagg 60 gtggtgaaca cagatgacta tgtgagcagg accagcatct tctaccatgc tggctccagc 120 agactgctga cagtgggcaa cccatacttc agggtgg tgc caagtggagc aggcaacaag 180 caggctgtgc caaaggtgtc tgcctaccaa tacagggtgt tcagggtggc tctgcctgac 240 ccaaacaagt ttggactgcc tgacagcacc atctacaacc ctgagaccca gagactggtg 300 tgggcttgtg tggggatgga gattggcagg ggacaaccac tgggcattgg actgtctgga 360 cacccattct acaacaaact ggatgacaca gagtctgccc atgctgccac agcagtgatt 420 acccaggatg tgagggacaa tgtgtctgtg gactacaagc agacccaact ttgtatcctg 480 ggctgtgtgc ctgccattgg agaacactgg gctaagggca ccctgtgtaa gcctgcccaa 540 ctccaacctg gagactgtcc tccattggaa ctgaaaaaca ccatcattga ggatggagat 600 atggtggaca caggctatgg agctatggac ttcagcaccc tccaagacac caagtgtga g 660 gtgccactgg acatctgtca gagcatctgt aaataccctg actacctcca aatgagtgct 720 gacccatatg gagacagtat gttcttctgt ctgaggaggg aacaactttt tgccagacac 780 ttctggaaca gggctggagt gatgggagac acagtgccaa cagacctcta catcaag ggc 840 acctctgcca atatgaggga gacacctggc tcctgtgtct acagcccaag cccatctggc 900 agcatcacca cctctgacag ccaacttttc aacaagccat actggctgca caaggctcaa 960 ggacacaaca atggcatctg ttggcacaac caactttttg tgacagtggt ggacaccacc 1020 aggagcacca acctgaccct gtgtgccagc accgaacc ctgtgccaaa cacctatgac 1080 ccaaccaagt tcaagcacta cagcaggcat gtggaggaat atgacctcca attcatcttc 1140 caactttgta ccatcaccct gacagcagag gtgatgagtt acatccacag tatgaactcc 1200 agcatcttgg agaactggaa ctttggagtg cctcctcctc caaccacctc cctggtggac 1260 acctacaggt ttgtccagtc tgtggctgtg acttgtcaga aggacaccac acctcctgag 1320 aagcaggacc catatgacaa actgaagttc tgg acagtgg acctgaaaga gaagttctcc    1380
          tctgacctgg accaataccc actgggcagg aagttcctgg tccaggctgg actgaaagcc    1440
          aagccaaaac tgaaaagggc tgccccaacc agcaccagga cctcctctgc caagaggaag    1500
          aaggtgaaga agtaaa                                                    1516
           <![CDATA[ <210> 99]]>
 <![CDATA[ <211> 1552]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 4505 Synthetic HPV45L1 gene]]>
 <![CDATA[ <400> 99]]> ctgggtacca tggctctgtg gagaccatct gacagcacag tctacctgcc tcctccatct 60 gtggcaaggg tggtgaacac agatgactat gtgagcagga ccagcatctt ctaccatgct 120 ggctccagca gactgctgac agtgggcaac ccatacttca gggtgg tgcc aagtggagca 180 ggcaacaagc aggctgtgcc aaaggtgtct gcctaccaat acagggtgtt cagggtggct 240 ctgcctgacc caaacaagtt tggactgcct gacagcacca tctacaaccc tgagacccag 300 agactggtgt gggcttgtgt ggggatgg ag attggcaggg gacaaccact gggcattgga 360 ctgtctggac acccattcta caacaaactg gatgacacag agtctgccca tgctgccaca 420 gcagtgatta cccaggatgt gagggacaat gtgtctgtgg actacaagca gacccaactt 480 tgtatcctgg gctgtgtgcc tgccattgga gaacactggg ctaagggcac cctgtgtaag 540 cctgcccaac tccaacctgg agactgtcct ccattggaac tgaaaaacac catcattgag 600 gatggagata tggtggacac aggctatgga gctatggact tcagcaccct ccaagacacc 660 aagtgtgagg tg ccactgga catctgtcag agcatctgta aataccctga ctacctccaa 720 atgagtgctg acccatatgg agacagtatg ttcttctgtc tgaggaggga acaacttttt 780 gccagacact tctggaacag ggctggagtg atgggagaca cagtgccaac agacctctac 840 atcaagggca cctctgccaa tatgaggggag acacctggct cctgtgtcta cagcccaagc 900 ccatctggca gcatcaccac ctctgacagc caacttttca acaagccata ctggctgcac 960 aaggctcaag gacacaacaa tggcatctgt tggcacaacc aactttttgt gacagtggtg 1020 gacaccacca ggagcaccaa cctgaccctg tgtgccagca cccagaaccc tgtgccaaac 1080 acctatgacc caaccaagtt caagcactac agcaggcatg tggaggaata tgacctccaa 1140 ttcatcttcc aactttgtac catcaccctg acagcagagg tgatgagtta catccacagt 1200 atgaactcca gcatcttgga gaactggaac tttggagtgc ctcctcctcc aaccacctcc 1260 ctggtggaca cctacaggtt tgtccagtct gtggctgtga cttgtcagaa ggacaccaca 1320 cctcctgaga agcaggaccc atatgacaaa ctgaagttct ggacagtgga cctga aagag 1380 aagttctcct ctgacctgga ccaataccca ctgggcagga agttcctggt ccaggctgga 1440 ctgaggagga gaccaaccat tggaccaagg aagagacctg ctgccagcac cagcacagcc 1500 agcagacctg ccaagagggt gaggattagg agcaagaagt aaactcgagc tc 1552 <![CDATA[ <210> 100]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 4506 Synthetic HPV33L1 gene]]>
 <![CDATA[ [400] acttca gcatcaagaa cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgt gt gggattggag attggcaggg gacaaccact gggagtgggc     360
          atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct     420
          ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt     480
          tgtctgctgg gctgtaagcc tccaacagga gaacactggg gcaagggagt ggcttgtacc     540
          aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat     600
          ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag     660
          tctgatgtgc caattgacat ctgtggcagc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga gggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 a agggctctg gcaccacagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggagcacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctgggag gtggacctga aaga gaagtt ctctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519 <![CDATA[ <210> 101]]>
 <![CDATA[ <211> 33]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 4507 HPV45L1 F1]]> <![CDATA[ <400> 101]]> cttggtacca tggctctgtg gagaccatct gac 33 <![CDATA[ <210> 102]]>
 <![CDATA[ <211> 32]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 4508 HPV45L1 R1]]> <![CDATA[ <400> 102]]> gcttggcttt cagtccagcc tggaccagga ac 32 <![CDATA[ <210> 103]]>
 <![CDATA[ <211> 1453]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <22]]>0> ]]>
 <br/> <![CDATA[ &lt;223> 4509 HPV45L1 expansion sequence 1]]&gt;
 <br/>
 <br/> &lt;![CDATA[ &lt;400&gt;103]]> <br/> <![CDATA[cttggtacca tggctctgtg gagaccatct gacagcacag tctacctgcc tcctccatct 60 gtggcaaggg tggtgaacac agatgactat gtgagcagga ccagcatctt ctaccatgct 120 ggctccagca gactgctgac agtgggcaac ccatacttca gggtggtgcc aagt ggagca 180 ggcaacaagc aggctgtgcc aaaggtgtct gcctaccaat acagggtgtt cagggtggct 240 ctgcctgacc caaacaagtt tggactgcct gacagcacca tctacaaccc tgagacccag 300 agactggtgt gggcttgtgt ggggatggag gg gacaaccact gggcattgga 360 ctgtctggac acccattcta caacaaactg gatgacacag agtctgccca tgctgccaca 420 gcagtgatta cccaggatgt gagggacaat gtgtctgtgg actacaagca gacccaactt 480 tgtatcctgg gctgtgtgcc tgccattgg a gaacactggg ctaagggcac cctgtgtaag 540 cctgcccaac tccaacctgg agactgtcct ccattggaac tgaaaaacac catcattgag 600 gatggagata tggtggacac aggctatgga gctatggact tcagcaccct ccaagacacc 660 aagtgtgagg tgccactgga catct gtcag agcatctgta aataccctga ctacctccaa 720 atgagtgctg acccatatgg agacagtatg ttcttctgtc tgaggaggga acaacttttt 780 gccagacact tctggaacag ggctggagtg atgggagaca cagtgccaac agacctctac 840 atcaagggca cctctgccaa tatgaggggag acacctggct cctgtgtcta cagcccaagc 900 ccatctggca gcatcaccac ctctgacagc caacttttca acaagccata ctggctgcac 960 aaggctcaag gacacaacaa tggcatctgt tggcacaacc aactttttgt gacagtggtg 1020 gacaccacca ggagcaccaa cctgaccctg tgtgccagca cccagaaccc tgtgccaaac 1080 acctatgacc caaccaagtt caagcactac agcaggcatg tggaggaata tgacctccaa 1140 ttcatcttcc aactttgtac catcaccctg acagcagagg tgatgagtta catccacagt 1200 atgaactcca gcatcttgga gaactggaac tttggagtgc ctcctcctcc aaccacctcc 1260 ctggtggaca cctacaggtt tgtccagtct gtggctgtga cttgtcagaa ggacaccaca 1320 cctcctgaga agcaggaccc atatgacaaa ctgaagttct ggacagtgga cctgaaagag 138 0 aagttctcct ctgacctgga ccaataccca ctgggcagga agttcctggt ccaggctgga 1440 ctgaaagcca agc 1453 <![CDATA[ <210> 104]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <2]]>20> ]]>
 <br/> <![CDATA[ &lt;223> 4510 HPV45L1]]&gt; <![CDATA[ F2
 <![CDATA[ <400> 104]]> ggctggactg aaagccaagc caaaactgaa aaggg 35 <![CDATA[ <210> 105]]>
 <![CDATA[ <211> 37]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 4511 HPV45L1 R2]]> <![CDATA[ <400> 105]]> ctgtctagat ttacttcttc accttcttcc tcttggc 37 <![CDATA[ <210> 106]]>
 <![CDATA[ <211> 101]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 4512 HPV45L1 extended sequence 2]]>
 <![CDATA[ <400> 106]]> ggctggactg aaagccaagc caaaactgaa aagggctgcc ccaaccagca ccaggacctc 60 ctctgccaag aggaagaagg tgaagaagta aatctagaca g 101 <![CDATA[ <210> 107]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 4513 Amino acid sequence 471-508 of HPV type 59 L1 protein]]>
 <![CDATA[ <400> 107]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35 <![CDATA[ <210> 108]]>
 <![CDATA[ <211> 474]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5101 HPV 51 L1 protein amino acid sequence 1-474]]>
 <![CDATA[ <400> 108]]> Met Ala Leu Trp Arg Thr Asn Asp Ser Lys Val Tyr Leu Pro Pro Ala 1 5 10 15 Pro Val Ser Arg Ile Val Asn Thr Glu Glu Tyr Ile Thr Arg Thr Gly 20 25 30 Ile Tyr Tyr Tyr Ala Gly Ser Ser Arg Leu Ile Thr Leu Gly His Pro 35 40 45 Tyr Phe Pro Ile Pro Lys Thr Ser Thr Arg Ala Ala Ile Pro Lys Val 50 55 60 Ser Ala Phe Gln Tyr Arg Val Phe Arg Val Gln Leu Pro Asp Pro Asn 65 70 75 80 Lys Phe Gly Leu Pro Asp Pro Asn Leu Tyr Asn Pro Asp Thr Asp Arg 85 90 95 Leu Val Trp Gly Cys Val Gly Val Glu Val Gly Arg Gly Gln Pro Leu 100 105 110 Gly Val Gly Leu Ser Gly His Pro Leu Phe Asn Lys Tyr Asp Asp Thr 115 120 125 Glu Asn Ser Arg Ile Ala Asn Gly Asn Ala Gln Gln Asp Val Arg Asp 130 135 140 Asn Thr Ser Val Asp Asn Lys Gln Thr Gln Leu Cys Ile Ile Gly Cys 145 150 155 160 Ala Pro Pro Ile Gly Glu His Trp Gly Ile Gly Thr Thr Cys Lys Asn 165 170 175 Thr Pro Val Pro Pro Gly Asp Cys Pro Pro Leu Glu Leu Val Ser Ser 180 185 190 Val Ile Gln Asp Gly Asp Met Ile Asp Thr Gly Phe Gly Ala Met Asp 195 200 205 Phe Ala Ala Leu Gln Ala Thr Lys Ser Asp Val Pro Leu Asp Ile Ser 210 215 220 Gln Ser Val Cys Lys Tyr Pro Asp Tyr Leu Lys Met Ser Ala Asp Thr 225 230 235 240 Tyr Gly Asn Ser Met Phe Phe His Leu Arg Arg Glu Gln Ile Phe Ala 245 250 255 Arg His Tyr Tyr Asn Lys Leu Val Gly Val Gly Glu Asp Ile Pro Asn 260 265 270 Asp Tyr Tyr Ile Lys Gly Ser Gly Asn Gly Arg Asp Pro Ile Glu Ser 275 280 285 Tyr Ile Tyr Ser Ala Thr Pro Ser Gly Ser Met Ile Thr Ser Asp Ser 290 295 300 Gln Ile Phe Asn Lys Pro Tyr Trp Leu His Arg Ala Gln Gly His Asn 305 310 315 320 Asn Gly Ile Cys Trp Asn Asn Gln Leu Phe Ile Thr Cys Val Asp Thr 325 330 335 Thr Arg Ser Thr Asn Leu Thr Ile Ser Thr Ala Thr Ala Ala Val Ser 340 345 350 Pro Thr Phe Thr Pro Ser Asn Phe Lys Gln Tyr Ile Arg His Gly Glu 355 360 365 Glu Tyr Glu Leu Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu Thr 370 375 380 Thr Glu Val Met Ala Tyr Leu His Thr Met Asp Pro Thr Ile Leu Glu 385 390 395 400 Gln Trp Asn Phe Gly Leu Thr Leu Pro Pro Ser Ala Ser Leu Glu Asp 405 410 415 Ala Tyr Arg Phe Val Arg Asn Ala Ala Thr Ser Cys Gln Lys Asp Thr 420 425 430 Pro Pro Gln Ala Lys Pro Asp Pro Leu Ala Lys Tyr Lys Phe Trp Asp 435 440 445 Val Asp Leu Lys Glu Arg Phe Ser Leu Asp Leu Asp Gln Phe Ala Leu 450 455 460 Gly Arg Lys Phe Leu Leu Gln Val Gly Val 465 470 <![CDATA[ <210> 109]]>
 <![CDATA[ <211> 26]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5102 HPV type 33]]>Amino acid sequence 474-499 of L1 protein
 <![CDATA[ <400> 109]]> Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr 1 5 10 15 Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25 <![CDATA[ <210> 110]]>
 <![CDATA[ <211> 500]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5103 Amino acid sequence of chimeric HPV type 51 L1 protein]]>
 <![CDATA[ <400> 110]]> Met Ala Leu Trp Arg Thr Asn Asp Ser Lys Val Tyr Leu Pro Pro Ala 1 5 10 15 Pro Val Ser Arg Ile Val Asn Thr Glu Glu Tyr Ile Thr Arg Thr Gly 20 25 30 Ile Tyr Tyr Tyr Ala Gly Ser Ser Arg Leu Ile Thr Leu Gly His Pro 35 40 45 Tyr Phe Pro Ile Pro Lys Thr Ser Thr Arg Ala Ala Ile Pro Lys Val 50 55 60 Ser Ala Phe Gln Tyr Arg Val Phe Arg Val Gln Leu Pro Asp Pro Asn 65 70 75 80 Lys Phe Gly Leu Pro Asp Pro Asn Leu Tyr Asn Pro Asp Thr Asp Arg 85 90 95 Leu Val Trp Gly Cys Val Gly Val Glu Val Gly Arg Gly Gln Pro Leu 100 105 110 Gly Val Gly Leu Ser Gly His Pro Leu Phe Asn Lys Tyr Asp Asp Thr 115 120 125 Glu Asn Ser Arg Ile Ala Asn Gly Asn Ala Gln Gln Asp Val Arg Asp 130 135 140 Asn Thr Ser Val Asp Asn Lys Gln Thr Gln Leu Cys Ile Ile Gly Cys 145 150 155 160 Ala Pro Pro Ile Gly Glu His Trp Gly Ile Gly Thr Thr Cys Lys Asn 165 170 175 Thr Pro Val Pro Pro Gly Asp Cys Pro Pro Leu Glu Leu Val Ser Ser 180 185 190 Val Ile Gln Asp Gly Asp Met Ile Asp Thr Gly Phe Gly Ala Met Asp 195 200 205 Phe Ala Ala Leu Gln Ala Thr Lys Ser Asp Val Pro Leu Asp Ile Ser 210 215 220 Gln Ser Val Cys Lys Tyr Pro Asp Tyr Leu Lys Met Ser Ala Asp Thr 225 230 235 240 Tyr Gly Asn Ser Met Phe Phe His Leu Arg Arg Glu Gln Ile Phe Ala 245 250 255 Arg His Tyr Tyr Asn Lys Leu Val Gly Val Gly Glu Asp Ile Pro Asn 260 265 270 Asp Tyr Tyr Ile Lys Gly Ser Gly Asn Gly Arg Asp Pro Ile Glu Ser 275 280 285 Tyr Ile Tyr Ser Ala Thr Pro Ser Gly Ser Met Ile Thr Ser Asp Ser 290 295 300 Gln Ile Phe Asn Lys Pro Tyr Trp Leu His Arg Ala Gln Gly His Asn 305 310 315 320 Asn Gly Ile Cys Trp Asn Asn Gln Leu Phe Ile Thr Cys Val Asp Thr 325 330 335 Thr Arg Ser Thr Asn Leu Thr Ile Ser Thr Ala Thr Ala Ala Val Ser 340 345 350 Pro Thr Phe Thr Pro Ser Asn Phe Lys Gln Tyr Ile Arg His Gly Glu 355 360 365 Glu Tyr Glu Leu Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu Thr 370 375 380 Thr Glu Val Met Ala Tyr Leu His Thr Met Asp Pro Thr Ile Leu Glu 385 390 395 400 Gln Trp Asn Phe Gly Leu Thr Leu Pro Pro Ser Ala Ser Leu Glu Asp 405 410 415 Ala Tyr Arg Phe Val Arg Asn Ala Ala Thr Ser Cys Gln Lys Asp Thr 420 425 430 Pro Pro Gln Ala Lys Pro Asp Pro Leu Ala Lys Tyr Lys Phe Trp Asp 435 440 445 Val Asp Leu Lys Glu Arg Phe Ser Leu Asp Leu Asp Gln Phe Ala Leu 450 455 460 Gly Arg Lys Phe Leu Leu Gln Val Gly Val Lys Ala Lys Pro Lys Leu 465 470 475 480 Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr Ser Ser Ala Lys Arg Lys 485 490 495 Lys Val Lys Lys 500 <![CDATA[ <210> 111]]>
 <![CDATA[ <211> 1504]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5104 Nucleotide sequence of chimeric HPV type 51 L1 protein]]>
 <![CDATA[ <400> 111]]> atggctctgt ggaggaccaa tgacagcaag gtctacctgc ctcctgcccc tgtgagcagg 60 attgtgaaca cagaggaata catcaccagg acaggcatct actactatgc tggctccagc 120 agactgatta ccctgggaca cccatacttt ccaatcccaa agaccagcac cagggctgcc 180 atcccaaagg tgtctgcctt ccaatacagg gtgttcaggg tccaacttcc tgacccaaac 240 aagtttggac tgcctgaccc aaacctctac aaccctgaca cagacagact ggtgtggggc 300 tgtgtgggag tggaggtggg caggggacaa ccactggggag tgggactgtc tggacacccca 360 ctgttcaaca aatatgatga cacagagaac agcaggattg ccaatggcaa tgcccaacag 420 gatgtgaggg acaacacctc tgtggacaac aagcagaccc aactttgtat cattggctgt 480 gcccctccaa ttggagaaca ctgggg catt ggcaccactt gtaagaacac acctgtgcct 540 cctggagact gtcctccatt ggaactggtg tcctctgtga ttcaggatgg agatatgatt 600 gacacaggct ttggagctat ggactttgct gccctccaag ccaccaagtc tgatgtgcca 660 ctggacatca gccagt ctgt gtgtaaatac cctgactacc tgaaaatgag tgctgacacc 720 tatggcaaca gtatgttctt ccacctgagg agggaacaga tttttgccag acactactac 780 aacaaactgg tgggagtggg agaggacatc ccaaatgact actacatcaa gggctctggc 840 aatggcaggg acccaattga g tcctacatc tactctgcca caccatctgg cagtatgatt 900 acctctgaca gccagatttt caacaagcca tactggctgc acagggctca aggacacaac 960 aatggcatct gttggaacaa ccaacttttc atcacttgtg tggacaccac caggagcacc 1020 aacctgacca tcagcacagc cacagcagca gtgagcccaa ccttcacacc aagcaacttc 1080 aagcaataca tcagacatgg agaggaatat gaactccaat tcatcttcca actttgtaag 1140 attaccctga ccacagaggt gatggcttac ctgcacacaa tggacccaac catcttggaa 1200 ca gtggaact ttggactgac cctgcctcca tctgcctcct tggaggatgc ctacaggttt 1260 gtgaggaatg ctgccacctc ctgtcagaag gacacacctc cacaggctaa gcctgaccca 1320 ctggctaaat acaagttctg ggatgtggac ctgaaagaga ggttctccct ggacctggac 1380 cagtttgccc tgggcaggaa gttcctgctc caagtggggag tcaaagccaa gccaaaactg 1440 aaaagggctg ccccaaccag caccaggacc tcctctgcca agaggaagaa ggtgaagaag 1500 taaa 1504 <![CDATA[ <210> 112]]>
 <![CDATA[ <211> 1534]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <22]]>3> 5105 Synthetic HPV51L1 gene]]>
 <br/>
 <br/> &lt;![CDATA[ &lt;400&gt;112]]> <br/> <![CDATA[ctgggtacca tggctctgtg gaggaccaat gacagcaagg tctacctgcc tcctgcccct      60
          gtgagcagga ttgtgaacac agaggaatac atcaccagga caggcatcta ctactatgct     120
          ggctccagca gactgattac cctgggacac ccatactttc caatcccaaa gaccagcacc     180
          agggctgcca tcccaaaggt gtctgccttc caatacaggg tgttcagggt ccaacttcct     240
          gacccaaaca agtttggact gcctgaccca aacctctaca accctgacac agacagactg     300
          gtgtggggct gtgtgggagt ggaggtgggc aggggacaac cactgggagt gggactgtct 360 ggacacccac tgttcaacaa atatgatgac acagagaaca gcaggattgc caatggcaat 420 gcccaacagg atgtgaggga caacacctct gtggacaaca agcagaccca actttgtatc 480 attggctgtg cccctccaat tggagaacac tgggg cattg gcaccacttg taagaacaca 540 cctgtgcctc ctggagactg tcctccattg gaactggtgt cctctgtgat tcaggatgga 600 gatatgattg acacaggctt tggagctatg gactttgctg ccctccaagc caccaagtct 660 gatgtgccac tggacatcag ccagtctgtg tgtaaatacc ctgactacct gaaaatgagt 720 gctgacacct atggcaacag tatgttcttc cacctgagga gggaacagat ttttgccaga 780 cactactaca acaaactggt gggagtggga gaggacatcc caaatgacta ctacatcaag 840 ggctctggca atggcaggga cccaattgag tcctacatct actctgccac accatctggc 900 agtatgatta cctctgacag ccagattttc aacaagccat actggctgca cagggctcaa 960 ggacacaaca atggcatctg ttggaacaac caacttttca tcacttgtgt ggacaccacc 1020 aggagcacca acctgaccat cagcacagcc acagcagcag tgagcccaac cttcacca 1080 agcaacttca agcaatacat cagacatgga gaggaatatg aactccaatt catcttccaa 1140 ctttgtaaga ttaccctgac cacagaggtg atggcttacc tgcacacaat ggacccaacc 1200 atcttggaac agtggaact t tggactgacc ctgcctccat ctgcctcctt ggaggatgcc 1260 tacaggtttg tgaggaatgc tgccacctcc tgtcagaagg acacacctcc acaggctaag 1320 cctgacccac tggctaaata caagttctgg gatgtggacc tgaaagagag gttctccctg 1380 gacctggacc agtttgcct gggcaggaag ttcctgctcc aagtggggagt ccagaggaag 1440 ccaagacctg gactgaaaag acctgcctcc tctgcctcct cctcctcctc ctcctctgcc 1500 aagaggaaga gggtgaagaa gtaaactcga gctc 153 4 <![CDATA[ <210> 113]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5106 Synthetic HPV33L1 gene]]>
 <![CDATA[ <400> 113]]> ctgggtacca tgagtgtgtg gagaccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtgagcagga ccagcatcta ctactatgct 120 ggctccagca gactgctggc tgtgggacac ccat acttca gcatcaagaa cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgt gt gggattggag attggcaggg gacaaccact gggagtgggc     360
          atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct     420
          ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt     480
          tgtctgctgg gctgtaagcc tccaacagga gaacactggg gcaagggagt ggcttgtacc     540
          aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat     600
          ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag     660
          tctgatgtgc caattgacat ctgtggcagc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga gggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 a agggctctg gcaccacagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggagcacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctgggag gtggacctga aaga gaagtt ctctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519 <![CDATA[ <210> 114]]>
 <![CDATA[ <211> 34]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5107 HPV51L1 F1]]> <![CDATA[ <400> 114]]> cttggtacca tggctctgtg gaggaccaat gaca 34 <![CDATA[ <210> 115]]>
 <![CDATA[ <211> 32]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5108 HPV51L1 R1]]> <![CDATA[ <400> 115]]> gcttggcttt gactcccact tggagcagga ac 32 <![CDATA[ <210> 116]]>
 <![CDATA[ <211> 1441]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5109 HPV51L1 expansion sequence 1]]>
 <![CDATA[ [400] cccaaa gaccagcacc 180 agggctgcca tcccaaaggt gtctgccttc caatacaggg tgttcagggt ccaacttcct 240 gacccaaaca agtttggact gcctgaccca aacctctaca accctgacac agacagactg 300 gtgtggggct gtgtggggt ggaggtggg c aggggacaac cactgggagt gggactgtct 360 ggacacccac tgttcaacaa atatgatgac acagagaaca gcaggattgc caatggcaat 420 gcccaacagg atgtgaggga caacacctct gtggacaaca agcagaccca actttgtatc 480 attggctgtg cccctccaat tggaga acac tggggcattg gcaccacttg taagaacaca 540 cctgtgcctc ctggagactg tcctccattg gaactggtgt cctctgtgat tcaggatgga 600 gatatgattg acacaggctt tggagctatg gactttgctg ccctccaagc caccaagtct 660 gatgtgccac tggacatcag ccagtctgtg tgtaaatacc ctgactacct gaaaatgagt 720 gctgacacct atggcaacag tatgttcttc cacctgagga gggaacagat ttttgccaga 780 cactactaca acaaactggt gggagtggga gaggacatcc caaatgacta ctacatcaag 840 ggctctggca atggcagg ga cccaattgag tcctacatct actctgccac accatctggc 900 agtatgatta cctctgacag ccagattttc aacaagccat actggctgca cagggctcaa 960 ggacacaaca atggcatctg ttggaacaac caacttttca tcacttgtgt ggacaccacc 1020 aggagcacca acctgaccat cagcacagcc acagcagcag tgagcccaac cttcacacca 1080 agcaacttca agcaatacat cagacatgga gaggaatatg aactccaatt catcttccaa 1140 ctttgtaaga ttaccctgac cacagaggtg atggcttacc tgcacacaat ggacccaacc 1200 atcttggaac agtggaactt tggactgacc ctgcctccat ctgcctcctt ggaggatgcc 1260 tacaggtttg tgaggaatgc tgccacctcc tgtcagaagg acacacctcc acaggctaag 1320 cctgacccac tggctaaata caagttctgg gatgtggacc tgaaagagag gttctccctg 1380 gacctggacc agtttgccct gggcaggaag ttcctgctcc aagtggggagt caaagccaag 1440 c 1441 <![CDATA[ <210> 117]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5110 HPV51L1 F2]]> <![CDATA[ <400> 117]]> agtggggagtc aaagccaagc caaaactgaa aaggg 35 <![CDATA[ <210> 118]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5111 HPV51L1 R2]]> <![CDATA[ <400> 118]]> ctgtctagat ttacttcttc accttcttcc tcttgg 36 <![CDATA[ <210> 119]]>
 <![CDATA[ <211> 101]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5112 HPV51L1 extended sequence 2]]>
 <![CDATA[ <400> 119]]> agtggggagtc aaagccaagc caaaactgaa aagggctgcc ccaaccagca ccaggacctc 60 ctctgccaag aggaagaagg tgaagaagta aatctagaca g 101 <![CDATA[ <210> 120]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5113 Amino acid sequence 471-508 of HPV type 59 L1 protein]]>
 <![CDATA[ <400> 120]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35 <![CDATA[ <210> 121]]>
 <![CDATA[ <211> 478]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5201 HPV 52 L1 protein amino acid sequence 1-478]]>
 <![CDATA[ <400> 121]]> Met Ser Val Trp Arg Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val 1 5 10 15 Pro Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Ser Arg Thr Ser 20 25 30 Ile Tyr Tyr Tyr Ala Gly Ser Ser Arg Leu Leu Thr Val Gly His Pro 35 40 45 Tyr Phe Ser Ile Lys Asn Thr Ser Ser Ser Gly Asn Gly Lys Lys Val Leu 50 55 60 Val Pro Lys Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Ile Lys Leu 65 70 75 80 Pro Asp Pro Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asn Pro 85 90 95 Glu Thr Gln Arg Leu Val Trp Ala Cys Thr Gly Leu Glu Ile Gly Arg 100 105 110 Gly Gln Pro Leu Gly Val Gly Ile Ser Gly His Pro Leu Leu Asn Lys 115 120 125 Phe Asp Asp Thr Glu Thr Ser Asn Lys Tyr Ala Gly Lys Pro Gly Ile 130 135 140 Asp Asn Arg Glu Cys Leu Ser Met Asp Tyr Lys Gln Thr Gln Leu Cys 145 150 155 160 Ile Leu Gly Cys Lys Pro Pro Ile Gly Glu His Trp Gly Lys Gly Thr 165 170 175 Pro Cys Asn Asn Asn Ser Gly Asn Pro Gly Asp Cys Pro Pro Leu Gln 180 185 190 Leu Ile Asn Ser Val Ile Gln Asp Gly Asp Met Val Asp Thr Gly Phe 195 200 205 Gly Cys Met Asp Phe Asn Thr Leu Gln Ala Ser Lys Ser Asp Val Pro 210 215 220 Ile Asp Ile Cys Ser Ser Val Cys Lys Tyr Pro Asp Tyr Leu Gln Met 225 230 235 240 Ala Ser Glu Pro Tyr Gly Asp Ser Leu Phe Phe Phe Leu Arg Arg Glu 245 250 255 Gln Met Phe Val Arg His Phe Phe Asn Arg Ala Gly Thr Leu Gly Asp 260 265 270 Pro Val Pro Gly Asp Leu Tyr Ile Gln Gly Ser Asn Ser Gly Asn Thr 275 280 285 Ala Thr Val Gln Ser Ser Ala Phe Phe Pro Thr Pro Ser Gly Ser Met 290 295 300 Val Thr Ser Glu Ser Gln Leu Phe Asn Lys Pro Tyr Trp Leu Gln Arg 305 310 315 320 Ala Gln Gly His Asn Asn Gly Ile Cys Trp Gly Asn Gln Leu Phe Val 325 330 335 Thr Val Val Asp Thr Thr Arg Ser Thr Asn Met Thr Leu Cys Ala Glu 340 345 350 Val Lys Lys Glu Ser Thr Tyr Lys Asn Glu Asn Phe Lys Glu Tyr Leu 355 360 365 Arg His Gly Glu Glu Phe Asp Leu Gln Phe Ile Phe Gln Leu Cys Lys 370 375 380 Ile Thr Leu Thr Ala Asp Val Met Thr Tyr Ile His Lys Met Asp Ala 385 390 395 400 Thr Ile Leu Glu Asp Trp Gln Phe Gly Leu Thr Pro Pro Pro Ser Ala 405 410 415 Ser Leu Glu Asp Thr Tyr Arg Phe Val Thr Ser Thr Ala Ile Thr Cys 420 425 430 Gln Lys Asn Thr Pro Pro Lys Gly Lys Glu Asp Pro Leu Lys Asp Tyr 435 440 445 Met Phe Trp Glu Val Asp Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp 450 455 460 Gln Phe Pro Leu Gly Arg Lys Phe Leu Leu Gln Ala Gly Leu 465 470 475 <![CDATA[ <210> 122]]>
 <![CDATA[ <211> 26]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5202 HPV 33 L1 protein amino acid sequence 474-499]]>
 <![CDATA[ <400> 122]]> Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr 1 5 10 15 Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25 <![CDATA[ <210> 123]]>
 <![CDATA[ <211> 504]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5203 Amino acid sequence of chimeric HPV type 52 L1 protein]]>
 <![CDATA[ <400> 123]]> Met Ser Val Trp Arg Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val 1 5 10 15 Pro Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Ser Arg Thr Ser 20 25 30 Ile Tyr Tyr Tyr Ala Gly Ser Ser Arg Leu Leu Thr Val Gly His Pro 35 40 45 Tyr Phe Ser Ile Lys Asn Thr Ser Ser Ser Gly Asn Gly Lys Lys Val Leu 50 55 60 Val Pro Lys Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Ile Lys Leu 65 70 75 80 Pro Asp Pro Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asn Pro 85 90 95 Glu Thr Gln Arg Leu Val Trp Ala Cys Thr Gly Leu Glu Ile Gly Arg 100 105 110 Gly Gln Pro Leu Gly Val Gly Ile Ser Gly His Pro Leu Leu Asn Lys 115 120 125 Phe Asp Asp Thr Glu Thr Ser Asn Lys Tyr Ala Gly Lys Pro Gly Ile 130 135 140 Asp Asn Arg Glu Cys Leu Ser Met Asp Tyr Lys Gln Thr Gln Leu Cys 145 150 155 160 Ile Leu Gly Cys Lys Pro Pro Ile Gly Glu His Trp Gly Lys Gly Thr 165 170 175 Pro Cys Asn Asn Asn Ser Gly Asn Pro Gly Asp Cys Pro Pro Leu Gln 180 185 190 Leu Ile Asn Ser Val Ile Gln Asp Gly Asp Met Val Asp Thr Gly Phe 195 200 205 Gly Cys Met Asp Phe Asn Thr Leu Gln Ala Ser Lys Ser Asp Val Pro 210 215 220 Ile Asp Ile Cys Ser Ser Val Cys Lys Tyr Pro Asp Tyr Leu Gln Met 225 230 235 240 Ala Ser Glu Pro Tyr Gly Asp Ser Leu Phe Phe Phe Leu Arg Arg Glu 245 250 255 Gln Met Phe Val Arg His Phe Phe Asn Arg Ala Gly Thr Leu Gly Asp 260 265 270 Pro Val Pro Gly Asp Leu Tyr Ile Gln Gly Ser Asn Ser Gly Asn Thr 275 280 285 Ala Thr Val Gln Ser Ser Ala Phe Phe Pro Thr Pro Ser Gly Ser Met 290 295 300 Val Thr Ser Glu Ser Gln Leu Phe Asn Lys Pro Tyr Trp Leu Gln Arg 305 310 315 320 Ala Gln Gly His Asn Asn Gly Ile Cys Trp Gly Asn Gln Leu Phe Val 325 330 335 Thr Val Val Asp Thr Thr Arg Ser Thr Asn Met Thr Leu Cys Ala Glu 340 345 350 Val Lys Lys Glu Ser Thr Tyr Lys Asn Glu Asn Phe Lys Glu Tyr Leu 355 360 365 Arg His Gly Glu Glu Phe Asp Leu Gln Phe Ile Phe Gln Leu Cys Lys 370 375 380 Ile Thr Leu Thr Ala Asp Val Met Thr Tyr Ile His Lys Met Asp Ala 385 390 395 400 Thr Ile Leu Glu Asp Trp Gln Phe Gly Leu Thr Pro Pro Pro Ser Ala 405 410 415 Ser Leu Glu Asp Thr Tyr Arg Phe Val Thr Ser Thr Ala Ile Thr Cys 420 425 430 Gln Lys Asn Thr Pro Pro Lys Gly Lys Glu Asp Pro Leu Lys Asp Tyr 435 440 445 Met Phe Trp Glu Val Asp Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp 450 455 460 Gln Phe Pro Leu Gly Arg Lys Phe Leu Leu Gln Ala Gly Leu Lys Ala 465 470 475 480 Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr Ser Ser 485 490 495 Ala Lys Arg Lys Lys Val Lys Lys 500 <![CDATA[ <210> 124]]>
 <![CDATA[ <211> 1516]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5204 Nucleotide sequence of chimeric HPV type 52 L1 protein]]>
 <![CDATA[ <400> 124]]> atgagcgtgt ggaggcccag cgaggccacc gtgtacctgc cccccgtgcc cgtgagcaag 60 gtggtgagca ccgacgagta cgtgagcagg accagcatct actactacgc cggcagcagc 120 aggctgctga ccgtgggcca cccctacttc agcat caaga acaccagcag cggcaacggc 180 aagaaggtgc tggtgcccaa ggtgagcggc ctgcagtaca gggtgttcag gatcaagctg 240 cccgacccca acaagttcgg cttccccgac accagcttct acaacccga gacccagagg 300 ctggtgtggg cctgcaccgg cc tggagatc ggcaggggcc agcccctggg cgtgggcatc 360 agcggccacc ccctgctgaa caagttcgac gacaccgaga ccagcaacaa gtacgccggc 420 aagcccggca tcgacaacag ggagtgcctg agcatggact acaagcagac ccagctgtgc 480 atcctgggct gcaagc cccc catcggcgag cactggggca agggcacccc ctgcaacaac 540 aacagcggca accccggcga ctgcccccccc ctgcagctga tcaacagcgt gatccaggac 600 ggcgacatgg tggacaccgg cttcggctgc atggacttca acaccctgca ggccagcaag 660          agcgacgtgc ccatcgacat ctgcagcagc gtgtgcaagt accccgacta cctgcagatg     720
          gccagcgagc cctacggcga cagcctgttc ttcttcctga ggagggagca gatgttcgtg     780
          aggcacttct tcaacagggc cggcaccctg ggcgaccccg tgcccggcga cctgtacatc     840
          cagggcagca acagcggcaa caccgccacc gtgcagagca gcgccttctt ccccaccccc     900
          agcggcagca tggtgaccag cgagagccag ctgttcaaca agccctactg gctgcagagg     960
          gcccagggcc acaacaacgg catctgctgg ggcaaccagc tgttcgtgac cgtggtggac 1020 accaccagga gcaccaacat gaccctgtgc gccgaggtga agaaggagag cacctacaag 1080 aacgagaact tcaaggagta cctgaggcac ggcgaggagt tcgacctgca gttcatcttc 1140 cagctgtg ca agatcaccct gaccgccgac gtgatgacct acatccacaa gatggacgcc 1200 accatcctgg aggactggca gttcggcctg acccccccc ccagcgccag cctggaggac 1260 acctacaggt tcgtgaccag caccgccatc acctgccaga agaacaccccc ccccaagggc 132 0 aaggaggacc ccctgaagga ctacatgttc tgggaggtgg acctgaagga gaagttcagc 1380 gccgacctgg accagttccc cctgggcagg aagttcctgc tgcaggccgg cctgaaagcc 1440 aagccaaaac tgaaaagggc tgccccaacc agcaccagga cctcctctgc caagaggaag 1500 aaggtgaaga agtaaa 1516 <![CDATA[ <210> 125]]>
 <![CDATA[ <211> 1531]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5205 Synthetic HPV52L1 gene]]>
 <![CDATA[ <400> 125]]> ctgggtacca tgagcgtgtg gaggcccagc gaggccaccg tgtacctgcc ccccgtgccc 60 gtgagcaagg tggtgagcac cgacgagtac gtgagcagga ccagcatcta ctactacgcc 120 ggcagcagca ggctgctgac cgtgg gccac ccctacttca gcatcaagaa caccagcagc 180 ggcaacggca agaaggtgct ggtgcccaag gtgagcggcc tgcagtacag ggtgttcagg 240 atcaagctgc ccgaccccaa caagttcggc ttccccgaca ccagcttcta caaccccgag 300 acccagaggc tggtgtgggc ctgcaccggc ctggagatcg gcaggggcca gcccctgggc 360 gtgggcatca gcggccaccc cctgctgaac aagttcgacg acaccgagac cagcaacaag 420 tacgccggca agcccggcat cgacaacagg gagtgcctga gcatggacta caagcagacc 480 ca gctgtgca tcctgggctg caagcccccc atcggcgagc actggggcaa gggcaccccc 540 tgcaacaaca acagcggcaa ccccggcgac tgcccccccc tgcagctgat caacagcgtg 600 atccaggacg gcgacatggt ggacaccggc ttcggctgca tggacttcaa caccctgcag 660 gccagcaaga gcgacgtgcc catcgacatc tgcagcagcg tgtgcaagta ccccgactac 720 ctgcagatgg ccagcgagcc ctacggcgac agcctgttct tcttcctgag gagggagcag 780 atgttcgtga ggcacttctt caacagggcc ggcaccctgg gcgaccccgt gcccggcgac 840 ctgtacatcc agggcagcaa cagcggcaac accgccaccg tgcagagcag cgccttcttc 900 cccaccccca gcggcagcat ggtgaccagc gagagccagc tgttcaacaa gccctactgg 960 ctgcagaggg cccagggcca caacaacggc atctgctggg gcaaccagct gttcgtgacc 1020 gtggtggaca ccaccaggag caccaacatg accctgtgcg ccgaggtgaa gaaggagagc 1080 acctacaaga acgagaactt caaggagtac ctgaggcacg gcgaggagtt cga cctgcag 1140 ttcatcttcc agctgtgcaa gatcaccctg accgccgacg tgatgaccta catccacaag 1200 atggacgcca ccatcctgga ggactggcag ttcggcctga cccccccccc cagcgccagc 1260 ctggaggaca cctacaggtt cgtgaccagc accgccat ca cctgccagaa gaacaccccc 1320 cccaagggca aggaggaccc cctgaaggac tacatgttct gggaggtgga cctgaaggag 1380 aagttcagcg ccgacctgga ccagttcccc ctgggcagga agttcctgct gcaggccggc 1440 ctgcaggcca ggcccaag ct gaagaggccc gccagcagcg cccccaggac cagcaccaag 1500 aagaagaagg tgaagaggta aactcgagct c 1531 <![CDATA[ <210> 126]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <22]]>0> ]]>
 <br/> &lt;![CDATA[ &lt;223&gt; 5206 Synthetic HPV33L1 gene]]&gt;
 <br/>
 <br/> &lt;![CDATA[ &lt;400&gt;126]]&gt; <br/> <![CDATA[ctgggtacca tgagtgtgtg gagaccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtgagcagga ccagcatcta ctactatgct 120 ggctccagca gactgctggc tgtgggacac ccatacttca gcatcaaga a cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgtgt gggattggag attggcaggg gacaaccact gggagtgggc 360 atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct 420 ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt 480 tgtctgctgg gctgtaagcc tccaacagga gaacactgg g gcaagggagt ggcttgtacc 540 aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat 600 ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag 660 tctgatgtgc caattgacat ctgtggca gc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga ggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 aagggctctg gcacc acagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggag cacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctggggag gtggacctga aagagaagtt ct ctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519 <![CDATA[ <210> 127]]>
 <![CDATA[ <211> 34]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5207 HPV52L1 F1]]> <![CDATA[ <400> 127]]> cttggtacca tgagcgtgtg gaggcccagc gagg 34 <![CDATA[ <210> 128]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5208 HPV52L1 R1]]> <![CDATA[ <400> 128]]> gcttggcttt caggccggcc tgcagcagga acttc 35 <![CDATA[ <210> 129]]>
 <![CDATA[ <211> 1453]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5209 HPV52L1 expansion sequence 1]]>
 <![CDATA[ <400> 129]]> cttggtacca tgagcgtgtg gaggcccagc gaggccaccg tgtacctgcc ccccgtgccc 60 gtgagcaagg tggtgagcac cgacgagtac gtgagcagga ccagcatcta ctactacgcc 120 ggcagcagca ggctgctgac cgtgg gccac ccctacttca gcatcaagaa caccagcagc 180 ggcaacggca agaaggtgct ggtgcccaag gtgagcggcc tgcagtacag ggtgttcagg 240 atcaagctgc ccgaccccaa caagttcggc ttccccgaca ccagcttcta caaccccgag 300 acccagaggc tggtgtgggc ctgcaccggc ctggagatcg gcaggggcca gcccctgggc 360 gtgggcatca gcggccaccc cctgctgaac aagttcgacg acaccgagac cagcaacaag 420 tacgccggca agcccggcat cgacaacagg gagtgcctga gcatggacta caagcagacc 480 ca gctgtgca tcctgggctg caagcccccc atcggcgagc actggggcaa gggcaccccc 540 tgcaacaaca acagcggcaa ccccggcgac tgcccccccc tgcagctgat caacagcgtg 600 atccaggacg gcgacatggt ggacaccggc ttcggctgca tggacttcaa caccctgcag 660 gccagcaaga gcgacgtgcc catcgacatc tgcagcagcg tgtgcaagta ccccgactac 720 ctgcagatgg ccagcgagcc ctacggcgac agcctgttct tcttcctgag gagggagcag 780 atgttcgtga ggcacttctt caacagggcc ggcaccctgg gcgaccccgt gcccggcgac 840 ctgtacatcc agggcagcaa cagcggcaac accgccaccg tgcagagcag cgccttcttc 900 cccaccccca gcggcagcat ggtgaccagc gagagccagc tgttcaacaa gccctactgg 960 ctgcagaggg cccagggcca caacaacggc atctgctggg gcaaccagct gttcgtgacc 1020 gtggtggaca ccaccaggag caccaacatg accctgtgcg ccgaggtgaa gaaggagagc 1080 acctacaaga acgagaactt caaggagtac ctgaggcacg gcgaggagtt cga cctgcag 1140 ttcatcttcc agctgtgcaa gatcaccctg accgccgacg tgatgaccta catccacaag 1200 atggacgcca ccatcctgga ggactggcag ttcggcctga cccccccccc cagcgccagc 1260 ctggaggaca cctacaggtt cgtgaccagc accgccat ca cctgccagaa gaacaccccc 1320 cccaagggca aggaggaccc cctgaaggac tacatgttct gggaggtgga cctgaaggag 1380 aagttcagcg ccgacctgga ccagttcccc ctgggcagga agttcctgct gcaggccggc 1440 ctgaaagcca agc 1 453 <![CDATA[ <210> 130]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5210 HPV52L1 F2]]> <![CDATA[ <400> 130]]> ggccggcctg aaagccaagc caaaactgaa aaggg 35 <![CDATA[ <210> 131]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5211 HPV52L1 R2]]> <![CDATA[ <400> 131]]> ctgtctagat ttacttcttc accttcttcc tcttgg 36 <![CDATA[ <210> 132]]>
 <![CDATA[ <211> 101]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5212 HPV52L1 expansion sequence 2]]>
 <![CDATA[ <400> 132]]> ggccggcctg aaagccaagc caaaactgaa aagggctgcc ccaaccagca ccaggacctc 60 ctctgccaag aggaagaagg tgaagaagta aatctagaca g 101 <![CDATA[ <210> 133]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5213 Amino acid sequence 471-508 of HPV type 59 L1 protein]]>
 <![CDATA[ <400> 133]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Pro Ala Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35
           <![CDATA[ <210> 134]]>
 <![CDATA[ <211> 467]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5601 HPV 56 L1 protein amino acid sequence 1-467]]>
 <![CDATA[ <400> 134]]> Met Ala Thr Trp Arg Pro Ser Glu Asn Lys Val Tyr Leu Pro Pro Thr 1 5 10 15 Pro Val Ser Lys Val Val Ala Thr Asp Ser Tyr Val Lys Arg Thr Ser 20 25 30 Ile Phe Tyr His Ala Gly Ser Ser Arg Leu Leu Ala Val Gly His Pro 35 40 45 Tyr Tyr Ser Val Thr Lys Asp Asn Thr Lys Thr Asn Ile Pro Lys Val 50 55 60 Ser Ala Tyr Gln Tyr Arg Val Phe Arg Val Arg Leu Pro Asp Pro Asn 65 70 75 80 Lys Phe Gly Leu Pro Asp Thr Asn Ile Tyr Asn Pro Asp Gln Glu Arg 85 90 95 Leu Val Trp Ala Cys Val Gly Leu Glu Val Gly Arg Gly Gln Pro Leu 100 105 110 Gly Ala Gly Leu Ser Gly His Pro Leu Phe Asn Arg Leu Asp Asp Thr 115 120 125 Glu Ser Ser Asn Leu Ala Asn Asn Asn Val Ile Glu Asp Ser Arg Asp 130 135 140 Asn Ile Ser Val Asp Gly Lys Gln Thr Gln Leu Cys Ile Val Gly Cys 145 150 155 160 Thr Pro Ala Met Gly Glu His Trp Thr Lys Gly Ala Val Cys Lys Ser 165 170 175 Thr Gln Val Thr Thr Gly Asp Cys Pro Pro Leu Ala Leu Ile Asn Thr 180 185 190 Pro Ile Glu Asp Gly Asp Met Ile Asp Thr Gly Phe Gly Ala Met Asp 195 200 205 Phe Lys Val Leu Gln Glu Ser Lys Ala Glu Val Pro Leu Asp Ile Val 210 215 220 Gln Ser Thr Cys Lys Tyr Pro Asp Tyr Leu Lys Met Ser Ala Asp Ala 225 230 235 240 Tyr Gly Asp Ser Met Trp Phe Tyr Leu Arg Arg Glu Gln Leu Phe Ala 245 250 255 Arg His Tyr Phe Asn Arg Ala Gly Lys Val Gly Glu Thr Ile Pro Ala 260 265 270 Glu Leu Tyr Leu Lys Gly Ser Asn Gly Arg Glu Pro Pro Pro Ser Ser 275 280 285 Val Tyr Val Ala Thr Pro Ser Gly Ser Met Ile Thr Ser Glu Ala Gln 290 295 300 Leu Phe Asn Lys Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn Asn 305 310 315 320 Gly Ile Cys Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp Thr Thr 325 330 335 Arg Ser Thr Asn Met Thr Ile Ser Thr Ala Thr Glu Gln Leu Ser Lys 340 345 350 Tyr Asp Ala Arg Lys Ile Asn Gln Tyr Leu Arg His Val Glu Glu Tyr 355 360 365 Glu Leu Gln Phe Val Phe Gln Leu Cys Lys Ile Thr Leu Ser Ala Glu 370 375 380 Val Met Ala Tyr Leu His Asn Met Asn Ala Asn Leu Leu Glu Asp Trp 385 390 395 400 Asn Ile Gly Leu Ser Pro Pro Val Ala Thr Ser Leu Glu Asp Lys Tyr 405 410 415 Arg Tyr Val Arg Ser Thr Ala Ile Thr Cys Gln Arg Glu Gln Pro Pro 420 425 430 Thr Glu Lys Gln Asp Pro Leu Ala Lys Tyr Lys Phe Trp Asp Val Asn 435 440 445 Leu Gln Asp Ser Phe Ser Thr Asp Leu Asp Gln Phe Pro Leu Gly Arg 450 455 460 Lys Phe Leu 465
           <![CDATA[ <210> 135]]>
 <![CDATA[ <211> 31]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5602 HPV 33 L1 protein amino acid sequence 469-499]]>
 <![CDATA[ <400> 135]]> Leu Gln Ala Gly Leu Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro 1 5 10 15 Thr Ser Thr Arg Thr Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25 30
           <![CDATA[ <210> 136]]>
 <![CDATA[ <211> 498]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5603 Amino acid sequence of chimeric HPV type 56 L1 protein]]>
 <![CDATA[ <400> 136]]> Met Ala Thr Trp Arg Pro Ser Glu Asn Lys Val Tyr Leu Pro Pro Thr 1 5 10 15 Pro Val Ser Lys Val Val Ala Thr Asp Ser Tyr Val Lys Arg Thr Ser 20 25 30 Ile Phe Tyr His Ala Gly Ser Ser Arg Leu Leu Ala Val Gly His Pro 35 40 45 Tyr Tyr Ser Val Thr Lys Asp Asn Thr Lys Thr Asn Ile Pro Lys Val 50 55 60 Ser Ala Tyr Gln Tyr Arg Val Phe Arg Val Arg Leu Pro Asp Pro Asn 65 70 75 80 Lys Phe Gly Leu Pro Asp Thr Asn Ile Tyr Asn Pro Asp Gln Glu Arg 85 90 95 Leu Val Trp Ala Cys Val Gly Leu Glu Val Gly Arg Gly Gln Pro Leu 100 105 110 Gly Ala Gly Leu Ser Gly His Pro Leu Phe Asn Arg Leu Asp Asp Thr 115 120 125 Glu Ser Ser Asn Leu Ala Asn Asn Asn Val Ile Glu Asp Ser Arg Asp 130 135 140 Asn Ile Ser Val Asp Gly Lys Gln Thr Gln Leu Cys Ile Val Gly Cys 145 150 155 160 Thr Pro Ala Met Gly Glu His Trp Thr Lys Gly Ala Val Cys Lys Ser 165 170 175 Thr Gln Val Thr Thr Gly Asp Cys Pro Pro Leu Ala Leu Ile Asn Thr 180 185 190 Pro Ile Glu Asp Gly Asp Met Ile Asp Thr Gly Phe Gly Ala Met Asp 195 200 205 Phe Lys Val Leu Gln Glu Ser Lys Ala Glu Val Pro Leu Asp Ile Val 210 215 220 Gln Ser Thr Cys Lys Tyr Pro Asp Tyr Leu Lys Met Ser Ala Asp Ala 225 230 235 240 Tyr Gly Asp Ser Met Trp Phe Tyr Leu Arg Arg Glu Gln Leu Phe Ala 245 250 255 Arg His Tyr Phe Asn Arg Ala Gly Lys Val Gly Glu Thr Ile Pro Ala 260 265 270 Glu Leu Tyr Leu Lys Gly Ser Asn Gly Arg Glu Pro Pro Pro Ser Ser 275 280 285 Val Tyr Val Ala Thr Pro Ser Gly Ser Met Ile Thr Ser Glu Ala Gln 290 295 300 Leu Phe Asn Lys Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn Asn 305 310 315 320 Gly Ile Cys Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp Thr Thr 325 330 335 Arg Ser Thr Asn Met Thr Ile Ser Thr Ala Thr Glu Gln Leu Ser Lys 340 345 350 Tyr Asp Ala Arg Lys Ile Asn Gln Tyr Leu Arg His Val Glu Glu Tyr 355 360 365 Glu Leu Gln Phe Val Phe Gln Leu Cys Lys Ile Thr Leu Ser Ala Glu 370 375 380 Val Met Ala Tyr Leu His Asn Met Asn Ala Asn Leu Leu Glu Asp Trp 385 390 395 400 Asn Ile Gly Leu Ser Pro Pro Val Ala Thr Ser Leu Glu Asp Lys Tyr 405 410 415 Arg Tyr Val Arg Ser Thr Ala Ile Thr Cys Gln Arg Glu Gln Pro Pro 420 425 430 Thr Glu Lys Gln Asp Pro Leu Ala Lys Tyr Lys Phe Trp Asp Val Asn 435 440 445 Leu Gln Asp Ser Phe Ser Thr Asp Leu Asp Gln Phe Pro Leu Gly Arg 450 455 460 Lys Phe Leu Leu Gln Ala Gly Leu Lys Ala Lys Pro Lys Leu Lys Arg 465 470 475 480 Ala Ala Pro Thr Ser Thr Arg Thr Ser Ser Ala Lys Arg Lys Lys Val 485 490 495 Lys Lys
           <![CDATA[ <210> 137]]>
 <![CDATA[ <211> 1498]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5604 Nucleotide sequence of chimeric HPV type 56 L1 protein]]>
 <![CDATA[ <400> 137]]> atggctacct ggagaccatc tgagaacaag gtctacctgc ctccaacacc tgtgagcaag 60 gtggtggcta cagactccta tgtgaagagg accagcatct tctaccatgc tggctccagc 120 agactgctgg ctgtgggaca cccatactac tctgtgacca aggacaacac caagaccaac 180 atcccaaagg tgtctgccta ccaatacagg gtgttcaggg tgagactgcc tgacccaaac 240 aagtttggac tgcctgacac caacatctac aaccctgacc aggagagact ggtgtgggct 300 tgtgtgggat tggaggtggg caggggacaa ccactgggag caggactgtc tggacacccca 360 ctgttcaaca gactggatga cacagagtcc agcaacctgg ctaacaacaa tgtgattgag 420 gacagcaggg acaacatctc tgtggatggc aagcagaccc aactttgtat tgtgggctgt 480 actcctgcta tggggagaaca ctggaccaag ggagcagtgt gtaagagcac ccaggtgacc 540 acaggagact gtcctccact ggctctgata aacacaccaa ttgaggatgg agatatgatt 600 gacacaggct ttggagctat ggacttcaag gtgctccaag agagcaaggc tgaggtgcca 660 ctggacattg tccagagcac ttgtaaatac cctgactacc tgaaaatgag tgctgatgcc 720 tatggagaca gtatgtggtt ctacctgagg agggaacaac tttttgccag acactacttc 780 aacagggctg gcaaggtggg agagaccatc cctgctgaac tctacctgaa aggcagcaat 840 ggcagggaac ctcctccatc ctctgtctat gtggctacac catctggcag tatgattacc 900 tctgaggctc aacttttcaa caagccatac tggctccaaa gggctcaagg acacaacaat 960 ggcatctgtt ggggcaacca actttttgtg acagtggtgg acaccaccag gagcaccaat 1020 atgaccatca gcacagccac agaacaactt agcaaatatg atgccaggaa gataaaccaa 1080 tacctgaggc atgtggagga atatgaactc caatttgtgt tccaactttg taagattacc 1140 ctgtctgctg aggtgatggc ttacctgcac aatatgaatg ccaacctgtt ggaggactgg 1200 aacattggac tgagccctcc tgtggctacc tccttggagg acaaatacag atatgtgagg 1260 agcacagcca tcacttgtca gagggaacaa cctccaacag agaagcagga cccactggct 1320 aaatacaagt tctggggatgt gaacctccaa gactccttca gcacagacct ggaccagttt 1380 ccactgggca ggaagttcct gctccaagca ggactgaaag ccaagccaaa actgaaaagg 1440 gctgccccaa ccagcaccag gacctcctct gccaagagga agaaggtgaa gaagtaaa 1498
           <![CDATA[ <210> 138]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5605 Synthetic HPV56L1 gene]]>
 <![CDATA[ <400> 138]]> ctgggtacca tggctacctg gagaccatct gagaacaagg tctacctgcc tccaacacct 60 gtgagcaagg tggtggctac agactcctat gtgaagagga ccagcatctt ctaccatgct 120 ggctccagca gactgctggc tgtgggacac ccatactact ctgtgaccaa ggacaacacc 180 aagaccaaca tcccaaaggt gtctgcctac caatacaggg tgttcagggt gagactgcct 240 gacccaaaca agtttggact gcctgacacc aacatctaca accctgacca ggagagactg 300 gtgtgggctt gtgtgggatt ggaggtgggc aggggacaac cactgggagc aggactgtct 360 ggacacccac tgttcaacag actggatgac acagagtcca gcaacctggc taacaacaat 420 gtgattgagg acagcaggga caacatctct gtggatggca agcagaccca actttgtatt 480 gtgggctgta ctcctgctat gggagaacac tggaccaagg gagcagtgtg taagagcacc 540 caggtgacca caggagactg tcctccactg gctctgataa acacaccaat tgaggatgga 600 gatatgattg acacaggctt tggagctatg gacttcaagg tgctccaaga gagcaaggct 660 gaggtgccac tggacattgtccagagcact tgtaaatacc ctgactacct gaaaatgagt 720 gctgatgcct atggagacag tatgtggttc tacctgagga gggaacaact ttttgccaga 780 cactacttca acagggctgg caaggtggga gagaccatcc ctgctgaact ctacctgaaa 840 ggcagcaatg gcagggaacc tcctccatcc tctgtctatg tggctacacc atctggcagt 900 atgattacct ctgaggctca acttttcaac aagccatact ggctccaaag ggctcaagga 960 cacaacaatg gcatctgttg gggcaaccaa ctttttgtga cagtggtgga caccaccagg 1020 agcaccaata tgaccatcag cacagccaca gaacaactta gcaaatatga tgccaggaag 1080 ataaaccaat acctgaggca tgtggaggaa tatgaactcc aatttgtgtt ccaactttgt 1140 aagattaccc tgtctgctga ggtgatggct tacctgcaca atatgaatgc caacctgttg 1200 gaggactgga acattggact gagccctcct gtggctacct ccttggagga caaatacaga 1260 tatgtgagga gcacagccat cacttgtcag agggaacaac ctccaacaga gaagcaggac 1320 ccactggcta aatacaagtt ctggggatgtg aacctccaag actccttcag cacagacctg 1380 gaccagtttc cactgggcag gaagttcctg atgcaacttg gcaccaggag caagcctgct 1440 gtggctacca gcaagaagag gtctgcccca accagcacca gcacacctgc caagaggaag 1500 aggaggtaaa ctcgagctc 1519
           <![CDATA[ <210> 139]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5606 Synthetic HPV33L1 gene]]>
 <![CDATA[ <400> 139]]> ctgggtacca tgagtgtgtg gagaccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtgagcagga ccagcatcta ctactatgct 120 ggctccagca gactgctggc tgtgggacac ccatacttca gcatcaagaa cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgtgt gggattggag attggcaggg gacaaccact gggagtgggc 360 atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct 420 ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt 480 tgtctgctgg gctgtaagcc tccaacagga gaacactggg gcaagggagt ggcttgtacc 540 aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat 600 ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag 660 tctgatgtgc caattgacat ctgtggcagc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga ggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 aagggctctg gcaccacagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggagcacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctggggag gtggacctga aagagaagtt ctctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519
           <![CDATA[ <210> 140]]>
 <![CDATA[ <211> 33]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5607 HPV56L1 F1]]>
           <![CDATA[ <400> 140]]> cttggtacca tggctacctg gagaccatct gag 33
           <![CDATA[ <210> 141]]>
 <![CDATA[ <211> 31]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5608 HPV56L1 R1]]>
           <![CDATA[ <400> 141]]> ctgcttggag caggaacttc ctgcccagtg g 31
           <![CDATA[ <210> 142]]>
 <![CDATA[ <211> 1420]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5609 HPV56L1 expansion sequence 1]]>
 <![CDATA[ <400> 142]]> cttggtacca tggctacctg gagaccatct gagaacaagg tctacctgcc tccaacacct 60 gtgagcaagg tggtggctac agactcctat gtgaagagga ccagcatctt ctaccatgct 120 ggctccagca gactgctggc tgtgggacac ccatactact ctgtgaccaa ggacaacacc 180 aagaccaaca tcccaaaggt gtctgcctac caatacaggg tgttcagggt gagactgcct 240 gacccaaaca agtttggact gcctgacacc aacatctaca accctgacca ggagagactg 300 gtgtgggctt gtgtgggatt ggaggtgggc aggggacaac cactgggagc aggactgtct 360 ggacacccac tgttcaacag actggatgac acagagtcca gcaacctggc taacaacaat 420 gtgattgagg acagcaggga caacatctct gtggatggca agcagaccca actttgtatt 480 gtgggctgta ctcctgctat gggagaacac tggaccaagg gagcagtgtg taagagcacc 540 caggtgacca caggagactg tcctccactg gctctgataa acacaccaat tgaggatgga 600 gatatgattg acacaggctt tggagctatg gacttcaagg tgctccaaga gagcaaggct 660 gaggtgccac tggacattgtccagagcact tgtaaatacc ctgactacct gaaaatgagt 720 gctgatgcct atggagacag tatgtggttc tacctgagga gggaacaact ttttgccaga 780 cactacttca acagggctgg caaggtggga gagaccatcc ctgctgaact ctacctgaaa 840 ggcagcaatg gcagggaacc tcctccatcc tctgtctatg tggctacacc atctggcagt 900 atgattacct ctgaggctca acttttcaac aagccatact ggctccaaag ggctcaagga 960 cacaacaatg gcatctgttg gggcaaccaa ctttttgtga cagtggtgga caccaccagg 1020 agcaccaata tgaccatcag cacagccaca gaacaactta gcaaatatga tgccaggaag 1080 ataaaccaat acctgaggca tgtggaggaa tatgaactcc aatttgtgtt ccaactttgt 1140 aagattaccc tgtctgctga ggtgatggct tacctgcaca atatgaatgc caacctgttg 1200 gaggactgga acattggact gagccctcct gtggctacct ccttggagga caaatacaga 1260 tatgtgagga gcacagccat cacttgtcag agggaacaac ctccaacaga gaagcaggac 1320 ccactggcta aatacaagtt ctggggatgtg aacctccaag actccttcag cacagacctg 1380 gaccagtttc cactgggcag gaagttcctg ctccaagcag 1420
           <![CDATA[ <210> 143]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5610 HPV56L1 F2]]> <![CDATA[ <400> 143]]> gaagttcctg ctccaagcag gactgaaagc caagcc 36 <![CDATA[ <210> 144]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5611 HPV56L1 R2]]> <![CDATA[ <400> 144]]> ctgtctagat ttacttcttc accttcttcc tcttgg 36 <![CDATA[ <210> 145]]>
 <![CDATA[ <211> 116]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5612 HPV56L1 expansion sequence 2]]>
 <![CDATA[ <400> 145]]> gaagttcctg ctccaagcag gactgaaagc caagccaaaa ctgaaaaggg ctgccccaac 60 cagcaccagg acctcctctg ccaagaggaa gaaggtgaag aagtaaatct agacag 116 <![CDATA[ <210> 146]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5613 HPV 59 L1 protein amino acid sequence 471-508]]>
 <![CDATA[ <400> 146]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35 <![CDATA[ <210> 147]]>
 <![CDATA[ <211> 473]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5801 HPV 58 L1 protein amino acid sequence 1-473]]>
 <![CDATA[ <400> 147]]> Met Ser Val Trp Arg Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val 1 5 10 15 Pro Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Ser Arg Thr Ser 20 25 30 Ile Tyr Tyr Tyr Ala Gly Ser Ser Arg Leu Leu Ala Val Gly Asn Pro 35 40 45 Tyr Phe Ser Ile Lys Ser Pro Asn Asn Asn Lys Lys Val Leu Val Pro 50 55 60 Lys Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Val Arg Leu Pro Asp 65 70 75 80 Pro Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asn Pro Asp Thr 85 90 95 Gln Arg Leu Val Trp Ala Cys Val Gly Leu Glu Ile Gly Arg Gly Gln 100 105 110 Pro Leu Gly Val Gly Val Ser Gly His Pro Tyr Leu Asn Lys Phe Asp 115 120 125 Asp Thr Glu Thr Ser Asn Arg Tyr Pro Ala Gln Pro Gly Ser Asp Asn 130 135 140 Arg Glu Cys Leu Ser Met Asp Tyr Lys Gln Thr Gln Leu Cys Leu Ile 145 150 155 160 Gly Cys Lys Pro Pro Thr Gly Glu His Trp Gly Lys Gly Val Ala Cys 165 170 175 Asn Asn Asn Ala Ala Ala Thr Asp Cys Pro Pro Leu Glu Leu Phe Asn 180 185 190 Ser Ile Ile Glu Asp Gly Asp Met Val Asp Thr Gly Phe Gly Cys Met 195 200 205 Asp Phe Gly Thr Leu Gln Ala Asn Lys Ser Asp Val Pro Ile Asp Ile 210 215 220 Cys Asn Ser Thr Cys Lys Tyr Pro Asp Tyr Leu Lys Met Ala Ser Glu 225 230 235 240 Pro Tyr Gly Asp Ser Leu Phe Phe Phe Leu Arg Arg Glu Gln Met Phe 245 250 255 Val Arg His Phe Phe Asn Arg Ala Gly Lys Leu Gly Glu Ala Val Pro 260 265 270 Asp Asp Leu Tyr Ile Lys Gly Ser Gly Asn Thr Ala Val Ile Gln Ser 275 280 285 Ser Ala Phe Phe Pro Thr Pro Ser Gly Ser Ile Val Thr Ser Glu Ser 290 295 300 Gln Leu Phe Asn Lys Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn 305 310 315 320 Asn Gly Ile Cys Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp Thr 325 330 335 Thr Arg Ser Thr Asn Met Thr Leu Cys Thr Glu Val Thr Lys Glu Gly 340 345 350 Thr Tyr Lys Asn Asp Asn Phe Lys Glu Tyr Val Arg His Val Glu Glu 355 360 365 Tyr Asp Leu Gln Phe Val Phe Gln Leu Cys Lys Ile Thr Leu Thr Ala 370 375 380 Glu Ile Met Thr Tyr Ile His Thr Met Asp Ser Asn Ile Leu Glu Asp 385 390 395 400 Trp Gln Phe Gly Leu Thr Pro Pro Pro Ser Ala Ser Leu Gln Asp Thr 405 410 415 Tyr Arg Phe Val Thr Ser Gln Ala Ile Thr Cys Gln Lys Thr Ala Pro 420 425 430 Pro Lys Glu Lys Glu Asp Pro Leu Asn Lys Tyr Thr Phe Trp Glu Val 435 440 445 Asn Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro Leu Gly 450 455 460 Arg Lys Phe Leu Leu Gln Ser Gly Leu 465 470 <![CDATA[ <210> 148]]>
 <![CDATA[ <211> 26]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5802 HPV 33 L1 protein amino acid sequence 474-499]]>
 <![CDATA[ <400> 148]]> Lys Ala Lys Pro Lys Leu Lys Arg Ala Ala Pro Thr Ser Thr Arg Thr 1 5 10 15 Ser Ser Ala Lys Arg Lys Lys Val Lys Lys 20 25 <![CDATA[ <210> 149]]>
 <![CDATA[ <211> 499]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5803 Amino acid sequence of chimeric HPV type 58 L1 protein]]>
 <![CDATA[ <400> 149]]> Met Ser Val Trp Arg Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val 1 5 10 15 Pro Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Ser Arg Thr Ser 20 25 30 Ile Tyr Tyr Tyr Ala Gly Ser Ser Arg Leu Leu Ala Val Gly Asn Pro 35 40 45 Tyr Phe Ser Ile Lys Ser Pro Asn Asn Asn Lys Lys Val Leu Val Pro 50 55 60 Lys Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Val Arg Leu Pro Asp 65 70 75 80 Pro Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asn Pro Asp Thr 85 90 95 Gln Arg Leu Val Trp Ala Cys Val Gly Leu Glu Ile Gly Arg Gly Gln 100 105 110 Pro Leu Gly Val Gly Val Ser Gly His Pro Tyr Leu Asn Lys Phe Asp 115 120 125 Asp Thr Glu Thr Ser Asn Arg Tyr Pro Ala Gln Pro Gly Ser Asp Asn 130 135 140 Arg Glu Cys Leu Ser Met Asp Tyr Lys Gln Thr Gln Leu Cys Leu Ile 145 150 155 160 Gly Cys Lys Pro Pro Thr Gly Glu His Trp Gly Lys Gly Val Ala Cys 165 170 175 Asn Asn Asn Ala Ala Ala Thr Asp Cys Pro Pro Leu Glu Leu Phe Asn 180 185 190 Ser Ile Ile Glu Asp Gly Asp Met Val Asp Thr Gly Phe Gly Cys Met 195 200 205 Asp Phe Gly Thr Leu Gln Ala Asn Lys Ser Asp Val Pro Ile Asp Ile 210 215 220 Cys Asn Ser Thr Cys Lys Tyr Pro Asp Tyr Leu Lys Met Ala Ser Glu 225 230 235 240 Pro Tyr Gly Asp Ser Leu Phe Phe Phe Leu Arg Arg Glu Gln Met Phe 245 250 255 Val Arg His Phe Phe Asn Arg Ala Gly Lys Leu Gly Glu Ala Val Pro 260 265 270 Asp Asp Leu Tyr Ile Lys Gly Ser Gly Asn Thr Ala Val Ile Gln Ser 275 280 285 Ser Ala Phe Phe Pro Thr Pro Ser Gly Ser Ile Val Thr Ser Glu Ser 290 295 300 Gln Leu Phe Asn Lys Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn 305 310 315 320 Asn Gly Ile Cys Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp Thr 325 330 335 Thr Arg Ser Thr Asn Met Thr Leu Cys Thr Glu Val Thr Lys Glu Gly 340 345 350 Thr Tyr Lys Asn Asp Asn Phe Lys Glu Tyr Val Arg His Val Glu Glu 355 360 365 Tyr Asp Leu Gln Phe Val Phe Gln Leu Cys Lys Ile Thr Leu Thr Ala 370 375 380 Glu Ile Met Thr Tyr Ile His Thr Met Asp Ser Asn Ile Leu Glu Asp 385 390 395 400 Trp Gln Phe Gly Leu Thr Pro Pro Pro Ser Ala Ser Leu Gln Asp Thr 405 410 415 Tyr Arg Phe Val Thr Ser Gln Ala Ile Thr Cys Gln Lys Thr Ala Pro 420 425 430 Pro Lys Glu Lys Glu Asp Pro Leu Asn Lys Tyr Thr Phe Trp Glu Val 435 440 445 Asn Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro Leu Gly 450 455 460 Arg Lys Phe Leu Leu Gln Ser Gly Leu Lys Ala Lys Pro Lys Leu Lys 465 470 475 480 Arg Ala Ala Pro Thr Ser Thr Arg Thr Ser Ser Ala Lys Arg Lys Lys 485 490 495 Val Lys Lys <![CDATA[ <210> 150]]>
 <![CDATA[ <211> 1501]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5804 Nucleotide sequence of chimeric HPV type 58 L1 protein]]>
 <![CDATA[ <400> 150]]> atgagcgtgt ggaggcccag cgaggccacc gtgtacctgc cccccgtgcc cgtgagcaag 60 gtggtgagca ccgacgagta cgtgagcagg accagcatct actactacgc cggcagcagc 120 aggctgctgg ccgtgggcaa cccctacttc agcat caaga gccccaacaa caacaagaag 180 gtgctggtgc ccaaggtgag cggcctgcag tacagggtgt tcagggtgag gctgcccgac 240 cccaacaagt tcggcttccc cgacaccagc ttctacaacc ccgacaccca gaggctggtg 300 tgggcctgcg tg ggcctgga gatcggcagg ggccagcccc tgggcgtggg cgtgagcggc 360 cacccctacc tgaacaagtt cgacgacacc gagaccagca acaggtaccc cgcccagccc 420 ggcagcgaca acagggagtg cctgagcatg gactacaagc agacccagct gtgcctgatc 480 ggctg caagc cccccaccgg cgagcactgg ggcaagggcg tggcctgcaa caacaacgcc 540 gccgccaccg actgcccccc cctggagctg ttcaacagca tcatcgagga cggcgacatg 600 gtggacaccg gcttcggctg catggacttc ggcaccctgc aggccaacaa gagcgacgtg 660 cccatcgaca tctgcaacag cacctgcaag taccccgact acctgaagat ggccagcgag 720 ccctacggcg acagcctgtt cttcttcctg aggagggagc agatgttcgt gaggcacttc 780 ttcaacaggg ccggcaagct gggcgaggcc gtgcccgacg acc tgtacat caagggcagc 840 ggcaacaccg ccgtgatcca gagcagcgcc ttcttcccca cccccagcgg cagcatcgtg 900 accagcgaga gccagctgtt caacaagccc tactggctgc agagggccca gggccacaac 960 aacggcatct gctggggcaa ccagctgttc gtgaccgtgg tggacacccac caggagcacc 1020 aacatgaccc tgtgcaccga ggtgaccaag gagggcacct acaagaacga caacttcaag 1080 gagtacgtga ggcacgtgga ggagtacgac ctgcagttcg tgttccagct gtgcaagatc 1140 accctgaccg cc gagatcat gacctacatc cacaccatgg acagcaacat cctggaggac 1200 tggcagttcg gcctgacccc cccccccagc gccagcctgc aggacaccta caggttcgtg 1260 accagccagg ccatcacctg ccagaagacc gcccccccca aggagaagga ggaccccctg 1320 aacaag taca ccttctggga ggtgaacctg aaggagaagt tcagcgccga cctggaccag 1380 ttccccctgg gcaggaagtt cctgctgcag agcggcctga aagccaagcc aaaactgaaa 1440 agggctgccc caaccagcac caggacctcc tctgccaaga ggaagaaggt gaagaagta a 1500 a 1501 <![CDATA[ <210> 151]]>
 <![CDATA[ <211> 1516]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5805 Synthetic HPV58L1 gene]]>
 <![CDATA[ <400> 151]]> ctgggtacca tgagcgtgtg gaggcccagc gaggccaccg tgtacctgcc ccccgtgccc 60 gtgagcaagg tggtgagcac cgacgagtac gtgagcagga ccagcatcta ctactacgcc 120 ggcagcagca ggctgctggc cgtgg gcaac ccctacttca gcatcaagag ccccaacaac 180 aacaagaagg tgctggtgcc caaggtgagc ggcctgcagt acagggtgtt cagggtgagg 240 ctgcccgacc ccaacaagtt cggcttcccc gacaccagct tctacaaccc cgacacccag 300 aggctggtgt gggcc tgcgt gggcctggag atcggcaggg gccagcccct gggcgtgggc 360 gtgagcggcc acccctacct gaacaagttc gacgacaccg agaccagcaa caggtacccc 420 gcccagcccg gcagcgacaa cagggagtgc ctgagcatgg actacaagca gacccagctg 480 tgcctgatcg gctgcaagcc ccccaccggc gagcactggg gcaagggcgt ggcctgcaac 540 aacaacgccg ccgccaccga ctgcccccccc ctggagctgt tcaacagcat catcgaggac 600 ggcgacatgg tggacaccgg cttcggctgc atggacttcg gcaccctgca ggccaacaag 660 agcgacgtgc ccatcgacat ctgcaacagc acctgcaagt accccgacta cctgaagatg 720 gccagcgagc cctacggcga cagcctgttc ttcttcctga ggagggagca gatgttcgtg 780 aggcacttct tcaacagggc cggcaagctg ggcgaggcc g tgcccgacga cctgtacatc 840 aagggcagcg gcaacaccgc cgtgatccag agcagcgcct tcttccccac ccccagcggc 900 agcatcgtga ccagcgagag ccagctgttc aacaagccct actggctgca gagggcccag 960 ggccacaaca acggcatctg ct gggcaac cagctgttcg tgaccgtggt ggacaccacc 1020 aggagcacca acatgaccct gtgcaccgag gtgaccaagg agggcaccta caagaacgac 1080 aacttcaagg agtacgtgag gcacgtggag gagtacgacc tgcagttcgt gttccagctg 1140 tgcaagatca ccctgaccgc cgagatcatg acctacatcc acaccatgga cagcaacatc 1200 ctggaggact ggcagttcgg cctgaccccc ccccccagcg ccagcctgca ggacacctac 1260 aggttcgtga ccagccaggc catcacctgc cagaagaccg ccccccccaa ggagaaggag 1320 gaccccctga acaagtacac cttctggggag gtgaacctga aggagaagtt cagcgccgac 1380 ctggaccagt tccccctggg caggaagttc ctgctgcaga gcggcctgaa ggccaagccc 1440 aggctgaaga ggagcgcccc caccaccagg gcccccagca ccaagaggaa gaaggtgaag 15 00 aagtaaactc gagctc 1516 <![CDATA[ <210> 152]]>
 <![CDATA[ <211> 1519]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5806 Synthetic HPV33L1 gene]]>
 <![CDATA[ <400> 152]]> ctgggtacca tgagtgtgtg gagaccatct gaggctacag tctacctgcc tcctgtgcct 60 gtgagcaagg tggtgagcac agatgaatat gtgagcagga ccagcatcta ctactatgct 120 ggctccagca gactgctggc tgtgggacac ccat acttca gcatcaagaa cccaaccaat 180 gccaagaaac tgctggtgcc aaaggtgtct ggactccaat acagggtgtt cagggtgaga 240 ctgcctgacc caaacaagtt tggctttcct gacacctcct tctacaaccc tgacacccag 300 agactggtgt gggcttgt gt gggattggag attggcaggg gacaaccact gggagtgggc     360
          atctctggac acccactgct gaacaagttt gatgacacag agacaggcaa caaataccct     420
          ggacaacctg gagcagacaa cagggagtgt ctgagtatgg actacaagca gacccaactt     480
          tgtctgctgg gctgtaagcc tccaacagga gaacactggg gcaagggagt ggcttgtacc     540
          aatgctgccc ctgccaatga ctgtcctcca ttggaactga taaacaccat cattgaggat     600
          ggagatatgg tggacacagg ctttggctgt atggacttca agaccctcca agccaacaag     660
          tctgatgtgc caattgacat ctgtggcagc acttgtaaat accctgacta cctgaaaatg 720 acctctgaac catatggaga ctccctgttc ttcttcctga gggagggaaca gatgtttgtg 780 agacacttct tcaacagggc tggcaccctg ggagaggctg tgcctgatga cctctacatc 840 a agggctctg gcaccacagc cagcatccag tcctctgcct tctttccaac accatctggc 900 agtatggtga cctctgagag ccaacttttc aacaagccat actggctcca aagggctcaa 960 ggacacaaca atggcatctg ttggggcaac caggtgtttg tgacagtggt ggacaccacc 1020 aggagcacca atatgaccct gtgtacccag gtgacctctg acagcaccta caagaatgag 1080 aacttcaagg aatacatcag gcatgtggag gaatatgacc tccaatttgt gttccaactt 1140 tgtaaggtga ccctgacagc agaggtgatg acctacatcc atgctatgaa ccctgacatc 1200 ttggaggact ggcagtttgg actgacacct cctccatctg cctccctcca agacacctac 1260 aggtttgtga ccagccaggc tatcacttgt cagaagacag tgcctccaaa ggagaaggag 1320 gacccactgg gcaaatacac cttctgggag gtggacctga aaga gaagtt ctctgctgac 1380 ctggaccagt ttccactggg caggaagttc ctgctccaag caggactgaa agccaagcca 1440 aaactgaaaa gggctgcccc aaccagcacc aggacctcct ctgccaagag gaagaaggtg 1500 aagaagtaaa ctcgagctc 1519 <![CDATA[ <210> 153]]>
 <![CDATA[ <211> 34]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5807 HPV58L1 F1]]> <![CDATA[ <400> 153]]> cttggtacca tgagcgtgtg gaggcccagc gagg 34 <![CDATA[ <210> 154]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5808 HPV58L1 R1]]> <![CDATA[ <400> 154]]> gcttggcttt caggccgctc tgcagcagga acttcc 36 <![CDATA[ <210> 155]]>
 <![CDATA[ <211> 1438]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5809 HPV58L1 expansion sequence 1]]>
 <![CDATA[ <400> 155]]> cttggtacca tgagcgtgtg gaggcccagc gaggccaccg tgtacctgcc ccccgtgccc 60 gtgagcaagg tggtgagcac cgacgagtac gtgagcagga ccagcatcta ctactacgcc 120 ggcagcagca ggctgctggc cgtgg gcaac ccctacttca gcatcaagag ccccaacaac 180 aacaagaagg tgctggtgcc caaggtgagc ggcctgcagt acagggtgtt cagggtgagg 240 ctgcccgacc ccaacaagtt cggcttcccc gacaccagct tctacaaccc cgacacccag 300 aggctggtgt gggcc tgcgt gggcctggag atcggcaggg gccagcccct gggcgtgggc 360 gtgagcggcc acccctacct gaacaagttc gacgacaccg agaccagcaa caggtacccc 420 gcccagcccg gcagcgacaa cagggagtgc ctgagcatgg actacaagca gacccagctg 480 tgcctgatcg gctgcaagcc ccccaccggc gagcactggg gcaagggcgt ggcctgcaac 540 aacaacgccg ccgccaccga ctgcccccccc ctggagctgt tcaacagcat catcgaggac 600 ggcgacatgg tggacaccgg cttcggctgc atggacttcg gcaccctgca ggccaacaag 660 agcgacgtgc ccatcgacat ctgcaacagc acctgcaagt accccgacta cctgaagatg 720 gccagcgagc cctacggcga cagcctgttc ttcttcctga ggagggagca gatgttcgtg 780 aggcacttct tcaacagggc cggcaagctg ggcgaggcc g tgcccgacga cctgtacatc 840 aagggcagcg gcaacaccgc cgtgatccag agcagcgcct tcttccccac ccccagcggc 900 agcatcgtga ccagcgagag ccagctgttc aacaagccct actggctgca gagggcccag 960 ggccacaaca acggcatctg ct gggcaac cagctgttcg tgaccgtggt ggacaccacc 1020 aggagcacca acatgaccct gtgcaccgag gtgaccaagg agggcaccta caagaacgac 1080 aacttcaagg agtacgtgag gcacgtggag gagtacgacc tgcagttcgt gttccagctg 1140 tgcaagatca ccctgaccgc cgagatcatg acctacatcc acaccatgga cagcaacatc 1200 ctggaggact ggcagttcgg cctgaccccc ccccccagcg ccagcctgca ggacacctac 1260 aggttcgtga ccagccaggc catcacctgc cagaagaccg ccccccccaa ggagaaggag 1320 gaccccctga acaagtacac cttctggggag gtgaacctga aggagaagtt cagcgccgac 1380 ctggaccagt tccccctggg caggaagttc ctgctgcaga gcggcctgaa agccaagc 1438 <![CDATA[ <210> 156]]>
 <![CDATA[ <211> 35]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5810 HPV58L1 F2]]> <![CDATA[ <400> 156]]> gagcggcctg aaagccaagc caaaactgaa aaggg 35 <![CDATA[ <210> 157]]>
 <![CDATA[ <211> 36]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5811 HPV58L1 R2]]> <![CDATA[ <400> 157]]> ctgtctagat ttacttcttc accttcttcc tcttgg 36 <![CDATA[ <210> ]]>158
 <![CDATA[ <211> 101]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5812 HPV58L1 expansion sequence 2]]>
 <![CDATA[ <400> 158]]> gagcggcctg aaagccaagc caaaactgaa aagggctgcc ccaaccagca ccaggacctc 60 ctctgccaag aggaagaagg tgaagaagta aatctagaca g 101 <![CDATA[ <210> 159]]>
 <![CDATA[ <211> 38]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5813 HPV 59 L1 protein amino acid sequence 471-508]]>
 <![CDATA[ <400> 159]]> Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr Ile Gly Pro Arg Lys Arg 1 5 10 15 Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser Pro Lys Arg Val Lys Arg 20 25 30 Arg Lys Ser Ser Arg Lys 35 <![CDATA[ <210> 160]]>
 <![CDATA[ <211> 508]]>
 <![CDATA[ <212> PRT]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5901 Amino acid sequence of HPV type 59 L1 protein]]>
 <![CDATA[ <400> 160]]> Met Ala Leu Trp Arg Ser Ser Asp Asn Lys Val Tyr Leu Pro Pro Pro 1 5 10 15 Ser Val Ala Lys Val Val Ser Thr Asp Glu Tyr Val Thr Arg Thr Ser 20 25 30 Ile Phe Tyr His Ala Gly Ser Ser Arg Leu Leu Thr Val Gly His Pro 35 40 45 Tyr Phe Lys Val Pro Lys Gly Gly Asn Gly Arg Gln Asp Val Pro Lys 50 55 60 Val Ser Ala Tyr Gln Tyr Arg Val Phe Arg Val Lys Leu Pro Asp Pro 65 70 75 80 Asn Lys Phe Gly Leu Pro Asp Asn Thr Val Tyr Asp Pro Asn Ser Gln 85 90 95 Arg Leu Val Trp Ala Cys Val Gly Val Glu Ile Gly Arg Gly Gln Pro 100 105 110 Leu Gly Val Gly Leu Ser Gly His Pro Leu Tyr Asn Lys Leu Asp Asp 115 120 125 Thr Glu Asn Ser His Val Ala Ser Ala Val Asp Thr Lys Asp Thr Arg 130 135 140 Asp Asn Val Ser Val Asp Tyr Lys Gln Thr Gln Leu Cys Ile Ile Gly 145 150 155 160 Cys Val Pro Ala Ile Gly Glu His Trp Thr Lys Gly Thr Ala Cys Lys 165 170 175 Pro Thr Thr Val Val Gln Gly Asp Cys Pro Pro Leu Glu Leu Ile Asn 180 185 190 Thr Pro Ile Glu Asp Gly Asp Met Val Asp Thr Gly Tyr Gly Ala Met 195 200 205 Asp Phe Lys Leu Leu Gln Asp Asn Lys Ser Glu Val Pro Leu Asp Ile 210 215 220 Cys Gln Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser Ala Asp 225 230 235 240 Ala Tyr Gly Asp Ser Met Phe Phe Cys Leu Arg Arg Glu Gln Val Phe 245 250 255 Ala Arg His Phe Trp Asn Arg Ser Gly Thr Met Gly Asp Gln Leu Pro 260 265 270 Glu Ser Leu Tyr Ile Lys Gly Thr Asp Ile Arg Ala Asn Pro Gly Ser 275 280 285 Tyr Leu Tyr Ser Pro Ser Pro Ser Gly Ser Val Val Thr Ser Asp Ser 290 295 300 Gln Leu Phe Asn Lys Pro Tyr Trp Leu His Lys Ala Gln Gly Leu Asn 305 310 315 320 Asn Gly Ile Cys Trp His Asn Gln Leu Phe Leu Thr Val Val Asp Thr 325 330 335 Thr Arg Ser Thr Asn Leu Ser Val Cys Ala Ser Thr Thr Ser Ser Ile 340 345 350 Pro Asn Val Tyr Thr Pro Thr Ser Phe Lys Glu Tyr Ala Arg His Val 355 360 365 Glu Glu Phe Asp Leu Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu 370 375 380 Thr Thr Glu Val Met Ser Tyr Ile His Asn Met Asn Thr Thr Ile Leu 385 390 395 400 Glu Asp Trp Asn Phe Gly Val Thr Pro Pro Pro Thr Ala Ser Leu Val 405 410 415 Asp Thr Tyr Arg Phe Val Gln Ser Ala Ala Val Thr Cys Gln Lys Asp 420 425 430 Thr Ala Pro Pro Val Lys Gln Asp Pro Tyr Asp Lys Leu Lys Phe Trp 435 440 445 Pro Val Asp Leu Lys Glu Arg Phe Ser Ala Asp Leu Asp Gln Phe Pro 450 455 460 Leu Gly Arg Lys Phe Leu Leu Gln Leu Gly Ala Arg Pro Lys Pro Thr 465 470 475 480 Ile Gly Pro Arg Lys Arg Ala Ala Pro Ala Pro Thr Ser Thr Pro Ser 485 490 495 Pro Lys Arg Val Lys Arg Arg Lys Ser Ser Arg Lys 500 505 <![CDATA[ <210> 161]]>
 <![CDATA[ <211> 1528]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Homo sapiens]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5902 Nucleotide sequence of HPV type 59 L1 protein]]>
 <![CDATA[ <400> 161]]> atggctctgt ggaggtcctc tgacaacaag gtctacctgc ctcctccatc tgtggctaag 60 gtggtgagca cagatgaata tgtgaccagg accagcatct tctaccatgc tggctccagc 120 agactgctga cagtgggaca cccatacttc aaggtg ccaa agggaggcaa tggcagacag 180 gatgtgccaa aggtgtctgc ctaccaatac agggtgttca gggtgaaact gcctgaccca 240 aacaagtttg gactgcctga caacacagtc tatgacccaa acagccagag actggtgtgg 300 gcttgtgtgg gagtggagat t ggcagggga caaccactgg gagtgggact gtctggacac 360 ccactctaca acaaactgga tgacacagag aactctcatg tggcatctgc tgtggacacc 420 aaggacacca gggacaatgt gtctgtggac tacaagcaga cccaactttg tatcattggc 480 tgtgtgcctg ccattggaga a cactggacc aagggcacag cctgtaagcc aaccacagtg 540 gtccagggag actgtcctcc attggaactg ataaacacac caattgagga tggagatatg 600 gtggacacag gctatggagc tatggacttc aaactgctcc aagacaacaa gtctgaggtg 660 ccactggaca tctgtcaga g catctgtaaa taccctgact acctccaaat gagtgctgat 720 gcctatggag acagtatgtt cttctgtctg aggagggaac aggtgtttgc cagacacttc 780 tggaacaggt ctggcacaat gggagaccaa cttcctgagt ccctctacat caagggcaca 840 gacatca ggg ctaaccctgg ctcctacctc tacagcccaa gcccatctgg ctctgtggtg 900 acctctgaca gccaactttt caacaagcca tactggctgc acaaggctca aggactgaac 960 aatggcatct gttggcacaa ccaacttttc ctgacagtgg tggacaccac caggagcacc 1020 aacctgtctg tgtgtgccag caccacctcc agcatcccaa atgtctacac accaacctcc 1080 ttcaaggaat atgccaggca tgtggaggag tttgacctcc aattcatctt ccaactttgt 1140 aagattaccc tgaccacaga ggtgatgagt tacatccaca atatgaacac caccat cttg 1200 gaggactgga actttggagt gacacctcct ccaacagcct ccctggtgga cacctacagg 1260 tttgtccagt ctgctgctgt gacttgtcag aaggacacag cccctcctgt gaagcaggac 1320 ccatatgaca aactgaagtt ctggcctgtg gacctgaa agaggttctc tgctgacctg 1380 gaccagtttc cactgggcag gaagttcctg ctccaacttg gagccagacc aaagccaacc 1440 attggaccaa ggaagagggc tgcccctgcc ccaaccagca caccaagccc aaagagggtg 1500 aagaggagga agtccagcag gaagtaaa 15 28 <![CDATA[ <210> 162]]>
 <![CDATA[ <211> 1546]]>
 <![CDATA[ <212> DNA]]>
 <![CDATA[ <213> Artificial sequence]]>
 <![CDATA[ <220> ]]>
 <![CDATA[ <223> 5903 Synthetic HPV59L1 gene]]>
 <![CDATA[ [400] ca aggtgccaaa gggaggcaat 180 ggcagacagg atgtgccaaa ggtgtctgcc taccaataca gggtgttcag ggtgaaactg 240 cctgacccaa acaagtttgg actgcctgac aacacagtct atgacccaaa cagccagaga 300 ctggtgtggg cttgtgtggg agtggagatt ggcaggggac aaccactggg agtgggactg 360 tctggacacc cactctacaa caaactggat gacacagaga actctcatgt ggcatctgct 420 gtggacacca aggacaccag ggacaatgtg tctgtggact acaagcagac ccaactttgt 480 atcattggct gtgtgcctgc cattggagaa cactggacca agggcacagc ctgtaagcca 540 accacagtgg tccagggaga ctgtcctcca ttggaactga taaacacacc aattgaggat 600 ggagatatgg tggacacagg ctatggagct atggacttca aactgctcca agacaacaag 660 tctgaggtgc cactggacat ctgtc agagc atctgtaaat accctgacta cctccaaatg 720 agtgctgatg cctatggaga cagtatgttc ttctgtctga ggagggaaca ggtgtttgcc 780 agacacttct ggaacaggtc tggcacaatg ggagaccaac ttcctgagtc cctctacatc 840 aagggca cag acatcagggc taaccctggc tcctacctct acagcccaag cccatctggc 900 tctgtggtga cctctgacag ccaacttttc aacaagccat actggctgca caaggctcaa 960 ggactgaaca atggcatctg ttggcacaac caacttttcc tgacagtggt ggacaccacc 1020 aggagcacca acctgtctgt gtgtgccagc accacctcca gcatcccaaa tgtctacaca 1080 ccaacctcct tcaaggaata tgccaggcat gtggaggagt ttgacctcca attcatcttc 1140 caactttgta agattaccct gaccacagag gtgatgagtt acatccacaa tatgaacac c 1200 accatcttgg aggactggaa ctttggagtg acacctcctc caacagcctc cctggtggac 1260 acctacaggt ttgtccagtc tgctgctgtg acttgtcaga aggacacagc ccctcctgtg 1320 aagcaggacc catatgacaa actgaagttc tggcctgt gg acctgaaaga gaggttctct 1380 gctgacctgg accagtttcc actgggcagg aagttcctgc tccaacttgg agccagacca 1440 aagccaacca ttggaccaag gaagagggct gcccctgccc caaccagcac accaagccca 1500 aagagggtga agaggaggaa gtccagcagg aagtaaactc ctc 1546
      

Claims (17)

A chimeric papillomavirus L1 protein, comprising, from its N-terminus to its C-terminus: a. an N-terminal fragment derived from a first type of papillomavirus L1 protein, wherein the N-terminal fragment retains the immunogenicity of the first type of papillomavirus L1 protein, and the first type of papillomavirus L1 protein is selected from HPV type 6, type 11, type 16, type 18, type 31, type 35, type 39, type 45, type 51, type 52, type 56 or type 58 L1 protein, wherein the N-terminal fragment is SEQ ID No: 1, SEQ ID No: 14, SEQ ID No: 27, SEQ ID No: 40, SEQ ID No: 53, SEQ ID No: 69, SEQ ID No: 82, SEQ ID No: 95, SEQ ID No: 108, SEQ ID No: 121, SEQ ID No: 134 or SEQ ID No: 147 has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity; and b. a C-terminal fragment derived from a second type of papillomavirus L1 protein, the second type of papillomavirus L1 protein is selected from HPV 33 type or HPV 59 type L1 protein, and the C-terminal fragment has 98%, 98.5%, 99%, 99.5%, 99% or 100% identity with the sequence shown in SEQ ID No: 2, SEQ ID No: 135 or SEQ ID No: 13; wherein the N-terminal fragment and the C-terminal fragment are directly connected; wherein the chimeric papillomavirus L1 protein has the immunogenicity of the first type of papillomavirus L1 protein. The chimeric papillomavirus L1 protein as described in claim 1, wherein the chimeric HPV type 6, type 11, type 16, type 18, type 31, type 35, type 39, type 45, type 51, type 52, type 56 and type 58 chimeric HPV L1 proteins are 98%, 98.5%, 99%, 99.5% or 100% identical to SEQ ID No: 3, SEQ ID No: 16, SEQ ID No: 29, SEQ ID No: 42, SEQ ID No: 55, SEQ ID No: 71, SEQ ID No: 84, SEQ ID No: 97, SEQ ID No: 110, SEQ ID No: 123, SEQ ID No: 136 and SEQ ID No: 149, respectively. A papillomavirus particle comprising a chimeric papillomavirus L1 protein as described in any one of claims 1 to 2. An isolated polynucleotide encoding a chimeric papillomavirus L1 protein as described in any one of claims 1 to 2. A vector comprising the isolated polynucleotide as described in claim 4. The vector as described in claim 5 is a bacilliform virus vector. A bacilliform virus comprising the isolated polynucleotide as described in claim 4. A host cell comprising the isolated polynucleotide as described in claim 4, the vector as described in claim 5 or 6, or the bacilli as described in claim 7. The host cell as described in claim 8 is an insect cell. A host cell as described in claim 9, wherein the insect cell is selected from Sf9 cells, Sf21 cells, Hi5 cells and S2 cells. A multivalent HPV immunogenic composition for preventing HPV-related diseases or infections, comprising the papillomavirus particles as described in claim 3, the isolated polynucleotides as described in claim 4, the vectors as described in claim 5 or 6, the rod-shaped virus as described in claim 7, and the host cells as described in any one of claims 8 to 10. The multivalent HPV immunogenic composition of claim 11 further comprises a physiologically acceptable carrier. The multivalent HPV immunogenic composition of claim 11 further comprises an adjuvant. The multivalent HPV immunogenic composition as described in claim 13, wherein the adjuvant is an aluminum phosphate adjuvant. A multivalent HPV immunogenic composition as described in any one of claims 11 to 14, comprising the papillomavirus-like particles as described in claim 3, and one or more HPV virus-like particles assembled from L1 proteins of other pathogenic HPV types. The multivalent HPV immunogenic composition of claim 15, comprising HPV type 6, type 11, type 16, type 18, type 31, type 35, type 39, type 45, type 51, type 52, type 56 and type 58 virus-like particles, wherein the chimeric HPV L1 protein constituting the virus-like particles has 98%, 98.5%, 99%, 99.5% or 100% identity with SEQ ID No: 3, SEQ ID No: 16, SEQ ID No: 29, SEQ ID No: 42, SEQ ID No: 55, SEQ ID No: 71, SEQ ID No: 84, SEQ ID No: 97, SEQ ID No: 110, SEQ ID No: 123, SEQ ID No: 136 and SEQ ID No: 149, respectively; and HPV type 33 and HPV type 59 virus-like particles, wherein the HPV type 33 L1 protein and the HPV The 59-type L1 protein has 98%, 98.5%, 99%, 99.5% or 100% identity with SEQ ID No: 66 and SEQ ID No: 160, respectively. Use of a chimeric papillomavirus L1 protein as described in any one of claims 1 to 2, a papillomavirus-like particle as described in claim 3, an isolated polynucleotide as described in claim 4, a vector as described in claim 5 or 6, a rod-shaped virus as described in claim 7, a host cell as described in any one of claims 8 to 10, or a multivalent HPV immunogenic composition as described in any one of claims 11 to 16 in the preparation of a vaccine or drug for preventing HPV-related diseases or infections.